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Proteomic technologies verified Anterior Gradient 2, AGR-2, as a protein over-
expressed in human cancers, including breast, prostate and oesophagus cancers, with 
the ability to inhibit the tumour suppressor protein p53. AGR-2 gene is a hormone 
responsive gene with an unexpected induction by the anti-cancer drug tamoxifen 
highlighting the proto-oncogenic role of this protein. Anterior Gradient-2 encodes 
one protein that gives rise to two forms· the full length and the mature one. Full 
length bears a leader sequence that leads the protein to secretion. Localization studies 
of both forms of AGR-2 were performed using fluorescence microscopy and 
subcellular fractionation, in order to determine in which compartment the protein 
functions. Localization mutants of the mature and full length protein determined the 
exact sequence required for certain localization patterns. Once localization was 
confirmed, the mechanism of how Anterior Gradient-2 localization within the cell 
can inhibit p53 was initiated. Furthermore, novel peptide aptamers that bound to the 
protein were cloned into GFP vectors and their effect on AGR-2 was investigated. 
AGR-3, another member of the family, was also examined in terms of localization 
and function in MCF-7 cells. Yeast two hybrid analysis has identified potential 
nuclear and cytoplasmic binding partners for AGR-2, essential for the upstream or 
downstream regulation of the AGR-2 pathway. In conclusion, we present data 
showing models of how the Anterior Gradient protein family might function as drug-
resistance survival factor in cancer as well as a p53 inhibitor, suggesting a multi-
potent role of its members when it comes to trafficking, cellular localization and 












a.a amino acids 
AGD                            amoebic gill disease 
AGR-2 anterior gradient 2 
AGR-3 anterior gradient 3 
AIF                       apoptosis inducing factor 
Akt alias of protein kinase B (PKB) 
ANF                               anterior neural folds 
AP-1                                activator protein 1 
Apaf-1                            apoptosis protease-activating factor 1 
APC adenomatous polyposis coli 
apg                                   autophagy related gene 
Apo1                                alias of CD95, Fas 
Apo3                                alias of DR3 
Apo3L                              Apo3 ligand 
APS ammonium persulfate 
AR androgen receptor 
ARF                               alias for cyclin-dependent kinase inhibitor CKDN 
ASOs                              anti-sense oligonucleotides 
Asp                                 Asparagine amino acid 
ATCC American tissue culture collection 
Atg                                   autophagy gene 
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ATN                               adenine nucleotide translocator 
ATR ataxia telengiectasia and Rad3 related 
ATRIP                            ATR interacting protein 
Bad                                 Bcl2-associated agonist of cell death 
BAI1 brain-specific angiogenesis inhibitor 1 
BAIAP3 BAI1-associated protein 3 
Bak                                 Bcl2-antagonist/killer 1 
BAT3 HLA-B associated transcript 3 
Bax                                  Bcl2-associated X protein 
Bcl-2                               B-cell lymphoma 2 
BCMP11 Breast cancer membrane protein 11 
Bid                                   BH3 interacting domain death agonist 
Bim                                  Bcl2-like 11 apoptosis facilitator 
Bip                                    alias of hspA5 
BMP bone morphogenic protein 
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BRCA1 breast cancer 1, early onset 
BSA bovine serum albumin 
B&W                             black and white 
CAK cyclin-activating kinase 
Caspase cysteine asaprtate protease 
CBP CREB binding protein 
CDK 4/6                          cyclin-dependent kinase 4/6 
CDH6 cadherin 6 
CDKN 1/2A                    cyclin-dependent kinase inhibitor 1/2A 
cDNA complimentary DNA 
C/EBP CCAAT/ enhancer binding protein 
Ced-3                              cell death abnormality family member 
CGH                                 Comparative Genome Hybridization 
Chk1/2                             checkpoint homolog 
CHUK                              conserved helix-loop-helix ubiquitous kinase 
CKAP2 cytoskeleton-associated protein 2 
Cop-1                               caspase-1 dominant-negative inhibitor pseudo-ICE 
CRUK Cancer Research United Kingdom 
CSS charcoal stripped serum 
Cys                                   cysteine 
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Dabco 1,4-Diazabicyclo[2.2.2]octane solution 
DAG1                              alpha dystroglycan 
DAPI 4’,6-Diamidino-2 phenylindole dihydrochloride 
DAPK death-associated protein kinase 
DBD DNA-binding domain 
DCA deoxycholic acid 
DDR                               DNA damage response pathway 
DISC                               death-inducing signalling complex 
DLG1 discs, large homolog 1 
DMSO dimethyl sulphoxide 
DNA-PK DNA-dependent protein kinase 
DR3/4/5  death receptor 3/4/5 
dsb double strand break 
dsRNA double-stranded RNA 
DTT Dithiothreitol solution 
Drp                                  dynamin-related protein 
E2                                    estradiol 
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E2F                                  E2F transcription factor 
ECACC European collection of cell cultures 
ECL enhanced chemiluminescence 
EDTA ethylene diamine tetra acetic acid 
EGF epidermal growth factor 
EGP                                  enhanced GFP 
EGFR epidermal growth factor receptor 
ER endoplasmic reticulum 
ERα estrogen receptor alpha 
ERBB2 v-erb2 erythroblastic leukemia viral oncogene homolog 2 
ERK                                   alias of MAPK1 
ERp                                    endoplasmic reticulum resident proteins 
ERR oestrogen receptor-related receptor 
EST expressed sequence tag 
FADD                                FAS-associated death domain 
FAS                                   TNF receptor superfamily, member 
FBS fetal bovine serum 
FCS foetal calf serum 
FISH                                 fluorescent in situ hybridization 
FOXA forkhead box protein 
FP                                      fluorescent protein 
FRET                                fluorescence resonance energy transfer 
GADD54                          growth arrest and DNA-damage-inducible 
GFP green fluorescent protein 
GI gastro-intestinal 
GIT1 G protein-coupled receptor kinase interactor 1 
Gob-4 alias of AGR-2 
GR glucocorticoid receptor 
GRH gonadotrophin releasing hormone 
GSTM4 glutathione S-transferase M4 
GTFIIH                            general transcription factor IIH, polypeptide 4 
HCC                                  hepatocellular carcinoma 
hCG                                   human choriogonadotropin 
HDAC histone deacetylase 
HDM                                 human homolog of mouse doubles minute 2 
HER2 herstatin, herceptin 2, alias of ERBB2 
HERC2 hect domain and RLD2 
HIC-1 hypermethylated in cancer 1 
HIF-1 hypoxia inducing factor 1 
[vii] 
 
HIP1R huntingtin interacting protein 1 related 
HRP horseradish peroxidase 
Hsp heat shock protein 
HUWE1 HECT, UBA and WWE domain containing 1 
ICE                                   alias of caspace 1,  interleukin 1-B converting enzyme 
IF                                       immunofluorescence 
IH                                      immunohistochemistry 
IGF-1 insulin growth factor-1 
IGF-1R insulin growth factor-1 receptor 
IkB                                    alias of CHUK 
IKK IκB kinase kinase 
IL-1 interleukin-1 
IPTG  Isopropylβ-D-1thiogalactopyranosidine 
IR ionising radiation 
IXL1 alias of MED29 
JNK                                   alias for MAPK8 
KCT3 keratinocytes associated transmembrane protein 
KIBRA alias of WWC1 
LC3                                   alias of MAP1LC3A 
LRBA LPS-responsive vesicle trafficking, beach and anchor 
containing 
MAST1 microtubule associated serine/threonine kinase 1 
MAP multiple antigenic peptides 
MAP1LC3A                     microtubule-associated protein 1 light chain 3 alpha 
MAPK mitogen-activating protein kinase 1 
Mdm2 mouse double minute 2 
Mdm                                 mitochondrial distribution and morphology protein 
MED29 mediator complex subunit 29 
MEF                                  mouse embryonic fibloblast 
Mfn 1/ 2                            mitofusin protein 1/ 2 
Mmm                                maintenance of mitochondrial morphology protein 
MOMP                              mitochondrial outer membrane permeabilization 
mRNA messenger RNA 
MRC                                 mitochondrial respiratory chain 
MS                                    mass spectrometry 
MTs                                     microtubules 
mtDNA                             mitochondrial DNA 
MTT methylthiazoletetrazolium 
MYBBP1A v-myb myeloblastosis viral oncogene homolog 
MYBBP1A MYB binding protein 
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NB                                     neuroblastoma 
NCBI National Centre for Biotechnology Information 
NEAA non-essential amino acids 
NES                                   nuclear export signal/sequence 
NF-κB nuclear factor kappa B 
NLS                                   nuclear localization signal/sequence 
NuMA                                nuclear protein associated with the mitotic apparatus 
Opa1                                 optic atrophy protein 1 
PAGE polyacrylamide gel electrophoresis 
P14ARF                             alias for CDKN2A 
PARG1 PTPL1-associated RhoGAP 1 
PBS phosphate buffered saline 
PBS-T phosphate buffered saline tween 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PDI protein disulfide isomerase 
PF parafolmadehyde 
Pfu plaque forming units 
PI3K phosphatidyl inositol 3 kinase 
PIKK phosphoinositide-3-kinase-related kinase 
Pirh-2                                alias fof RCHY1 
PKC protein kinase C 
PM                                    plasma membrane 
PPM1D                             protein phosphatase 1D magnesium-dependent, delta 
isoform 
PR                                     progesterone receptor 
Prod1                                proximal distal determination 
PS                                     phospatidylserine 
PSA prostate specific antigen 
PSME1 proteasome (prosome, macropain) activator subunit 1 (PA28 
alpha) 
PTEN                                phosphatase and tensin homolog 
Puma                                 Bcl2 binding component 3 
qRT-PCR quantitative real-time PCR 
RAR                                  retinoic acid receptor 
Rb retinoblastoma 
RCHY1                             ring finger and CHY zinc finger domain containing 1 
RFP                                   red fluorescent protein 
RGB                                 red green blue 
RIP140 nuclear receptor interacting protein 140 
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R.L.U Relative Light Units 
RNA                                  ribonucleic acid 
ROI reactive oxygen intermediate 
ROS                                  reactive oxygen species 
RU                                     relative units 
RUVBL2 RuvB-like 2 
SELEX Systematic Evolution of Ligands by EXponential enrichment
Ser                                    serine amino acid 
shRNA                             short hairpin RNA 
Siah-1                               seven in absentia homolog 1 
siRNA small interfering RNA 
SDS sodium dodecyl sulphate 
SPTBN1 spectrin, beta, non-erythrocytic 1 
ssDNA                             single strand DNA 
STAT signal transducers and activators of transcription 
TBP TATA-binding protein 
TCA trichloracetic acid 
TFIIH                               alias of GTFIIH 
TGF transforming growth factor 
TLN1 talin 1 
TNF tumour necrosis factor 
TNFR                              TNF receptor 
TRAIL TNF-related apoptosis-inducing ligand 
TRAPP  transport protein particle 
tRNA transfer RNA 
Trx                                  thioredoxin 
UPR                                unfolded protein response 
US                                   United States 
UV ultra-violet 
VDAC                             voltage-dependent anion channel 
VEGF vascular endothelial growth factor 
VTCs                               vesiculotubular clusters 
v/v volume/volume 
w/v weight/volume 
WAF1                             alias of CDKN1 
Wip-1                              alias for PPMID 
WT1                                Wilm’s tumour 1 
WWC1 WW and C2 domain containing 1 
Y2H                                 Yeast-two-hybrid 
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1.1 Cancer: a multistep process 
 
1.1.1 History of cancer 
 
Hippocrates first described cancer. He called benign tumours oncos, Greek for 
swelling, and malignant tumours carcinos, Greek for crab or crayfish. This name 
comes from the appearance of the cut surface of a solid malignant tumour, with the 
veins stretched on all sides as the animal the crab has its feet, whence it derives its 
name (as described by Paul of Aegina, 7th century of AD) [342]. He later added the 
suffix -oma, Greek for swelling, giving the name carcinoma. Since it was against 
Greek tradition to open the body, Hippocrates only described and made drawings of 
apparently visible tumors on the nose, skin and breasts [342]. Through the centuries 
it was discovered that cancer could occur anywhere in the body. Today, the Greek 
term carcinoma is the medical term for a malignant tumour derived from epithelial 
cells, which cover more than 86% of all tumours. Cancers of glandular tissue are 
called adenocarcinomas (e.g breast) and the ones that derive from mesoderm cells 
(e.g muscle, bones) are termed as sarcomas [461]. It is Celsus who translated 
carcinos into the Latin cancer, also meaning crab. Galen used "oncos" to describe all 
tumours, the root for the modern word oncology, modern Greek for swelling [342]. 
Cancer is a class of diseases in which a number of cells exhibit uncontrolled 
proliferation, growth, invasion in adjacent tissues and sometimes metastasis to other 
sites in the body. These three malignant properties differentiate malignant tumours 
from benign ones which do not invade or metastasize [461].  According to WHO 
2007, cancer is responsible for 13% of all deaths worldwide 
(www.who.int/topics/cancer/en/) with lung, stomach, liver, colon and breast cancer 
accounting for most of these deaths. Cancer development is a multi-step process 
involving different and variable activation and inactivation pathways. The 
transformation of a ‘normal’ cell to a cancerous one requires a cascade of mutated 
genes, oncogenes, tumor suppressor genes and other genes modulating cell cycle, 
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which are being silenced or overexpressed. There are many different kinds of cancer 
(more than 100 have already been classified) associated with almost every cell type, 
establishing cancer as a multistage and widely spread ‘disease’ [461].  In 2000, after 
detailed analysis, Hanahan and Weinberg defined six hallmarks of most, if not all, 




Figure 1.1: Acquired capabilities of cancer. Most if not all cancers have acquired the same 
set of functional capabilities during their development  (Image adapted from [245] ). 
 
 
Most cancers are caused by genetic abnormalities due to the effect of carcinogens, 
UV, radiation, chemicals, tobacco smoke or viruses (responsible for 15% of all 
cancers, www.who.int/topics/cancer/en/). Genetic abnormalities, including DNA 
mutations, also involve inheritance of certain cancer-promoting oncogenes or cancer-
protecting tumour suppressor genes. Cancer is usually classified according to the 
tissue from which the cells originate, the primary tumor, as well as the normal cell 
type they most resemble in terms of location and histology [342]. Diagnosis usually 
requires medical tests such as blood tests, X-rays, endoscopy and computed 
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tomography, CT, scans. Histological examination of a tissue biopsy or surgery 
specimen by a pathologist follows and the histological grade of the tumour along 
with other characteristics is classified and prognosis is being determined. The 
prognosis of cancer patients is most influenced by the type of cancer, as well as 
the stage, or extent of the disease. In addition to histological grading, the presence of 
specific molecular markers can also be useful in establishing prognosis, as well as in 
determining individual treatments. Cancer can be treated 
by surgery, chemotherapy, radiotherapy, immunotherapy, monoclonal antibody 
therapy, or even combination of some methods (Figure 1.2). The choice of therapy 
depends upon the location and grade of the tumour and the stage of the disease, as 
well as the general state of the patient and these characteristics determine cure. As 
research develops, treatments are refined for different types of cancer. There has 
been significant progress in the development of targeted therapy drugs that act 
specifically on molecular abnormalities in certain tumours, and which minimize 
damage to normal cells. Monoclonal antibody therapy targeted strategy in which the 
therapeutic agent is an antibody which specifically binds to a protein on the surface 
of the cancer cells. Examples include the anti-HER2/neu antibody trastuzumab 
(Herceptin) used in breast cancer [417, 620], and the anti-CD20 antibody rituximab, 
used in a variety of B-cell malignancies [113]. Targeted therapy can also involve 
small peptides as "homing devices" which can target and  bind to cell surface 
receptors or other molecules that play a role in cancer [9, 429]. Small molecule 
targeted therapy drugs can also belong to inhibitors of enzymatic domains on 
mutated, overexpressed, or otherwise critical proteins within the cancer cell. 
Prominent examples are the tyrosine kinase inhibitors imatinib and gefitinib. 
[4] 
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Figure 1.2: Therapeutic approaches to cancer. Several different methods are followed to 
cure cancer and sometimes more than one of the above methods is applied. 
 
 
1.1.2 Hormone dependent cancers 
 
Hormone dependent cancers include prostate, ovarian and breast cancer. Prostate 
cancer is the commonest non-skin cancer in men. Sex hormones such as androgens 
and estrogens play a vital role when it comes to the differentiation and the 
progression of prostate cancer as well as the other hormone-dependent cancers [132, 
215, 319]. Ovarian cancer is the first leading cause of death from gynaecological 
malignancies [73, 116]. In the last 30 years much has been achieved when it comes 
to endocrine treatment and therapy [226]. An important benefit of these therapies is 
their low toxicity compared to chemotherapy and radiation, providing less severe 
side effects and a better quality of life for cancer patients.  Some ERα-positive 
tumours fail to respond to endocrine therapy or become resistant in time. Moreover, a 
third of all breast cancer patients has ERα-negative tumours and therefore is less 
prone to endocrine therapy [389]. In that case a more aggressive form of 
combinational therapy is followed, combining radiation and chemotherapy with 
taxanes, anthracyclines, anti-tumour antibiotics, gonadotrophin-releasing hormone 
[5] 
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agonists, retinoids, rexinoids, vitamin D derivatives and more recently platins which 
are platinum-based drugs [92, 182, 378].  
 
 
1.1.2.1 Breast cancer 
 
Breast cancer is amongst the most frequent types of human cancer, especially in 
women (www.who.int/topics/cancer/en/). Various factors have been implicated in the 
development and progression of breast cancer [307]. Reproductive hormones, such 
as estrogens, play a vital role in the progression of breast cancer. In particular, breast 
cancer incidence is decreased by late menarche, early first childbirth or early 
menopause whereas the risk of developing breast cancer is increased by pregnancy, 
shorter period of breastfeeding, lower parity and administration of estrogens, such as 
the contraceptive pill [472]. Other known risk factors for the development of breast 
cancer are age, ethnicity, estrogen exposure, abnormal proliferation of the tissue 
within the breast (atypical hyperplasia or lobular carcinoma in situ), radiation 
exposure, family history/ genetic predisposition, and lifestyle factors, such as obesity, 
alcohol consumption, and lack of exercise [421]. Despite the high incidence of breast 
cancer, the survival rate is relatively higher than in other forms of cancer, if 
diagnosed early [369]. In Scotland, the relative survival rate in female breast cancer 
at eight years after diagnosis, for patients diagnosed in the period 1987-93 was 
increased due to various therapies used such as with radiotherapy, chemotherapy and 
surgical removal [578]. 
After diagnosis of breast cancer, treatment depends upon the disease stage and 
pathologic features such as steroid and growth factor receptors status and tumor 
grade [174, 585]. Disease stage is determined by tumor size, the number and location 
of lymph nodes involved, histological grade and the presence or absence of distant 
metastatic disease and the tumour is evaluated from stage 0-IV scaling up severeness. 
For the purpose of diagnosis, prognosis and response to therapy, breast cancer is 
divided into two main types based on the hormone receptor status (Estrogen receptor, 
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ERα, positive or negative) and origin of the epithelial cells (basal or luminal). Basal 
or luminal types are immunohistologically distinguished by the type of cytokeratins 
expressed in each one [549, 594]. Luminal-like tumours are the most commons ones 
and have gene expression patterns that resemble the ones in the luminal epithelial 
cells that line the duct and are characterized by cytokeratins 8 and 18 [238, 549, 
594]. Basal-like tumours resemble the gene expression pattern found in basal 
epithelial cells in the normal mammary gland and are characterised by expression of 
cytokeratins 5/6 and 17 [466, 549, 550, 594] and are ERα-ve. Interestingly, the last 
expression patterns mentioned are common in BRCA1 hereditary mutation carriers 
[203]. According to their gene expression profile there are five types of breast cancer 
tumours universally used within the scientific community to classify breast cancer 
and predict, to some extent, their clinical outcome and determine treatment [466, 
549, 550]. These types are divided into two ERα+ subtypes that are classified as 
luminal A (ERα+ve/PR+ve/HER2-ve) and luminal B 
(ERα+ve/PR+ve/HER2+ve/HER1+ve) [549, 550] and three ERα -ve (basal) subtypes 
which are further subclassed as HER2 overexpressing, “normal-like” (unclassified) 
and triple negative (EGFR+ve, ERα-ve, PR-ve and HER2-ve) [118, 430] and should 
be treated as different diseases [466, 481, 482]. It is indicative that 2/3 of women 
aged <50 years will have ERα+ breast cancer  and more than 80% of women aged 
>50 years are ERα+ [21]. The most favourable type of breast cancer in terms of 
treatment and clinical outcome is the luminal A type, followed by the luminal B one 
whereas the worst types are the basal ones [594]. Histological grading in breast 
cancers is based on the evaluation of 3 features: (i) the percentage of tubule 
formation, (ii) the degree of nuclear polymorphism and (iii) the mitotic count in a 
defined field area [56, 280]. The grading criteria were unified by Elston and Ellis, 
who designed a modification of the Bloom and Richardson grading system, namely 
the Nottingham combined histologic grade [173]. This system was based on the 
semiquantitative evaluation of the three morphologic features mentioned above and 
was established as a universal one [173]. Another potential marker for breast cancer 
is the progesterone receptor, PR. PR is an ERα-related gene and there is evidence 
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that PR+ tumours respond better to Tamoxifen treatment but these findings are not 
universal [38]. PR is synthesized by tumour cells that are stimulated by estrogens 
through interaction with ERα. Because the presence of PR reflects a functional ERα 
pathway, smaller benefit from tamoxifen for ERα+/PR- tumors compared with 
ERα+/PR+ tumors would be expected [24]. However, the increased need for novel 
biomarkers, indicative of the follow-up treatment of different types of breast and not 
only cancers, has lead to new approaches in research. Biomarkers therefore, are 
useful tools for cancer detection. They can predict who is likely to develop cancer 
(BRCA1 mutation status) and/or detect the disease at an early stage (mammographic 
image). They can indicate a particular stage in the disease guide treatment decisions 
(circulating tumor cells, pathological response, HER2+,  ERα+, PR+), and, 
importantly, aid in the identification of novel targets for therapy [598]. 
Existing therapies predominantly target proliferation either with ionizing radiation, 
cytotoxic agents, or inhibition of estrogen receptor and HER2 growth factor 
signaling pathways. Combining these treatments together with radiortherapy, surgery 
and chemotherapy has contributed to the improved survival rate in breast cancer. 
Clinical application of targeted therapy is based on the identification of credentialed 
markers that are biologically relevant to the disease [151]. Cancer cells exhibit 
significant genetic and molecular differences [598]. The target should have specific 
characteristics including clinical relevance, reproducibility between patients, to be 
easily measurable and minimum toxicity.  Potential targets for maximum efficiency 
include characteristics of malignancy such as uncontrolled proliferation, insensitivity 
to drugs, lack of apoptosis and senescence, genomic instability, metastatic potentials 
and angiogenesis. 
Tamoxifen and aromatase inhibitors are the most commonly-used drugs against 
breast cancer. Tamoxifen citrate treatment has long been considered the gold 
standard due to its efficacy and safety and was first approved in 1977 by the US 
Food and Drug Administration. It binds to ERα and inhibits the growth of tumour 
cells. It has been widely used for three decades as the standard treatment for node-
positive and node-negative breast cancers [163]. It is an orally active selective ERα- 
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modulator and it is used in pre- and post-menopausal women. When bound to the 
ERα  it forms a nuclear complex that decreases DNA synthesis and halts the cells in 
G1 or G0 phase of the cell cycle, acting as a cytostatic rather than cytotoxic drug. 
Tamoxifen itself is a pro-drug and has to be metabolized by cytochrome P450 to its 
active form 4-hydroxytamoxifen and des-N-methyl-4-hydroxytamoxifen [141, 297, 
298] that antagonize estrogens’ binding to their receptor [609]. This active 
metabolite possesses a 30- to a 100- fold higher efficiency in inhibiting estrogen-
dependent cell proliferation [69, 122, 297, 493]. Aromatase inhibitors, in turn, are 
anti-estrogen agents that target the aromatase enzyme in the final step of most of 
estrogen production and block oestrogen synthesis. They have been developed as 
first- (aminoglutethimide), second- (formestane) and third-generation inhibitors 
minimizing their side-effects [82]. The third generation aromatase inhibitors include 
letrozole (non-steroidal), exemestane (steroidal) and anastrozole (non-steroidal), 
which are equally or more efficient to tamoxifen inhibiting aromatization with a 98% 
efficiency and also exhibit a better toxicity profile. ERα-negative cancers are more 
difficult to treat and require combinational therapy including radiation, 
chemotherapy and surgery [541]. Last but not least Herceptin, as mentioned before, 
is a humanized monoclonal antibody against the extracellular domain of HER2-
receptor and promotes G1arrest and stops proliferation. It has been suggested that the 
drug induces some of its effect by downregulation of HER2 leading to disruption of 
the receptor dimerization and PI3K signalling [30]. Further improvements in therapy 
must attack other hallmarks of malignancy and will undoubtedly be accompanied by 
better means of individual patient selection for such therapies while selectively 
promote elimination of cancer cells [151]. Despite all the different approaches used 
to achieve therapy, they all come to one goal: induce cell cycle arrest or apoptosis 
(programmed cell death) of cancer cells [167]. Cell death consists of apoptosis (Type 
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Figure 1.3: Overview of cell death pathways. Cell death consists of three main pathways 





Apoptosis plays an important role in cell maintenance, development and tissue 
homeostasis. Cells undergo apoptosis through two major pathways, the intrinsic 
pathway that involves the mitochondria and the extrinsic pathway that involves cell 
death receptors (overview of cell death in Figure 1.3). In either case the leftovers of 
the dead cell are packaged into apoptotic bodies which are recognised by 
neighbouring cells or macrophages and cleared out by phagocytosis. 
Apoptosis was first observed by Walther Flemming in 1885 who called it 
chromatolysis because the nucleus was gradually disappearing. Apoptosis as we 
know it, was later studied and described in detail by Kerr and co-workers in 1972 
[309] and involves a series of morphological and biochemical features that are 
distinctive of this type of cell death. Hallmarks of apoptosis consist of membrane 
blebbing, cell shrinkage, cell surface exposure of phosphatidylserine, loss of 
mitochondrial membrane potential, nuclear fragmentation (karyorhexis from the 
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greek ‘karyon’:nucleus and ‘rhexis’: disruption) chromatin condensation and large-
scale DNA fragmentation finally leading to phagocytosis of the ‘dead’ cell by 
macrophages or neighbouring cells and so protecting tissues from inflammatory 
injury due to toxic contents of the dying cells [627]. Apoptosis is totally different 
from necrosis, since the last one is the consequence of extreme damage of the cell 
microenvironment leading to loss of membrane integrity, blebbing and therefore 
strong inflammatory response of the damaged tissue [349]. Apoptosis consists of two 
pathways, the extrinsic and the intrinsic (Figure 1.3) which both end up at the 
formation of the apoptosome which is the last step of programmed cell death. 
 
 
1.2.1.1 Extrinsic apoptotic pathway 
 
The extrinsic pathway is initiated when death-inducing ligands bind to cell surface 
receptors, called death-receptors, and stimulate a cascade of events leading to the 
apoptotic characteristics mentioned above. Death receptors belong to the tumour 
necrosis factor gene superfamily and contain similar and variable in numbers 
cysteine-rich domains that are exposed to the cell surface to be recognised by their 
ligands [236], as well as a cytoplasmic death domain that ensures signal cytotoxicity 
and enables the receptors to directly initiate the apoptotic response [285, 571]. The 
best characterized death receptors include TNFR, DR3 (Death Receptor 3, also called 
Apo3), DR4, DR5 and Fas (also called Apo1, CD95). The ligands that activate these 
receptors belong to the TNF gene superfamily [236, 546] and include TRAIL (binds 
to DR4 and DR5) [372, 454, 455, 520], TNF (binds to TNFR), CD95 ligand (binds to 
Fas) and Apo3L, ligand, (binds to DR3) [114]. Once bound to its ligand the receptor 
oligomerises and triggers the recruitment of FADD, FAS-associated death domain, 
and caspase 8, forming a death-inducing signalling complex (DISC). The initiator 
caspase 8 then activates the effector caspases 3, 6 and 7 [27].  
Caspases were first discovered after genetic analyses of the nematode C.elegans 
from the ced-3 gene that encodes a homologue of the interleukin-1β processing 
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enzyme [645]. Ced-3 gene is abundant during embryogenesis where most of 
programmed cell death happens and was proposed to act as a cysteine protease that 
controls cell death by proteolytic activation or inactivation of substrates [645]. In the 
same study it was also revealed that specific mutations in the conserved region 
irreversibly inhibited the 131 programmed cell death processes that would otherwise 
occur during the hermaphrodite development. When Ced-3 was overexpressed in 
Rat-1 mammalian cells, it was able to induce apoptosis [404]. A number of similar 
type apoptosis-inducing proteins were termed as ‘caspases’ (cysteine aspartate-
specific proteases) [17]. The ‘c’ reflects a cysteine protease mechanism and the 
‘aspase’ refers to their ability to cleave after aspartic acid which is the most 
characteristic feature of this family. Individual family members were distinguished 
by an arabic numeral following after the ‘caspase’ term, which indicated the date of 
its publication. Fourteen mammalian caspases have been identified and cloned so far 
and they all contain a prodomain followed by p20 large and p10 small subunits. They 
are first synthesized as inactive precursors, then proteolytically cleaved at internal 
caspase recognition sites to active enzymes during apoptosis and in turn cleave 
substrates at Asp-Xxxx motives [580]. Based on their function caspases are classified 
into three categories. The first one consists of inflammatory caspases -1, -4, -5, -11, -
12, -13 and -14 which are involved in inflammation after bacterial infection or 
change, entry of intracellular pathogens in the ionic cellular environment and bear an 
activation and recruitment domain [385]. The second category includes the initiator 
caspases which possess large prodomains with either death-effector domain, in the 
case of caspases-8 and -10, or a caspase activation and recruitment domain, caspases- 
2 and -9, respectively. Initiator caspases are involved in the interaction with upstream 
adaptor molecules to initiate apoptotic response [580]. The third category contain the  
effector caspases -3, -6 and -7 which are characterized by short prodomain and 
cleave variable cellular substrates after upstream caspases’ activation [93, 192, 237, 
269, 426, 567, 610]. Initiator caspases are autoproteolyticaly activated when brought 
to close distance, a model called ‘the close proximity model’ [425, 543, 554]. The 
model suggested that pro-caspases, although inactive, shown low activity which is 
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sufficient to induce cleavage of another molecule of the same pro-caspase and thus 
activate it when brought to close distance, in an autoprocessing manner [509]. The 
cleavage takes place in a short domain between the large and the small subunits of 
the catalytic domain in Asp 297 which is the highly conserved amino acid that directs 
cleavage specificity in this domain [655]. The above model was later refined by ‘the 
proximity induced dimerization model’ which suggests that dimerization induces 
auto-activation [64, 146]. In this model, initiator caspases are activated when inactive 
monomers dimerize within macromolecular structures such as DISC and apoptosome 
[64, 146]. Effector caspases are proteolytically cleaved and activated at Asp-X sites 




1.2.1.2 Intrinsic apoptotic pathway 
 
The intrinsic pathway is initiated by various intrinsic apoptotic stimuli such as UV 
damage, drugs, X-rays, oxidative stress or starvation. The key event is what is called 
mitochondrial outer membrane permeabilization (MOMP) which is controlled by the 
pro-apoptotic Bcl-2 family members such as Bad, Bid, Bak and Bax. The function of 
these proteins involves the formation of pores in the outer mitochondrial membrane 
from where cytochrome c is being released to the cytoplasm [41]. Basanez and co-
workers, 1999, supported the instabilization of the phospholipid bilayers of the outer 
mitochondrial membrane and the disruption of the permeability barrier as a potential 
mechanism that leads to the formation of these pores, the so called apoptotic pores 
[41]. When this large pores are formed, Bax enters the inner mitochondrial 
membrane and destabilizes it, leading to (i) loss of the mitochondrial electrochemical 
potential, (ii) activation of the permeability transition pore and (iii) mitochondrial 
swelling [325, 388, 459, 542, 596]. Once MOMP is initiated a whole cascade of 
either releasing of molecules or mitochondrial loss of function begins. Cytochrome c 
is being released rapidly from their inner membrane compartment into the cytosol 
[13] 
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where it binds to Apaf-1 and activates procaspase-9 through oligomerization, 
creating, an intracellular DISC-like complex known as the apoptosome [366]. The 
apoptosome then activates the executioner caspases -3, -6 and 7 [356, 659]. In vivo 
studies in Apaf-1, caspase-9 or caspases 3 deficient MEFs showed that the 
aforementioned molecules are essential to apoptosis and in their absence no apoptotic 
response is achieved [96, 242, 330, 356, 642], and is sometimes accompanied by 
lethality or defective development [242, 330]. After caspase -3 activation, the two 
pathways converge and a whole cascade of protein activation and deactivation 
begins. 
Besides mitochondria, ER is another major player in the intrinsic apoptotic pathway. 
Oxidative stress, Ca++ ionophores, toxic reagents or inhibitors of ER glycosylation 
such as tunicamycin, blocking of ER-Golgi transport [365], depletion of intracellular 
Ca++ levels [152, 357] can induce the Unfolded Protein Response, UPR, and affect 
the quality control mechanism which ensures that only the correct folded proteins are 
processed along the secretory pathway and that prefolded and misfolded proteins are 
degraded so that they cannot cause any harm to the cell [395, 523, 587]. The UPR 
pathway controls transcription of genes encoding ER-resident protein chaperones 
that regulate folding, assembly and modification of cellular proteins [323]. During 
UPR the upregulation of these chaperones increases the folding capacity of this 
organelle. If UPR persists, then ER-associated protein degradation occurs and leads 
to apoptosis.  What is more, Ca++ , which is stored to the ER, is released to the 
cytosol during apoptosis and uptaken by the mitochondria and triggers cytochrome c 
release which in turns induces more Ca++ release and a positive feedback loop is 
created, thus triggering dramatic caspases activation [490, 519]. Interestingly, pro-
apoptotic Bcl-2 family members participate in ER targeting by interrupting ER and 
mitochondria crosstalk [437, 519, 658]. Bax/Bak mediate ER stress-induced 
apoptosis by ensuring Ca++ homeostasis in the ER [437, 519, 658]. ER-stress causes 
conformational changes and oligomerization of the aforementioned proteins on the 
ER membrane and jeopardise membrane integrity. On the other hand, overexpression 
of either Bax or Bak causes accumulation of the protein in the ER or mitochondria 
[14] 
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and induces caspase-independent Ca++ release and accumulation to the mitochondria, 
a process depending on the Bcl-2 family members [437]. In ER-mediated apoptosis, 
ER-targetted Bak induces caspase-12 cleavage [658] and then caspase-12 is being 
released from the ER to the cytosol, where in cleaves procaspase-9 and triggers 
caspases-3 activation leading to the formation of the apoptosome. 
 
 
1.2.1.3 Apoptosome as the last step before total extinction 
 
The last step of apoptosis includes packaging of the dead cell content into cavities, 
called apoptosomes. Apoptosomes then release signals to phagocytes uptaken by 
rertain receptors, for the phagocytosis to begin so that the extracellular environment 
is clear of the unwanted leftovers and no inflammation is induced around the dying 
cells. Phagocytes can be ‘professional’ such as the macrophages or ‘amateurs’ such 
as fibroblasts, neutrophils, melanoma cells, other types of epithelial cells, Sertoli 
cells, Jurkat T cells, tumour cells or vascular smooth muscle cells [49, 183, 184, 260, 
422]. Phagocytes receptors include CD14, lectins or integrins [399]. 
Amongst these signals is phosphatidylserine, which normally faces the cytoplasmic 
side of the cell membrane, but in a cell undergoing apoptosis is exposed to the 
external surface of the cell membrane [183, 184, 422]. In non-apoptotic cells, 
phospholipids are distributed in an asymmetric way in the cell membrane with 
cholide-containing lipids in the outer membrane and amino-phospholipids in the 
inner leaflet. The first category of cholide-containing lipids includes 
phosphatydilcholine and sphingomyelin and the second category of amino-
phospholipids includes phosphatidylethanolamine and phospatidylserine, PS, [183, 
184].  Loss of phospholipid asymmetry and exposure of PS to the outer leaflet of the 
cell membrane is a universal apoptotic phenomenon and was first identified in 
apoptotic lymphocytes by Fadok and co-workers in 1992 [183, 184]. PS is then 
recognised in a stereospecific manner by phagocytes [183, 184]. It has been known 
that macrophages can recognise cells which have lost membrane asymmetry [195] 
[15] 
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but it has been also supported that they specifically recognise negatively charged 
liposomes and especially PS [16, 195]. Other ‘eat me’ signals include changes in 
membrane sugars that are being recognised my macrophage-lectins [547]. Lectins 
and their receptors are produced in large quantities during the early infection stage 
and are involved in pathogen recognition by identifying bacterial surfaces as well as 





Autophagy (from the greek word auto:self and phagy:feed which literary means to 
‘eat oneself’) is a conserved catabolic process that degrades long-lived proteins, 
organelles and bulk cytoplasm, recycling it back as metabolic precursors. Autophagy 
has been associated with both cell survival and cell death. Short-lived proteins are 
degraded by the ubiquitin-proteosome pathway but analysing this process remains 
beyond the aims of this project. Cells can undergo autophagy in response to 
extracellular stress, such as nutrient starvation, high temperature, hypoxia, high 
population density [134, 223], intracellular stress, such as accumulation of damaged 
or extra organelles that are no longer required, and even under normal physiological 
conditions where massive cell elimination is required such as neuronal degeneration, 
insect metamorphosis [435, 503], organogenesis and tissue remodelling, in 
Drosophila salivary gland, [137, 348]. Autophagy is considered a survival 
mechanism of the cells in times of stress and especially famine because at that point 
the cellular constituents are degraded to ensure sufficient energy production. Two 
types of autophagy have been identified in eukaryotic cell, macro-autophagy and 
micro-autophagy [562]. These two modes differ to the pathway by which 
cytoplasmic material is delivered to the lysosomes but share the same characteristics 
when it comes to packing and degradation of the unwanted contents. Micro-
autophagy is characterised by direct engulfment of the cytoplasm to the lysosomes 
whereas macro-autophagy utilizes the formation of double-membrane vacuoles that 
lead portions of the cytoplasm to the lysosomes (Figure 1.4). We will focus on 
[16] 
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macro-autophagy, which will be from now on be referred as autophagy, because it is 




Figure 1.4: Formation of autophagosome. Induction results in the formation of a double-
membraned autophagic vacuole that encloses cytoplasmic components that need to be 
degraded. The autophagic vacuole then docks against the lysosome, to form an 
autophagolysosome and the fusion of the outer autophagic vacuole membrane with the 
lysosome releases the inner membrane-bound cytoplasmic components into the lysosome 
where degradation occurs (designed by Servier Tools Medical Art Software).  
 
 
A morphological characteristic of autophagy is the rearrangement of subcellular 
membranes and the formation of autophagosomes (Figure 1.4), cytoplasmic double 
membrane vacuoles that contain bulk cytoplasm and/or cytoplasmic organelles such 
as mitochondria and ER [53]. The origin of the double-membrane was believed to 
come from rough ER, as several protein markers used as immunological probes for 
all the types of cell membranes (Golgi, endosomes and plasma) failed to label these 
vacuoles whereas antisera against several integral ER membrane proteins did [159]. 
Nevertheless, recent studies revealed that autophagic vacuoles are formed de novo 
through nucleation, assembly and elongation of small membrane structures [566] 
which are called pre-autophagosomal structures and contain many apg proteins (apg 
genes is a subset of what was later called ‘ atg’ genes in nomenclature [316] and 
included apg (autophagy)-aut (autophagy)-cvt (cytoplasm-to-vacuole targetting) 
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genes. No ER, Golgi or late-endosomal markers were detected [312]. After engulfing  
bulk cytoplasm/ organelles, the autophagosomes fuse to lysosomes to form an 
autolysosome and their contents are degraded and recycled (Figure 1.4) [31, 300]. 
Key pH-sensitive lysosomal enzymes called hydrolases are used to digest the 
unwanted cargo [608]. Lysosomal permeases then release the digested material back 
to the cytosol for macromolecular synthesis and/or bioenergetics. 
Autophagic cell death is considered as the type II cell death. It is distinctive from 
apoptosis in terms of morphological changes as well as biochemical ones. Genes and 
proteins that regulate autophagy were first studied in yeast but some of their 
mammalian orthologues have also been characterised. An autophagosome-associated 
protein microtubule-associated protein II light chain (LC3) has been used as a 
popular marker for this type of cell death. The shift in localization of LC3 from the 
cytoplasm to the membrane of the autophagosomes is indicative of autophagy [300]. 
Two forms of LC3 are produced post-translationally in cells by proteolytic cleavage 
at the C-terminus, cytosolic type I and membrane-bound type II, [300]. The two 
forms have different molecular weights. Another popular marker for autophagy is 
Beclin-1, which is the mammalian orthologue of the yeast apg6 (autophagy 
related gene) protein that is involved in the early steps of autophagic vacuoles 
formation. Several atg-deficient yeast strains have indicated that these genes are 
essential for sporulation, survival during starvation and differentiation after 
starvation in yeast [518, 590]. Similar mutation studies in the sole amoeba 
Dictyostelium discoideum also showed that orthologues of the yeast atg genes were 
essential for viability and formation of a multicellular organism (a well-characterised 
mechanism of this amoeba to overcome famine, where a lot of amoebas are clustered 
together and form multicellular structures) during nutrient starvation [450]. However, 
a very surprising result in Beclin-1 haploinsufficient mice was that the animals, as 
they age, displayed a pronounced increase in the incidence of lymphoma and 
carcinoma of the lung and liver [480]. In addition, mammary tissues in these animals 
displayed hyperproliferative, pre-neoplastic changes in response to Beclin-1 deletion.  
Beclin-1 deficiency in mice results in embryonic lethality due to inability of 
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undergoing remodelling and differentiation of ventral ectoderm and extensive cell 
death indicating a potential pro-survival role of autophagy [646]. In the same study, 
it was shown that although the protein is not essential for apoptosis, as Beclin-1 -/- ES 
cells showed normal apoptotic response after UV and serum withdrawal compared to 
the control wt ones, it is important to regulate autophagy because in the same cells 
autophagic response to nutrient deprivation was totally abnormal. If autophagy was a 
cell suicide mechanism then the Beclin-deficient cells would have been resistant to 
cell death. Apart from suggesting a cell survival role of autophagy the above 
experiment also explains the behaviour of tumour cells that utilize autophagy in a 
regular basis [646]. Indeed, when cancer cells face nutrient depletion, for example 
after blood supply is disrupted, they use autophagy as an energy mechanism until 
new blood vessels are formed and nutrient supply is restored. Evidence also exist that 
Beclin-1 regulates the degradation of proteins [166]. Overexpression of a Beclin-1 
binding protein located primarily in the Golgi apparatus, CAL 
(CFTR associated ligand, also known as PIST), reduces the rate of appearance and 
halflife of CFTR (cystic fibrosis transmembrane conductance regulator) chloride 
channel in the plasma membrane [110]. Thus, a Beclin 1-containing protein complex 
may regulate the trafficking and turnover of other plasma membrane proteins that are 
involved in signal transduction and/or nutrient acquisition. Interestingly, Beclin-1 is 
mapped on the 17q21 locus, 150kb centromeric of BRCA1 gene, which is 
monoallelically deleted in a lot of cancers including ovarian (75%) [12, 164, 500], 
breast (50%) [209, 505] and prostate cancer (40%) [211], suggesting tumour-
suppressing potentials. This tumour-suppressing role was refined by FISH analysis of 
22 breast cancer cell lines that revealed a percentage of 41% Beclin-1 allelic deletion 
[12] along with protein expression data from a different team that showed total 
protein loss or attenuation in breast cancers [359]. Transfection of Beclin-1 into a 
transformed breast carcinoma cell line decreased its tumourigenic potential in nude 
mice, further supporting the aforementioned data. 
 In plants, autophagy gene mutations, in the atg genes, do not have implications on 
the plant life cycle but do induce shorter life cycle that results in earlier senescence, 
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under normal conditions. Under carbon or nitrogen depletion these mutant plants 
show enhanced chlorosis (state where the plants becomes yellow due to chlorophyll 
degradation) [143, 243]. 
Is autophagy a survival or a cell death mechanism then? Much debate has been going 
on in the field. In favour of the survival role, researchers support that since 
autophagy provides the cell with amino-acids and other essential molecules it can be 
adapted as a supporting energy-producing mechanism in times of nutrient 
deprivation [62]. Liver, for example, is totally dependent on autophagy after amino 
acid deprivation and total energy production for the whole organism depends on that 
exact mechanism. What is more, damaged or excess organelles, like mitochondria, 
ER, peroxisomes, are removed by the autophagy pathway, maintaining the cellular 
homeostasis. By removing damaged mitochondria, autophagy protects the cell from 
the release of pro-apoptotic molecules that would trigger apoptotic response, as well 
as limiting the exposure of cellular DNA to genotoxic stresses such as free radicals 
[350]. It was also shown that ionizing radiation or certain drugs can induce the 
formation of acidic vesicular organelles in breast cancer cells that lack caspase-3, 
such as MCF-7 [26]. The same autophagy induction is observed in prostate and colon 
cancer after irradiation [452]. In this radiation-induced autophagy, the autophagy 
inhibitor bafilomycin A1, an H+-ATPase inhibitor, induced apoptosis in cancer cells, 
suggesting a protective role for autophagy in terms of apoptosis escape [452]. 
Research in the last decade has revolutionized our knowledge on the molecular 
mechanisms involved in autophagy. Novel functions for autophagy genes have been 
unraveld, implicated in yeast sporulation, multicellular development of 
Dictyostelium [320], insect metamorphosis, organogenesis, neuro-differentiation and 
early plant senescence. All these processes share a common need for a competent 
catabolic pathway that degrades and recycles unwanted intracellular material through 
different developmental stages across several different species.  To date there is no 
ultimate proof that autophagy is required to maintain cell survival. Autophagy is a 
self-limited process and cells dependent on this mechanism are capable of 
[20] 
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maintaining bioenergetics until a point when their internal resources will be 





Apoptosis is different from necrosis or oncosis (derived from the Greek word ‘oncos’ 
which means swelling, type III cell death) in which the cells suffer from a major 
insult  such as osmosis, extreme physico-chemical stress, detergent stress, freezing-
thawing cycles, mechanical stress and die abruptly after losing membrane integrity 
and swelling. The term oncosis was first proposed by Von Recklinbauer in 1910 to 
mean cell death by swelling [377]. The cellular contents are released into the 
surrounding environment and alert the innate immune system due to the presence of 
proinflammatory molecules in the necrotic spot. Necrosis is characterised by rapid 
cytoplasmic vacualization and swelling, irreversible changes in the nucleus including 
karyolysis and pyknosis dut not DNA fragmentation and organised chromatic 
condensation. Necrosis was believed to be uncontrolled but recent studies came to 
reveal that it is tightly regulated as it can include signs of controlled processes such 
as mitochondrial dysfunction, ATP-depletion [102, 349, 583], proteolysis and early 
membrane rupture [102]. In addition, it was also shown that inhibition of proteins 
with a role in apoptosis (caspases) [599] or autophagy (atg encoded proteins) [320] 
can favour necrotic death [86, 102]. Therefore, programmed necrosis can be tightly 
upregulated by several pathways which are characteristic of the other types of cell 
death, and it can be set as a default death pathway after inhibition of apoptosis or 
autophagy. Under normal physiological conditions this type of cell death  occurs 
during tissue development (e.g. the death of chrondrocytes controlling the 
longitudinal growth of bones) [491] and in adult tissue homeostasis (e.g. in intestinal 
epithelial cells) [39]. Whereas apoptotic cells, that undergo budding, are engulfed 
completely by phagocytes with the formation of tight fitting phagosomes [229, 230], 
necrotic cells (which swell) are internalized by a macro-pinocytotic mechanism, 
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meaning that only parts of the cell are taken up by phagocytes through multiple 
broad membrane ruffles directed towards the necrotic material [326, 584]. In 
negative terms, necrosis is characterized by the absence of caspase activation, 
cytochrome c release and DNA fragmentation [327] and it can be discriminated from 
apoptosis by microscopy, time-lapse or DIC, flow cytometry, transmission electron 
microscopy and accurate biochemical methods although a very detailed and multi-
disciplinary approach combining several biomarkers, such as PS, caspases, 
cytochrome c that are distinctive of apoptosis, along with morphological 
characteristics is required. 
Other types of cell death include mitotic catastrophy, anoikis, excitotoxicity, 
Wallerian degeneration and cornification of the skin but analysing all these different 
types remains beyond the objectives of this project. 
 
 
1.3 Tumour suppressor genes and oncogenes 
 
Cancer is a complex genetic disease, arising from accumulation of mutations that 
promote clonal selection of cells with increasingly aggressive behaviour [188]. The 
two groups of genes believed to be mainly involved in cancer development are 
oncogenes and tumour suppressor genes. Oncogenes are genes that when mutated 
they express more protein-product that usual or have amplified activity and therefore 
act in a dominant manner and initiate carcinogenesis [460]. In this class belong genes 
that positively regulate cell growth, proliferation such as growth hormone receptors, 
growth hormones themselves [370, 460], inhibitors of cell death, such as Bcl-2, 
[370], stimulators of cell proliferation, such as c-Myc, [370], and also cell cycle 
genes such as cyclins [81]. Tumour suppressor genes on the other hand, encode 
proteins that have inhibitory effects in tumour formation and progression [460]. 
Tumour suppressor genes restrict unusual cell proliferation and include many cell 
cycle genes, cell death-regulators etc [615]. These genes induce apoptosis and/or cell 
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cycle arrest in malignant cells [445]. Mutations in these key-regulator genes can lead 
to cancer.  
 
 
1.3.1 p53- a tumour suppressor gene 
 
One of the most highly involved genes in the progression of most cancers, as well as 
breast cancer, is the p53 tumor-suppressor gene. p53 was first described in 1979 and 
thought to be an oncogene by virtue of its ability to cooperate with mutant Ras genes 
in transforming primary rodent fibroblasts [343, 447]. The gene is found to be 
mutated or absent in almost half of human cancers [34, 91, 258, 392, 432] due to its 
unique post-translational responsiveness that involves a broad range of signals. 
Genotoxic and non-genotoxic, stimuli such as hypoxia/anoxia and activation of cell 
cycle/growth signalling cascades, may drive p53 expression and lead to uncontrolled 
cell proliferation and therefore cancer through transcriptional activation of multiple 
genes that control cell cycle.  
 
 
1.3.1.1 p53 structure 
 
The homotetrameric tumor suppressor p53 consists of folded core and 
tetramerization domains, each of 393 residues [581] (Figure 1.5). Each chain has 
three functionally distinct domains: the N-terminal domain where the transcription 
activation domain lays along with a proline rich domain. This N-terminal domain 
contains major, residues 1-42, and minor, residues 45-56, transactivation domains 
(Figure 1.5). The transcriptional activation of p53 is modulated through binding of 
target molecules to this N-terminus on the transcription activation domain [136]. 
This domain is followed by a highly conserved sequence-specific DNA binding 
domain, residues 98-296, also termed as the core domain, that aids p53 to act as a 
transcription factor, and a complex C-terminal region containing tetramerization 
motifs, residues 319-363, linked to the core domain by an intrinsically disordered 
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sequence, as well as a domain exerting negative regulation on DNA-binding activity, 
residues 364-393 [136]. The C-terminal part of the protein contains a sequence 
unspecific DNA-binding regulatory domain [10]. The C-terminal domain neither 
interacts with other regions of p53 nor has an effect on the conformation of the 
molecule but interestingly C-terminal p53 deletions prevent the interaction of the 
protein to the p21-cyclin dependent kinase inhibitor [464]. The inactive form of the 
protein, highly unstable, adopts a conformation in which the C-terminal domain 
mediates interactions of the DNA-binding domain with its target [276]. Hupp and 
colleagues demonstrated that phosphorylation, antibody interaction or deletion of the 




Figure 1.5: Graphical representation of p53 protein structure. The N-terminal activation 
domains, the core DNA-binding domain and the C-terminal tetramerization domain are all 
depicted in the diagram. 
 
 
1.3.1.2  p53 and its various roles 
 
The p53 protein plays a vital role in cell proliferation, genome stability, accurate 
chromosome segregation, cell cycle progression [602, 647] and protection from 
DNA damage by ionizing radiation, oxidative stress or hypoxia. The gene is also 
involved in the regulation of the cell cycle arrest and apoptosis. When p53 is active 
then the apoptotic pathway is enhanced, whereas when p53 is mutated or absent the 
apoptotic pathway is inhibited. It has been shown that p53-/- cells cannot undergo 
apoptosis and malignant transformation is being established [52, 392]. 
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Figure 1.6: p53 activation by various stimuli. Genotoxic stress includes UV exposure, 
ionizing radiation (IR) and other DNA-damaging agents. Non-genotoxic stress is 
summarized in hypoxic/anoxic and induced growth signalling conditions which are 
characteristic of cancer development (Designed by Servier Medical Art Tools software). 
 
 
p53 can act as a transcription factor by binding to TFIIH (nucleotide excision repair 
mechanism) complex. As far as the cell cycle is concerned, p53 affects G1 block 
[392] by transcriptional activation of the p21WAF1 gene [168] as well as regulating 
G2/M block after DNA damage [8, 559].  p53 binds to DNA as a tetrameric protein 
[121, 324] and is capable of directly inhibiting DNA replication by interacting with a 
single-stranded DNA-binding protein complex required for DNA unwinding during 
replication [392]. 
Maltzman and Czyzyk ,1984, were the first to discover that UV or even UV-mimetic 
chemical carcinogens activate p53 in mouse cells [380]. This discovery was much 
later supported, 1991, by Kastan and co-workers that demonstrated that p53 was 
essential for cell cycle arrest after genotoxic stress such as DNA damage or 
irradiation [303] (Figure 1.6). The first role found for p53 was the regulation of gene 
expression as a sequence specific transcription factor [308]. The so called ‘guardian 
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of the genome’ is sensing and reacting to DNA damage by the ATM/ATR and 
Chk1/Chk2 pathway. It is the main regulator of the DNA damage response pathway 
(DDR pathway) activated by DNA bases modifications, DNA double or single strand 
breaks after exposure to genotoxic agents or ionizing radiation or even replication 
stress during S phase in the case of ssDNA. The aforementioned DNA lesions such 
as oxidative lesions or bulky adducts, are being repaired by the nucleotide excision 
repair and base excision repair pathways through the ATR/ATRIP pathway (ATM 
and Rad3-related kinase /ATR interacting protein) which is activated after replication 
stress and DNA damage and especially after ssDNA formation [126, 185, 661]. ATM 
and DNA-PKcs respond mainly to DNA double-strand breaks, whereas ATR is 
activated by single stranded DNA and stalled DNA replication forks. In particular, 
ionizing radiation, radiomimetic agents and other dsDNA damage agents activate 
mainly the ATM pathway, whereas, UV and UV-mimetic agents, such as cisplatin, 
promote base damages and stimulate the ATR pathway [126, 185, 661]. When the 
above pathways are deficient then the lesion is converted into a DNA double strand 
break and the DDR pathway takes control by activating ATM [293]. Along to ATM, 
the DNA-dependent protein kinase is being activated and leads to p53 
phosphorylation on serine 15 and 37 [506]. On the other hand, ATM activation leads 
to direct or indirect p53 phosphorylation on serine 6, 9, 15 (direct), 20, 37(direct), 46 
and Thr 18 as well as phosphorylation of other checkpoint kinases [36, 253, 506] 
such as Chk2 which phosphorylate p53 on serine 20 [103, 255, 530]. Interestingly, 
all three of the phosphoinositide 3-kinase-related kinases (PIKK) ATM, ATR and 
DNA-PK, as well as Chk1 and Chk2 can also phosphorylate downstream targets with 
important roles in cell cycle checkpoints and DNA repair [185]. p53 phosphorylation 
reduces binding of mdm-2 ubiquitin transferase to the p53 molecule which then 
enables replacement of the ubiquitin molecules by acetylation, resulting in p53 
stabilization [413]. Mdm-2 binds to the N-terminal transcriptional activation domain 
of p53 and disrupts its interaction with the general transcription machinery, as well 
as promote its nuclear export and proteosomal degradation [106, 197, 413]. After 
activation, p53 acts as a suppressor or activator of various genes and can translocate 
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to the mitochondria to induce apoptosis or localize directly in the nucleus and 
promote DNA repair [45, 384, 511]. 
p53 is also activated by non-genotoxic stress such as hypoxia/anoxia and activation 
of growth signalling pathways (Figure 1.6). Hypoxia/anoxia refers to the low 
presence (less that 1.5%) or total absence of O2, respectively. Under hypoxic 
conditions p53 activates genes involved in G1 arrest, such as GADD45, through 
nuclear translocation of p53 [227]. The exact mechanism in which p53 is being 
induced is yet to be determined. Interestingly, the prevalent hypotheses implicate 
changes in the mitochondrial permeability and release of mitochondrial dependent 
ROS that create an oxidizing signal in the cytosol [99], induction of transcription 
factors such as the hypoxia-inducible factor Hif-1α that might bind p53 leading to its 
stabilization and modulation of proline hydroxylation [20, 90, 99]. It should be noted 
that it is difficult to exclude any DNA damage implications, as hypoxia has been 
shown to induce certain endonucleases in vitro from chronically anoxic fibroblasts 
but no increase in cellular DNA strand breaks was measured [501].  
In conclusion, genotoxic stress leads to rapid and high-levelled accumulation of p53 
which in turn activates a series of genes participating in apoptosis, while on the other 
hand, non-genotoxic stress induces a long-lasting moderate accumulation of p53 with 
activation of cell cycle inhibitory genes (Figure 1.7). The two processes mentioned 
before are not fundamentally different as the first one leads to total extinction of the 
dysfunctional cell through apoptosis whereas the second leads to permanent or not 
cell cycle arrest from the pool of the replicating population depending on the dose, 
duration and type of the stress applied to the particular cell each time. 
Genomic instability is a major cause of cancer [379] with mice with germline 
deficiencies in p53 are curtailed by cancer [145]. p53 heterozygotes mice develop 
neoplasms by the first 6-8 months of age including sarcomas, ovarian 
choriocarcinoma and lymphomas whereas p53-deficient mice develop various 
primary neoplasms in terms of cell type, malignancy and early onset, indicating the 
essential role of p53 in tumour suppression and progression [145]. Moreover, the 
absence of the p53 gene or the functional protein predisposes the organism to 
[27] 
 
Chapter 1                                                                                                     Introduction 
develop cancer at a young age with most well-known the Li-Fraumeni syndrome, 




Figure 1.7: Summary of different types of stress. Genotoxic stress (UV exposure, ionizing 
radiation and DNA-damaging agents) compared to non-genotoxic stress (hypoxic/anoxic and 
induced growth signalling conditions) and different types of p53 activation effects. 
 
 
1.3.1.3  p53, estrogens and hormone-dependent cancers 
 
The structure and the function of the human breast tissue are under the regulation of 
various hormones such as steroids, progesterone and estradiol. Most of the above 
hormones, along with other signalling molecules, are implicated in the 
transformation of a normal tissue into cancerous and are also related to tumour 
response to treatment. Mutations in the p53 gene are implicated in various cancers 
with breast and ovarian cancer amongst them. Notably breast cancers, maintain the 
wild-type p53 gene indicating that other epigenetic or genetic events can inactivate 
p53 pathway and promote cancer progression [657]. In breast cancer, p53 is 
inactivated between a 0-40% inactivation rate in non-invasive breast cancers and 20-
50% rate in invasive ones [135]. p53 mutations are associated with a decrease in 
disease-free period and shorter overall survival after systemic treatment of lymph 
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node-positive patients [54, 55, 540]. On the other hand, overexpression of p53 
protein in the nucleus is an indicator of poor prognosis [540] and therefore it can be 
postulated that p53 plays a role in the progression of breast cancer from a hormone-
dependent phenotype to a more aggressive hormone-unresponsive phenotype [23]. 
When it comes to estrogens and p53, it has been established that estrogen treatment 
in ERα-negative and -positive cancer resulted in elevated levels of phosphorylated 
Rb, an inhibitor of the E2F mitogenic transcription factors [277] and negative 
regulator of G1 re-entry [352]. Rb phosphorylation is controlled by cyclins cdk-4 and 
-6 complex who act in favour of G1 transition after mitogenic stimuli [352]. A 
noticeable difference between the ERα-positive and -negative cell lines was that in 
the first ones hyperphosphorylation of pRb occurred earlier than in the negative ones. 
In both cases medium containing E2 was essential for the hyperphosphorylation of 
the protein [277, 420] but this effect was selective only for E2 and not other steroids 
[420]. Further supporting these data, recent studies of MCF-7 xenografts in mice 
came to reveal [130] that tumours derived from MCF-7 overexpressing an inactive 
mutant of p53, after hormone stimulation, developed a characteristic metastatic 
phenotype with increased tumour growth, higher tumour histopathology grade, 
poorer differentiation whereas its molecular characteristic included centrosome 
amplification, loss of nuclear ERα expression, increased expression of Mdm-2 
oncoprotein which induces ERα degradation [160], Rb hyperphosphorylation, lack of 
p21 which is a cdk inhibitor, premature expression of cyclin E and A (promoters of 
G1-S transition and initiators of DNA replication [278]) and resistance to the 
antiestrogen tamoxifen [130]. All the above features resemble the triple negative 
tumours ERα-PR-HER- and suggest a model for the development of ERα- phenotype 
from ERα+ tumours.  
Further supporting the above model comes the fact that p53 upregulates ERα, which 
is an estradiol-activated transcription factor, suggesting that specific p53 mutations in 
breast tumours may contribute not only to oncogenesis and drug resistance, as in the 
case of doxorubicin [540],  but also to a more aggressive phenotype associated with 
the loss of ERα expression [23]. Loss of ERα expression involves a mechanism with 
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p53 abrogation, deregulation of cdk2 activity and centrosome amplification as 
mentioned above [130]. In a p53-null mouse model for mammary tumorigenesis, 
cancer cells arising from ERα-positive breast carcinomas develop loss of ERα 
expression [396], and as known tumours with no ERα display more aggressive 
phenotype [23], proposing that abrogation of p53 function may accelerate the 
development of phenotypic heterogeneity in breast cancer. 
It is worth mentioning that apart all the above functions, p53 is implicated in the 
transcriptional activation and inactivation of various genes of other hormone-
responsive tumours, such as WT-1, which act as an anti-oncogenic protein in Wilm’s 
tumours and is responsible for gonadal dysgenesis in ovarian and Sertoli cells of the 
testis [582]. The ability of gonadotropins to prevent granulose cells apoptosis has 
been related with the activity of Bax and bcl-2 which are regulated by p53 [582]. In 
vivo treatment with gonadotropin in ovarian cells resulted in reduction of the p53 
mRNA levels and bax protein, as verified by immunohistochemical experiments 
showing p53 restrained in the nucleus. Moreover, recent experiments showed that 
estrogen treatment also involve mdm-2 protein as well as TNF. As far as the TNF is 
concerned it was demonstrated that estrogen treatment resulted in resistance of MCF-
7 to the cytotoxic action of TNF. 
 
 
1.3.1.4.p53 and Tamoxifen 
 
Cytostatics, radiation and tamoxifen can induce apoptosis via p53 dependent or 
independent pathways [52]. Benefits of chemotherapy with the anti-estrogen 
tamoxifen have been widely demonstrated and related to most of the ERα-positive 
breast cancers [420]. However, the molecular basis for the drug’s activity and its 
association to the cell cycle has not yet been clearly established. Several molecular 
and cellular mechanisms have been proposed as contributors to the acquisition of this 
resistant phenotype including loss of ERα, selection of ERα mutants, shift in 
metabolism toward the accumulation of estrogenic metabolites, altered growth factor 
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production from breast cancer cells towards other targets, ligand-independent ERα-
mediated transcription, active recruitment of corepressor or coactivator proteins to 
produce a mixed transcriptional phenotype based on the antagonist’s DNA-binding 
properties, among others [568, 621]. Only two mechanisms will be analysed in this 
thesis involving, (i) HER2 association and (ii) a novel cdk/centrosome pathway. 
Tumours overexpressing HER2 are resistant to antiestrogen therapy and have lower 
clinical response [67, 248, 268]. HER2 overexpression in MCF-7 cells results in 
enhanced activity of mitogen-activated protein kinase MAPK [335]. MAPK has been 
shown to phosphorylate Ser118 in the ERα which is required for full activity of its 
activating function, leading to steroid-independent activation of ERα with loss of the 
inhibitory effect of tamoxifen on ERα-mediated transcription [78, 531]. Moreover, 
MAPK has been suggested to alter ERα association with corepressors [335] and 
therefore tamoxifen can no longer recruit those corepressors to the AF-2 region in the 
hormone-binding domain of the ERα to block ERα-mediated transcription [287, 568]. 
The second mechanism has been recently developed and suggests an alternative 
tamoxifen-resistant pathway focused on antitumor effects of the drug due to the 
expression of cyclin-dependent kinase inhibitors, especially p21(WAF1) which in 
turn are regulated by a decrease in wild-type p53 [279]. Different mechanisms may 
be responsible for antiestrogen resistance and that can explain studies in patients 
diagnosed with breast cancer and treated with adjuvant tamoxifen which supported 
that elevated p53 levels are associated with poorer survival [170]. Other studies 
demonstrated that there is no correlation between p53 levels and response to 
tamoxifen treatment [25], although it is clear that this era is not yet fully 
characterised. Since all these therapeutic approaches act through genomic damage 
and can therefore induce apoptosis and because p53 can respond to genomic 
instabilization and promote apoptosis [640], it can be hypothesized that an intact p53 
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1.3.1.5 UV damage, breast cancer and p53-dependent apoptosis 
 
In response to a wide variety of apoptotic stimuli, cells immediately activate a 
defensive response characterized by mitochondrial activation, manifested by rapid 
up-regulations of multiple mitochondrial respiratory chain (MRC) proteins and 
enhanced MRC activities such as oxygen consumption. In the meantime, Bcl-2 
proteins undergo dynamic alterations in an attempt to keep the cells alive [100]. 
Proteins in the Bcl family control cell death by altering the permeability of the outer 
mitochondria membrane in response to exogenous or endogenous stimuli, such as 
UV or due to oxidative phosphorylation (intrinsic apoptotic pathway thoroughly 
analysed in section 1.2.1.2). In short after UV damage, (i) cytosolic cytochrome c is 
being released, (ii) complex consisting of Apaf-1, dATP and pro-caspase-9 is being 
formed [240, 242, 366], (iii) activation of caspase-3 and caspase-7 follows, (iiii) 
caspase-3 then cleaves pro-caspase 9 to its active form creating a positive feedback 
loop [555]. Caspase-9, is required for p53-mediated apoptosis [504, 548].  
Interestingly, a variation of this mechanism exists in MCF-7 breast cancer cells. In 
these cells endogenous cytochrome c is being released in the cytosol but is unable to 
induce pro-caspase-9 cleavage [543, 553], whereas exogenous cytochrome or a cell-
free system from MCF-7 lysates is able to induce pro-caspase-9 activation in a dose-
dependent manner [60, 190]. These data support the hypothesis of a cytosolic 
cytochrome-c inhibitor present in MCF-7 cells. On an independent study, Blanc and 
co-workers revealed that absence of caspase 3 leads to delayed cytochrome c release 
and defects in pro-caspase 9 activation [60]. In the same study it was also found that 
caspase-3 reconstitution in MCF-7 cells (caspase-3 deficient) enables cytochrome c 
release to the cytosol and pro-caspase 9 cleavage. Interstingly, in pro-caspase-3 
reconstituted MCF-7 cells cytochrome c was capable of inducing caspase-3 activity 
but after incubation at 37°C, suggesting additional defects in cytochrome c-mediated 
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1.3.1.6  p53 and subcellular redistribution 
 
Normal p53 undergoes cell cycle-dependent translocation. In growth-stimulated 
synchronous populations of 3T3 cells newly synthesised p53 stays in the cytoplasm 
during G1 phase, translocates to the nucleus prior to G1-S transition where it remains 
till initiation of DNA synthesis and then recycled back into the cytoplasmic 
compartment [524]. DNA damage leads to the accumulation of p53 in the nucleus 
where it acts as a transcription factor and transactivates a myriad of target genes 
implicated in apoptosis, cell cycle arrest and DNA repair [168]. The tetramerization 
domain and the exposed nuclear localization signal are necessary for nuclear import 
and retention, and thus activation of the p53 protein whereas residues Arg 306 and Lys 
305 are implicated in cytoplasmic localization of the protein. Cytoplasmic localization 
of p53 has been observed in breast tumours as well as other neoplasms, embryonic 
stem cells [334] and undifferentiated neuroblastomas [410]. Cytoplasmic retention of 
p53 results in severe functional defects in the p53-mediated G1 checkpoint response 
[411] after DNA damage but studies in NB cells showed that when the cytoplasmic 
capacity is exceeded due to p53 overflow (excess DNA damage), p53 enters the 
nucleus where it is transcriptionally active [411]. The same study suggested a rather 
interesting mechanism to explain this cytoplasmic localization of p53 which included 
the presence of a molecular chaperone that binds to the protein and is present in 
limited amounts in the cytoplasm. This speculation was supported by the presence of 
distinct p53-associated punctate structures in the cytoplasm. Once all of the available 
binding sites of this anchor protein-chaperone are occupied, p53 is no longer trapped 
and is free to move. Hsp70 proteins utilize this mechanism of cytoplasmic retention 
when bound upon their targets (steroid receptors or kinases) but once the ligand 
binds to the receptor then the last one is released and enters the nucleus where it 
activates transcription [411].  
The relationship between hormonal stimuli and the pattern of p53 expression may be 
quite complex as suggested by the absence of cytoplasmic p53 in 50% of normal 
breast samples but this may be due to the presence of different hormonal levels in 
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each patient at the time of the surgery [334]. Experiments with the MCF-7 breast 
cancer cell line, which contains p53wt gene [499] have demonstrated that the protein 
is being mislocalized after estradiol treatment [351, 408]. In particular, cells grown in 
charcoal stripped serum had p53 in the nucleus and the cytosol, whereas after 
estrogen treatment most of the p53 protein was detected in the cytoplasm instead of 
the nucleus. In p53-mutated breast cancer cells, nuclear translocation does not occur 
[351]. The above results suggest that estrogen treatment may mediate p53 
inactivation and prevent p53-mediated growth arrest [525, 526]. In normal ovarian 
epithelial tissue, DNA damage along with hCG treatment has resulted in elevated 
levels of nuclear p53 [334]. Nuclear exclusion is therefore, a non-mutational 
mechanism for attenuating p53 suppressor function but other ways of inhibiting the 
protein are via its interaction by certain inhibitor proteins. Only a few p53 inhibitors, 
have been identified so far with the most well characterised being mdm-2. 
 
 
1.3.1.7 p53 and mdm2 
 
A variety of positive and negative feedback loops between p53 and a series of other 
genes have been described in literature. All these loops provide a means to connect 
p53 with a series of diverse signal transduction pathways and orchestrate cell growth 
and division as well as backing up the cell in case of a system’s malfunction. Each of 
these loops consists of a series of proteins whose activity or rate of synthesis is 
affected by p53 activation and this in turns results in the adaptation of p53 activity. 
Of these, seven are negative feedback loops that modulate down p53 activity (mdm-
2, Cop-1, Pirh-2, p73 delta N, cyclin G, Wip-1 and Siah-1) and three are positive 
feedback loops (PTEN-AKT, p14/19 ARF and Rb) that positively modulate p53 
activity [249]. Interestingly, six of these feedback loops act through mdm-2 (mdm-2, 
cyclin G, Siah-1, p14/19 ARF, AKT and Rb) to modulate p53 activity. 
The mdm-2 gene was originally cloned as a cellular oncogene amplified on a mouse 
double-minute chromosome from a transformed derivative of 3T3 cells cDNA 
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library [84]. In the same study, in situ hybridization mapped mdm-2 on chromosome 
10, regions C1-C3. The crystal structure of the 109-residue amino-terminal domain 
of mdm-2 that binds to a 15-residue transactivation domain peptide of p53 revealed 
that mdm-2 has a deep hydrophobic cleft on which the p53 peptide binds as an 
amphipathic  helix [336]. What is more, mdm-2 encodes a putative nuclear 
localization signal and is characterized by an acidic domain often found in 
transactivators [262]. The amino-terminal domain of p53 is rich in negatively-
charged acidic amino acids that are required for the transactivation function of the 
protein and therefore influence the p53-dependent transcription machinery [106]. A 
genetic analysis of p53 and mdm-2 mutations, of the targeted amino acids to alanine, 
that block this protein complex has identified critical amino-acid residues in each 
protein that are important for this binding interaction [205, 361]. The interaction was 
tested by Y2H and site-directed mutagenesis in vitro as well as the p53 
transcriptional control in vivo by transient transfection in mammalian cells [205]. 
These same amino-acid residues have been shown to make these protein contacts in 
the crystal structure of the amino-terminus of HDM-2 (the human protein) and a 
peptide from the amino-terminus of p53 [336]. Residues phenyalanine 19, tryptophan 
23 and leucine 26 of p53 form the major contacts in the mdm-2 hydrophobic pocket. 
Phosphorylation of residues serine 20 and possibly serine 15 should weaken these 
contacts, and peptides and drugs that compete with these contacts block the p53-
mdm-2 complex and promote apoptosis in cells [315].  
Mdm-2 forms a complex with p53 and down regulates its ability to activate 
transcription [37, 328, 413, 625] (Figure 1.8), therefore affecting p53 stability [328] 
as well as growth inhibition [196], G1 arrest and apoptosis [107]. The p53-mdm-2 
protein complex was originally detected in a cell line containing a temperature-
sensitive p53 protein, which behaved like the wild-type p53 protein at 32°C and a 
mutant p53 protein at 37°C -39°C [387, 413]. The p53-mdm-2 complex was readily 
detected at 32°C and only poorly observed at 37°C -39°C even though it was clear 
that mdm-2 bound well to mutant p53 protein [254], undoubtedly indicating that 
mdm-2 synthesis is being controlled by the presence of wild type p53 [625]. Mdm-2 
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is an E3 ubiquitin ligase which keeps p53 levels low in undamaged cells. It binds p53 
and targets it for ubiquitin-mediated proteosomal degradation, therefore inhibiting its 
tumour suppressor function [261, 328]. There is evidence to suggest that mdm-2 
shuttles p53 from the nucleus to the cytoplasm [497] where mdm-2 interacts with 
p300 resulting in the breakdown of p53 [235] and also accelerating p53 degradation 
by the proteosome. Mdm-2 also regulates p53 by blocking the ability of p53 to bind 
to the transcriptional machinery creating a negative auto-feedback loop whereby p53 
upregulates mdm-2 [625]. On the other hand, p14ARF stabilizes p53 by inhibiting 
mdm-2 thus helps maintaining a steady state level of p53 in undamaged cells (Figure 
1.8). Interestingly, mdm-2 knockout mice are lethal 6 days after fertilization at the 
blastocyst developmental stage. This may be triggered by hypoxia caused at this 
stage, activating p53 in the absence of mdm-2 and leading to apoptosis. Consistent 
with this analysis is the observation that a p53/mdm-2 double knockout mouse is 




Figure 1.8: p53/mdm-2/p14ARF loop. Arrows denote stimulatory interactions, whereas 
horizontal bars instead of arrowheads indicate inhibitory influences (described in 1.3.1.7). 
 
 
Recently, it has been revealed that this p53-mdm2 autoregulatory loop triggers an 
oscillatory effect with the two proteins’ levels increasing and decreasing over time 
under mathematical precision like a ‘digital clock’ [338] (Figure 1.9). The oscillatory 
reaction includes release of well-timed quanta of p53 in discrete pulses after stress 
[36] 
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[338]. Digital behaviour may require a damage checkpoint functioning when p53 
levels are low and releasing the next pulse only if the damage is still present. 
Interestingly, the higher the damage the more pulses of p53 are being triggered 
whereas the pulses’ size and shape remains unaffected. By releasing quanta of p53 
after a certain period of time, the cells are able to repair their DNA without risking 




Figure 1.9: Digital behaviour of p53-mdm-2 loop. Digital systems show an increased 
number of pulses with increasing signal, but the pulse size and shape do not depend on the 
signal strength (adapted from [338]). 
 
 
The mdm-2 gene has been amplified in many cancers. In more detail, the protein is 
overexpressed in 30-40% of sarcomas, in many leukemias and glioblastomas [76, 
443] which are characterised by escape from p53-regulated growth control. The wild 
type p53 gene should be intact, although the p53 protein is apparently inactive, so 
that drugs that disrupt the p53-hdm-2 complex should activate p53. In addition, many 
other cancers appear to express the hdm-2 gene product at high levels even when the 
hdm-2 gene is not amplified. In these types of cancers blocking hdm-2 activity or 
releasing p53 from this complex could well promote apoptosis selectively in the 
cancer cells. Therefore, the p53-mdm-2 complex and the mdm-2 ubiquitin ligase 
activity have become a major drug target for some cancers. Nutlins, or else cis-
imidazoline derivatives, are novel non-peptidic mdm-2 antagonists that disrupt the 
physical interaction between p53 and mdm-2 [19, 623].  
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1.3.1.8 p53 and other inhibitors 
 
Apart from mdm-2 other p53 inhibitors have been identified including iASPP which 
regulate the ability of p53 to bind promoter elements of proapoptotic target genes. 
The ASPP family consists of two pro-apoptotic family members,  (i) ASPP1 and 
ASPP2 [510], both of which bind to p53 and aid transcription of pro-apoptotic genes, 
(ii) and one anti-apoptotic family member, iASPP, which binds to p53 and represses 
its apoptotic transactivation potential [46, 51, 633], plus binding to the NF- B subunit 
p65 to inhibit its transcriptional activity [633]. It is worth mentioning that one 
mechanism by which wild-type p53 is tolerated in human breast carcinomas is 
through loss of ASPP activity [51]. iASPP expression is upregulated in human breast 
carcinomas expressing wild-type p53 and normal levels of ASPP.  Overexpression of 
iASPP confers resistance to the cytotoxic effects of ultraviolet radiation and to 
cisplatin-induced p53-mediated apoptosis while silencing of the protein leads to p53-
dependent apoptosis [51]. Another group of p53 inhibitors includes histone 
deacetylases HDACs. Histone deacetylases are chromatic-modified enzymes that 
facilitate a closed chromatin structure and therefore transcriptional repression [439]. 
HDACs inhibit p53 through the p21 pathway [362, 439, 495] but analysing this 
pathway remains beyond the focus of this project. Recently, another gene was added 
to the list of p53 inhibitors, termed AGR-2 which belongs to the Anterior Gradient 
protein family [474]. 
 
 
1.3.2 Anterior Gradient 2 
 
1.3.2.1 Anterior Gradient 2 in Xenopus development 
 
The hAGR-2 (human Anterior Gradient 2, also known as HAG2, AG2, GOB4) gene 
is the human homologue of the Xenopus laevis cement gland gene xAG-2. AGR-2 
was first described in 1997 by virtue of expression in Xenopus eggs, where the 
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protein was reported to be secreted. In X.laevis the xAG family is highly expressed in 
the ectoderm during the early stages of the embryo development, but certain 
members of the xAG family, such as AG-1, AG-2 and AG-3 are downregulated as 
development progresses [3]. xAG-2 is involved in the anterior specification of the 
Xenopus embryonic ectoderm giving rise to forebrain and cement gland. Its 
expression is induced by signals deriving from the Specmann’s organizer and a 
certain concentrations of the protein is being required in order to induce 
differentiation [3]. In frog embryo, xAG-2 protein is expressed in the cement gland, a 
mucus secreting organ that facilitates the attachment of the embryo to a solid 
sterigma, essential for the feeding and growth of the embryo whereas in adult frog, 
the gene encodes a protein highly expressed in the lung primordium and the pharynx 
[3]. Recently, another xAG-2 homologous gene, named XAgr-2, was identified in 
Xenopus embryos, which in addition to the cement gland, was found to be expressed 
in the otic vesicles, specifically in the ventromedial region that later develops to the 
cochlea,  and notochord, especially in the tailbud and neurula stages [436]. This 
XAgr-2 gene had greater sequence homology to the hAGR-2 and mAGR-2 than 
xAG-1and xAG-2 (Figure 1.10). XAgr-2 was identified as a target of the xAnf-1, 
for Xenopus anterior neural folds, gene that is a novel homeobox gene essential for 
the development of the telencephalon [649]. 
 
 
Figure 1.10: Alignment of the Agr homologous genes. XAgr2 has a higher homology to  
mouse and human Agr-2 genes than to the  XAG-1 and XAG-2 genes (adapted from [436]).                             
[39] 
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1.3.2.2 Anterior Gradient 2 in adult salamander 
 
Recent studies identified AGR-2, termed as nAG, as a key player in limb 
regeneration in adult salamander. The regeneration occurs only if there is 
simultaneous regeneration of the severed nerves [331]. The limb blastemal cells of 
the salamander regenerate the structures remote to the level of amputation, and the 
surface protein Prod-1 is a key player in this process. Prod-1 is a cell surface protein 
expressed in a proximal-to-distal gradient in the newt limb regeneration blastema and 
is critical determinant of their proximodistal identity. Prod-1 is expressed at the cell 
surface as a glycosylphosphatidylinosotol (GPI)–anchored protein of the Ly6/CD59 
superfamily and mediates cell-to-cell interaction and positional identity [415]. Its 
expression is graded (Proximal > Distal) in both normal and regenerating limbs and 
is regulated by retinoic acid [415]. nAG was found to interact with Prod-1 after Y2H 
and co-immunoprecipitation analyses and promote cell division [331]. nAG was 
found to be essential to rescue nerve dependence but not to enhance nerve 
regeneration. When nAG was expressed, it induced formation of nAG-positive 
glands in the wound epidermis and secreted nAG acted directly on the limb [331]. 
Understanding how vertebrates such as the newt can re-grow body parts may explain 
why mammals have limited re-growth abilities and have major effects in regenerative 
medicine. In humans, hAGR-2 was found to interact with the C4.4 protein that is a 
GTI-anchored protein and has two Lys6-type domains and is associated with 
metastasis [199]. C4.4 and Prod-1 both have small Cys-rich domains and their 
interaction with AGR-2 suggests a conserved pathway of protein complexes. 
 
 
1.3.2.3 Anterior Gradient 2 homologues in other vertebrates 
 
In the zebrafish, Danio rerio, AGR-2 is expressed in most organs such as epidermis, 
otic vesicles, pharynx, esophagus, olfactory bulbs, pneumatic duct, gills, swim 
bladder, and the goblet cells of the mid-intestine [532]. zAGR-2 contains a putative 
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similar sequence to xAG-2 and the gene was found as a duplicate with identical 
nucleic acid and amino acid sequences in chromosomes 7 and 19. Interestingly, the 
cleavage site was predicted between Gly20 and Lys21, suggesting that the zebrafish 
homologue may encode a secreted protein similar to the Xenopus and human 
homologues [3]. Recent studies by Morrison and co-workers, revealed that AGR-2 is 
upregulated in the Atlantic salmon, affected with the amoebic gill disease, an 
ectoparasitic condition that creates reduced appetite, lethargy, respiratory distress and 
loss of equilibrium in fish [418]. These AGR-2 mRNAs were cloned, sequenced and 
shown to be predominantly expressed in epithelial-rich tissue of the gills, intestine 
and brain in healthy fish [418], a pattern of expression consistent with the role of the 
protein in Xenopus [532]. Interestingly, p53 mRNA was downregulated in the same 
AGD lesions that AGR-2 was high, consistent with data from human cell lines that 
propose AGR-2 as a p53 inhibitor [474]. AGR-2 mRNA is downregulated during 
Mycobacterium marinum insfection in zebrafish [397]  Other genes found to be 
downregulated in the same model were muscle-specific genes, MHC genes, Major 
Histocompatibility Complex, and other genes that reflected the general disease state 
of the animal, which is widely used as a human tuberculosis model and reveals new 
insights for mycobacterial pathogenesis. Interestingly, similar profile studies 
concerning the transcriptome response of the salmon fish after Aeromonas 
salmonicida exposure that stimulates acute bacterial response, revealed that AGR-2 
was amongst the genes downregulated in the gills [386]. The gills are regarded as a 
primary site of infection and are shown to be immunologically active as they have 
high numbers of antibody-secreting cells [150]. Both independent studies suggested a 
role of AGR-2 in inflammatory response especially after bacterial expression but the 
exact mechanism is yet unidentified.  
Mouse AGR-2 (also called Gob4) is expressed mainly in the adult stomach, 
intestines, and colon and localized in mucus-secreting cells of the intestine, named 
goblet cells, as verified by in situ hybridization [318]. Goblet cells are part of the 
small intestine epithelium and are thought to derive from stem cells in the basal 
region of a crypt. Same analysis detected the protein in the lower crypt region cells 
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of the colon and in mucous neck cells of the stomach. Amino-acid sequence analysis 
revealed that Gob-4 is similar to xAGR-2, with a 46% homology. Both, human and 
mouse genes encode a protein of 175a.a and have a similarity of 98.3% [612]. 
mAGR-2 also bears a putative signal sequence like hAGR-2 and the most likely 
cleavage site was predicted between Ala20 and Lys21 [318]. At nucleotide level 
mAGR-2 and  hAGR-2 share 87% homology [577]. 
Major differences among anterior gradient homologues in vertebrates are caused by 
length variations in the N-terminal region, 22-45 residues long, and low sequence 
similarity in this region [532] (Figure 1.11). Phylogenetic analyses in this variable N-
terminal region revealed that zebrafish AGR-2 is clustered with homologues from the 
Atlantic salmon (sAGR-2) and pufferfish (tAGR-2) and this group also included the 
human and mouse anterior gradient 2 genes.  The same study also revealed that 
human and mouse AGR homologues (HAGR-3, mAGR-3) are clustered together 
with the Xenopus XAG-1 and XAG-2 genes, suggesting a closer relationship between 
these genes (Figure 1.11). The aforementioned results proposed a model supporting 
the existence of one anterior gradient 2 gene in teleosts and that human AGR-2 and 
AGR-3 are the products of a tandem duplication event due to adjacent chromosome 
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Figure 1.11: Alignment of the amino acid sequence of zebrafish agr2 with other 
anterior gradient 2 homologues from the pufferfish, Atlantic salmon, Xenopus, human, and 
mouse. Identical amino acid sequences which are greater than or equal to seven are shown in 
black boxes. Gaps are introduced as represented by dots to optimize the alignment. The 
percentage of amino acid similarity between zebrafish agr2 and each homolog is shown. 
Sequences are pufferfish Tagr2 Tetraodon nigroviridis, Atlantic salmon Sagr2 Salmo salar;  
human HAGR2 and HAGR3, mouse MAgr2 and MAgr3, zebrafish Zagr2 this study and 
Xenopus XAG-1 XAG-2 and XAgr2 (adapted from [532]) 
[43] 
 
Chapter 1                                                                                                     Introduction 
1.3.2.4 The human hAGR-2 
 
The hAGR-2 gene was mapped to chromosome band 7p21.3 [470].  The gene was 
first described in the MCF-7 breast carcinoma cell line, and found to be co-expressed 
with the Estrogen Receptor α, in ERα-positive cell lines [612] [577] and also 
upregulated under hypoxic, serum deprived or stress conditions [662]. The same 
study also revealed that in ERα-negative tumours the protein’s expression was 
associated with PgR expression. Four putative oestrogen response elements have 
been discovered in the AGR-2 promoter and have been suggested to play a role in the 
oestrogen-dependent expression of AGR-2 in breast cancers [273]. Recent reports 
demonstrate that AGR-2 enhances colony formation in clonogenic assays, attenuates 
p53-dependent gene expression, and suppresses ATM-mediated p53 phosphorylation 
at Ser15 and Ser356 after DNA damage, proposing a p53-inhibitory role for the protein 
in the premalignant metaplastic epithelium, called Barret’s oesophagus [474].  
The protein is expressed in some normal tissues such as liver, heart, placenta, 
stomach and kidneys apart from cancer ones [650]. AGR-2 encodes a protein that 
gives rise to two different isoforms, the full length and the mature one [3, 650]. The 
full length protein contains a leader signal peptide that is processed to yield the 
mature protein. The main difference in these two forms of the protein is that the full 
length one contains the leader sequence targeting the protein to secretion, whereas 
the mature form does not bear this sequence. This N-terminal hydrophobic leader 
sequence is predicted to be cleaved between Ala20/Lys21 giving rise to a 17,949Da 
mature protein. AGR-2 is a 19,797Da protein and is under regulation by the 
proteosome [474]. Staining of primary breast tissues from patients showed 
cytoplasmic and membranous staining of the protein [282]. 
More recently AGR-2 has been identified as a novel member of the protein disulfide 
isomerase family consisting of protein disulfide isomerases (PDIs) and ER proteins 
(ERps) [467]. The active motif of such proteins is a CXXC domain, also contained in 
thioredoxins and therefore termed the Tx domain [194]. AGR-2 has  homology to 
ERp18/19 (Figure 1.13), and while it does not contain a CXXC motif, it does have a 
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CXXS domain which was recently identified in two other ERp proteins [22] and 
shown to have lower activity that the original CXXC motif. AGR-2 and AGR-3, 
another member of the AGR family, also show conserved intron position with 
respect to protein sequence when compared to Erp18/19 as well as exon boundaries 
[468]. Such data suggest that AGR-2 may have evolved from PDI/ERps but no 
longer retains its characteristic function.  
 
 
1.3.2.5 AGR-2 in secretory cells 
 
In Xenopus oocytes AGR-2 is found in the secretory cement gland where it regulates 
its differentiation as well as ectodermal patterning throughout the different 
developmental stages [3]. The gene has 91% similarity to the Gob-4 gene in mice, 
which is highly expressed in mucous-secreting goblet cells of the intestine [318]. 
Moreover, upregulation of the gene in Barret’s epithelium, a condition which is 
characterised by an increased number of goblet cells in the lower oesophagus [484, 
485] along with protein’s expression data in mucus-secreting cells and endocrine 
organs [652] further support the list of secretory cells that overexpress the protein. 
Recently, AGR-2 has been identified as a candidate gene for inflammatory bowel 
syndrome under the control of goblet cell-specific transcription factors FOXA1 and 
FOXA2 [652]. Pilot studies involving the AGR-2 protein fused to a C-terminal GFP 
revealed that is also secreted from HeLa cells [364] consistent to secretory data from 
androgen-inducible prostate cancer cell lines [650]. The same study revealed that 
AGR-2 was overexpressed in the secretory epithelial cells of the prostate gland, it 
encodes two proteins and the shortest isoform is secreted upon androgen treatment 
although both transcripts were induced by dose-dependent treatment with 
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1.3.2.6 AGR-2 in metastasis, tumour growth and cell survival 
 
Anterior Gradient-2 was found to be overexpressed in metastatic cancer cell lines 
[364] as well as in the circulating tumour cells in the peripheral blood of advanced 
metastatic cancer patients [544] and was therefore recommended as a potential 
detection and characterization marker for these cells. A strong correlation between 
AGR-2 expression, the presence of metastasis and patient survival has been observed 
in a group of tamoxifen-treated patients with ERα-positive breast cancers and 
elevated levels of AGR-2 that exhibited a statistically significant poorer survival rate 
and higher incidence of metastasis, than those without AGR-2 mRNA [364]. AGR-2 
has also been implicated to interact with a metastasis gene that encodes 
glycosylphosphatidylinositol-anchored protein C4.4A [199], which is upregulated in 
several types of metastatic cancers. Furthermore, studies in SEG-1 esophageal 
adenocarcinoma cells  further supported the role of AGR-2 in metastasis and cell 
migration [611]. In these studies media from SEG-1-AGR-2 cells was transfused into 
SEG-1 KD1 cells that were AGR-2 deficient (due to retroviral shRNA) and induced 
migration by a 2.5 fold factor, as measured by in vitro migration assays.  
Recent studies have shown that AGR-2 increases the growth rate of mouse fibroblast 
NIH3T3 cell line by in vitro assays that included the formation of discrete foci or 
compromising anchorage independent growth in soft agar [611]. Stable cells 
expressing AGR-2 showed up to 7-fold increase in colonies compared to NIH3T3 
control cells consistent with the protein’s role in enhancing colony formation in 
H1299 cells [474]. These xenographs of NIH3T3 AGR-2-positive cells in mice were 
15-fold larger in size 21 days after implantation. This is also related to data 
indicating that AGR-2 transfection enhances the level of attachment of AGR2- 
negative cell lines to an extracellular matrix [611]. 
Interestingly, experiments mimicking the tumour microenvironment in terms of low 
oxygen and growth factors status, showed AGR-2 upregulation under these 
conditions [662]. The same study also revealed that this upregulation occurs through 
a MAPK/ERK-dependent pathway, by treating with certain inhibitors of signalling 
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pathways such as JNK, p38, PI3K and ERK1/2, which are involved in anti-apoptotic 
cell response [239, 489]. Therefore, a survival role for AGR-2 under physiological 
stress conditions that promote selection of more aggressive types of tumour cells was 
supported. This conclusion is consistent with the findings that AGR-2 acts as a p53 
inhibitor in response to UV damage, which is a type of stress, and rescues cells from 
death [474]. These stress-induced experiments were performed in ERα-negative cell 
lines and showed independence of ERα status for AGR-2 induction, supporting the 
observation that 20% of ERα-negative cancers show elevated AGR-2 expression and 
revealing a new model of action, regardless of the ERα status [199]. On the other 
hand,  ERα- positive cells growing in estrogen depletion have lower levels of AGR-2 
than cells growing in the presence of estrogens suggesting that ERα status is essential 
to AGR-2 function and further affects survival and tumour behaviour in these cell 




Figure 1.12: Schematic diagram of AGR-2 roles in human cancer. Human AGR-2 is 
implicated in cell survival, metastasis, tumour growth and p53 inhibition in cancer cells. The 
exact mechanism of action has not yet beed characterised. 
[47] 
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1.3.3 Anterior Gradient 3  
 
Human anterior gradient-3 (AGR-3) was discovered several years after AGR-2 by a 
group researching unknown human and mouse genes [561]. The gene, named Breast 
Cancer Membrane Protein 11 (BCMP11) was also identified during proteomic 
analysis of purified membrane proteins of breast tumour derived cell lines, shown to 
localise to endosomes of T47D breast cancer cells and implicated as being secreted 
[4]. Around the same time Fletcher and co-workers also found BCMP11 and reported 
its homology with AGR-2, leading to the name being altered to AGR-3, in line with 
it being a member of the anterior gradient family [199]. hAGR-3 and hAGR-2  share 
a 71% sequence identity and they are both candidate members of the thierodoxin 
superfamily of proteins due to the characteristic CXXS motif and also the high 
degree of homology with ERp18/19 [468] (Figure 1.13). AGR-3 is a 19,176Da 
protein and proposed to have an N-terminal signal sequence, which is predicted to be 
proteolytically cleaved between Ala23/Ala24 resulting in a mature protein of 
16,822Da. Both hAGR-2 and hAGR-3 genes comprise seven coding exons with 
similar exon/intron boundaries, which along with the high similarity and close 
genomic locality suggest that they arose from a gene duplication event [199]. The 
majority of differences between the two genes are found within the predicted 
hydrophobic leader sequence. AGR-3 also shows a correlation with ERα expression 
in samples derived from breast cancer patients and processed with RT-PCR [199] but 
the exact role of the protein is yet undefined. As well as being implicated in breast 
cancer, AGR-3 is also upregulated in patients with inflammatory bowel disease, 
albeit to a lesser extent than AGR-2 [652]. AGR-3 also binds to the C4.4 metastasis 
associated protein and alpha-dystroglycan (DAG-1) and the minimum binding 
domains, as identified by overlapping contigs, were restricted to the extracellular part 
of DAG-1 (alpha dystroglycan chain) or C4.4a consistent with the secretory nature of 















Figure 1.13 Homology between anterior gradient proteins and ERp18/19 Sequence 
identity between AG-2, AG-3 and ERp18/19.Highlighted areas indicate regions of homology 
between the proteins (adapted from [468]). 
 
 
1.4 PDI family of proteins 
 
Since AGR-2/AGR-3 both are novels members of the PDI family, separate attribute 
to this family should be made. Endoplasmic reticulum contains a broad network of 
chaperones that facilitate the correct folding and processing of the proteins targeted 
to secretion. The protein disulfide isomerases, PDIs, play an important role as they 
catalyse formation, reduction and isomerization of disulfide bonds, depending on the 
redox environment, and thereby stabilizing intermediate conformations during 
protein maturation in the lumen of the ER [522]. In particular, PDIs are involved in 
the proper folding, formation and reshuffling of the disulfide bridges of the proteins 
synthesized in the rough ER, imported in the lumen of this structure and destined to 
be secreted or incorporated in the cell membrane [593]. Interestingly, several of these 
proteins that reside in the ER in normal cells, have been shown to accumulate at the 
cell surface in cancer cells as part of larger molecular complexes [18] and may affect 
antigen presentation [131]. 
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It has also been supported by literature that certain members of the PDI family act in 
other cellular compartments apart from the endoplasmic reticulum. In non-ER 
locations they are present in lower amounts and it has been suggested that a less 
oxidative environment, compared to the ER, alters their function [593]. Proteins of 
this family have also been reported of being secreted from hepatocytes, platelets, 
aortic endothelial cells [267] and pancreatic exocrine cells. Reports of their presence 
in the cytosol involve ERp57 mainly [354] as well as other members such as Erp49 
but remain beyond the aims of this project. Protein disulfide isomerase activity has 
been detected in the mitochondria as well, especially at the membrane level and not 
the matrix, and a protein was purified but the molecular weight was much smaller 
than the PDIs one and an anti-PDI antibody could not recognize it [487]. Moreover, 
the protein was suggested to have a role in the mitochondrial membrane permeability 
by reducing protein disulfides and affecting redox regulation. When it comes to the 
nuclei, it is noteworthy that ERp57 and PDI are present in the nuclei, either by direct 
detection of the protein [213] or by in vitro evidence that these proteins influence 
processes at the DNA level, such as DNA binding to transcription factors or 
structural nuclear proteins. PDIs facilitates the binding of NFκB and AP-I to DNA 
[120]. The above observations were not free of criticism due to the peripheral 
localization of the ER around the nucleus and possible cross-contamination of the 
one compartment to the other in vitro. Immunohistochemical proof of nuclear 
localization of ERp57 followed in Hela and 3T3 cells and was verified by DNA-
protein cross linking experiments [124]. In conclusion, the PDI family includes 
proteins with diverse mobility and localization patterns, activating different pathways 
and triggering various reactions, depending on their distribution and the redox 
environment. 
The active binding motif of the proteins is the CXXC, which is also characteristic of 
another protein family, the thioredoxins (Txs). For that reason this motif is referred 
to as a Tx-domain motif [206]. Members of the PDI contain up to four Txs motifs 
[15, 193]. Another characteristic motif that most of the PDIs harbour is the H/KDEL 
[50] 
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ER retrieval signal, or derivatives of the last such as QEDL, KTEL, RTEL etc in 
different species [468] but this motif is analysed in chapter 3.1.1.3. 
 
 
1.5 Objectives of project 
 
AGR-2 and AGR-3 enhance colony survival and cell growth of cancer cells but the 
exact pathway of their oncogenic activity needs to be refined. As AGR-2 and AGR-
3 are over-expressed in breast cancers, this thesis examines by molecular biological, 
immunochemical, and microscopic techniques (i) the localization of each AGR-2/3 
protein intracellularly to aid in defining the function of both proteins and whether 
they compensate for each other (chapters 3 and 4), (ii) developing proof-of-concept 
peptide-inhibitors towards AGR-2 to determine whether p53 function can be 
rescued (chapter 5), and (iii) formulate a model that describes potential pathways in 
which AGR2/3 proteins can mediate their pro-oncogenic effects in cancer (chapter  
6).   The data demonstrate that AGR-2 and AGR-3 carry out distinct functions in 
cells based on compartmentalization and that the proteins can have distinct effects 
on inhibiting the p53-Bax pathways in cancer.  
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2.1 Reagents and Materials 
All chemicals were puschased from Sigma or BDH unless otherwise stated. Tissue 
culture and other plasticware were obtained from Nunc or TPP. 
 
 
2.2 Cell culture 
 
2.2.1 Cell lines and cell culture 
All cells were kept in a humidified Hera incubator equipped with CO2 gas cylinders. 
No antibiotics were used in any of the cell lines. 
 
Cell line Description Growth 
conditions 
Culture media 
MCF-7 Human, breast 
adenocarcinoma, 
Estrogen receptor +/+ 
5% CO2, 37 °C DMEM, 10%FBS 
LCC1 Human, breast 
adenocarcinoma, 
Estrogen receptor +/+, 
MCF-7 derived 
5% CO2, 37 °C Modified DMEM -L-
Glu, -Pyruvate, 5% 
Charcoal stripped 
FBS*, 1%L-Glutamine 
LCC9 Human, breast 
adenocarcinoma, 
Estrogen receptor +/+ 
MCF-7 derived 
5% CO2, 37 °C Modified DMEM -L-







Estrogen receptor -/- 
5% CO2, 37 °C DMEM, 10%FBS 
 
Table 2.1: Cell lines used. Brief description of their origin, growth conditions and the media 
used for culturing (*kindly provided by Dr. Hrstka, Czech Republic). 
[53] 
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DMEM: Dulbecco-s Minimal Essential Media, containing Puryvate, L-Glutamine, 
4500mg/L Glucose and Phenol Red. 
ModifiedDMEM: Dulbecco-s Minimal Essential Media, withoutPuryvate, L-
Glutamine, Glucose and Phenol Red. 
FBS:Fetal Bovine Serum 
*Charcoal stripped FBS obtained from LSI 
 
 
2.2.2 Media and supplements 
 
Media (GIBCO) was supplemented with fetal bovine serum (FBS, GIBCO) at 10%, 
unless otherwise stated. LCC1 and LCC9 cell lines were grown in DMEM without 
L-Glutamine and Pyruvate, plus 5% charcoal stripped fetal bovine serum and 1% L-
Glutamine to ensure absence of endogenous steroids and growth factors.  
No antibiotics were used in any of the cell lines. Media was stored at 4 °C and heated 
at 37 °C prior to use. Fetal bovine serum and charcoal stripped serum aliquots were 
kept at -20 °C and thawed at 37 °C prior to use. Trypsin-EDTA, 0.05%, was kept at 4 
°C and warmed at room temperature before use. 
 
 
2.2.3 Subculturing, storage and recovery of cells 
 
Freezind media 
Fetal bovine serum supplemented with 10% (v/v) DMSO 
 
Cells were sub-cultured 2-3 times per week in 10cm diameter culture dishes in sterile 
conditions. The media was discarded and the cells were washed with 10ml sterile 
PBS. Trypsinization of cells followed with 3ml Trypsin-EDTA solution and 
incubation for 1-3 minutes at the 37 °C incubator, when the cells start to detach from 
the dish. Subsequent dilutions, varying from 1:2 to 1:10 depending on the time and 
[54] 
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type of the experiment, were applied. The final volume per 10 cm diameter dish was 
10ml in any condition. Cells grown in 25-cm diameter dish were cultured in 25ml 
media whereas cells grown in 100mm diameter dish in 2ml media. 
 
To prepare cells for storage a 10cm diameter culture dish with 80-95% confluent 
cells was trypsinized as normal and the cells collected were diluted in 10ml finale 
volume media and centrifuged in sterile Falcon tubes at 1000rpm, 5min, at room 
temperature. The cell pellet was gently resuspended in ice cold freezing media, 5ml, 
and transferred to cryotubes (Nunc) at 1ml/tube. The cells were frozen down 
gradiently in NalgeneTM Cryo freezing containers and then transferred to -80 °C. 
Twenty-four hours after, the vials were transferred at cryoboxes in liquid nitrogen. 
Same conditions applied in cells growing in the 100mm or 25cm culture dishes with 
the only difference of the volumes added in each step, summarized below: 
100mm dish: 1ml Trypsin-EDTA and 1ml media, then centrifuge and resuspend in 
2ml freezind media. 1ml of cell/vial. 
25m dish: 6ml Trypsin-EDTA and 14ml media, then centrifuge and resuspend in 
10ml freezing media. 1ml of cell/vial. 
 
To recover the cells from liquid nitrogen storage, each vial was incubated at the 37°C 
waterbath till half of the volume is thawed. By pippeting, the rest of the frozen stock 
was thawed and the cells were transferred in a 100mm diameter culture dish 
containing fresh media. Cells were left to reach 80% confluency and then transferred 
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2.2.4 Transient transfections 
 
Cells were counted using a Haemocytometre and plated out at 2-4x105 
cells/well(according to the LipofectamineTM 2000 (InVitrogen) protocol, into 6-well 
plates with 2ml of the appropriate medium for each cell line.  Cells were incubated 
overnight at 37 °C, in 10% CO2 or 5%CO2 depending on the cell line used, to 90% 
confluence. DNA/liposome complexes were prepared separately according to the 
manufacturer’s protocol. For each DNA to be transfected 5μg of plasmid DNA 
ligated to the gene of interest, were diluted in OptiMEM(GIBCO) up to 100μl. The 
LipofectamineTM 2000 reagent (InVitrogen) was diluted in OptiMEM as well 1:10 
dilution. The Lipofectamine/OptiMEM suspension was combined with the 
DNA/OptiMEM one. Following a 20min incubation at room temperature, 200μl of 
the DNA/Lipofectamine were added to each well, and incubated overnight at 37 °C. 
Cells were harvested after 24h unless otherwise stated. Protocol was adjusted to 
smaller or larger cell volumes and numbers according to the protocol. 
 
 
2.3 Microbiological techniques 
 
All microbiological techniques were carried out under aseptic conditions 
 
 
2.3.1 Growing bacterial cultures 
 
Luria- Bertani (LB) broth                                        Selective antibiotics 
1% (w/v) Tryptone                                                      Ampicillin (Sigma) at 100μg/ml 
0.5% (w/v) Yeast extract                                             Kanamycin (Sigma) at 30μg/ml 
1% (w/v) NaCl                                                             Filter-sterilised 
Sterilised by autoclaving at 121°C for 20min 
[56] 
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3ml LB media containing the appropriate antibiotic was inoculated with a colony of 
bacteria from a stock plate or from a glycerol stock and incubated for 8h at 37 °C at 
225rpm. This starter culture was then transferred to a 250ml LB media plus antibiotic 
culture at 1:1000 dilution and incubated overnight under the conditions mentioned 
above. Culture flask capacities were at least 4x the volume of the culture being 
grown to allow sufficient aeration. 
 
 
2.3.2 Glycerol stocks 
 
Glycerol stocks of bacterial cells were prepared by adding 125μl of bacterial culture 
to 875μl of sterile glycerol, 80% v/v, in a cryovial (NUNC) and snap freeze in liquid 
nitrogen. The cells were then stored at -80 °C. 
 
 
2.3.3 Agar bacterial culture dishes 
 
LB agar 
1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
1.5% (w/v) agar powder 
Sterilised by autoclaving at 121°C for 20min 
 
LB agar was liquefied by heating in a microwave oven, maximum heat, 5min. The 
agar was left to cool down at room temperature and when hand-warmed the 
antibiotic was added and then poured into 90mm diameter Petri dishes (Sterilin) and 
left to solidify. Prior to use the dishes were left at 37 °C for 1h to dry out. If no 
transformation followed, the dishes were kept at 4 °C, sealed with parafilm till use 
and no longer than 3 weeks. 
[57] 
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2.3.4 Preparation of competent cells 
 
 
2.3.4.1 Heat shock method 
 
Transformation buffer I (TFBI)                        Transformation buffer II (TFBII) 
30Mm Potassium acetate                                       10mM MOPS 
100mM RbCl                                                         75mM CaCl2 
10mM CaCl2                                                                                      10mM RbCl 
50mM MnCl2                                                                                    15% (v/v) Glycerol 
15% (v/v) Glycerol 
Adjust to pH 5.8 with dilute acetic acid                Adjust to pH  6.8 with NaOH and 
sterilize by filtration                                                sterilize by filtration 
 
 A starter culture of DH5α bacterial cell was set by inoculating 2-3ml LB broth with 
glycerol stock of bacteria in a 15ml sterile Falcon tube and shake overnight at 37 °C 
at 225rpm. This culture was diluted 1:200 in LB broth and incubated until OD600nm 
reached 0.3 (Logarithmic growth phase, Figure 2.1). Cells then were centrifuged at 
8000rpm for 5min at 4 °C, the pellet was resuspended in ice-cold TFBI, 16ml 
TFBI/50ml culture, and the incubated on ice for 30min. After a second centrifuge at 
1000rpm, at 4 °C for 5min, the pellet was resuspended in 4ml TFBII and incubated 
on ice for another 30min. DH5α cells were then snap-frozen in liquid N2, in 100 μl 
aliquots and stored at -80 °C till use. 
[58] 
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Figure 2.1: Bacterial growth curve. E.coli strain K grown in minimal media supplemented 
with glycose.The four phases of growth are depicted: lag (i), exponential (ii), stationary (iii) 
and death phase (iv) are shown (chart adapted from www.bact.wisc.edu).  
 
 
2.3.5 Transformation of bacteria 
 
 
2.3.5.1 Heat shock method 
 
100 μl of competent cells, thawed on ice, were mixed gently with 0.05-0.5μg of the 
desired plasmid DNA. The cells were incubated on ice for 30min, then heat shocked 
at a 42°C waterbath for 1.5min and incubated on ice again for an extra 5min. 500μl 
of sterile LB was added and the cells were left to grow at a 37 °C waterbath for 1h 
before plating out on LB agar plates containing the selective antibiotic and being left 







Chapter 2                                                                                       Materials & Methods
   
2.3.5.2  KCM method 
 
Competent cells (100μl) were thawed on ice and 10.05-0.5μg of the desired plasmid 
DNA was added to 20μl of 5xKBII and sterile  H2O was added up to a final volume 
of 100μl. Bacterial cells were then added to the diluted DNA mix and incubated on 
ice for 20min and then at room temperature for another 10min. 1ml of 2YT buffer 
was added to the mix and the culure was left to grow at a 37 °C water bath for 1h. 
Cells were then plated out onto an agar plate containing the appropriate antibiotic 
incubated at 37 °C overnight. 
2YT media KCM buffer II (KBII) 
1.6% (w/v) Bacto-Tryptone 
1% (w/v) Yeast extract 
0.5% (w/v) NaCl 








2.4 Plasmid DNA 
 
 
2.4.1 Amplification of plasmid DNA 
 
A single colony of bacteria containing the plasmid was used to inoculate a 3ml 
starter LB culture containing the selective antibiotic and incubated at 37 °C at 
225rpm for 8h. This culture was then transferred in a 1:1000 dilution in 250ml LB 






Chapter 2                                                                                       Materials & Methods
   
2.4.2 Purification of plasmid DNA 
 
 
2.4.2.1 Maxi-prep DNA 
 
DH5α cells from a 250ml culture were collected after centrifuge at 6000rpm/20min 
at 4 °C (in a Sorvall-spin centrifuge). Plasmid DNA was then isolated and purified 
using the Qiagen MaxiTM kit according to the manufacturer’s protocol. The DNA 
was resuspended in endotoxin-free TE buffer, unless otherwise specified, and stored 
at -20 °C. 
 
 
2.4.2.2 Mini-prep DNA 
 
Cells from a 5ml culture mentioned above, were collected after centrifuge at 
6000rpm/20min at 4 °C. Plasmid DNA was then isolated and purified using the 
Qiagen MiniTM kit according to the manufacturer’s protocol. The DNA was 









Plasmid DNA was diluted in 1:100 in ddH2O into glass DNA cuvettes and 
absorbance of DNA at 260nm was measured by spectrometer (DigiLab 
HitachiU2800). Blank measurements were made by ddH2O only. Alternatively, 
[61] 
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concentration was measured by NanoDrop, by adding 1µl of undiluted DNA and 
measuring absorbance at 260nm. 
  
 
2.5 SDS-PAGE  
 
2.5.1 Preparation of cell lysates 
 
2.5.1.1 Cell lysis 
 
Urea lysis buffer 
8M Urea                          
10x Triton  
5M NaCl                         
20mM HEPES, pH 8.0 
1M DTT 
Buffer prepared prior to use                        
 
1% Triton X-100 lysis buffer 
50mM HEPES pH 8.0 
0.1mM EDTA 
150Mm NaCl 
1x Protease inhibitor mix 




CHAPS lysis buffer 
150 mM NaCl,  
10 mM HEPES, pH 7.4 
1.0% (w/v) CHAPS 
1:100 dilution of Protease Inhibitors 
Cocktail 




RIPA lysis buffer 
50mM Tris HCL pH 7.5 
150mM NaCl  
1% Nonidet p40 (IGEPAL) 
0.5% sodium deoxycholate 
0.1% SDS  
1x Protease inhibitor mix 
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Protease Inhibitor cocktail 
Complete mini protease Inhibitor 
cocktail tablets supplied by Roche 
SDS sample buffer (5x) 
0.25M Tris pH 6.8 
10% (w/v)SDS 
50% (w/v) Glycerol 
0.025% (w/v)Bromophenol blue 
0.05M DTT (added just prior to use) 
 
Cells were washed twice with ice old PBS and scraped with 1ml/10cm dish, or 500 
μl/100mm dish, PBS into sterile microcentrifuge 1.5ml tubes and then centrifuged at 
4000 rpm for 5min at 4 °C. The supernatant was discarded and the pellet was 
resuspended in lysis buffer, 100 μl/100mm dish or 500 μl/10cm dish, and kept on ice 
for 30min, exemptions apply to Urea and CHAPS lysis where the incubation time 
was 1h instead of 30min. After incubation, the cell lysate was centrifuged at 
13.000rpm for 15min at 4 °C to precipitate nuclei and non-lysed cells. The 




2.5.1.2 Subcellular fractionation of proteins 
 
For the subcellular extraction of the cellular compartments the ProteoExtract® 
Subcellular Proteome Extraction Kit (Calbiochem®) was used.  The cells were grown 
in 6-well plates at a seeding density of 106 cells/ml. Twenty-four hours post-
transfection the cells were harvested in ice cold 1x PBS and centrifuged at 4000rpm, 
4 oC. The supernatant was discarded and the cell pellet was transferred to new pre-
cooled Eppendorf tubes and snap-frozen in liquid N2 unless processed for 
fractionation. The protocol followed was the one adjusted for frozen cell pellets 
according to the manufacturer’s instruction. Four different composition buffers 
ensured high quality cytosolic, membrane, nuclear and cytoskeleton extracts. All 
[63] 
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extraction buffers contain protease inhibitors and all steps were carried out at 4 oC 
unless stated. All fractions were stored at -80 oC and analysed by immunoblotting 
 
 
 2.5.1.3 Protein quantification 
 
BIORAD Bradford Reagent was diluted 1:5 in ddH2O and filter-sterilized. 1μl of 
each sample was added in 200μl of 1x Bradford into a 96-well plate (NUNC) and 
incubated at room temperature for 5min. The 96-well plate was then shaken by using 
an ordinary plate-shaker (Jencons) for less than 1min to allow mix of the samples. 
The absorbance of the samples at 595nm was measured with the Powerwave XSTM 
Microplate Spectrophotometer (Biotek) and the exact concentration, μg/μl, according 
to the Standard curve was calculated by using the KC-Junior programme. The protein 
standard curve for the Bradford method is created by diluting BSA, 1mg/ml BSA 
stock solution (≤96% pure grade, A-7638 Sigma) in ddH2O at a final concentration 
of 0.5-1-2-4-8 μg/μl, w/v, and measuring absorbance at 595nm.There should be a 
linear relationship between absorbance and protein concentration. 
To determine the protein concentration of urea cell lysates, the BCATM Assay kit 
(Pierce, Perbio Science) in a 96-well plate was used. Absorbance at 562nm was 
measured with the Powerwave XSTM Microplate Spectrophotometer (Biotek) and the 
exact concentration, μg/μl, w/v, according to the Standard curve, standard 
concentration samples provided in the kit, was calculated by using the KC-Junior 
programme. 
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2.5.2 Preparation of gels and separation of proteins by SDS-PAGE 
 
 






192 mM Glycine 
25 mM Tris 
20% (v/v) Methanol 
10 x Phosphate Buffered Saline (PBS) 1x PBS-Tween (PBS-T) 
1.37 M NaCl 
0.1 M Na2HPO4 
0.027 M KCl 
0.018 M KH2PO4 
adjusted to pH 7.4 with HCl 
1x PBS  
0.1% (v/v) Tween -20 
 
Blocking Buffer 1x 
 
1x PBS-T  
5 %(w/v) low fat dry Milk (Marvel) 
 
 
Stacking gel – 5 %  (per 1 ml) 
30 % Acrylamide mix*  0.17 ml 
1.5 M Tris (pH 6.8)  0.13 ml 
10 % SDS  0.01 ml 
10 % Ammonium peroxidisulphate  0.01 ml 
TEMED (Sigma)  0.001 ml 




Separating gel – 10%  (per 5 ml) 
30 % Acrylamide mix*  1.7 ml 
1.5 M Tris (pH 8.8)  1.3 ml 
10 % SDS  0.05 ml 
10 % Ammonium peroxidisulphate  0.05 ml 
TEMED (Sigma)  0.002 ml 
dH2O  1.9 ml 
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Separating gel – 15 %  (per 5 ml) 
30 % Acrylamide mix*  2.5 ml 
1.5 M Tris (pH 8.8)  1.3 ml 
10 % SDS  0.05 ml 
10 % Ammonium peroxidisulphate  0.05 ml 
TEMED (Sigma) 0.002 ml 
dH2O  1.1 ml 
 
* Acrylamide mix (National Diagnostics; Ultrapure Protogel) consists of 30 % (w/v) 
acrylamide and 0.8 % (w/v) bis-acrylamide. 
 SDS-polyacrylamide gels, 10% or 15%, were prepared in glass plates cleaned with 
70% ethanol. The separating gel was left to polymerise at room temperature overlaid 
with water to straighten the top of it. The water was then removed and the stacking 
gel was added along with a equivalent comb, 10- or 15- well and 0.75mm or 1.5mm 
thickness size, respective to the number and amount of the samples to be assayed. 
After polymerization, the combs were removed and the glass plates with the gels 
were adjusted in the appropriate tank filled with 1x SDS running buffer. 
SDS sample buffer (5x) was added to the lysates, 10-20μg of total protein,the 
mixtures were spinned at 13.000rpm for 1min and heated up to 95°C in a thermal 
block for 1min immediately prior to loading. 5μl of pre-stained protein standards, 
low range or high range (Biorad) depending on the protein sizes and gel type, were 
loaded in the first lane as size markers. Electrophoresis separation was performed at 
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ECL Solution 1 ECL Solution 2 
100 mM Tris pH 
8.5 
100 mM Tris 
pH8.5 





Following electrophoresis on the SDS-PAGE gel, proteins were transferred to 
nitrocellulose membranes (Hybond-C, Amersham) in tanks filled with transfer buffer 
and ensuring low temperature by ice-blocks present in the tank. Electroblotting was 
performed at 300mA for 100min. After transfer protein blots were ink stained 
(Pelikan) and washed 3x with PBS-T for 5min to remove excess ink. Membranes 
were then blocked by washing in PBS/0.1% Tween-20/+5% (w/v) milk (dried 
skimmed, Marvel), at room temperature on an orbital shaker for 1h. The primary 
antibody was added and diluted in 5% milk in PBS-Tween (0.1% v/v), and incubated 
overnight at 4 °C (Table 2.2). Following 3x5min washes in PBS-Tween, the 
appropriate secondary antibody conjugated to horse radish peroxidase was added and 
the blot was incubated for 1h at room temperature (RT). Blots were then washed 
4x15min in PBS-Tween and visualized by enchanced chemiluminesence (ECL). 
Membranes were covered in ECL 1+2 (1:1 v/v ratio), left at room temperature for 
3min and after removal of excess ECL by tissue, exposed to Hyperfilm for the 
appropriate time (Kodak) and then developed (Mediphot 937). 
 
2.5.3.2 Immunobloting of phosphorylated antibodies 
 
According to the manufacturer’s protocol (Cell Signalling). 
[67] 
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2.5.3.3 Coomassie brilliant blue staining 
 
Destain 1 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
 
Destain 2 
7.5 % (v/v) Methanol 
10 % (v/v) Acetic acid 
Coomassie brilliant blue stain 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
0.2 % (w/v) Coomassie Blue R-250 
 
 
Gels were transferred to a dish containing Destain 1 for >5min and then placed into 
another dish containing Coomassie Blue Stain. The duration of the staining 
procedure depended on the strength of the staining required (5min to 12h) and in 
some cases the stain was preheated to 45 ºC to increase staining even further. Gels 
were then placed in a dish containing Destain 2. A folded tissue was used to absorb 
excess dye and Destain 2 was renewed as needed. Destaining was performed until 
the bands became visible and the background staining was removed. Gels were air-
dried in between DryEase MiniCellophaneTM sheets (Invitrogen) in a DryEase 
GelDryingTM system (Invitrogen).   
 
2.5.3.4 Stripping nitrocellulose membranes 
 
Antibodies bound to membranes were removed by stripping the blots with 0.1N 
NaOH, when blots needed to be reprobed for similar size proteins or with antibodies 
raised in the same species. Blots were first washed with H2O for 5min at room 
temperature and then with PBS-T for 5min. 0.1N NaOH was added to the blots for 
10min on a orbital shaker. The membranes were then washed 3x in PBS-T for 3min 
each lapse and blocked in 5%milk in PBS-T for 1h before adding the primary 
antibody diluted in 5%milk+PBS-T as normal. 
[68] 
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kDa Antibody Type Company Dilution 
50 β-actin Mouse monoclonal Sigma 
  1:4000 
53 




  1:1000 
53 




  1:1000 
53 p53 P-Ser
15 Mouse 
polyclonal Cell signalling 
  1:1000 
21 Bax Mouse monoclonal InVitrogen 
  1:1000 
20 Bid Mouse monoclonal InVitrogen 
  1:1000 
21 Bcl-2 Mouse monoclonal InVitrogen 
  1:1000 
20 Bax 6A7 Mouse monoclonal InVitrogen 
  1:1000 
16 Cytochrome c 
Mouse 
monoclonal Calbiochem 
  1:1000 
20 AGR-2 Mouse monoclonal Abnova 
  1:1000 
19 AGR-3 Mouse monoclonal 
Moravian 
Biotechnologies
  1:1000 
70 Hsp70 Mouse monoclonal Stressgen 
  1:1000 
17 LC3 Mouse monoclonal Cell Signalling 
  1:500 
116/89c PARP Mouse monoclonal Cell Signalling 




  1:1000 
  - FLAG 
Mouse 
monoclonal Sigma 
  1:1000 
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2.6  DNA amplification 
 
 
2.6.1 Polymerase chain reaction  
 
 
2.6.1.1 Primer design 
 
A primer is a short synthetic oligonucleotide which is used in many molecular 
techniques from PCR to DNA sequencing. These primers are designed to have a 
sequence which is the reverse complement of a region of template or target DNA to 
which we wish the primer to anneal.  Primers for the amplification of the AGR-2 
gene (NCBI accession number NM_006408), from a DNA template, AGR-2 in 
pDEST 3.2, were designed with a length of 39-40bp recognizing the start and the end 
of the gene (Figure 2.2, Table 2.3). Restriction enzyme recognition sites were 
integrated in the 5’ of each of the primers to enable ligation to the desired vectors, 
AcGFP-N1 and DsRed Express N1. The primers had a melting temperature of 76-
82°C and a G+C content between 46-50% of the total primer sequence. No primer 
dimers were formed according to the Sigma-Aldrich primer design tool 
(www.sigmaaldrich.com). Last but not least, all the primers started (5’) with a GC to 
increase the efficiency of priming and were PAGE- purified. Extra bases were 
integrated where required to keep the gene in frame. 
The same reverse primer was used for the wt gene amplification whereas different 
reverse primers were used for the KTEL deletion (ΔKTEL) and the KDEL mutants (T-
D mutation). To sum up, at the end of the amplification 6 fragments were amplified: 
mature AGR-2wt, full length AGR-2wt, mature AGR-2KDEL, full length AGR-2KDEL, 
mature AGR-2ΔKTEL, full length AGR-2 ΔKTEL. Each one of them was subcloned into 
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 1  atggagaaaa ttccagtgtc agcattcttg ctccttgtgg ccctctccta 
cactctggcc 
61  agagatacca cagtcaaacc tggagccaaa aaggacacaa aggactctcg 
acccaaactg 
121 ccccagaccc tctccagagg ttggggtgac caactcatct ggactcagac 
atatgaagaa 
181 gctctatata aatccaagac aagcaacaaa cccttgatga ttattcatca 
cttggatgag 
241 tgcccacaca gtcaagcttt aaagaaagtg tttgctgaaa ataaagaaat 
ccagaaattg 
301 gcagagcagt ttgtcctcct caatctggtt tatgaaacaa ctgacaaaca 
cctttctcct 
361 gatggccagt atgtccccag gattatgttt gttgacccat ctctgacagt 
tagagccgat 
421 atcactggaa gatattcaaa tcgtctctat gcttacgaac ctgcagatac 
agctctgttg 
481 cttgacaaca tgaagaaagc tctcaagttg ctgaagactg aattgtaa 
 
 
 Figure 2.2: The AGR-2 cDNA sequence (NCBI NM_006408). The leader sequence is 
highlighted in red. The mature form of the protein contains no leader sequence and starts 
from site 61aga whereas the full length form starts from the 4gag site. The KTEL encoding 
sequence is highlighted in blue at position 517act. 
 
 
Primers for the N-terminal Fluorescent vectors 
 





81.8°C XhoI GCAAGG   CTCGAG   ATG AGA 




77.3°C EcoRI GCAAGG     GAATTC     CAA TTC 




79.1°C XhoI GCAAGG CTCGAG ATG GAG AAA 




76.2°C EcoRI GCAAGG  GAATTC CAG CAA CTT 








GCAAGG  GAATTC CAA TTC ATC 
CTT CAG CAA CTT G   
Table 2.3: AGR-2 primers. Highlighted in bold are AGR-2 codon sequences whereas in 
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2.6.1.2 Hot-start Taq polymerase amplification 
 
PCR Master mix/reaction Cycling conditions 
1xPCR buffer (Qiagen) 
 1mΜ dNTPs (Promega)  
0.5mM MgCl2(Qiagen) 
0.1μM forward and reverse primers  
5% (v/v) DMSO 
1μg DNA template 
HotstarTaqTM DNA polymerase 
5units/reaction (Qiagen)  
ddH2O up to a final volume of 50 μl 
 Taq activation:95°C for 15min, 
Denaturation:95°C for 30sec, 
Annealing: 53.6°C for 30sec, 
Elongation:72°C for 1min  
Cycle to step 2 x30 times, 
72°C x 5min. 
4 °C for t∞ 
 
 
In order to ensure maximum yield of amplification for each product, different 
annealing times, varying from 50-70°C, along with elongation times between 30sec-
3min, were tried. Different concentration of MgCl2 and DMSO covering a range 
between 0.1-3mM and 1-10% (v/v) per reaction respectively, ensured maximum 
primer efficiency. 100ng of DNA template were used as initial concentration. 
 
 
2.6.1.3 PFU polymerase reaction 
The reason for trying PFU® Turbo amplification was that unlike Taq DNA 
polymerase, highly thermostable Pfu DNA polymerase possesses 3' to 5' exonuclease 
proof-reading activity that enables the polymerase to correct nucleotide-
misincorporation errors. This means that Pfu DNA polymerase-generated PCR 
fragments will have fewer errors than Taq-generated PCR inserts. All reactions 
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2.6.1.3 PFU Turbo polymerase amplification 
PCR Master mix/reaction Cycling conditions 
1x cloned PFU® buffer (Stratagene) 
 1mΜ dNTPs (Promega) 
0.5mM MgCl2 (Qiagen) 
0.1μM forward and reverse primers  
5% (v/v) DMSO 
1μg DNA template 
PFU® Turbo DNA polymerase 2.5 
units/reaction (Stratagene)  
ddH2O up to a final volume of 50 μl 
 Taq activation:95°C for 15min, 
Denaturation:95°C for 30sec, 
Annealing: 53.6°C for 30sec, 
Elongation:72°C for 1min  
Cycle to step 2 x30 times, 
72°C x 5min. 
4 °C for t∞ 
 
PfuTurbo® properties list 
• Ideal for high-fidelity amplification  
• 3'-5' exonuclease activity provides a low error rate  
• One of the most thermostable DNA polymerases known  
• Lack of extendase activity means no unwanted 3’ overhangs  
• Optimal for blunt-end PCR cloning  
• Optimum temperature near 75°C  
• 95% active after 1-hour incubation at 98°C 
 
2.6.2 Site Directed Mutagenesis 
 
 
2.6.2.1 Primer Design 
 
To mutate specific tyrosines to phenylalanines, the QuickChange mutagenesis XL kit 
(Stratagene) was employed according to the manufacturer’s instructions. Primers 
were designed according to the guidelines laid out in the QuickChangeTM Site 
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Directed Mutagenesis Kit Manual (Stratagene) (Table 2.4). Oligonucleotides were 
purchased from Sigma-Genosys, PAGE purified and reconstituded in sterile dd H2O. 
The Quick Change Site Directed mutagenesis kit was used in order to reconstitute the 
original wt form of the AGR-2 DNA and correct the mutations integrated from the 
PCR reaction, referring to simple aminoacid substitutions or in frame reconstitution 
of the gene. Starting with two antiparallel primers carrying codons for the required 
substitutions (purchased from InVitrogen), vectors containing AGR2 DNA were 
PCR-amplified by Pfu DNA polymerase according to the manufacturer’s protocol. 
The incorporation of oligonucleotide primers generates a mutated plasmid containing 
staggered nicks. 
 
Name Tm Sequence 
Forward wt AGR2 
Inframe 
 
82°C AAG TTG CTG AAG  ACT GAA TTG 
CGA ATT CTG CAG TCG ACG 
 
Reverse wt AGR2 
Inframe 
 
82°C CGT CGA CTG CAG AAT TCG CAA 







AAA GCT CTC AAG TTG CTG CGA 







CGT CGA CTG CAG AAT TCG CAG 







AAG TTG CTG AAG  GAT GAA TTG 







CGT CGA CTG CAG AAT TCG CAA 







CTC AAG TTG CTG AAG GCT GAA 








CTG CAG AAT TCG CAA TTC 






C TA TAT AAA TCC AAG ACA AGC 
AAC AAA CCC TTG ATG ATT ATTC 
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GAAT AAT CAT CAA GGG TTT GTT 





CAT CTG CCG ACG TGA ATT TAT 








CCC CGG CGG ACC ATA ATA AAT 







CTG CCG ACG ACG ATT TAT GCT 






TCA CCC CGG CGGACC AGC ATA 
AAT CGT CGT CGG CAG 
 
Table 2.4: Site-Directed mutagenesis primers. Muatted sequences are shown in bold. 
 
 
2.6.2.2 Site Directed mutagenesis reaction 
 
The QuickChange mutagenesis XL kit (Stratagene) was employed according to the 
manufacturer’s instructions. The 68°C step was adjusted to the size of the plasmid-
to-be amplified and the number of cycles was 16 for a single amino acid change or 
18 for multiple amino acid changes. 
 
 
2.6.2.3 DpnI digestion 
 
The product was then digested with Dpn I endonuclease, specific for methylated and 
hemimethylated DNA, hence the parental DNA template was digested (since DNA 
originating from E. coli is usually dam methylated). The nicked vector DNA carrying 
the desired mutations was proliferated in Epicurian coli XL1-Blue supercompetent 
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2.6.3 DNA Sequencing 
 
 
2.6.3.1 Primer design 
 
Sequencing primers were designed with a length of around 20-30 bp spaced over the 
MCS of each vector and a melting temperature of around 65.8-70°C. The 
oligonucleotides were HPLC purified (Sigma-Aldrich) and reconstituted in sterile 
ddH2O (Table 2.5).  
 
 












65.8°C TTTGTTTTGGCACCAAAATCAA  
Reverse 
 DsRed Express-N1 
 
67.9°C TGAAGCGCATGAACTCCTTGAT3’  
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2.6.3.2 Sequencing analysis 
 
Sequencing reaction 
20ul of each primers (10uM) 
5ul of DNA isolated by Qiagen MaxiTM kit or 
10ul DNA isolated by Qiagen MiniTM kit 
 
The DNA template along with the primers was sequenced in the Medical Research 
Council- Human Genetics Unit by experienced researchers (MRC-HGU, IGMM 
centre, University of Edinburgh). 
 
 
2.6.4 PCR purification of amplified DNA 
 
The PCR products designated to sub-cloning into different vectors were purified 
immediately after amplification using the QIAquick PCR purification kit (Qiagen) to 
ensure removal of primers, nucleotides, enzymes, mineral oil, salt and other 
impurities from DNA samples 
 
 
2.6.5 Annealing of single strand oligos for aptamer construction 
 
Single-strand Oligos (Sigma-Genosys), dissolved into nuclease free water (Promega) 
into a final concentration of 100µM, were mixed, forward and reverse oligo, and 
2μM of each was diluted in 10mM Tris-HCl, pH6.8. The mixture was heat-shocked 
at 85°C for 10min, cooled to room temperature for 1h, incubated at 37°C for 15min 
for the oligos to anneal and left at room temperature for another 10min. The 
concentration of the final annealed double-strand oligo was determined by 
spectrometry at 260nm (Digilab Hitachi).  Annealing efficiency was tested by 
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polyacrylamide gel electrophoresis and annealed oligos were digested and cloned 
into the appropriate vector, as described. 
 
 
2.7 Agarose and polyacrylamide gel electrophoresis for DNA 
 
2.7.1 Agarose gel electrophoresis of DNA fragments above 300bp 
 
50x TAE (Tris-Acetate EDTA) 6x DNA loading buffer 
2M Tris pH 6.8,  
0.1M Na2EDTA.2H2O 
 4% Acetic acid (v/v) 
Adjust pH to 8.5 
0.25% Bromophenol blue (w/v)  
0.25% Xylene cyanol (w/v) 
 15%   Ficoll 400 (w/v) 
 
TAE buffer was diluted (50x) to 1x and 1% (w/v) ultrapure agarose was added. The 
solution was heated in a microwave oven until the agarose is completely dissolved 
and left to cool down to handwarm under the hood. Ethidium Bromide EtBr was 
added to a final concentration of 5% (w/v). The solution was then poured into a 
horizontal electrophoresis gel tray with a 10-well or bigger comb inserter and left to 
solidify. When solid, the agarose gel was submerged in a horizontal electrophoresis 
tank filled in 1xTAE buffer. DNA loading buffer (6x) was added to the samples (3μl 
of site-directed mutagenesis DNA or 10μl of PCR amplified DNA) to 1x and then 
loaded onto the gel. 1kb DNA ladder was also loaded at 5μl volume. Electrophoresis 
at 100V at room temperature followed till adequate separation was achieved and then 
the bands were visualized by UV light using a CHEMI Genius2 BioImaging 
SystemTM (Syngene) and the GenesnapTM tool with an ethidium bromide filter and 
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2.7.2 Polyacrylamide gel electrophoresis of small DNA fragments 
 
 
10x TBE (Tris-Acetate EDTA) 50% polyacrylamide gel 
2M Tris pH 6.8,  
0.1M Na2EDTA.2H2O 
 4% Acetic acid (v/v) 
Adjust pH to 8.5 
50% polyacrylamide (v/v)  
50% 1xTBE (v/v) 
 300 μl Ammonium Pelsulfate (APS) 
10 μl TEMED 
 
17% polyacrylamide gel  
17% polyacrylamide (v/v)  
83% 1xTBE (v/v) 
300 μl Ammonium Pelsulfate (APS) 
10 μl TEMED 
 
Polyacrylamide gels have smaller pore sizes than agarose gels and allow precise 
separations of molecules from 10–1500bp. Due to the small size of the aptamers, the 
agarose gel was no option and for that reason a polyacrylamide gel approach was 
adopted. The 50% polyacrylamide gel was poured first and left to become solid in 
vertical glass plates. The 17% gel was poured above the 50% and 15-well comb was 
inserted and left to become solid. When solid, the gel was submerged in a vertical 
electrophoresis tank filled in 1xTBE buffer. DNA loading buffer (6x) was added to 
the samples (1μl of DNA diluted in 20μl ddH2O) to 1x and then loaded onto the gel. 
100bp DNA ladder(Biorad) was also loaded at 3μl/lane volume. Electrophoresis at 
110V at 4 °C for 6h followed till adequate separation was achieved. The gel was then 
washed in 1x TBE supplemented with 5% EtBr for 6h. The bands were visualized by 
UV light using a CHEMI Genius2 BioImaging SystemTM (Syngene) and the 
GenesnapTM tool with an ethidium bromide filter and transilluminator. The images 
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2.8 Restriction enzyme digestion and ligation 
 
2.8.1 Restriction enzyme digestion 
 
Single Restriction enzyme reaction Double Restriction enzyme reaction 
1xNEB/Roche buffer (1:10 v/v) 
supplemented with  
100μg/ml Bovine Serum Albumin (BSA, 
New England Biolabs) where required 
1μg of DNA  
1unit of restriction endonuclease 
 
1xNEB/Roche buffer (1:10 v/v) 
supplemented with  
100μg/ml Bovine Serum Albumin (BSA, 
New England Biolabs) where required 
2μg of DNA  
1unit of each restriction endonuclease 
 
Negative Restriction enzyme reaction  
1xNEB/Roche buffer (1:10 v/v) 
supplemented with  
100μg/ml Bovine Serum Albumin (BSA, 
New England Biolabs) where required 
1μg of DNA  
no restriction endonuclease 
 
 
Restriction enzyme digestion of the vector and the DNA-insert is required after  PCR 
amplification. The restriction endonucleases recognize specific sequences to digest. 
As far as the insert is concerned the adequate restriction enzymes were chosen 
according to the Multiple Cloning Site (MCS) of the vector to be inserted in. The 
DsRed-Express N1 and the AcGFP-N1 plasmids have an identical MCS and so the 
mature and full length wt and mutants AGR-2 fragments contained the same 
EcoRI/XhoI sites on the 5’-3’ end respectively (Table 2.6). 
Single, containing only one of the enzymes, and double, with both of the enzymes, 
reactions were performed in the vector. The single restriction enzyme reaction 
ensured the functionality of the enzyme as the linear DNA runs slower than the 
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circular when electrophorised onto a 1% agarose gel. Most of the enzymes used were 
purchased from NEB and the maximum efficiency buffer (1, 2, 3 or 4) was chosen 
according to the NEBbuffer chart (www.neb.com). When enzymes from different 
companies needed to be used, the compatibility of the buffers was compared 
according to their composition. When EcoRI (NEB) was combined with XhoI 
(Roche) the buffer from Roche was used which had the same composition as buffer 1 




Company Recognition site Activation 
temperature 
BamHI New England 
Biolabs  
37 °C 




EcoRI New England 
Biolabs  
37 °C 
EcoRV New England 
Biolabs  
37 °C 









Table 2.6: Restriction enzymes. 
 
 
2.8.2 DNA gel purification 
 
After incubation at 37°C, the entire DNA was run on a 1%, w/v, agarose gel in TAE 
buffer supplemented with 5% EtBr, after diluting it in 1x DNA loading buffer (6x). 
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Low temperature melting agarose (Sigma) was used for electrophoresis. The gel was 
then run at 100V for 1h and the bands were visualized and excised under UV light 
(Flowgen). The resulting agarose fragments containing the digested DNA were 
transferred to sterile Eppendorf 1.5ml tubes and weighed. The Gel Extraction kit 
(Qiagen) was used to extract and purify the digested DNA. 
 
 
2.8.3 Dephosphorylation of recessed 5’ends or blunt ends 
 
Dephosphorylation reaction Formula for the amount of CIAP 
needed 
1x Alkaline Phosphatase Calf  
Intestinal (CIAP) buffer (10x, Promega) 
CIAP (0.5U/pmols of ends, Promega) 
Digested DNA 
Sterile H2O up to 100μl 
 
μg of vector to be phopshorylated x 3.04 
               size of vector (Kb) 
Dephosphorylation is the essential process of removing phosphate groups from 
an organic compound (as ATP) by hydrolysis. The opposite process 
is phosphorylation.  Dephosphorylation of a DNA template, usually a vector plasmid, 
is essential when it comes to ligating a phosphorylated digested insert to a digested 
vector, as it increases the ligation ability of each other. After addition of the 
phosphatase, the reaction was incubated at a 37 °C waterbath for a time of 15min and 
then at 56 °C heated stage for another 15min. A second aliquot of the enzyme was 
added (0.5U/pmols of ends) and the incubation times at both temperatures were 
repeated. The higher temperature ensures accessibility of the recessed end. 0.5M 
EDTA, pH8.0, was used to stop the reaction. Unless processed to ligation directly the 





Chapter 2                                                                                       Materials & Methods
   
2.8.4 Ligation of DNA in the appropriate vector 
 
 




Formula for the vector:insert ratio 
1x Ligation Buffer (10x Promega) 
10-100ng vector DNA 
xng insert 
10units of T4 ligase (10u/ μl , Promega)
ddH2O up to 10μ 
 
μg of vector x size of  insert (Kb)    x ratio insert 
         size pf vector (Kb)                             vector 
After digestion the vector plasmid and the DNA-insert were ready to be ligated. The 
above reaction was incubated at 4 °C in Eppendorf tubes, overnight. For each 
ligation different ratios insert:vector were applied each time, varying between 1:1 
and 5:1, according to the size of the insert when compared to the vector.  
 
 
2.8.4.2 Transformation of the ligated mixture into competent cells 
 
After ligation 1-10μl of the mixture was added to 100μl of DH5α cells or 20-50μl 
XL-Blue supercompetent cells (Stratagene) and the heat-shock transformation 
method was applied. The transformed bacteria were then plated out in LB-agar plates 
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2.9 Co-immunoprecipitation assay 
 
IP  Wash buffer A IP Wash buffer B 
1%NP40 
25mM Tris pH.7 
0.4M KCl 
Keep at 4 °C 
0.1% NP40 
 25mM Tris pH.7.5 
150mM  KCl 
 Keep at 4°C 
 
 
IP Lysis buffer 
 
Protease Inhibitor cocktail 
IP Wash Buffer A 
1M DTT (7μl per 7ml buffer),  




Complete mini protease Inhibitor 
cocktail tablets supplied by Roche 
Cells were cultured for 24h, in a 10cm plate at 37 °C until reached 80-95% 
confluence. Twenty-four hours post-plating, the cells were rinsed twice with 10ml 
sterile ice cold 1xPBS, and harvested in 1ml sterile ice cold PBS. The eluate was 
then centrifuged at 13000rpm, 4 °C and the pellet was resuspended in IP Lysis buffer 
(500μl/10cm dish). The suspension was incubated at 4 °C for 30min on a rotary 
shaker and following centrifugation at 13000rpm, snap frozen in liquid N2 unless 
processed for co-immunoprecipitation on the same day.  30μl of Protein G Fast Flow 
beads (SantaCruz) per reaction were washed 5x in IP wash buffer B, at 4 °C with 
rotation and centrifuged at 3000rpm for 1min each time and in the final step 
resuspended in 50μl IP Wash buffer B. 500μg -1mg of protein, as measured by 
Bradford method, were incubated overnight at 4 °C with 1ml IP Buffer B plus 1M 
DTT and protease inhibitors in the presence of 50μl of beads (SantaCruz) and 2μl of 
the appropriate primary antibody. The protein plus beads-primary antibody complex 
was recovered by centrifugation for 1min at 13000rpm and washed 6x with 1ml IP 
Wash buffer B buffer on a rotary shaker. The third time wash was for 15 min instead 
of 5 min and the last centrifuge was at 13000 rpm instead of 6000rpm. The pellet was 
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resuspended in 75μl of sample buffer (5x) containing DTT. Samples were boiled at 
90 °C for 1min prior to SDS-PAGE analysis.  
 
 
2.10 Fluorescence analysis 
 
 
2.10.1 Immunofluorescence analysis 
 
 
2.10.1.1 Antibodies for fluorescent microscopy 
 
 
Antibody Specificity Type Dilution Company 




 1:1000 Abcam 




 1:500 Abcam 
Anti-AGR2 AGR-2 protein mouse 
monoclonal 
 1:1000 Abnova 
Anti-AGR3 AGR-3 protein mouse 
monoclonal 
 1:1000 Moravian 
Biotechnologies
Anti-HA HA epitope tag mouse 
monoclonal 
 1:1000 Sigma 




 1:5000 Sigma 
 
Table 2.7: Primary antibodies list for immunofluorescent microscopy. 
 
 
Antibody Specificity Excitation colour 
Alexa 594 Goat anti-mouse red 
Alexa 488 Goat anti-mouse green 
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2.10.1.2 Immunofluorescence analysis for endogenous proteins 
 
 
Wash buffer Fixatives 
1x PBS 
0.01% Tween-20 
4% Parafolmadehyde  (w/v) or 
100% Methanol (v/v) or 




0.5% Triton-X100 (v/v) 
Freshly prepared each time 
 
Antibody solution 
1% Bovine Serum Albumin (w/v)  
1x PBS 
Filter sterilized 
Stored at 4°C 
Blocking solution 
3% BSA (w/v) 
1x PBS 
Filter sterilized 
Stored at 4 °C 
 
 
Cells were seeded at a density of 0.13x106 cell/ ml and plated in sterile four-
chambered slides (NUNC). Twenty-four hours post-plating the medium from the 
cells was removed and the slides were washed 2x in sterile PBS. 4% PF, 200μl/per 
chamber, was added for 15min as a fixative and 3x washes in sterile 1x PBS 
followed. Cells were also fixed in ice cold methanol or a mixture of 
methanol:acetone (1:1, v/v) for 5min, and air-dried in order to specify the optimal 
fixing method. This fixation method does not require a permeabilization step. 
Parafolmadehyde fixed cells were permeabilised in freshly prepared 0.5% (w/v) 
TritonX-100 in 1xPBS, and slides were washed 3x with 1x PBS for 10min. 
Following washes with 1x PBS, nonspecific sites were blocked for 1h with 3% (w/v) 
BSA/PBS in room temperature under shaking. After 3 washes in 1xPBS, the plastic 
chambers from each slide were removed by forceps and cells were incubated 
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overnight with the primary antibody diluted in 1% (v/v) BSA/PBS at 4 °C 
(200μl/chamber). Different antidoby dilutions were used in order to define the best 
concentration that ensured low background staining and higher epitope binding.  
Twenty-four hours post-incubation, the slides were washed 5x in 0.1% (v/v) PBS-
Tween and incubated with the secondary antibody conjugated to Alexa for 30min at 
room temperature (200μl/chamber). After the secondary antibody incubation cells 
were washed 3x in 0.1% (v/v) PBS-Tween and the cells were mounted with 




2.10.1.3 Immunofluorescence analysis for transfected proteins 
 
Same protocol as 2.10.2.2 followed with the only modification in the transfecting 
step. Transfections were performed with the Lipofectamine reagent (InVitrogen). 
Cells were seeded at a density of 0.13x106 cell/ml and plated in sterile four-
chambered slides (NUNC). Twenty-four hours post-plating the growth media from 
the cells was removed and fresh media was added. Cells were transfected with 
1μg/ml total DNA. In co-transfections, 0.5μg/ml DNA along with 0.5μg/ml pDEST 
3.2 control DNA was added to ensure a total amount of 1μg/ml per chamber. The 
slides were then processed as described previously. 
 
 
2.10.2 Nuclear staining for fluorescent microscopy 
 
 
2.10.2.1 Epifluorescence microscopy nuclear staining 
 
DAPI or 4', 6-diamidino-2-phenylindole is a fluorescent stain that binds strongly 
to DNA. Since DAPI will pass through an intact cell membrane, it was used to stain 
fixed cells (4% parafolmadehyde, ethanol/acetone fixed). DAPI is excited 
with ultraviolet light (UV). When bound to double-stranded DNA its absorption 
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maximum is at 358nm and its emission maximum is at 461nm. This emission is 
fairly broad, and appears blue/cyan. DAPI will also bind to RNA, though it is not as 
strongly fluorescent. Its emission shifts to around 500nm when bound to RNA Apart 
from labelling cell nuclei, the most popular application of DAPI is in detection 
of mycoplasma or virus DNA in cell cultures. 
At the last step before mounting the fixed cells, DAPI stain was added to the DAKO 
Cytomation mounting media at a concentration of μl per 1ml media. No incubation 
time was required and the slides were ready for observation immediately. 
 
 
2.10.2.2 Confocal fluorescence microscopy nuclear staining 
 
TO-PRO 3 stain is a useful counterstain and dead cell indicator, with long-
wavelength red fluorescence, excites at 633nm, easily distinguished from fluorescein 
and rhodamine fluorescence.  
TOPRO 3 solution (1mM, InVitrogen) was diluted 1:1000 in 37°C pre-warmed PBS 
and  added to each chamber of the slide, at approximately 200μl per chamber. The 
slides were then incubated at a 37°C dark incubator and washed 3x in PBS-T, room 
temperature warm, each for 5min, on a vertical shaker. The PBS was then discarded 
and the slides were mounted with DAKO Cytomation mounting media. Unless 
directly processed to imaging, the slides were kept at 4°C, covered in foil to ensure 
no light conditions and fading of the signal. 
 
 
2.10.2.3 Live cell imaging nuclear staining 
 
mCherry (kanR) plasmid pBS34 (kindly provided by Dr. Lierres, University of 
Dundee) was added to the cells at the 37 °C incubator under normal Lipofectamine 
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2.10.3 Live cell imaging analysis 
 
Cells designated to live cell imaging analysis were directly grown at 4-chamber glass 
slides (NUNC) after seeded at a density of 0.13x106 cell/ ml. Twenty-four hours 
post-plating, CO2 independent growing media (GIBCO), containing no phenol red 
was added to the cells and slides were adjusted to an inverted Leica SP-5 confocal 
microscope (Leica), equipped with a temperature controlled chamber. Distribution 
and localization of the protein of interest was exported and analysed as AVI file by 
the Leica Application Suite software. 
 
 
2.11 ELISA analysis 
 
AGR-2 and AGR-3 peptides were coated in a 96-ELISA plate in 0.1M NaHCO3 (pH 
8.6) and incubated overnight at 4 °C. Templates were washed 6x PBS-T (0.1%) in a 
final volume of 200µl/well and blocked by 4% BSA/PBS-T (w/v) for 1h on a rotary 
shaker. Primary antibodies diluted in 3% BSA/PBS-T (1:1000, v/v) were added and 
incubated at 4 °C overnight. The plate was then washed 6x PBS-T (0.1%) in a final 
volume of 200µl/well and HRP-conjugated anti-mouse secondary antibodies, diluted 
in 3% BSA/PBS-T, were added on a rotary shaker for 1h, at room temperature. 
ECL1/2 (1:1, v/v) was added (50µl/well) and emission was measured in RLU under a 
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3.1 Introduction 
 
3.1.1 Protein trafficking within the cell 
 
3.1.1.1 Sequences defining the localization of proteins 
 
Signal sequences play a vital role in targeting as well as in protein topogenesis by 
orienting themselves in the translocon [244], and the membrane [250, 552, 607]. 
Cleavable signals for secretory proteins were found to expose their C-terminal 
cleavage site to signal peptidase on the luminal surface of the ER membrane and the 
N-terminus towards the cytosol [217]. A major factor that determines orientation is 
the distribution of charged amino acids on either end of the hydrophobic sequence 
due to electrostatic interactions with charges at or near the translocon [217]. The 
more positively charged flanking sequence is usually found on the cytosolic side of 
the membrane in both prokaryotic and eukaryotic cells [250]. Another important 
factor which might affect protein topogenesis is the folding of N-terminal sequences, 
whereas the size of this sequence does not seem as a limiting factor [139].  
Various models were suggested to explain the protein translocation and orientation 
when it comes to ER [217, 456, 527]. Some of them are quite contradictory but they 
all come to one conclusion:  the flanking charges are vital in determining protein 
translocation and orientation. One of the most common ER retention sequence is the 
KDEL (HDEL in yeast) sequence. 
 
 
3.1.1.2 Endoplasmic Reticulum and protein trafficking  
 
In order to understand the role of AGR-2, it is essential to study the secretory 
pathway where the two different isoforms of the AGR-2 protein are involved. In the 
secretory pathway, proteins travel from the Endoplasmic Reticulum (ER) where they 
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are synthesised through the Golgi apparatus and then are redirected to secretion, 
plasma membrane, and towards secretory and endocytic organelles (Figure 3.1). The 
biosynthetic pathway is balanced by the opposite-way pathway that includes 
endocytosis of extracellular molecules as well as recycling of intracellular proteins 
[601]. Trafficking is being accomplished by fusion vesicles or connecting tubules. 
Most proteins are retained in the ER until they are correctly folded and assembled. 
Besides allowing post-translational modifications such as protein-folding, 
glycosylation, disulfide bond formation, proline-hydroxylation, and tyrosine 
sulfation, the secretory machinery has to fulfill another important task, namely the 
distribution of correctly folded proteins to their final destination [57]. Misfolded 
proteins are retrotranslocated to the cytosol, in a process involving ER chaperones 
and key-proteins of the import machinery, and degraded by the proteasome, most 
times by polyubiquitination [66]. Correctly folded proteins leave the ER, ‘exit sites’, 
and selectively exported by COPII vesicles to the Golgi apparatus [171] (Figure 3.1). 
Once the COPII vesicles have detached from the ER and formed vesiculotubular 
clusters (VTCs) with the microtubules, the COPII coat is replaced by the COPI coat. 
COPI vesicles are formed in the cis-Golgi compartment and mediate the formation of 
return vesicles back to the ER (Figure 3.1) through a retrograde pathway. Finally, the 
trans-Golgi network, from which cargo moves to the plasma membrane (PM) and 
through endosomes to lysosomes serves as a location for the rerouting of some 
misfolded proteins that are to be degraded [171]. Secretory proteins usually enter the 
ER post-translationally. In terms of the machinery involved, secretory transport can 
be dissected into at least four distinct steps: ER import/quality control, ER to Golgi 
transport, intra-Golgi transport/ER retrieval and post-Golgi transport [57]. Their 
translocation depends on the N-terminal signal peptide. This signal peptide is 
removed by a signal peptidase post-translationaly while the protein is exiting the ER 
[601]. If a protein contains a stop-transfer signal then translocation is halted and the 
hydrophobic regions are inserted into the membrane and join transmembrane 
domains [601].  
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Figure 3.1 : Schematic overview of the organelles of the secretory pathway. Synthesized 
proteins enter the pathway at the ER and are subjected to repeated sorting and transport 
between membrane organelles until they arrive at their designated destination. PM:plasma 
membrane, ER:endoplasmic reticulum, VTC:vesiculotubular cluster. (for detailed 
explanation consult 3.1.1.2, adapted from [171]) 
 
 
3.1.1.3 KDEL sequence as an ER-retrieval sequence 
 
The ER, as mentioned above, contains a number of resident proteins whose roles 
include: protein and lipid modification, processing of N-linked glycans, vesicle 
formation, protein sorting and transport [246]. Proteins that are transported along the 
secretory pathway are membrane proteins, soluble lysosomal/vacuolar proteins and 
secreted proteins [57, 171] as mentioned above. Soluble ER proteins include 
chaperones and components of the quality control machinery [171]. The localization 
of these proteins in the ER or the processing to the Golgi is established by certain 
retention or retrieval mechanisms involving specific sequence motifs within the 
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polypeptide chain [573]. ER-residency is achieved in two ways: (i) prevention of 
residents from entering newly forming transport vesicles and (ii) retrieval of those 
residents that escape [573]. The latter mechanism is directed by discrete retrieval 
motifs. One of the most thoroughly studied and best characterized sequence 
responsible for ER-retention is the KDEL sequence (HDEL in yeast) present in 
soluble ER-resident proteins [353, 631] in their C-terminus. It is a tetrapeptide 
sequence consisting from K-D-E-L, Lysine-Aspartic acid-Glutamic acid-Leucine, 
and recognized by specific receptors, named KDEL receptors, in post-ER 
compartments (Figure 3.2) that return the proteins to the ER. This retrograde 
transport triggers the formation of the COPI-coated vesicles mentioned above that 
transport the protein from the Golgi back to the ER [57, 171]. 
ER-retrieval sequences ensure return of proteins that have left the compartment in 
which they reside. It is noteworthy that apart from the KDEL motif, ER-residency is 
achieved by direct retention involving association and interaction of protein subunits 
into large complexes through their transmembrane or luminal domains [433, 446]. 
The aforementioned subunits escape packaging through preventing being exported 
from the ER. The ER-resident lumen proteins, known as reticuloplasmins, are 
conserved between eukaryotic cell types from plants, animals and fungi. Examples of 
these proteins include the molecular chaperones BiP, HSP and PDIs (analysed in 
chapter 1.4). Apart from the KDEL motif, many ER transmembrane proteins contain 
a dilysine motif (KKXX) at their C-terminal cytoplasmic tail that ensures ER-
retention and not ER-retrieval. 
Interestingly, plants utilize two ER-retention sequences, HDEL and KDEL. In some 
proteins, such as the SH-EP (cysteine protease) superfamily, the KDEL sequence is 
being post-translationally removed [441]. The removal of the KDEL sequence from 
SH-EP in homologous Vinus mungo cells and in heterologous SF-9 cells is so far 
unique amongst the retention sequence-bearing proteins that have been described 
[441]. Several studies  have shown partial or enhanced retention within the 
ER/nuclear envelope that usually ends up to trafficking to the endomembrane 
system, indicating that the KDEL sequence itself is not sufficient to ensure complete 
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retention within the ER [138]. However, in the above studies the exact fate of the 
retention signal was not established and the possibility of post-translational 
processing masking its effects still remains.  
 
 
3.1.1.4 The KDEL receptor mediates ER retrieval 
 
The KDEL receptor (Figure 3.2), also known as ERD2, is a Golgi/intermediate 
compartment-located integral membrane protein [231] that carries out the retrieval of 
escaped ER-proteins bearing a C-terminal KDEL sequence [83]. The receptor 
recognizes and binds to this KDEL tetrapeptide. It consists of a seven-
transmembrane domain protein with a short 12-13 amino acid tail at the C-terminus, 
orientated towards the cytosol that is responsible for the retrieval of ER-proteins 
from the Golgi complex [586]. Phosphorylation of the KDEL receptor at serine 209 
(in the consensus site KKLSL) is necessary for its function [83]. The retrieval of the 
KDEL-bearing proteins by the receptor happens through retrograde traffic mediated 
by COPI-coated transport vesicles [83] (Figure 3.1).  The receptor has high affinity 
for this tetrapeptide and after release of the protein to the ER, is recycled back to the 
Golgi for further cycles of retrograde transport. The pH difference between the ER 
and the Golgi has been proposed to be responsible for the different affinity exhibited 
by the receptor towards different kinds of proteins, enabling binding of KDEL 
proteins in the Golgi and release upon to the ER [622]. 
 
 
Figure 3.2: Structure of the KDEL receptor. This receptor is responsible for retrieval of 
KDEL-proteins back to the ER. (picture adapted from www.georgetown.edu, June 2006). 
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3.1.2 Fluorescent microscopy as a localization tool 
 
One of the most commonly used techniques to detect intracellular protein 
localization and trafficking, and the one used thoroughly throughout the whole 
project, is fluorescence microscopy. Fluorescence imaging is a useful method for 
studying the localization or concentration of molecules to subcellular loci, as it is 
non-invasive, of high sensitivity and specificity. Fluorescence occurs when light 
absorbed by a molecule is emitted after a very short period (approximately 10−8s) 
following light absorbance. Emitted light is always produced at a longer wavelength 
than absorbed (named Stokes shift) due to a small dissipation of energy during the 
excited state [175, 476]. This shift is of course crucial for the detection of 
fluorescence as it makes it possible to discriminate between the excitation and the 
emission signal. Fluorescence is gaining more and more ground over the recent 
years, resulting in many different techniques that stem from the same principle: 
emission and excitation of fluorophores when light activation occurs. 
Neither Y2H, nor MS provide data on the interaction of proteins in their native 
environment. The development of highly sophisticated equipment along with the 
wide use of fluorescent proteins in cell biology, enabled researchers to study protein 
interactions in vivo, even transient ones. Most of these methods are based on the 
excitation of a donor-fluorescent fused molecule and an acceptor-fluorescent fused 
one followed by fluorescent measurements. Fluorescense Resonance Energy Tranfer 
[406], Bioluminescence Energy Transfer [628], Fluorescence Correlation 
Spectroscopy, Fluorescence Lifetime Imaging [390] and co-localization assays are 
only very few of the techniques that fall into this category [476] (Table 3.1). 
Bioluminescent RET is similar to FRET, but in this case the candidate protein is 
fused to a bioluminescence luciferase and the potential binding partners to a GFP 
protein. When the two proteins interact, the luciferase and the GFP are brought close 
enough for resonance energy transfer to happen, and therefore the bioluminescence 
emission is shifted [628]. Both methods offer no limitations when it comes to the 
localization of the proteins, compared to the Y2H, but are dependent on the 
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orientation and conformation of the binding partners. Moreover, cell type specific 
interactions can be detected, as both systems utilize fluorescence change and this is 
feasible to any model. On the other hand, because the fluorophore/ luciferace tags are 
fused to ends of potentially interacting proteins and because resonance energy 
transfer requires distance between 10-100 Å, some interactions may not be detectable 
despite occurring because the fluorophore/luciferase do not come in close distance. It 
is also possible to test the kinetics of interaction in vivo [628]. 
 
 
3.1.2.1 Fluorescent techniques for imaging 
 
Following is a brief summary of the techniques widely used in fluorescent 
microscopy for variable studies concerning protein trafficking, secretory pathways, 
protein interactions [476] (Table 3.1) 
 





Visualization of protein distribution in fixed or living 
cells. Quantification is less difficult than that of 





Change in location of a protein in a living cell over 
time. Motion/dynamics ofvisible organelles and 




Change in location of a protein in a single living cell 
over time. Typically used to determine kinetics of 
transfer of a bolus of protein between organelles. 
Varying degrees of sophistication can be applied 
ranging from determination of general timescale to 
fitting mathematical models based on systems of 
differential equations 
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Determines ability of a protein to diffuse within a 
single membrane or within cytosol, effectively a 
probe of local environment. Also commonly used to 
visualize kinetics of exchange of a protein between 
two compartments in cases where the trafficking of 
the protein cannot be effectively synchronized. The 
two compartments can be organelles of the secretory 





Locates particular protein–protein interactions inside 
cells. Requires a fluorescent tag on each of the 
proteins. FRET is sensitive to the exact distance 
between these fluorescent tags and will fail if they are 





FCS can determine diffusion coefficients, degree of 
clustering of a molecule and molecular 
concentrations. It can have advantages over FRAP for 
fast-diffusing (i.e., cytosolic) proteins and when the 
fluorescent protein is a mix of fast-diffusing and slow-
diffusing species. Requires a specialized apparatus. 





FCS variant used to detect complexes between two 
proteins each carrying a different fluorescent tag. 
Unlike FRET the technique is insensitive to the 





Same uses as FCS but can be implemented with 
standard confocal microscope capable of rapid image 
acquisition. Can give some spatial resolution as well 
as directional information in the case of protein flow. 






ICS-based technique to detect interaction between two 
proteins tagged with different fluorophores. Requires 
a confocal microscope capable of rapid simultaneous 
acquisition of two channels. Current generation 
confocal microscopes are generally capable of this. 
However specialized mathematical expertise and 
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Fluorescence Lifetime 
Imaging Microscopy 
Primarily used as a sensitive technique to detect 






Detects events occurring very close to the cell surface 
(e.g. vesicle fusion). Can also be used to visualize 
single fluorescent molecules on or very near the cell 
surface. 
 
Table 3.1: List of different fluorescent-based techniques and applications. Right panel 
refers to the definition and the left panel explains the exact application of each technique 
(adapted after [476]). 
 
 
3.1.2.2 Directly labelled proteins 
 
Direct labelling of the target protein was used in this project to visualize different 
proteins in subcellular compartments. In this method, the cells are transfected with 
plasmids encoding the gene of interest fused with a fluorescent protein (green, 
yellow, cyan and red are the most widely used, Table 3.2).  The fused gene is the 
introduced into the cells where it is being expressed fused to the FP protein and its 
localization is detected by fluorescent microscopy using the excitation and emission 
wavelengths specific for each fluorescent probe (Table 3.2). 
Endogenous fluorescent proteins are usually found in many cnidarians [301, 535] 
including many jellyfishes and corals as energy-transfer acceptors in 
bioluminescence. FPs fluoresce in vivo upon receiving energy from either a 
luciferase-oxyluciferin excited-state complex or a Ca+2-activated phosphoprotein 
[475]. Fluorescence in these species serves reproductive and survival purposes and is 
genetically controlled. The emission and excitation wavelengths vary from colour to 
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Colour Excitation Emission 
Green 395 nm 509 nm 
Red 558 nm 583 nm 
Cyan 434 nm 475 nm 








Table 3.2: Excitation and emission wavelengths of each of the 4 most widely used 
fluorescent proteins (information adapted from www.BDbiosciences.com) 
 
 
Although fluorescent proteins are quite useful in research, they also have drawbacks 
and features that can reduce their quality as reporter genes. For that reason most of 
the fluorescent proteins than are used in biology are developed and optimized so 
variants are being selected [43]. Each variant has different spectra of characteristics, 
leading to enhanced fluorescence emission. The insertion of different promoters to 
drive expression of the gene of interest, usually under cytomegalovirus promoter, and 
mutations to the sequence are also used to increase their efficiency and stability as 
molecular markers. The most commonly used fluorescent proteins are the Green 




3.1.2.3 Green Fluorescent Protein 
 
The Green-Fluorescent Protein (GFP) has become an important reporter for 
monitoring gene expression and protein localization within cells [660]. Prasher and 
co-workers, 1992, were the first to clone the green fluorescent protein found in the 
medusa Aequorea Victoria [475]. The protein consists of a β-barrel with 11 anti-
parallel strands, capped at both ends, and a coaxial helix, with the chromophore 
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forming from the central helix in the internal cavity [448] (Figure 3.3). When GFP is 
expressed it yields green fluorescence when excited by ultraviolet (UV) or blue light. 
To utilize their fluorescence in molecular biology, many variants of the GFP protein 
are constructed. These variants aim to reduce GFPs disadvantages and increase its 
useful characteristics (summarized in Table 3.3). One of these variants is the AcGFP-




Figure 3.3: Structure of the GFP protein. The barrel-like structure of GFP. The 
fluorophore is the one retained in the internal cavity (adapted from www.tsienslab.usbc, 
December 2005) 
 
Green  Fluorescent Protein 
Pros Cons 
Stable variant Low fluorescent intensity in blue light 
Species-independent Poor expression in some mammalian cell lines 
Non-invasively monitored Low sensitivity 
Direct measurement of 
transfection efficiency 
Lag in the development of fluorescence after protein 
synthesis 
No need of substrates or 
cofactors 
Not very high half life 
Table 3.3: Advantages and Disadvantages of the Green Fluorescent Protein (GFP) 
widely used in fluorescence microscopy. 
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The AcGFP1 variant derives from the jellyfish Aequora coerulescens and is a novel 
alternative to monomeric GFP. AcGFP1 is an engineered fluorescent mutant of the 
wild-type protein with 94% homology to enhanced-GFP, EGFP a bioengineered GFP 
with enhanced fluorescent abilities, at the amino acid level. The plasmid that 
contains this variant (obtained from BD Biosciences) features an open reading frame 
in which the coding sequence has been optimized for expression in human cells. This 
optimization increases the translational efficiency of the AcGFP1 mRNA and results 
in higher expression levels. The AcGFP1 protein is stable and can be detected 
without cofactors or substrates. The last feature makes it a valuable tool for 
transfections and immunofluorescent microscopy. The protein can be fused to the N- 
or C- terminus of the protein, characterised as AcGFP-C1 and AcGFP-N1 in respect 
to which terminus of the GFP the target gene is fused. 
 
 
3.1.2.4 DsRed and its variants 
 
Another fluorescent protein, which emits red fluorescence and that will be used 
widely, is the DsRed protein, a variant of the Anthozoan reef coral Discosoma sp. 
fluorescent protein [391]. Reef corals consist of a variety of colours. These corals 
have the ability to tolerate different intensities of light depending on the depth they 
are into [508]. Fluorescent proteins, yellow and red, of these corals have the ability to 
protect them from intense light exposure in shallow water but on the other hand, they 
enhance availability and absorption of light in deep water [508]. Anthozoa animals 
do not have bioluminescent properties unlike Aequorea victoria, suggesting that in 
Nature fluorescent proteins are not always linked to bioluminescence. 
The fluorescence excitation and emission maxima of the protein are at the 
wavelengths 558nm and 583nm, respectively which are well separable from that of 
GFP and therefore attracts great interest as an expression marker and fusion partner 
for multicolor cellular imaging [382]. DsRed, 28kDa size, is a tetramer and this 
structure is essential for the fluorochrome’s maturation [637]. It is also believed that 
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this tetrameric configuration provides the needed photoprotective character to the 
corals [637]. Each DsRed monomer has an 11-stranded α-can tertiary structure 
(Figure 3.4) similar to that of GFP. These monomers units interact with each other 
via hydrophobic and hydrophilic interactions to form a tetrameric unit [637]. The 
advantage of DsRed compared to GFP is that the first one’s fluorescent spectra is 
unaffected by pH (in the range 5–12 [33]) and its orange-red emission (wavelength 
maximum 583nm) is spectrally distant from green cellular autofluorescence. These 
properties should make DsRed a better choice as a label in some applications 
compared with GFP. However DsRed has some drawbacks including, slow 
maturation, strong oligomerization to form a tetrameric structure, and a tendency to 
aggregate which can limit its applications [33, 85, 406, 537]. Modifications of DsRed 
to improve its properties and create monomeric, faster-folding, more efficient and 
photostable variants are underway with the help of molecular evolution and genetic 





Figure 3.4: The structure of the DsRed tetramer. The X-ray crystal structure of DsRed 
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3.1.3 Objectives of chapter 
 
Anterior Gradient 2 is present intracellularly in two isoforms. The full length which 
has a cleavable N-terminal signal peptide designating the protein to secretion and the 
mature form without this signal peptide. Both forms bear the same putative ER-
retention C-terminal tetrapeptide. No evidence exists whether one isoform is 
predominant compared to the other in a cancer cell. This chapter investigates the 
localization of endogenous AGR-2 in a panel of breast cancer cell lines. Moreover, 
fluorescent-tagged AGR-2wt and different mutants are examined in an attempt to 
fully characterize the distribution of the protein based on specific sequences present 
in either of the two isoforms. Co-localization data with different subcellular 
organelles and chemical fractionation of subcellular compartments are shown, further 
defining the variable localization patterns of the wild type proteins and mutants and 
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3.2.1 Localization of endogenous AGR-2 
 
3.2.1.1 Subcellular localization of endogenous AGR-2 in breast cancer panel  
 
Subcellular fractionation of endogenous AGR-2 protein was performed by the S-
PEK kit (Calbiochem) according to the manufacturer’s protocol, in order to study the 
localization of the endogenous AGR-2 in MCF-7, LCC1 and LCC9 cell lines at the 
protein level. LCC1 and LCC9 cell lines are MCF-7-derived and show different 
resistance to Tamoxifen and other antiestrogens, with the LCC9 cells being totally 
resistant to the drugs. The monoclonal antibody recognized a single band of 
approximately 20kDa. The migration of the protein onto the gel matched the 
predicted protein molecular weight (Figure 3.5). 
The AGR-2 band was present in the cytosolic (F1), cell membrane (F2) and nuclear 
fractions (F3) of all cell lines but differences in the expression levels were observed 
(Figure 3.5.A). No AGR-2 was detected in the cytoskeletal fractions (F4) in any of 
the cell lines. In MCF-7 cells, AGR-2 was expressed in higher levels in the cytosolic 
and cell membrane/organelles fraction, whereas nuclear AGR-2 was less dominant. 
On the other hand, in LCC1 cells the protein was more cytosolic and nuclear and less 
in the cell membrane/organelles fraction. In LCC9 cells, AGR-2 was highly nuclear 
and cytosolic, following the same pattern as in LCC1 cells, but with slightly more 
elevated nuclear levels. To sum up, the LCC1 and LCC9 cell panels appeared to 
express cytosolic and nuclear AGR-2 in higher levels that the MCF-7, whereas MCF-
7 showed elevated AGR-2 levels in the cytoplasm and lower levels in the nucleus 
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Figure 3.5: Intracellular localization of endogenous AGR-2 in breast cancer cell lines. 
A) MCF-7 (lanes 3 and 6) LCC1 (lanes 2 and 5) and LCC9 (lanes 1 and 4) were processed 
using fractionation methodologies into F1 (cytosolic), F2 (membrane/organelles), F3 
(nuclear), and F4 (cytoskeletal), as indicated.  The distribution of endogenous AGR-2 protein 
(~ 18 kDa) was determined by immunoblotting. B) Representative coomassie blue staining 
used as a control for fractionation.  
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Immunofluorescent data after staining for endogenous AGR-2 with rabbit polyclonal 
antibody (Moravian Biotechnologies) showed cytoplasmic distribution of the protein 
with strong perinuclear staining (Figure 3.6). No nuclear signs of AGR-2 were 
detected. The same motif was repeated in MCF-7, LCC1 and LCC9 cells. MDA-MB 
231 negative control cells had no signs of endogenous protein, as expected. 
Furthermore, immunostaining with a mouse monoclonal antibody against AGR-2 
followed similar distribution patterns in MCF-7 cells, with the only difference that 
this antibody was able to detect nuclear AGR-2 as shown by the white arrows 
(Figure 3.7). The protein was again detected in the cytoplasm with strong perinuclear 
staining. Cells grown in the absence of FCS for two days showed no change in the 
localization motives (Figure 3.7, panels D-F). Same observation was made with cells 
irradiated with 50J/m2 and left to grow for six hours before immunostained for AGR-
2 (Figure 3.7, panels G-I). Another striking difference when compared to the rabbit 
polyclonal antibody was that the monoclonal one showed a rather reticulum-like 
distribution pattern of the protein, with few granules distributed around the nucleus 
whereas the polyclonal one showed diffuse localization pattern but no signs of 
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Figure 3.6: Intracellular localization of endogenous AGR-2 using fluorescent 
microscopy. Fluorescent images of endogenous AGR-2 in MCF-7 (panels A-C), LCC1 
(panels D-F), LCC9 (panels G-I), AGR-2 positive, breast carcinoma cells, visualized by 
fluorescence microscopy. MDA-MB 231 (panels J-L), AGR-2 negative, cells were used as a 
negative control for unspecific antibody binding. After fixation the protein was visualized 
using anti-AGR2 antibody and Alexa-conjugated secondary antibody was applied (Alexa-
594, Molecular Probes). Nuclei were visualized by DAPI. Images captured by Sony Cool 
Snap 3.2 (Anti-AGR2: panels B, E, H and K, DAPI: A, D, G and J, merge: C, F, I and L) by 
Zeiss Axionplan microscope. Same exposure times used for all images. Figure showing 
representative of 3 independent experiments. Scalebar represents 10μm. 
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Figure 3.7: Intracellular localization of endogenous AGR-2 in MCF-7 using fluorescent 
microscopy and commercial anti-AGR2 antibody. Fluorescent images of endogenous AGR-
2 in MCF-7 cells grown in the presence of FCS (panels A-C), absence of FCS (panels D-F), 
UV irradiated panels G-I) and non-UV irradiated (panels J-L). After fixation the protein was 
visualized using monoclonal anti-AGR2 antibody (Abnova) and Alexa-conjugated secondary 
antibody was applied (Alexa-549, Molecular Probes).  Nuclei were visualized by DAPI. 
Images captured by Sony Cool Snap 3.2 (Anti-AGR2: panels B, E, H and K, DAPI: A, D, G 
and J, merge: C, F, I and L) by Zeiss Axionplan microscope . Same exposure times used for 
all images.). Scalebar represents 10μm. 
[109] 
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3.2.2 Localization of transfected mature and full length AGR-2 wt. 
 
3.2.2.1 Immunofluorescence verified AGR-2 localization  
 
MCF-7 (Figure 3.8), LCC1 (Figure 3.10), LCC9 (Figure 3.11) and MDA-MB 
231(Figure 3.9) cells were transfected with: 
• Mature  AGR-2wt pDEST 3.2, V-5 tagged,(Gateway) 
• Full length AGR-2wt pDEST 3.2, V-5 tagged, (Gateway) 
• pDEST 3.2 vector only (Gateway)  
Untransfected cells were also used for detecting endogenous AGR-2 and as a 
comparing control. Twenty four hours post-transfection cells were incubated with a 
rabbit polyclonal anti-AGR-2 antibody (Moravian Biotechnologies). In all the cell 
lines tested, including the AGR-2-negative MDA-MB 231 cell line (Figure 3.9), both 
full length and mature transfected cells exhibited the same localization patterns 
(Figures 3.8-3.11). The protein was detected in the cytoplasm distributed in a 
diffused pattern whereas no signs of membrane staining were present. No difference 
in proteins’ localization between the different cell lines was observed. In particular, 
cells transfected with the full length form of the protein,, showed no membrane 
staining, with most of the signal detected in the cytosolic area in all cell lines. Cells 
expressing the mature form of the protein that bears no leader sequence, excited most 
of the red light in the cytoplasm. As far as the endogenous AGR-2 is concerned, it is 
noteworthy that the pattern was the same as in the transfected ones, with the protein 
being detected in the cytoplasm and slightly in the nucleus, rather than in other cell 
compartments in LCC1 and LCC9 cels. The above data are consistent with the 
results from subcellular fractionation, which showed AGR-2 predominantly in the 
cytosolic fraction (Figure 3.5), although differences in the nuclear fraction were 
observed amongst cell lines. The cytosolic localization of AGR-2 was also confirmed 
by immunohistochemistry experiments in breast cancer tissues (kindly provided by 
R. Nenutil, Czech Republic) from ductal and lobular carcinomas (Figure 3.12). 
[110] 
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Figure 3.8: Intracellular localization of transfected mature and full length AGR-2 using 
fluorescent microscopy in MCF-7. Fluorescent images of the mature (panels A-C) and full 
length (panels G-I) AGR-2pDEST-3.2 constructs. MCF-7 cells were transfected with the 
constructs and visualized by fluorescence microscopy. Minus primary antibody controls 
were included (panels D-F, J-L). Protein was visualized by Alexa-conjugated antibody 
(Alexa-594, Molecular Probes). Nuclei were visualized by DAPI. Images captured by Sony 
Cool Snap 3.2 (red:panels B, E, H and  K, DAPI panels A, D, G and J merge:panels  C, F, I 
and L) under a Zeiss microscope. Same exposure times used for all images (scalebar:10μm). 
[111] 
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Figure 3.9: Intracellular localization of transfected mature and full length AGR-2 using 
fluorescent microscopy in MDA-MB 231. Fluorescent images of the mature (panels A-C) 
and full length (panels G-I) AGR-2pDEST-3.2 constructs. MDA-MB 231, AGR-2 negative, 
cells were used as a control for antibody binding. Minus primary antibody controls were 
included (panels D-F, G-I). Protein was visualized by Alexa-conjugated antibody (Alexa-
594, Molecular Probes). Nuclei were visualized by DAPI. Images captured by Sony Cool 
Snap 3.2 (red:panels B, E, H and  K, DAPI panels A, D, G and J merge:panels  C, F, I and L) 
under a Zeiss microscope. Same exposure times for all images. Scalebar represents 10µm. 
[112] 
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Figure 3.10: Intracellular localization of endogenous and transfected mature/full length 
AGR-2 using fluorescent microscopy in LCC1. Fluorescent images of the endogenous 
(panels A-C) mature (panels D-F) and full length (panels G-I) AGR-2pDEST-3.2 constructs. 
Minus primary antibody controls were included (panels J-L and M-O). Protein was 
visualized by Alexa-conjugated antibody (Alexa-594). Nuclei were visualized by DAPI. 
Images captured by Sony Cool Snap 3.2 (red:panels B, E, H, K and N, DAPI panels A, D, G, 
J and M, merge:panels  C, F, I, L and O) under a Zeiss microscope. Same exposure times for 
all images. Scalebar represents 10µm. 
[113] 
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Figure 3.11: Intracellular localization of endogenous and transfected mature/full length 
AGR-2 using fluorescent microscopy in LCC9. Fluorescent images of the endogenous 
(panels A-C) mature (panels D-F) and full length (panels G-I) AGR-2pDEST-3.2 constructs. 
Minus primary antibody controls were included (panels J-L and M-O). Protein was 
visualized by Alexa-conjugated antibody (Alexa-594). Nuclei were visualized by DAPI. 
Images captured by Sony Cool Snap 3.2 (red:panels B, E, H, K and N, DAPI panels A, D, G, 
J and M, merge:panels  C, F, I, L and O) under a Zeiss microscope. Same exposure times for 
all images. Scalebar represents 10µm. 
[114] 
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Figure 3.12: Immunohistochemistry of breast cancer tissues. Breast cancer sections 
showing the cytosolic localization of Anterior Gradient 2. Ductal and lobular carcinoma refer 
to different types of breast cancer regarding the type of the cells affected. The black arrows 
indicate the location of the protein (kindly provided by Dr. Nenutil).  
 
 




3.2.3.1 Cloning of mature and full length AGR-2 GFP/RFP 
 
AGR-2 exists in two isoforms: one full-length isoform with an N-terminal 
hydrophobic leader sequence (FL or F.l or f.l-AGR2) and a mature form with the N-
terminus removed by proteolytic processing (m-AGR2) (Figure 3.13.A). The mature 
isoform is the one capable of inhibiting p53 transactivation function and capable of 
inducing cell survival in clonogenic assays [474]. AGR-2 has been previously 
suggested to reside extracellularly as part of a secretory pathway that promotes cell 
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migration or metastasis [199, 650].  To build further on our knowledge of the AGR-2 
pathway, we examined AGR-2 subcellular localization using two approaches (i) 
RFP-tagged AGR-2 tested by confocal microscopy and (ii) subcellular chemical 
extraction methodologies into cytosolic, membrane/organelle, nuclear, and 
cytoskeletal fractions.  To study the different localization of AGR-2 due  to the 
leader sequence as well as the role of its KTEL sequence as a potential ER-retention 
sequence, a number of fluorescent-conjugated constructs were cloned (Figure 3.13):  
1. Full length AGR-2wt in pAcGFP-N1. This fuses the fluorescent protein to the 
C-terminus of full length AGR-2. Includes the AGR-2 signal sequence and 
the KTEL C-terminal tetrapeptide. 
2. Mature AGR-2wt in p pAcGFP -N1. This fuses the fluorescent protein to the 
C-terminus of mature AGR-2. Does not include the AGR-2 signal sequence 
but only the KTEL tetrapeptide. 
3. Full length AGR-2ΔKTEL in pAcGFP-N1. This fuses the fluorescent protein to 
the C-terminus of full length AGR-2 minus the last four amino acids that 
make up the putative ER retention sequence. Still includes the signal 
sequence. 
4. Mature AGR-2ΔKTEL in pAcGFP-N1This fuses the fluorescent protein to the 
C-terminus of mature AGR-2 minus the KTEL tetrapeptide. Does not include 
the AGR-2 signal sequence. 
5. Full length AGR-2 KDEL in pAcGFP-N1. This fuses the fluorescent protein 
to the C-terminus of full length AGR-2 but bears the C-terminal KDEL ER-
retention sequence instead of KTEL. Still includes the AGR-2 signal 
sequence. 
6. Mature AGR-2 KDEL in pAcGFP-N1. This fuses the fluorescent protein to 
the C-terminus of mature AGR-2 but bears the C-terminal KDEL ER-
retention sequence instead of KTEL. Still includes the AGR-2 signal 
sequence. 
The same constructs will be cloned to the DsRed Express-N1 vector in order to be 
fused to a red fluorescent protein, for co-localization experiments (Figure 3.13). 
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Figure 3.13: Representative diagram of the clones fused to green or red fluorescent 
protein. A) Detailed amino acid composition of AGR-2. B) Different mutants of the wt 
protein (BI). Mutation of the KTEL sequence (BIII) as well as complete deletion of the 
sequence (BII) are shown. The GFP/RFP fusion tags are integrated in the C-terminus of the 
constructs. Leader sequence shown in blue and KTEL in yellow. Mutant KDEL sequence is 
depicted in orange. 
 
The full length and mature AGR-2 fused to GFP or RFP were tested by microscopy 
(fl. and m. respectively). The full length constructs, that contain the leader sequence, 
were all granular-shaped and distributed within the cytoplasm (Figure 3.15, panels 
A-C). Full length wt protein showed intense granular appearance (Figure 3.15 panel 
A) but within the whole cytoplasm whereas the fl.KDEL RFP mutant had intense 
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perinuclear granular appearance (Figure 3.15 panel B). The fl.ΔKTEL RFP mutant had 
the exact same granular appearance as the previously described constructs but with a 
more diffused pattern (Figure 3.15 panel C) when compared to the wt and KDEL 
ones. As far as the mature protein is concerned (Figure 3.15 panels D-F), the wt form 
was highly nuclear and also distributed in a diffused way within the cytoplasm with 
only a few granules detected (Figure 3.15 panel D). The m.KDEL RFP mutant was 
also nuclear and cytosolic but more granules were detected compared to the wt one 
(Figure 3.15 panel E). The m.ΔKTEL mutant had no signs of nuclear allocation and 
was distributed within the cytoplasm (Figure 3.15 panel F). This last mutant was 
highly unstable, as the fluorescent signal bleached after a short time and when that 
was not the case, it emitted very low fluorescence when compared to the AcGFP-N1 
empty vector control (Figure 3.14). AcGFP-N1 (Figure 3.14 panels D-F) and DsRed-
N1 (Figure 3.14 panels A-C) empty vector transfected cells were included in the 
experiment and showed non-specific distribution as they were detected everywhere 
within the cells. 
  
 
Figure 3.14: Subcellular distribution of pAcGFP-N1 and DsRed Express-N1. MCF-7 
cells were single transfected with pAcGFP-N1 (panels D-F) and DsRed Express-N1 (panels 
A-C) and analysed by microscopy. DAPI (panels A and D). Images visualized by Zeiss 
Axionplan microscope and captured by a photometric CoolSnap HQ camera. Figure showing 
representative of 5 independent experiments. Scalebar represents 10µm. 
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Figure 3.15: Intracellular localization of mature and full length AGR-2 GFP/RFP using 
fluorescent microscopy Merge images of MCF-7 carcinoma cells transfected with full 
length  (panels A-C) or mature (panels D-F) AGR-2wt RFP/GFP constructs and visualized 
by fluorescence microscopy. KDEL (panels B and E) and KTEL deletion (ΔKTEL) (panels C 
and F) fluorescent mutants of both isoforms are also depicted. Small images included in 
white frames of each photo show the localization of each construct without DAPI staining. 
Images visualized by Zeiss Axionplan microscope and captured with the photometric 
CoolSnap HQ camera. Same exposure times applied for all images. Figure showing 
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3.2.3.2 Co-localization of the mature and full length AGR-2 RFP constructs with ER 
and Golgi 
 
The transfection of the “inactive” full length  AGR-2wt RFP, that bears the KTEL 
sequence, expression vector results in largely cytosolic RFP-protein expression, 
which in turn co-localizes to a relatively high degree with the endoplasmic-reticulum 
marker protein PDI (Figure 3.16-3.17 panels A-D). DAPI along with brightfield 
microscopy independently verified this co-localization (Figure, 3.16-3.17 panels A-
D). Quantitation of Fl AGR-2wt RFP revealed that ~33% of cells showed essentially 
complete, 100%,  co-localization of AGR-2 with the endoplasmic-reticulum (Figure 
3.22 panel B first column), whilst ~67% of cells showed less that 100% AGR-2 co-
staining with the endoplasmic-reticulum (Figure 3.22 panel A). These results indicate 
that this isoform is not apparently expressed extracellularly and that it is largely an 
ER- localized isoform.  Moreover, this form was not strictly co-localized to the ER 
indicating the dynamic nature of the protein, as it was also detected in the cytoplasm 
of transfected cells. Co-staining for the Golgi compartment showed no clear sign of 
co-localization (Figure 3.18 panels A-D). 
The transfection of full length AGR-2 KDEL RFP containing the point mutation in 
the C-terminal domain, exhibited a more pronounced co-staining with the 
endoplasmic-reticulum (Figure 3.16-3.17 panels E-H) totally consistent to the 
presence of the KDEL ER-retention sequence which is typical of many of the ER-
resident proteins. Quantitation revealed that approximately 79% of cells exhibited 
complete ER localization and 21% of cells exhibited less than 100% ER localization 
(Figure 3.22 panel B second column) so there was higher co-localization rate when 
compared to the wt RFP isoform that has the KTEL sequence (Figure 3.22 panel B 
first column). Brightfield was consistent to nuclear localization data (Figure 3.16-
3.17 panels A).Thus, mutation of the KTEL sequence also resulted in ER 
sequestration of the protein and no evidence was seen of extracellular or plasma 
membrane localization (Figure 3.16-3.17 panels E-H). The divergence of the highly 
conserved KTEL sequence of AGR-2 away from the canonical KDEL endoplasmic-
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reticulum retention sequence presumably lowers the affinity of AGR-2 for the 
endoplasmic-reticulum receptor protein and allows AGR-2 to exit the endoplasmic-
reticulum at a higher rate.  Again, no Golgi co-localization was detected, although 
these two compartments show high affinity to each other and collaborate in the 
secretory pathway (Figure 3.18 panels E-H). Transfection of the deletion mutant full 
length AGR-2ΔKTEL RFP resulted in a less distinct co-staining with the endoplasmic 
reticulum, (Figure 3.16-3.17 panels I-L) although a percentage of 37% of the cells 
exhibited total co-localization (Figure 3.22 panel B third column). Interestingly 63% 
of the cells showed less that 100% co-localization (Figure 3.22 panel B third column) 
to the ER. These non-co-localization levels for the full length AGR-2ΔKTEL RFP were 
much lower than the KDEL mutant and a bit less than wt construct, as expected, due 
to the absence of the KTEL sequence (Figure 3.22 panel B). No Golgi co-staining 
was again observed (Figure 3.18 panels I-L).  
The transfection of the “active” mature AGR-2wt RFP expression vector results in a 
qualitatively different distribution than the full-length isoform of AGR-2, although 
extracellular or plasma membrane expression was again not observed. Mature AGR-
2wt RFP exhibited both nuclear and diffuse cytosolic expression (Figure 3.19 panels 
A-D) with only relatively small amounts of co-localization with the endoplasmic-
reticulum compartment (Figure 3.19 panels A-D). Interestingly, the protein was 
excluded from the nucleoli of the cells. Co-localization percentages varied amongst 
cells, so to enable graphical representation and grouping the 10% rate was chosen as 
a reference point for all graphs. Quantitation revealed that approximately 34% of 
cells showed nuclear and cytosolic expression with no endoplasmic-reticulum 
localization, whilst 66% of cells exhibited nuclear and cytosolic distribution but with 
less than 10% of granular endoplasmic-reticulum co-localization (Figure 3.22 panel 
A first column).   
Similar to the full-length AGR-2KDEL RFP mutant, the transfection of the mature 
AGR-2KDEL RFP expression vector resulted in increased retention of AGR-2 in the 
endoplasmic reticulum (Figure 3.19 panels E-F) but qualitatively different 
distribution than the full-length isoform of AGR-2 (Figure 3.16-3.17 panels E-H), 
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although extracellular expression was again not observed. Mature AGR-2KDEL RFP 
exhibited little nuclear and diffuse cytosolic expression (Figure 3.19 panels E-F). The 
expression of mature AGR-2KDEL RFP was confined predominantly to granular 
endoplasmic reticulum with 43% of cells showing more than 10% endoplasmic 
reticulum co-localization while the rest of the cells had less that 10% co-localization 
rate (Figure 3.22 panel A second column). Nevertheless, all the cells had distinct 
granules within the cytoplasm which were more in number and density that in the wt 
form of the protein (Figure 3.19 panels A-D). Together, these data indicate that the 
N-terminal leader sequence of AGR-2 shifts the equilibrium of AGR-2 towards the 
ER whilst the C-terminal sequence is required for entry of AGR-2 into nuclear pools.  
Interestingly, the mature AGR-2 ΔKTEL GFP mutant was characterised by total 
absence of granules within the cytoplasm and all the cells showed diffused cytosolic 
distribution as well as dimly nuclear localization of the protein (Figure 3.19 panels I-
L). It is worth mentioning, that this construct behaved in a rather unstable way and 
was bleached after a few exposures under the microscope whereas the GFP vector 
was highly steady and durable even after very long exposures (Figure 3.21 A-H. No 
Golgi co-staining was observed in none of the mature constructs (Figure 3.20 panels 
I-P). Control AcGFP-N1 (Figure 3.21 panels I-P) and DsRed-N1 (Figure 3.22 panels 
A-H) empty vector transfections were performed as well for every localization 
marker tested (Figure 3.21, ER: panels A-D and I-L, Golgi: panels E-H and M-P). 
Both FPs showed non-selective distribution patterns and were detected everywhere 
in the cells, including the nucleoli, although very few DsRed-transfected cells 
excluded the protein from the nucleoli but these were not more that 5% of all 
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Figure 3.16: Intracellular localization of full-length AGR-2 RFP in respect to the 
endoplasmic reticulum. MCF-7 cells were transfected with the indicated vector expressing 
full-length AGR-2wt RFP (panels A-D), full-length RFP-tagged AGR-2 containing a 
mutation in the C-terminal KTEL motif (AGR-2T173D) (panels E-H) or full-length RFP-
tagged AGR-2 with no KTEL sequence (ΔKTEL) (panels I-L). After fixation of cells, the 
endoplasmic reticulum was visualized using an anti-PDI-specific antibody. The brightfields 
are shown in panels A , E and I; AGR-2 localization is highlighted in panels B, F and J; PDI 
expression is depicted in panels C, G and K, and the extent of co-localization of AGR-2 and 
PDI was determined by merging the respective images (D, H and L) using a Leica SP5 
confocal microscope. Figure is representative of at least 5 independent experiments.  
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Figure 3.17: Intracellular localization of full-length AGR-2 RFP in respect to nuclear 
markers and ER. MCF-7 cells were transfected with the indicated vector expressing full-
length AGR-2wt RFP (panels A-D), full-length RFP-tagged AGR-2 containing a mutation in 
the C-terminal KTEL motif (AGR-2T173D) (panels E-H) or full-length RFP-tagged AGR-2 
with no KTEL sequence (ΔKTEL)(panels I-L). After fixation of cells, the endoplasmic 
reticulum was visualized using an anti-PDI-specific antibody. DAPI is shown in panels A, E 
and F, AGR-2 localization is highlighted in panels B, F and J; PDI expression is depicted in 
panels C, G and K, and the extent of co-localization of AGR-2 and PDI was determined by 
merging the respective images (D, H and L) using a Zeiss microscope equipped with spectral 
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Figure 3.18: Intracellular localization of full-length AGR-2 RFP in respect to the Golgi 
compartment. MCF-7 cells were transfected with the indicated vector expressing full-length 
AGR-2wt RFP (panels A-D), full-length RFP-tagged AGR-2 containing a mutation in the C-
terminal KTEL motif (AGR-2T173D) (panels E-H) or full-length RFP-tagged AGR-2 with no 
KTEL sequence (ΔKTEL) (panels I-L). After fixation of cells, the Golgi compartment was 
visualized using an anti-Golgin-specific antibody. The brightfields are shown in panels A , E 
and I; AGR-2 localization is highlighted in panels B, F and J; Golgin expression is depicted 
in panels C, G and K, and the extent of co-localization of AGR-2 and Golgin was determined 
by merging the respective images (D, H and L) using a Leica SP5 confocal microscope. 
Figure is representative of at least 5 independent experiments.  
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Figure 3.19: Intracellular localization of mature AGR-2 RFP in respect to the 
endoplasmic reticulum. MCF-7 cells were transfected with the indicated vector expressing 
mature RFP-tagged AGR-2wt (panel s A-D), mature AGR-2 RFP containing a mutation in 
the C-terminal KTEL motif (AGR2T173D) (panel s E-H), or mature GFP-tagged AGR-2 
without the C-terminal KTEL tetrapeptide (ΔKTEL) (panels I-L). After fixation of cells, the 
endoplasmic reticulum was visualized using an anti-PDI-specific antibody (C, G, and K). 
The extent of co-localization of AGR-2 and PDI was determined by merging the respective 
images (D, H, and L) using a Leica confocal microscope. Figure is representative of at least 
5 independent experiments.  
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Figure 3.20: Intracellular localization of mature AGR-2 RFP in respect to the Golgi 
compartment. MCF-7 cells were transfected with the indicated vector expressing mature 
RFP-tagged AGR-2wt (panels A-D), mature AGR-2 RFP containing a mutation in the C-
terminal KTEL motif (AGR2T173D) (panel s E-H), or mature GFP-tagged AGR-2 without the 
C-terminal KTEL tetrapeptide (ΔKTEL) (panels I-L). After fixation of cells, the Golgi was 
visualized using an anti-Golgin-specific antibody (C, G, and K). The extent of co-
localization of AGR-2 and PDI was determined by merging the respective images (D, H, and 
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Figure 3.21: Intracellular localization AcGFP-N1 and DsRed-N1 control vectors. MCF-7 
cells were transfected with the indicated vector DsRed-N1 (panels A-H) or AcGFP-N1 
(panels I-P) expressing only the fluorescent protein without any additional proteins fused to 
its C-terminus. After fixation of cells, the endoplasmic reticulum was visualized by anti-PDI-
specific antibodies (panels C and K) and the Golgi using an anti-Golgin-specific antibody 
(panels G and O). Images taken by a Leica SP5 confocal microscope. Figure is 
representative of at least 5 independent experiments. 
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Figure 3.22: Graphical representation of the co-localization extent of each mature or 
full length RFP/GFP construct, wt KDEL and ΔKTEL. MCF-7 cells transfected with 
each of the constructs and blotted against the ER, were tested for co-staining rate. Co-
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3.2.3.3 Mitochondrial localization of the full length AGR-2wt and ΔKTEL fluorescent 
clones 
 
To further investigate whether the full length wt and ΔKTEL AGR-2 RFP clones were 
co-localized with other organelles apart from the endoplasmic reticulum and the 
Golgi compartment, the mitochondria network was tested (Figure 3.23 panels A-H). 
The full length AGR-2KDEL RFP mutant was not tested because it showed almost 
total co-localization with the ER (Figure 3.22 B second column, Figure 3.16 panels 
E-F).  Mitotracker Green is a green fluorescent dye that stains the mitochondria of 
the cells. Mitochondria, in MCF-7 cells, are distributed around the nucleus in a 
string-alike reticulum and usually take up most of the cytoplasm. The wt RFP form 
of the full length protein did not co-localize with the mitochondria and interestingly 
it showed a rather peri-mitochondrial distribution (Figure 3.23 panels A-D). The 
same pattern was followed by the KTEL deletion RFP mutant (Figure 3.23 panels A-
D). The protein was detected around and on the top of mitochondria, on an anterior-
posterior orientation axis, but no co-localization was observed. Control DsRed-N1 
vector-only transfected cells emitted red fluorescence in the nucleus and within the 
cytoplasm and small co-staining with the mitochondria was observed, with only a 
few co-localization areas stained in yellow, as expected by a non-specific FP (Figure 
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Figure 3.23: Intracellular localization of full-length AGR-2 RFP in respect to the 
mitochondria network. MCF-7 cells transfected with full-length AGR-2wt RFP (panels A-
D), full-length RFP-tagged AGR-2 without the C-terminal KTEL motif (ΔKTEL) (panels E-H) 
or DsRed-N1 vector control (panels I-L). Before fixation, Mitotracker Green was added to 
the cells to visualize mitochondria (panels B, F and J). Brightfields are shown in panels A, E 
and I; AGR-2 RFP localization is highlighted in panels C, G and K; Mitotracker is depicted 
in panels B, F and J, and the extent of co-localization of AGR-2 and Mitotracker was 
determined by merging the respective images (D, H and L) using a Leica SP5 confocal 
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3.2.3.4 Subcellular fractionation of the fluorescent constructs 
 
We next complemented the confocal microscopy by examining the localization of the 
endogenous AGR-2 and transfected AGR-2 RFP using subcellular chemical 
extraction methodologies in order to determine whether (i) the C-terminus of AGR-2 
permits nuclear entry of the AGR-2 isoform and (ii) endogenous AGR-2 can enter 
the nucleus. Two different exposures are shown for quantification purposes (Figure 
3.24 right and left panels). In more detail, mature AGR-2wt RFP resulted in a 
relatively different distribution when compared to the endogenous protein, with 
AGR-2wt RFP highly expressed in the F1 cytosolic and F3 nuclear fractions when 
compared to the F2 cell membrane and organelles fraction (Figure 3.24 A). The 
mutation to KDEL resulted in confinement of the mature AGR-2KDEL RFP protein 
to the cytosolic and membrane fractions and lower expression in the nuclear F3 
(Figure 3.24 B). These data again are relatively consistent with the microscopy 
(Figure 3.19 panels A-H), which indicated that the mature-AGR-2wt RFP can be 
diffuse cytosolic and nuclear, but mutation of the KTEL to KDEL shifts the 
equilibrium to a more confined compartmentalization outside the nucleus although 
nuclear localization is still present but in much lower levels than in the wt form of 
the protein (Figure 3.19 panels E-H). This difference was quantified and depicted in 
Figure 3.25. As a control, the endogenous AGR-2 protein appears as only one band, 
at ~18kDa, and detected in three fractions: the F1 cytosolic, the F2 
membrane/organelles and the F3 nuclear fractions (Figure 3.24 panels A-C bottom 
lane) resembling the siatridution of the mature AGR-2wt RFP protein. Total deletion 
of the KTEL sequence resulted in strictly cytosolic localization but in very low levels 
(Figure 3.24 C), further supporting the fluorescent microscopy data, which suggested 
a rather unstable cytosolic form of the protein (Figure 3.19 panels I-L).  
The transfection of RFP-tagged full length AGR-2wt resulted in a distribution into 
the cytosolic, membrane/organellar fraction, nuclear, and cytoskeletal fractions 
(Figure 3.24 A). The full length AGR-2wt RFP when compared to the mature form 
of the protein showed higher organelles/membrane F2 expression levels (Figure 3.24 
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A), further supporting the fluorescent microscopy data that the full length isoform 
strongly co-localizes to the endoplasmic reticulum (Figure 3.22 A-B first columns). 
The mutation to KDEL resulted in confinement of the full-length AGR-2 RFP 
protein to the cytosolic and membrane/organelles fractions (Figure 3.24 B). These 
data are relatively consistent with the microscopy, which indicated that mutation of 
the KTEL to KDEL shifts the equilibrium to a more confined compartmentalization 
(Figure 3.22 B). This full length KDEL RFP mutant had much higher cytosolic and 
membrane distribution that the equivalent mature one which is presumably due to the 
presence of the leader sequence that supposed to designate the protein to secretion 
(Figure 3.24 B). The full length AGR-2wt RFP followed the same patterns when it 
came to the first three fractions with very strong presence of the protein in F2 fraction 
which is the one representing the cell membrane and organelles extract (Figure 3.24 
A). The full length deletion mutant AGR-2ΔKTEL RFP showed lower expression 
levels in F1 cytosolic and F2 membrane/organelles fractions when compared to the 
full length wt and KDEL mutant, as expected (Figure 3.24 C). This mutant is the one 
that has the lowest co-localization rate to the endoplasmic reticulum (Figure 3.22 B 
third column) and, as shown by Western blotting here, the lowest expression levels in 
the cytosolic and membrane/organelles fraction compared to the wt and KDEL RFP 
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Figure 3.24: Intracellular localization of AGR-2 RFP isoforms using chemical fraction. 
MCF-7 cells were transfected with the indicated vector expressing mature or full length 
AGR-2wt RFP (panel A), mature/full-length AGR-2 RFP containing a mutation in the C-
terminal KTEL motif (AGR2T173D) (panel B), mature/full length GFP/RFP-tagged AGR-2 
without the C-terminal KTEL tetrapeptide (ΔKTEL) (panel C) respectively. The cells were 
processed using fractionation methodologies into F1 (cytosolic), F2 (membrane/organelles), 
F3 (nuclear), and F4 (cytoskeletal) as indicated. The distribution of the RFP-tagged AGR-2 
isoform (top section, ~ 50 kDa) or endogenous AGR-2 protein (bottom section, ~ 18 kDa) 
was determined by immunoblotting. Different exposure times are depicted. Figure is 
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Figure 3.25: Quantitation of RFP-tagged mature AGR-2wt and mature AGR-2 KDEL 
isoforms distribution into nuclear and cytosolic fractions. 
 
 
3.2.4 Localization of wt/KDEL and ΔKTEL AGR-2 RFP constructs in an 
AGR2-negative cell line 
 
To further characterize the distribution differences between the mature and full 
length wt-KDEL and ΔKTEL RFP constructs, MDA-MB 231 breast cancer cells were 
used. This cell line is Estrogen Receptor α /AGR2-negative and is normally used as a 
negative control. MCF-7 cells have high levels of endogenous AGR-2 and so the 
pathways that the protein participates are active. On the other hand, MDA-MB 231 
do not have endogenous protein and are useful in investigating the localization 
differences of the mutants in a cell system deficient in AGR-2. 
Interestingly, mature AGR-2wt RFP was detected in the cytosolic, nuclear and 
cytoskeleton fraction (Figure 3.26 B). No membrane/organelle distribution was 
observed. AGR-2 was highly expressed in the nuclear fraction and also detected in 
the cytoskeleton but in much lower levels. Mutation of the KTEL sequence to KDEL 
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shifted the equilibrium to the cytosolic and membrane/organelles fractions although 
nuclear localization was still retained (Figure 3.26 B). Interestingly, the expression 
levels of the mature AGR-2KDEL RFP protein in the membrane and organelles 
fraction was induced and reached similar levels to the cytosolic and nuclear 
expression of the protein, when compared to the equivalent wt form.  Deletion of the 
KTEL sequence in the C-terminus restored the localization patterns to the cytosolic 
and nuclear fractions and interestingly the cytosolic distribution of this mutant was 
relatively more intense when compared to the wt protein patterns (Figure 3.26 B), 
whereas nuclear AGR-2 was expressed in a much lesser extent when the KTEL 
sequence was deleted.  
As far as the full length constructs is concerned, the full length AGR-2wt RFP was 
distributed in the first three fractions and was more intense in the cytosolic and 
nuclear fraction (Figure 3.26 C). Moreover, the membrane/organelles fraction 
showed relatively higher AGR-2 expression levels when compared to the mature wt 
that had undetectable protein levels (Figure 3.26 B and C). However, the full length 
isoform had lower nuclear AGR-2wt RFP that the mature one. The cytoskeleton 
fraction also had low but detectable levels of AGR-2. Mutation of the KTEL 
sequence to KDEL induced the protein’s expression levels in all fractions and 
especially in the membrane/organelles fraction (Figure 3.26 C). The cytosolic and 
nuclear levels were elevated as well compared to the wt form of the full length 
isoform. The induction of full length AGR-2 RFP after KDEL mutation, resembled 
the pattern observed when the mature AGR-2wt RFP was mutated to KDEL in the 
same cell line, where the same mutation caused elevation of AGR-2 levels in all the 
fractions apart from the cytoskeleton one (Figure 3.26 B and C).  Deletion of the last 
four KTEL amino acids resulted in total loss of the protein from the nuclear fraction 
and further engaged it to the cytosolic and membrane fractions (Figure 3.26 C). The 
membrane/organelles fraction had much higher protein levels when compared to the 
wt form. Control untransfected and vector only samples showed no signs of the 
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Figure 3.26: Intracellular localization of AGR-2 isoforms using chemical fraction in an 
AGR-2 negative cell line. MDA-MB 231 cells were transfected with the indicated vector 
expressing full-length AGR-2wt RFP, full-length AGR-2 RFP containing a mutation in the 
C-terminal KTEL motif (AGR2T173D), full length RFP-tagged AGR-2  without the C-terminal 
KTEL tetrapeptide (ΔKTEL) (panel C) and mature AGR-2 RFP, mature AGR-2 RFP 
containing a mutation in the C-terminal KTEL motif (AGR2T173D)/ mature GFP-tagged 
AGR-2 without the C-terminal KTEL tetrapeptide (ΔKTEL) (panel B). Control vector AcGFP-
N1 and DsRed-N1 transfections were included in the experiment (panel A). The cells were 
processed using fractionation methodologies into F1 (cytosolic), F2 (membrane/organelles), 
F3 (nuclear), and F4 (cytoskeletal) as indicated. The distribution of the RFP-tagged AGR2 
isoform (top section, ~ 50 kDa) was determined by immunoblotting.  
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3.2.5 Mature and Full length AGR-2KAEL RFP 
 
Since the last four amino acids are essential to AGR-2 activity [474] and also the 
KTEL sequence plays an important role in maintaining nuclear localization we 
further mutated this sequence to KAEL. This substitution was chosen in order to 
further define the role of the threonine, T, which was the one mutated to aspartic 
acid, D, and affected the full length protein’s localization towards the endoplasmic 
reticulum (Figure 3.22 B). A neutral mutation of this threonine to alanine will assist 
in determining the importance of this amino acid to localization of the protein. Site-
directed mutagenesis on the mature and the full length AGR-2wt RFP that bears the 
KTEL sequence was applied. Subcellular fractionation of different cellular 
compartments revealed that presence of the KAEL mutated sequence highly induced 
the expression of mature AGR-2KAEL RFP mutant in the cytoplasm whereas 
reduced it in the membrane/organelles and nuclear fractions, when compared to the 
AGR-2wt RFP construct (Figure 3.27 A). Nuclear reduction was much stronger 
compared to the organellar one. As far as the full length AGR-2 is concerned, 
presence of the KAEL sequence did not significantly alter the distribution of the 
protein in the cytosolic and membrane/organelles fraction (Figure 3.27 B). On the 
other hand, the nuclear fraction was again affected, with the KAEL mutant’s 
expression levels being reduced compared to the wt control (Figure 3.27 A). What is 
more, KAEL presence in the C-terminus of the mature and the full length form of the 
protein as well, lead to increase of AGR-2 in the cytoskeleton fraction F4. 
Endogenous AGR-2 control expression levels remained unaltered in all the samples 
(Figure 3.27 A and B). 
To further evaluate the KAEL mutant, fluorescent microscopy was performed 
(Figure 3.28). ER and Golgi markers were used to test for co-staining (Figure 3.28 
panels C/G and K/O, respectively). Mature AGR-2KAEL RFP was again nuclear 
with some granules distributed within the cytosol but very low endoplasmic 
reticulum co-localization was observed. Only a few granules co-stained with the anti-
PDI marker with less than 5% co-localization rate (Figure 3.28 panels E-H). The full 
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length AGR-2KAEL RFP vector had granular appearance and distributed within the 
cytosol but under a perinuclear pattern. The mutant was localized around the 
endoplasmic reticulum in a spherical way and some co-staining was detected (Figure 
3.28 panels A-D). Neither mature nor full length AGR-2KAEL RFP mutants co-
localized with the Golgi marker (Figure 3.28 panels I-P). Interestingly, the full length 
AGR-2KAEL RFP vector followed a characteristic distribution pattern around and 
adjacent to the Golgi compartment (Figure 3.28 panels I-L). 
 
 
Figure 3.27: Intracellular localization of mature and full length AGR-2 RFP KAEL 
mutants by chemical fraction. MCF-7 cells were transfected with vectors expressing full-
length AGR2wt RFP /Fl AGR-2 RFP containing a mutation in the C-terminal KTEL motif 
(AGR2T173A) (panel B) or mature AGR-2wt/mAGR-2 RFP containing a mutation in the C-
terminal KTEL motif (AGR2T173A) (panel A). The cells were processed using fractionation 
methodologies into F1 (cytosolic), F2 (membrane/organelles), F3 (nuclear), and F4 
(cytoskeletal) as indicated. The distribution of the RFP-tagged AGR2 isoform (top section, 
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Figure 3.28: Intracellular localization of of mature and full length AGR-2KAEL RFP 
mutants by confocal microscopy. MCF-7 cells were transfected with the indicated vector 
expressing full length RFP-tagged AGR-2 containing a mutation in the C-terminal KTEL 
motif (AGR2T173A) (panel A-D and I-L) or mature AGR-2 RFP with the same mutation in the 
C-terminal KTEL motif (AGR2T173A) (panel E-H and M-P). After fixation of cells, the 
endoplasmic reticulum was visualized using an anti-PDI-specific antibody (panels C and G) 
whereas the Golgi compartment by an anti-Golgin-specific antibody (panels K and O). The 
extent of co-localization of AGR-2 and PDI was determined by merging the respective 
images (D, H, L and P) using a Leica confocal microscope.  




MCF7-derived cells show different AGR-2 distribution    
ocalization studies are a useful tool when it comes to defining the role of many 
ooperate toward a common physiological function. The position of a protein, most 
 
3.3.1 MCF-7 and 
 
L
proteins. Proteins must be localized in the same subcellular compartment to 
c
of times, determine its role, as transcription factors are distributed in the nucleus 
[368], secretory proteins in the cytoplasm, transporters in  the cytoplasm as well, 
receptors in the cell membrane and so on, although the equilibrium is highly dynamic 
and changes according to environmental or not conditions. There are no studies up to 
present that suggest a principal form of the protein within the cell and the antibodies 
used recognise both forms, full length and mature as well. Since there is no way to 
discriminate between these two forms, the staining pattern observed is a combination 
of these both, cytoplasmic, perinuclear and nuclear. Endogenous AGR-2 in MCF-7 
cells was distributed in a diffuse cytoplasmic way totally coherent to immunostaining 
data from cancer tissues [199](IH data presented here, Dr Nenutil) that showed the 
protein to be present in the cytoplasm (Figure 3.6). Monocolonal antibody 
immunostaining, detected the protein in the cytoplasm as well as in the perinuclear 
space and some signal was emitted from the nucleus as well (Figure 3.7). Subcellular 
fractionation of different cellular compartments (Figure 3.5) showed expression of 
the protein predominantly in the cytosol, less in membrane/organelles fraction and 
traces of the protein detected in the nuclear fraction coherent to the microscopy data. 
MCF7-derived cell lines that show different resistance to Tamoxifen and ICI 182,780 
have the same distribution patterns (Figure 3.6) but different expression levels of the 
protein in each compartment (Figure 3.5). LCC9 cells, which are totally resistant to
Tamoxifen and the steroidal anti-oestrogen ICI 182,780 [75], show high nuclear 
levels of AGR-2 but the exact mechanism conferring this resistant phenotype is yet 
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unclear as many molecular mechanisms that vary between these cell lines are 
undefined. Interestingly, these data were consistent with high total protein expression 
levels and estrogen-independence in the LCC9, as performed by a separate group  
although Tamoxifen treatment induced AGR-2 expression [270]. The anti-oestrogen 
ICI 182/780 disrupts ERα shuttling from the nuclei to the cytoplasm by blocking its 
nuclear uptake [133]. It is proposed that these cells prevent ICI 182/780-induced 
effect on ER turnover or even alter events downstream the ER thereby bypassing 
effects on receptor turnover [75]. Interestingly, LCC9 have elevated PgR protein 
expression levels when grown without estrogenic supplementations although the ER 
levels remain unchanged compared to the MCF-7 cells. In addition, other 
considerable variations in gene expression including p21, p27, cyclin A, cyclin D1, 
cyclin E and CDK4 and other genes implicated in tumourigenesis and regulation of 
oestrogen and anti-oestrogen cell cycle, were observed after SNP (Single Nucleotide 
Polymorphisms) and CGH (Comparative Genome Hybridization) analysis between 
LCC9 and MCF-7 [295], suggesting that AGR-2 might belong to the same category 
of differentially expressed genes and affect Tamoxifen resistance. LCCI on the other 
hand, have essentially comparable ER and PgR levels when compared to the parental 
MCF-7 cell line [75]. In our studies LCC1 showed intermediate nuclear expression 
levels of the protein comparable to MCF-7 (Figure 3.5) although studies have shown 
that the protein is elevated in LCCI cells as well [270]. Amplification or deletion of 
gene copies, alterations in transcriptional and translational regulation may contribute 
to altered protein production. Protein function or rate of degradation may be altered 
by changes in post-translational modifications. Alterations in the levels and activity 
of cellular proteins may be responsible for the development of tamoxifen or anti-
oestrogen resistance. AGR-2 is a strong candidate protein for this resistance, since it 
was found to be associated with patient cell survival and response to anti-oestrogens 
while at the same time our data have supported that the protein is localized in 
different compartments and show variable expression levels in cell lines that have 
different response to anti-cancer drugs, consistent to previous studies [270]. 
Moreover, the protein is overexpressed in ER+ cancers which are the ones that have 
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better clinical outcome compared to ER- ones and is upregulated by Tamoxifen [270] 
but downregulated by aromatase inhibitors [374]. MCF7-derived cell lines that have 
different resistance to anti-oestrogens and show different AGR-2 localization 
patterns are an ideal system to start exploring the mechanisms conferring resistance 
and lead the way to a targeted therapy with better clinical outcome. Of course, more 




3.3.2 Endoplasmic reticulum retention is predominantly controlled by 
e N-terminal leader sequence in the full length AGR-2 RFP 
teins should 
e secreted or incorporated into a cytoplasmic membrane. Signal sequences have 
th
 
Presence of a cleavable signal sequence, at position A20-R21, in AGR-2 leads the 
protein to secretion [3]. In general, signal sequences define whether pro
b
common features in their sequences but lack in primary structural homology [119]. 
Nonetheless, they share common properties including a positively charged N-
terminal region (usually Lysine or Arginine but Histidine is sometimes an option, 
AGR-2 has Lysine3) that is not essential for signal sequence function but improves 
its efficiency [479], a hydrophobic core of 10 amino acids which often ends with a 
turn-forming residue, and a 6-8 amino acid-long, less hydrophobic (but usually 
uncharged) region that includes the cleavage site information [71, 603] (Figure 3.29). 
KTEL sequence, on the other hand, is implicated to endoplasmic reticulum retention. 
It is known that variants of the KDEL motif also work to keep proteins ER resident. 
A large study of 24 possible variants is listed as the Prosite motif for the ER 
localization of soluble proteins [KRHQSA]-[DENQ]-E-L; [274] and can be found 
online at www.expasy.org. However, there are several human proteins that are ER-
located and contain variants of the KDEL motif that do not fit the Prosite motif such 
as ERp18 and ERp27 [14, 15]. Hence, it is possible that other motifs might also work 
as ER-retrieval signals. Bioinformatics approach identified motifs found on soluble 
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human proteins that enter the secretory pathway, i.e., motifs that might function in a 
natural system to ER-designate human proteins [483].  Based on the initial screen of 
AXDEL, AKXEL, AKDXL, and AKDEX variants, the bioinformatics analysis was 
restricted to human proteins that contained the motif XX[DE][FLM] at their extreme 
C terminus. Proteins containing these motifs were identified using Protein Prospector 
[98] and their sequences were analyzed by BLAST searches, SignalP [48] which 
predicts the signal peptide cleavage site, and PSORT II [265] which defines features 
such as polarity, hydrophobicity etc, to confirm that the sequence was the full-length 
protein, contained an N-terminal ER signal sequence, and that it was not predicted to 
be a transmembrane protein. This analysis identified 113 proteins that had 63 KDEL-
like variants at their C-termini. In the same study the 37 KDEL-like variants ending 
in L that came out of the bioinformatics screen and had not previously been analyzed 
were made in the reporter construct, and the subcellular localization of the transiently 
transfected constructs was determined by immunofluorescence microscopy. The 
results revealed that 15 of these motifs resulted in efficient ER localization (>80% of 
HeLa cells showing ER localization), whereas many others resulted in at least partial 
ER localization. AGR-2 was also identified in this screen as a representative KTEL-
motif protein [483] and will be further analysed below. 
Pilot studies involving the AGR-2 gene fused to a C-terminal Green Fluorescent 
Protein  showed that the fusion protein is secreted from HeLa cells [364].  Moreover, 
the gene is found to be upregulated in many secreting organs such as oesophagus, 
liver, breast and placenta, not to mention the secretory epithelial cells of the prostate 
gland [650]. The KTEL sequence is also characteristic of many of the proteins that 
belong to the thierodoxin superfamily to which AGR-2 is proposed to belong [468]. 
In our cell system, the leader sequence combined with the KTEL motif ensured a 
granular distribution of the protein fused to red fluorescent marker within the cytosol 
and a courteous percentage of endoplasmic reticulum co-localization whereas no cell 
membrane staining was observed (Figures 3.16, 3.17 and 3.22). These data are totally 
coherent to a study by Raykhel and co-workers that identified AGR-2 in a screen of 
200 proteins with KDEL-like motives [483]. In this study AGR-2 was found to be 
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ER-co localized in 80% of HeLa cells tested whereas Golgi co-localization was 
observed in 20% of cells. In our cell system no Golgi co-localization was observed 
(Figure 3.18). Proteins to be secreted also pass from the endoplasmic reticulum, so it 
is possible that the leader sequence plays a role in this staining pattern, as it leads the 
protein to secretion after ER-passing through, although no secretion was detected in 
MCF-7.  In the same study the protein was found to interact with all three ERD 
receptors ERD21, ERD22 and ERD23 but the interaction was stronger with the 
ERD21 receptor which appeared to be less a specialist as it bound to most of KDEL-
like motives [483]. However, as a generalization, KDEL-like motifs are conserved 
between human and the African clawed frog (Xenopus laevis), which also has three 
KDEL receptors, as 83% of proteins would use the same human receptor most 
efficiently. This is also the fact with the KTEL sequence of AGR-2, which is 
conserved in human mouse and frog further supporting the essentiality and 
importance of it. In AGR-2 null cells transfected wt protein was distributed in the 
cytosol and nucleus whereas traces of the protein were detected in the 
membrane/organelles fraction (Figure 3.26). This pattern can be explained by the fact 
that different cell lines show different distribution of proteins depending on which 
pathways are activated and where this protein is needed. 
Endoplasmic reticulum entrapment was further enhanced by mutation of the last four 
KTEL amino acids in the extreme C-terminus of the protein to the most commonly 
found KDEL endoplasmic reticulum-retention sequence, typical of mammalian 
proteins that reside in the endoplasmic reticulum [355, 521]. This motif interacts with 
KDEL receptors localized in the intermediate compartment and Golgi apparatus, and 
especially ERD21. Such binding triggers conformational change to the receptor and 
leads to retrieval back to the ER via a coat protein I–dependent pathway [171]. When 
this KTEL to KDEL mutation was made to the full length form of AGR-2 RFP the 
outcome was remarkable endoplasmic reticulum retention from a percentage of 33% 
observed in the wt protein to 80% of this KDEL mutant, suggesting that the KDEL 
sequence is much stronger and determinative when it comes to endoplasmic 
reticulum entrapment than the KTEL one (Figure 3.25). This particular KTEL 
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sequence can be implicated in partial endoplasmic reticulum-retention, as suggested 
by studies in a viral glucoprotein that is temporarily trapped in the endoplasmic 
reticulum [597], so it is possible that AGR-2 remains in the endoplasmic reticulum 
for some time and then released to enter the secretory pathway, but when KTEL is 
mutated to KDEL then the protein is trapped in the endoplasmic reticulum and not 
being processed. Similar cases involving non-ER resident proteins have been 
described, such as lysozyme in which the presence of the KDEL tetrapeptide at the 
carboxyl-terminus ensured endoplasmic reticulum retention and prevented secretion 
[423]. In the AGR-2 negative cell line, presence of the KDEL tetrapeptide in the C-
terminus of the protein promoted membrane/organelles distribution as expected 
(Figure 3.26). 
Deletion of the KTEL sequence did not have tremendous effects on endoplasmic 
reticulum affinity and the percentage of cells having 100% ER-co-localization was 
similar to the wt form of the RFP-tagged protein that had this C-terminal sequence, 
indicating that the presence of the leader sequence is alone sufficient to ensure a 
certain extent of ER co-localization. The aforementioned effects were also observed 
by Raykhel and colleagues in HeLa and Cos cells [483]. In their study many of the 
proteins that had KDEL-like motives were tagged and tested my 
immunofluorescence either with the putative ER-retention motif present or by 
insertion of a stop codon right before it. Interestingly, AGR-2 was amongst the ones 
that did not require the presence of the KTEL sequence for endoplasmic reticulum 
localization, which can be explained by the fact that these studies were performed 
with the full length form of the protein designated to secretion due to the presence of 
the signal sequence. Therefore, the KTEL sequence is not essential to ER-retention 
and the N-terminal signal sequence is the one that targets the protein to enter the ER. 
On the other hand, in some cases deletion of the carboxyl-terminal retention 
sequence of ER-resident proteins, either viral-plant-mammalian, results in 
redistribution of the protein intracellularly and leads to secretion, as studies in ER-
resident proteins have revealed [423, 442, 515]. This mechanism of action involves 
deficient binding of the protein to the KDEL receptors and therefore failure to be 
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recycled back to the endoplasmic reticulum via the COPI and II retrograde vesicle-
mediated pathway [442, 515, 576]. 
Substitution of the last threonine with alanine did not alter the localization of the 
protein. Threonine is a slightly polar amino acid that is phosphorylated in order to 
facilitate signal transduction process whereas alanine is a rather neutral amino acid, 
non-hydrophobic, non-polar and non-reactive which does not play important roles in 
protein function [58]. For the aforementioned properties alanine is the most 
commonly used amino acid in substitutions, where the effect of another amino acid is 
to be determined without  further affecting the protein’s structure and function by 
selecting a polar or hydrophobic or rather reactive amino acid. In MCF-7 cells, this 
construct did not show significantly different localization patterns when compared to 
the full length wt protein (Figures 3.27and 3.28). The full length AGR-2 KAEL RFP 
had granular appearance distributed around the endoplasmic reticulum with some co-
staining but did not reached 100% co-localization rate as the KDEL one. The 
distribution pattern strongly resembled the one observed in the wild type form of the 
protein (Figure 3.28). Further supporting these data, subcellular fractionation 
experiments came to verify that this mutant have analogous expression levels in the 
cytosolic and membrane/organelles fraction to the wt protein (Figure 3.27). On the 
other hand, more protein was expressed in the cytoskeleton fraction suggesting 
enhance mobility of the mutant. Our findings were also supported by literature, since 
the KAEL sequence was described to be able of maintaining endoplasmic reticulum 
localization after studies with methionine sulfoxide reductases [311]. Reductases that 
had a typical secretory signal peptide and the putative ER-retention KAEL sequence 
were detected in the endoplasmic reticulum while others that had no secretory signal 
peptide but only the KAEL tetrapeptide in their C-terminus were distributed in the 
cytosol. On the other hand, mutant proteins with the typical secretory peptide in their 
N-terminus and deletion of the KAEL sequence in their C-terminus were not 
localized in the endoplasmic reticulum. These data demonstrated that ER residency is 
partially dependent on the tetrapeptide KAEL which can act as a putative ER-
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retention signal but the presence of a signal peptide is still required to define and 




Figure 3.29: Representative diagram of hydrophobic amino acids. These amino acids 
have side-chains that do not like to reside in an aqueous (i.e. water) environment. For th
 is worth mentioning that when it came to full length constructs, some nuclear 
xpression was detected by immunoblotting whereas no nuclear staining was present 
is 
reason, one generally finds these amino acids buried within the hydrophobic core of the 






in microscopic studies (Figures 3.17 and 3.24). This can be due to the close 
proximity of the endoplasmic reticulum with the nuclear membrane and therefore the 
possibility of some bleed through between these two fractions during isolation should 
be taken into account. Differences in expression levels in the nuclear fraction 
between the wt protein and the mutants can be explained by the fact that every 
construct shows different co-staining rate to the endoplasmic reticulum and this can 
lead to variable bleed through detection after fractionation. A second reason might be 
the presence of the protein in the nuclear membrane and therefore isolation in the 
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equivalent fraction. Especially the wild type and KAEL constructs show elevated 
nuclear distribution whereas the KDEL and ΔKTEL constructs do not. Since the KTEL 
tetrapeptide is essential in maintaining nuclear localization of the mature form, as 
later described, there is no reason why this ability could be totally vanished in the 
full length isoform. Maybe KTEL maintains part of it nuclear retention properties but 
the signal peptide is the one that plays the leading role for the localization pattern of 
the full length isoform. Another possible reason might be the presence of the red 
fluorescent protein which is quite big in size, 28kDa, and can affect solubility of the 
constructs which is then detected after fractionation that is based on these properties 
and not during microscopy that does not include any solubility parameters. It is 
common in literature for some tags to affect solubility of the protein under study with 
a lot of fusion tags such as GST (Glutatheione-S-Transferase), SUMO (Small 
Ubiquitin MOdifier), T7PK (phage T7 Protein Kinase) and a lot more to act in favour 
of it [179]. Green Fluorescent Protein is amongst the tags that affect solubility 
depending on which terminus the GFP is fused [162]. It has been previously shown 
that proteins prone to mis-folding and aggregation can arrest GFP folding when 
fused at the C-terminus [471, 605]. However, when the soluble protein is fused at the 
N-terminus, this would be translated first and perhaps increase the solubility of the 
downstream protein domain folding intermediates, increasing their half lives prior to 
irreversible aggregation. This would allow greater reversibility in the individual steps 
along the folding pathway and increase the probability that the protein would 
eventually reach the lowest free energy native conformation. Especially DsRed, 
which is the chromophore used in our case, is accused of poor solubility [59] when 
existed in wild type form whereas new variants, including the one used in our 
experiments,  have reduced net charge near the N-terminus and thus higher solubility 
leading to less tendency to aggregate, although the problem is not yet fully 
overcome. Therefore, solubility problems may arise, affect fused protein’s solubility 
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3.3.3 Nuclear distribution of the full length RFP isoform is controlled by 
uclear distribution was also observed in the AGR-2 negative cell line (Figure 3.26). 
the KTEL sequence in the AGR-2 negative cell line 
 
N
Since these cells do not have endogenous AGR-2 there is a high possibility that the 
secretory-transportation pathway for this protein is deficient. Deficient secretory 
mechanism means that the leader sequence might no longer be as important as in the 
AGR-2 positive cell lines. As analysed below, KTEL plays a role in the nuclear 
maintenance of the mature wt isoform and absence of it depletes the protein from the 
nucleus (Figure 3.24) of MCF-7 cells. Substitution with the KDEL sequence elevated 
the endoplasmic reticulum retention rate but did not eliminate the protein from the 
nucleus in MCF-7 (Figure 3.24). It can be proposed that similar patterns are followed 
in the MDA-MB 231 cells; a less ‘active’ and deficient leader sequence combined 
with a KTEL sequence that might retain its ability to control nuclear distribution can 
lead the full length wild type isoform to be present in the nucleus. Similarly, the full 
length KDEL one is present in the nucleus but also elevated in the organelles fraction 
due to the KDEL sequence and last but not least the ΔKTEL one totally absent from 
the nucleus since no KTEL sequence is present to control nuclear retention. What is 
suggested here is that the leader sequence is not totally inactive since if that was 
happening then the localization patterns between the mature and the full length 
isoform would be identical, which is not the case here (Figure 3.26). Therefore, it is 
recommended that the signal peptide still has some effect in orientating the protein to 
the membrane/organelles but it is the KTEL sequence that plays the leading role for 
the localization patterns and defines the expression levels in the nucleus and the 
membrane/organelles fraction. Of course, all the aforementioned reasons, RFP 
solubility problems--endoplasmic reticulum and nuclear proximity--nuclear 
membrane localization, explaining full length AGR-2 nuclear presence in the MCF-7 
cells can also be valid for the MDA-MB 231 ones. In conclusion, the leader sequence 
and the KTEL sequence still play a very important role in determining the protein’s 
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localization even in AGR-2 deficient cells and therefore the equilibrium can be easily 
disrupted and manipulated. 
 
 
3.3.4 Nuclear retention of the mature AGR-2wt RFP is controlled by the 
C-terminal KTEL sequence 
 
On the other hand, the mature form of the protein fused to red fluorescent marker, 
was mainly nuclear and diffuse cytoplasmic (Figures 3.19, 3.20, 3.22 and 3.24). The 
mature form of the protein was distributed within the whole nucleus but was 
excluded from the nucleoli. Absence of the signal peptide was therefore sufficient to 
disrupt ER-retention and shift the equilibrium towards the nucleus. Moreover, no 
serious endoplasmic reticulum co-staining was observed although some granules 
were detected in the cytoplasm but exhibited less that 10% co-localization rate 
(Figure 3.25). Same patterns were followed when it came to Golgi co-staining, with 
the protein having no signs of co-localization (Figure 3.20). All the cells tested 
showed nuclear distribution and variations existed only in the cytosolic staining 
pattern with most cells, 66% of total population, having granules but less than 10% 
co-localization with the endoplasmic reticulum and even less cells showing diffuse 
cytosolic allocation with no granules at all (Figure 3.25). In the AGR-2 negative 
cells, the mature wild type protein was highly expressed in the nuclear fraction and 
only traces in the cytosol which can be due to the absence of the signal sequence that 
exports the protein from the nucleus and equally distributes it to the cytosol, 
membrane/organelles and nuclear fraction, as shown by the full length isoform in the 
same cells (3.26). Interestingly, the mature form of AGR-2 is the one that acts as a 
p53 inhibitor [474]so the finding that this form is nuclear can explain this inhibitory 
action, based on the fact that both proteins have the same topology. Other proteins 
have also been listed as p53 inhibitors when localised in the nucleus, with the most 
fully characterised mdm-2 [107, 413].  Mdm-2 must localize to the nucleus to bind 
p53, and repress p53-mediated transactivating and apoptotic activities [477] although 
[151] 
 
Chapter 3                                                                                                       Discussion 
the final p53 degradation happens in the cytoplasm [570]. When mdm-2 is 
sequestrated in the cytoplasm by an inhibitor such as PTEN, its p53 binding and 
inhibitory functions are repressed [393, 654]. On the other hand, p53 activation also 
happens in the nucleus as in the case of the PML, a nuclear phosphoprotein that acts 
as a tumour suppressor [201] and stimulates p53 activity by recruiting it to nuclear 
foci, termed as PML nuclear bodies [180, 558, 614]. Certain tumours constitutively 
accumulate wild-type p53, which is functionally inactive because it is sequestered in 
the cytoplasm [411, 449]. In addition, treatment of human primary cells with 
Leptomycin B, a drug that specifically blocks nuclear export, induces the 
relocalization of p53 into punctate subnuclear structures, reminiscent of the so-called 
nuclear bodies (NBs) [339] where mdm-2 and p53 co-localize and therefore interact. 
In conclusion, inhibition or activation of p53 is highly dependent on the localization 
of the proteins implicated in the interaction and so mature AGR-2, the one that 
inhibits p53, is mainly localized in the same compartment where the tumour 
suppressor acts,  making the interaction possible to happen. 
Mutation of the last four amino acids to KDEL, enhanced the percentage of granules 
detected in the cytoplasm and having more than 10% co-localization rate with the 
endoplasmic reticulum (Figure 3.25). ER-retention was expected since KDEL 
ensures efficient residency in this compartment and also reduced the protein’s 
expression levels in the nucleus, while at the same time induced cell 
membrane/organelles expression levels (Figure 3.24). This reduction can be 
explained by the fact that more protein is exported from the nucleus, since the 
presence of the KDEL sequence leads the protein to the endoplasmic reticulum, but 
the KDEL tetrapeptide alone is not sufficient to totally deplete AGR-2 from the 
nucleus. In AGR-2 negative cell line, the equilibrium was shifted from nuclear 
localization of the wild type protein to enhanced distribution of the KDEL mutant in 
the cytosol and membrane/ organelles fraction, further supporting the role of the 
KDEL endoplasmic reticulum-retention sequence (Figure 3.26). Interestingly, 
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Substitution of the last threonine to alanine reduced nuclear expression levels in 
MCF-7 cells, but no induction in the cytosolic and membrane/organelles fraction was 
observed, since the KAEL sequence is not alone sufficient to lead the protein to any 
other compartments as it requires the presence of a leader signal sequence, either 
secretory or targeting it to mitochondria and other cellular compartments [311]. 
Studies with methionine sulfoxide reductases revealed that absence of a signal 
sequence leads the protein to the cytosol, even in the presence of the KAEL sequence 
[311] consistent to our data. On the other hand, the cytoskeleton fraction showed 
elevated expression levels of the mutant, so it is possible that this sequence induces 
association to the cytoskeleton and promotes protein transportation, although more 
experiments need to be done to refine this observation. 
Deletion of the last four amino acids remarkably disrupted the equilibrium and the 
protein could only be detected in the cytosol (Figure 3.24). No nuclear nor organellar 
expression was detected. In the AGR-2 negative cell line, the construct was again 
present in elevated levels in the cytosol and very little in the nucleus which might be 
a GFP artefact or maybe the GFP protein is too big to be exported from the nucleus 
(Figure 3.26). On supporting these data, deletion of the last ten aminoacids, including 
KTEL, leads to attenuation of the inhibitory action on p53 [474] which can be 
explained by the finding that this deletion mutant is no longer localized to the 
nucleus where it can interact with p53. Moreover, no endoplasmic reticulum nor 
Golgi co-staining was observed (Figures 3.19 and 3,20), since there is neither KTEL 
nor signal peptide to lead the protein these compartments as it happens with the full 
length form of AGR-2. What is more, GFP is accused of being unstable and 
sometimes folding of the fluorescent protein may interfere with the fused protein 
properties [286, 600]. In addition, GFP exhibits slow or incomplete fluorescence 
maturation which can explain why this AGR2- ΔKTEL GFP is so sensitive and 
bleaches after a very short exposure on its excitation wavelength. Many Anthozoa 
GFP-like proteins also form non-specific, high molecular weight aggregates both in 
vitro and in vivo that are toxic to cells and this can reduce the target protein’s 
expression levels [636] and also interfere with the fluorescent signal which can, in 
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our case, explain why this AGR-2 construct is detected in the nucleus along with the 
cytosol by microscopy and only in the cytoplasm by subcellular fractionation 
experiments (Figures 3.19 and 3.24, respectively). Aggregation-accumulation 
happens due to the presence of hydrophobic pockets within the fluorescent protein 
[636] and this state can be interrupted by treating with detergents or other agents, as 
in the case of isolation of different sub-cellular compartments. All these fluorescent 
proteins are being subjected to molecular engineering in order to minimize their 
limitations and acquire the desired properties  but drawbacks still exist [405].  
 
 
3.3.5 Endogenous AGR-2 is a dynamic equilibrium between the two 
isoforms 
 
If the localization patterns of the two distinct forms of AGR-2, full length and 
mature, are combined, the result is the staining pattern supported by immunostaining 
with the monoclonal anti-AGR2 antibody, which showed diffuse cytoplasmic, 
perinuclear and nuclear distribution of the endogenous protein (Figure 3.7).  Nuclear 
and diffuse cytoplasmic distribution is identical to the mature AGR-2wt RFP protein, 
whereas perinuclear staining is similar to the full length AGR-2wt RFP isoform. This 
distribution pattern was also supported by fractionation experiments, isolating 
endogenous AGR-2 in the cytosol, membrane/organelles and nuclear fraction fo 
MCF-7 cells (Figure 3.24). This pattern was expected, since the antibody recognizes 
both forms of the protein, whose only difference is the presence of the N-terminal 
leader sequence. Small differences in the staining pattern between the polyclonal and 
the monoclonal anti-AGR-2 antibodies (Figures 3.6 and 3.7) can be explained by 
different epitope recognition, as well as the possibility of a masked epitope 
recognized by any of those antibodies. Of course polyclonal antibodies also have 
issues when it comes to specificity of binding that therefore affects efficiency. 
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3.3.6 Conclusions of chapter 
 
In conclusion, results presented in this chapter demonstrated that AGR-2 follows 
diverse distribution patterns in breast cancer cells that have different resistance to 
tamoxifen and other anti-estrogens. The exact sequences essential for each 
localization were defined by fluorescent-tagged AGR-2. The KTEL tetrapeptide in 
the C-terminal of the protein ensured nuclear retention in the absence of the N-
terminal signal peptide that acts in a predominant way when present in the protein 
and designated the protein to the cytosol maintaining partial ER co-localization even 
in the absence of this KTEL tetrapeptide. This co-localization was enhanced by 
mutating the KTEL to KDEL. On the other hand, the minimum domain required for 
nuclear residency was narrowed down to KXEL, since total deletion of this 
tetrapeptide lead to nuclear exclusion, always in the absence of the leader peptide, 
whereas substitution of the KTEL with KDEL or KAEL was not sufficient to inhibit 
nuclear localization. Absence of the leader sequence and process to the mature form 
of the protein causes nuclear localization accompanied with diffuse cytosolic pattern. 
It is under these non-ER localizing conditions (i.e. cytosolic or nuclear localizations) 
which correlate with the protein’s ability to inhibit p53 [474]. Deletion of the last 
four KTEL amino acids shifts the equilibrium to a less nuclear and more cytosolic 
pattern even in AGR-2 negative cells. Together, our data with previous experiments 
[474], provide a correlation between mature AGR-2 nuclear localization and the 
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4.1 Introduction 
 
4.1.1 Mitochondria and energy sufficiency 
 
Mitochondria are the energy plants of the cells, as they produce most of the energy it 
needs, generate endogenous reactive oxygen species and participate in apoptosis via 
the mitochondrial permeability transition pore which consists of anti- and pro- 
apoptotic Bcl-2 and Bax family members, respectively. Mitochondria are transported 
to regions where ATP consumption is high and they disperse when the ratio of 
ADP/ATP increases [28, 29, 462]. Interestingly, in neuronal processes 1/3 of the 
mitochondria are in constant motion whereas the rest are stationary [202, 416] and 
ultrastructural studies showed the formation of cross-bridges between the 
mitochondria and microtubules [50, 256] or intermediate filaments [256]. 
These organelles play an important role in cancer, as cancer cells rely heavily on 
glycolysis and energy production, the so called Warburg effect, as it was firstly 
described by Warburg in 1930. This effect can be summarised in the observation that 
cancer cells even in the presence of sufficient oxygen levels undergo glycolysis to 
synthesize the required ATP for their metabolic activity [108]. Glycolysis consists of 
glucose catabolism into excessive lactic acid by consuming oxygen. During this 
process they upregulate glucose transporters as well as other enzymes of glycolysis 
[463]. A possible mechanism that contributes to the Warburg effect involves 
mutations in the mtDNA. mtDNA is a supercoiled, double stranded circular DNA 
molecule that codes for 13 of the 87 respiratory chain subunits, 12S and 16S rRNA 
and 22tRNAs required for mitochondrial protein synthesis [88]. Cancer cells often 
accumulate defects of the mitochondrial genome leading to deficient mitochondrial 
respiration and ATP production [72]. Mitochondrial defects fall into two categories 
(i) one associated with germline mutations in the mitochondrial genome that creates 
genetic predisposition to cancer development and (ii) one involving acquired 
mutations that exhibit oxidative phosphorylation, increased production of reactive 
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oxygen species (ROS) and thus uncontrolled cell proliferation and metastasis [72]. 
mtDNA often bears mutations in various types of cancer such as prostate cancer 
[105],  breast cancer [656], gastric cancer [651], neck, bladder, head cancer [200] 
and leukaemia [88, 89]. Several factors contribute to the high mutation rate and 
vulnerability of the mitochondrial genome, such as weak DNA repair capacity, lack 
of protective histones, low percentage of introns in the genome, close proximity to 
the electron transport chain that creates superoxide radicals and therefore higher 
genomic instability leading to biologicaly relevant mutations and affecting the 
metabolic pathway of the cell, which struggles to meet its energy requirements [89]. 
Nevertheless the biological impact of each mutation may be variable because each 
cell has more than one mitochondria and therefore mutant mtDNA may coexist with 
wt mtDNA, a state called heteroplasmy, but the total proportion of mutant DNA is 
the one that determines cell fate and behaviour. Germline mutations, insertions or 
deletions, are more common in syndromes such as Leber’s hereditary optic 
neuropathy, maternally inherited diabetes mellitus and Leigh’s syndrome, whereas 
somatic mutations are more commonly linked to cancer [88]. Another mechanism 
contributing to Warbug effect is the adaptation of cancer cells to hypoxic 
environment [212]. Hypoxia is a situation that characterizes most of cancer 
malignacies and is associated with low percentage of oxygen in the tissue 
environment. If that is the case, then cancer cells are forced to use the glycolytic 
pathway for ATP production [212]. 
In the last decade of the twentieth century it was discovered that the mitochondria 
from cancer cells are often resistant to the induction of mitochondrial outer 
membrane permeabilization (MOMP) which is a process that mediates apoptosis 
[228, 648] through the intrinsic apoptotic pathway (thoroughly described in chapter 
1.2.1.2). MOMP is a quite complicated and multifactorial phenomenon that 
implicates a lot of different components. Amongst them are pro-apoptotic proteins 
such as the Bcl-2 protein [111, 643], proteins of the permeability transition pore 
complex [74] whose primary role is regulate oxidative phosphorylation and utilize it 
for energy production [233], transcription factors such as the tumour suppressor p53 
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protein [409] and mitochondrial lipids as well [233]. This process leads to release of 
proteins that are normally localized between the inner and the outer membrane of the 
mitochondria, such as cytochrome c [220]. Inhibition of MOMP results in disabled 
apoptosis and therefore tumour progression. The mechanistic link between MOMP 
and aerobic glycolysis awaits further elucidation.  
 
 
4.1.2 Mitochondrial and cytoskeleton 
 
Mitochondria are not static organelles but they undergo frequent changes in their 
shape and position depending on the cell type, cell cycle and the organism. They can 
be spherical due to fusions or fragmentation of their membrane or elongated after 
interaction with cytoskeletal filaments. Interactions between mitochondria and the 
cytoskeleton are essential to their normal function as well as for localization of the 
organelles to their sites of action within the cell when required. Cytoskeleton 
participates in mitochondrial respiratory activity, fusion, fission and inheritance as 
well as ensuring localization of mitochondria into the right position in cells, such as 
where energy requirements are higher, where reactive oxygen species are generated, 
where calcium homeostasis takes place and of course where apoptosis is happening. 
On the other hand, mitochondria in turn, utilize cytoskeleton to be assembled 
correctly, to control their movement and anchorage within a cell. High energy 
demanding cells, such as neurons, are characterized by rapid mitochondrial 
movement towards their axons by interaction of the mitochondria with the dynamic  
+end of microtubules [630] towards the axons and retrograde movement towards the 
opposite direction [257]. Moreover, during mitosis in yeast, mitochondria appear to 
attach to the spindle pole bodies and move to the cellular ends during spindle 
elongation [630]. Chada and Hollenbeck recently found that placing a nerve growth 
factor, NGF, coated bead on the axon of a chick neuron, results in TrkA-mediated 
accumulation of mitochondria in this site and that agents that inhibit actin 
polymerization halt this accumulation [97]. 
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Mitochondria co-localize with intermediate filaments, IFs, which are part of the 
cytoskeletal system of the cell. Several evidence that associate mitochondria to IFs 
exist in various cell types and organisms [156, 165, 419]. Treatments with drugs that 
disrupt microtubules or intermediate filaments cause redistribution of mitochondria 
[564] and change the organization of the cellular organelles as well [165]. 
Interestingly, in muscle cells, silencing of desmin, IF protein, leads to disassembly of 
the mitochondria as well as respiratory dysfunction  [402]. The same observations 
were made by knock-out mice that had no intermediate filament desmin and showed 
no mitochondria motility [363, 402]. On the other hand, overproduction of Bcl-2 
when combined with total deletion of desmin, restores mitochondrial function and 
capacity and corrects cardiomyopathy in des-/- mice suggesting a potential 
mechanism through which cells deficient in cytoskeleton components may overcome 
this problem, restore mitochondrial function and escape cell death [618]. 
When it comes to microtubules, another component of the cytoskeleton, it is 
noteworthy that mitochondria can use cytoskeleton-based mechanisms for movement 
that are distinct from the mechanism for force generation by kinesins and dyneins 
along cytoskeletal tracks [630]. Studies in fission yeast showed that mitochondrial 
movement is microtubule-dependent and destabilization of the last causes 
mitochondrial disassembly and other morphological defects [629, 630]. In the same 
model organism, polymerization and depolymerization of microtubules plays a key 
role in mitochondrial localization and behaviour during interphase and  a protein 
called Mmd1p links mitochondria to microtubules and stabilizes the last in yeast 
[616], but no evidence for such protein exist in mammalian cells so far. It is 
noteworthy that spindle aster microtubules have also been implicated with 
mitochondria as well as other structures such as ER, microbodies, lipids, vacuoles 
movement during mitosis in yeast and Drosophila [11, 465] ensuring equal 
distribution of the mitochondria and other structures to the daughter cells.  
Attachment of cellular organelles to the growing ends of microtubules has also been 
observed in mammalian cells, sometimes associated with the ER [575] and others 
associated with phagosomes [61, 219, 469] and of course chromosomal movement 
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during cell division. Interestingly, in different phases of their movement, 
phagosomes exhibit altered preference for microtubules, with the early phagosomes 
attached to the plus end of the microtubules whereas the late did not [61]. It is 
noteworthy that cells deficient in microtubules or actin filaments fail to maintain 
mitochondrial mobility and correct docking [416]. 
As far as the actin is concerned, experiments in plants [528, 595], neurons [322] and 
budding yeast shed light to the interaction between mitochondria and actin and of 
course implications in the apoptotic pathway. In these cells, mitochondria exhibit 
track-dependent short-distance movement along F-actin, polymerized actin, and 
immobilization of the organelle to the cell cortex. In yeast, mitochondria bind to 
actin bundles and undergo both anterograde and retrograde movement [189].  During 
cell division, this interaction requires the presence of several proteins, called Mmms 
or Mdms in yeast that affect the maintenance of mitochondrial morphology or 
mitochondrial distribution and morphology,  that organize the complex and deletion 
of any of these proteins result in mitochondrial mislocalization and malfunction [251, 
394]. Experiments in Jurkat cells revealed that gelsolin, a Ca2+ actin regulatory 
protein and a substrate for caspase-3  that is mainly localized in the cytosol [321], is 
also present in the mitochondria and inhibit apoptosis by blocking cytochrome c 
release [322]. The mechanism of inhibition resembles the one observed by anti-
apoptotic Bcl-2 family members in terms of a product cleaved by caspase-3 and 
capable of stimulating cell death [109, 534]. Gelsolin acts through blocking 
cytochrome c release and also regulates the mitochondrial permeability transition 
pore [322] along with the voltage dependent Ca2+ ion channel [208].  Surprisingly, 
there is no evidence for a direct role of myosin in actin-based mitochondrial 
movement in any animal cells or fungi [189, 257]. 
All the above suggest a dynamic system that plays a role in mitochondria localization 
and distribution and is under the strong influence of different components of the 
cytoskeleton which can act synergistically or substitunionally in the presence of 
drug-induced inhibition. The factors and conditions regulating these interactions are 
difficult to be determined and examined in in vivo systems. 
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4.1.3 Mitochondria and cell death 
 
During apoptosis mitochondria undergo two major alterations. The first one refers to 
the permeabilization of the outer mitochondrial membrane due to huge accumulation 
of Ca+2 and is highly regulated by pro-apoptotic Bcl-2 family members. The second 
refers to the loss of the electrochemical gradient, normally present across the inner 
mitochondrial membrane, an effect called ‘membrane depolarization’, sometimes 
mediated by the permeability transition pore. The whole process is known as the 
intrinsic apoptotic pathway or mitochondrial pathway or Bcl-regulated pathway. Bcl-
2 family members interact with mitochondria either constitutively or on induction of 
apoptosis and have a impact on the outer mitochondrial membrane (OMM) [643]. 
 
 
Figure 4.1:  Diagram depicting intrinsic and extrinsic pathways of apoptosis. Details on 
both pathways can be found in sections 1.2.1/1.2.1.2/4.1.3. The Bcl-2 family regulates the 
intrinsic pathway and can modulate the extrinsic pathway when cleavage of BID 
communicates between the two pathways. FAS/TNFR3: cell surface death receptors, BH3-
only proteins: Bim/Puma, APAF1: apoptosis protease-activating factor 1, dotted line shows 
activation whereas red T line indicates inhibition.  (Adapted from [643]) 
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The number and shape of mitochondria is tightly regulated by a dynamic equilibrium 
between mitochondrial fission and fusion process, which in turns is regulated by 
several mitochondrial proteins [291]. These mammalian mitochondria-shaping 
proteins include the large nuclearly-encoding mitochondrial transmembrane GTPases 
mitofusins Mfn1 and Mfn2 [104, 494], the optic atrophy protein Opa1 [514] of the 
inner mitochondrial membrane, dynamin-related protein Drp1 [204, 545] of the outer 
mitochondrial membrane and hFis 1 which regulates mitochondrial fission [641].  
Mitochondrial shape is a result of dynamic alterations between fusion and fission 
events that lead from rod-globular to tubular shape and vice versa [252].  Both 
processes are necessary to ensure appropriate distribution of the mitochondria during 
mitosis and have distinct roles in apoptosis. Disturbance of the equilibrium leads to 
abnormally-shaped mitochondria such as elongated, clustered [545] or fragmented 
ones (summarised in Figure 4.2) [291]. As already mentioned previously (Chapter 
1.2.1.2), mitochondria are the main component of the intrinsic apoptotic pathway and 
Bcl-2 family of pro-apoptotic and anti-apoptotic proteins is a key player in this 
process as they regulate the outer mitochondria membrane integrity and function 
[234, 310, 444] (summarised in Figure 4.1). In this chapter the relation of AGR-3 
with mitochondrial proteins will be investigated and for that reason each family 
member should be analysed in more detail here. The Bcl-2 family can be divided into 
three different groups based on Bcl-2 homology (BH) domains and function [6, 306], 
(i)The anti-apoptotic members, such as Bcl-2 and Bcl-xL, that typically have BH1 
through BH4 domains,  [337]: (ii) the pro-apoptotic family members with BH1, BH2 
and BH3 domains, such as Bax and Bak, and those (iii) pro-apoptotic family 
members with only BH3 domains, such as Bad, Bid, Puma and Bim [6, 589]. Briefly, 
the mitochondrial apoptotic cascade includes the membrane-permeability transition 
pore, which is regulated by all the above Bcl-2 family members through the 
composition of the voltage-dependent anion cells (VDAC, also called mitochondrial 
porin channel) [534] and adenine nucleotide translocator (ATN). The last two 
proteins are components of the permeability transition pore in the outer and inner 
side of the pore respectively. Studies by Narita and co-workers supported that pro-
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apoptotic Bax and Bak accelerated the opening of the VDAC which is then 
permeable to cytochrome c, whereas anti-apoptotic Bcl-xL closes the pore by binding 
directly to VDAC [427, 534],  and also that Bax and VDAC form a large pore [534]. 
BH3-only proteins can directly activate pro-apoptotic Bax/Bax or act indirectly via 
binding and neutralising of pro-apoptotic Bcl-2 which prevents mitochondria 
permeabilization through Bax/Bak inhibition (Figure 4.1). Once activated, Bax and 
Bak, promote cytochrome c release and mitochondrial fission, which leads to the 
activation of APAF1 into an apoptosome and activates caspase-9 to activate caspase-
3. Caspases in turn cleave a series of substrates, activate DNases and orchestrate the 
destruction of the cell. The extrinsic pathway can detour the mitochondrial step and 
activate caspase-8 directly, which leads to caspase-3 activation and cell death [643]. 
Recent data also support that Bcl-2 inhibition is not sufficient to induce apoptosis 




Figure 4.2: Correlation between mitochondrial morphology and apoptotic sensibility. 
Blocking of mitochondrial fission by knockdown (RNAi) of Fis1 or Drp1 expression induces 
mitochondrial fusion. HeLa cells with the elongated and interconnected mitochondria show 
apoptosis resistance. Fis1 RNAi cells show stronger anti-apoptotic phenotype than Drp1 
RNAi cells. Elongated mitochondria in the Fis1 RNAi cells inhibit both Bax translocation to 
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mitochondria and cytochrome c release from mitochondria. Elongated mitochondria, 
however, in the cells depleted of Drp1 inhibit cytochrome c release but not Bax 
translocation. In contrast to hFis1 and Drp1 RNAi cells, Opa1 RNAi cells having fragmented 
mitochondria are more sensitive to apoptosis induced by various stimuli compared to the 
control cells. Fragmented mitochondria in the cells promote both Bax translocation and 
cytochrome c release. In the cells depleted of both hFis1 and Opa1, despite of mitochondria 
are extensively fragmented, the cells show apoptosis resistance (adapted from [291]). 
 
 
4.1.4 Mitochondria and p53 
 
p53 mediates apoptosis primarily via the mitochondrial pathway by stimulating 
transcription of various mitochondria-anchored pro-apoptotic genes like Puma, Bax, 
Bid, that participate in mitochondrial cell death, in response to various exogenous or 
endogenous stimuli. p53 can also mediate trans-repression of anti-apoptotic genes 
such as Bcl-2. Various stimuli such as DNA damaging agents, UV irradiation, γ-
irradiation, hypoxia, chemotherapeutics, ROS agents, RNA interference  and growth 
factor deprivation can cause p53 mitochondrial translocation [401, 511, 651]. This 
translocation is rapid and happens in less that 1h, preceding early dysfunctional 
changes in the mitochondrial membrane potential. Mitochondrial p53 stimulates a 
series of events including cytochrome c release, change in the membrane potential 
and pro-caspase-3 activation. The majority of p53 is localized to the membranous 
mitochondrial compartment whereas a fraction is found in complex with the 
mitochondrial import motor mtHsp70 [383]. Anti-apoptotic regulators such as Bcl-2 
and Bcl-xL specifically block stress-induced p53 translocation and therefore 
apoptosis, but interestingly do not halt nuclear p53 induction and cell cycle arrest 
suggesting a regulatory feedback loop in the organellar level [383]. p53 directly 
forms inhibitory complexes with the Bcl-xL/2 via its DNA-binding domain [401] and 
these interactions terminate in the permeabilization of the outer mitochondrial 
membrane and therefore cytochrome c release and activation of effector caspases. 
The ability of Bcl-xL/2 to block p53-mediated cytochrome c release parallels that 
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[166] 
 
seen with Bax and Bid from isolated mitochondria [140]. In p53 null cells, total 
mitochondrial p53 expression was capable of triggering post-mitochondrial caspase 
cascade and lead to apoptosis in comparable levels as with the nuclear p53 [383].The 
above data are consistent with the observation by Ding and co-workers, who showed 
that p53 protein from cell-free post-nuclear extracts directly activates caspase-3 
through an unknown mechanism, provided that cell-free extracts are derived from 
irradiated tumours [142]. This result is a clear biochemical evidence of an inducible, 
transcription-independent pro-apoptotic function of p53. Of note, these extracts 
contained mitochondria and therefore could have been the source of the p53-
dependent effect [142]. Interestingly, it was also found that mitochondrial p53 
translocation apart from triggering caspase-3 activation cascade, it also triggers a 
second slower transcription-dependent p53 death wave that includes p53-target gene 
induction and a further increase in active caspase-3 levels [177]. p53  mitochondrial 
translocation has been observed in various tissues such as testis, thymus [401], 
spleen in vivo [177] which are also radiosensitive organs and in primary cells 
cultures including human mammary epithelial [65], dermal fibroblasts and skin 
keratinocytes. On the other hand, p53 mitochondrial translocation does not occur in 
p53-independent apoptotic pathway nor p53-mediated cell cycle arrest [383]. 
The precise signal on p53 for its mitochondrial translocation is yet undefined. A 
translocation motif within the p53 amino-acid sequence has not been found and 
phosphorylation/acetylation modifications of p53 are not determinants for 
mitochondria translocation [428]. Studies on the Arg/Pro codon 72 variants proposed 
that mdm-2-mediated polyubiquitylation of p53 mediates nuclear export and 
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4.1.5 Objectives of chapter 
 
AGR-3 is the second member of the AGR family studied in terms of localization and 
function. Not much evidence exists regarding the distribution and the exact role of 
the protein in cancer although few data suggest the endosomal residency of the 
protein [5]. As far as the function is concerned, AGR-3 was found to enhance colony 
survival, but not much is known regarding the exact mechanism of action [270]. 
Characterization of newly-generated antibodies along with immunofluorescent 
microscopy and chemical fractionation in the cellular level will aid in studying the 
localization of the endogenous protein in MCF-7 cells. Small interference RNA 
technology will elucidate the role of the protein and also a series of other proteins 
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4.2 Results 
 
4.2.1 Evaluation of AGR-3 antibodies 
 
Anti-AGR-3 mouse monoclonal antibodies (Moravian Biotechnologies) were tested 
by ELISA for epitope recognition. Peptides representing the full length AGR-3 and 
AGR-2 proteins (Figure 4.3, kindly provided by Dr. Murray) were bound to an 
ELISA 96-well plate and incubated overnight with each of the four antibodies, 




Figure 4.3: Diagram of peptides used in epitope mapping of anti-AGR3 antibodies. 
Peptides 1-16 represent AGR-2 a.a composition whereas peptides 17-31 correspond to AGR-
3. Black arrows indicate the peptide recognised by the two AGR3-specific antibodies, 1.2 
and 2.2. Underlined sequences are the exact epitope recognised when the overlapping 
sequences of adjacent peptides are excluded (shown in blue).  
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Figure 4.4: Representative ELISA diagram of epitope mapping. Anti-AGR3 antibodies , 
termed 1.2, 2.2 and 4.1, were tested by ELISA for efficient binding to peptides representing 
AGR-2 and AGR-3 full length proteins.  
 
 
The 1.2 antibody bound strongly and repetitively to peptide 26 (Figure 4.4, red label) 
but not to peptide number 27 nor 25 which have some overlapping peptides with 26 
(Figure 4.3 indicated in blue letters, Figure 4.4,), further narrowing down epitope 
mapping for this antibody to: knlsp (Figure 4.3, underlined). The second antibody 
tested, 2.2, strongly recognised epitope 23 of the AGR-3 peptides (Figure 4.4, blue 
label). Again no strong binding was observed with partially overlapping peptides 24 
and 22, further defying the exact sequence of recognition to: lkkvf (Figure 4.3, 
underlined). The 3.1 antibody showed no specific binding as this antibody recognised 
a lot of epitopes without overlapping sequences and totally different to each other as 
well as giving contradictory and non-repetitive results throughout multiple 
experiments (Figure 4.4) and for that reason was not included in the study. The last 
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antibody tested, 4.1, was consistent in identifying peptides 2, 6, 7, 9 and 10 which 
represent AGR-2 sequence as well as to AGR-3 peptides number 21, 22, 25 and 26, 
behaving like a polyclonal antibody,  although RLU were much lower to the 1.2 and 
2.2 antibodies (up to 30x more than 4.1, Figure 4.4, green label). Since the two 
proteins share high homology, this antibody cannot be used for accurate experiments.  
To further characterize their binding affinity and specificity to AGR-3 and not be 
restricted to only one evaluation method, the same four antibodies were tested for in 
vivo recognition of endogenous AGR-3 (Figure 4.5) in MCF-7 cells that have 
endogenous AGR-2 and AGR-3. Lysates were pulled down with each of the 
antibodies and then immunoblotted against AGR-3 (antibodies 1.2, 2.2 and 4.1 
depicted in Figure 4.5 A, C and D, respectively) and AGR-2 (Figure 4.5 B).  The 
antibodies used for pulling down endogenous protein included a monoclonal anti-
AGR-2 antibody (Figure 4.5 lanes A2, B2, C3 and D2), antibodies 1.2, 2.2, 3.1 and 
4.1 anti-AGR-3 ones (Figure 4.5). The anti-AGR-3 ones were not able of pulling 
down endogenous AGR-3 from MCF-7 cells. The 1.2 antibody recognised the 
protein in total lysate before immunoprecipitation but after pulling down with the 
same antibody, no AGR-3 signal was detected (Figure 4.5 A lane 1 and 3 
respectively). The other two antibodies, 2.2 and 3.1 were unable to recognise 
endogenous AGR-3 neither in crude lysate nor after precipitation with themselves. 
Only the 4.1 antibody pulled down a protein of 20kDa, which was positive when 
tested by the AGR-2 antibody (Figure 4.5 D lanes 1 and 3). As verified before, by 
ELISA, this antibody is able to recognize AGR-2 epitopes as well as AGR-3 ones 
(Figure 4.4, green label), which explains why after immunoprecipitation with the 
monoclonal anti AGR-2 antibody, the 4.1 detects the right 20kDa size band of AGR-
2 (Figure 4.5 D lanes 1 and 2). Control co-immunoprecipitation experiments with the 
anti-AGR-2 monoclonal antibody, ensured efficient experiment conditions regarding 
solutions, temperature and beads’ concentration. The monoclonal anti-AGR-2 
detected AGR-2 in lysate before and after co-immunoprecipitation by the same 
antibody, as expected (Figure 4.5 B lanes 1 and 2). Negative-lysate control pull 
downs were performed to test for unspecific binding of the antibodies to the beads 
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and potential interference with the results (Figure 4.5 A lane 7 and C lane 1). Light 
chain and heavy chain of the antibodies was detected at ~54 and ~305kDa, 




Figure 4.5: Anti-AGR3 antibodies do not IP endogenous AGR-3. Endogenous AGR-3 
protein from MCF-7 cells was pulled-down with a series of antibodies including monoclonal 
anti-AGR-2 (Lanes A2/B2/C3/D2), 1.2 anti-AGR3 (lanes A3/B3/C4/D3), 2.2 anti-AGR3 
(lanes A4/B4/C5/D4), 3.1 anti-AGR3 (lanes A5/B5/C6/D5) and 4.1 anti-AGR2 (lanes A6/ 
B6/C7/D6). Lysates were immunoblotted with a monoclonal anti-AGR-2 antibody (panel 
B1-B6) and AGR-3 with the same 1.2 (lanes A1-A6), 2.2 (lanes C1-C7), and 4.1antibodies 
(lanes D1-D6) against AGR-3. Beads only and total cell lysate pre-IP were used as controls. 
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The last step of evaluation involved immunofluorescence testing for endogenous 
AGR-3 in MCF-7 cells. The first antibody tested was 1.2 and it gave a string-like 
pattern around the nucleus resembling the endoplasmic reticulum but with thicker 
and more extensive structures within the cytoplasm and not strictly around the 
nucleus (Figure 4.6 panels A-C and Figure 4.8 panels D-F). Comparing these string-
like structures with MCF-7 fluorescent images presented in the literature, resulted in 
the conclusion that this pattern strongly resembled mitochondrial staining. Apart 
from this reticulum-like staining, this antibody also showed signs of low diffused 
cytoplasmic AGR-3 expression (Figures 4.6 panels A-C and 4.8 panels D-F). This 
observation concerning mitochondrial detection was further characterised in Chapter 
4.2.2. The second antibody, termed as 2.2, gave a totally different pattern resembling 
cell membrane staining, with signal detected in the boundaries of the cells and 
(Figure 4.6 panels D-F), which was also separately determined by brightfield 
microscopy in a confocal Leica microscope and (Figure 4.7 panels A-I). The third 
antibody, 3.1, gave no positive results at all which was totally expected as the 
antibody does not recognise any AGR-3 epitopes, as determined by ELISA and co-
immunoprecipitation (data not shown). Last but not least, the 4.1 antibody, gave a 
rather peculiar model which resembled the 1.2 string-like staining (Figures 4.6 panels 
A-C and 4.8 panels D-F) and the monoclonal anti-AGR2 antibody diffused staining 
within the cytoplasm (Figure 4.8 panels A-C). This staining pattern was thought to be 
a combination between diffused cytoplasmic and string-like reticulum accompanied 
by small granules within the cytoplasm (Figures 4.6 panels G-I and 4.8 panels G-I) 
consistent with to the ELISA data which characterised the 4.1 antibody as a 
polyclonal-like one, due to its multi-epitope recognition (Figure 4.4, green label). 
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Figure 4.6: Intracellular localization of endogenous AGR-3 in MCF-7 using fluorescent 
microscopy. After fixation the protein was visualized using 1.2 (panels A-C) 2.2 (panels D-
F) and 4.1 anti-AGR3 (panels G-I) antibodies and Alexa-conjugated secondary antibody was 
applied (Alexa-549, Molecular Probes).  Nuclei were visualized by DAPI. Images captured 
by Sony Cool Snap 3.2 (Anti-AGR3: panels B, E and H, DAPI: A, D and G, merge: C, F and 
I) by Zeiss Axionplan microscope. Same exposure times used for all images. Figure showing 
representative of at least 4 independent experiments. Scalebar represents 10μm. 
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Figure 4.7: Membrane staining of endogenous AGR-3 in MCF-7 using fluorescent 
microscopy. After fixation the protein was visualized using 2.2 anti-AGR3 (panels A-I) 
antibody and Alexa-conjugated secondary antibody was applied (Alexa-488, Molecular 
Probes).  Nuclei were visualized by DAPI. Images visualised by concfocal Leica SP5 
microscope (Anti-AGR3: panels B, E and H, Brightfield: A, D and G, merge: C, F and I) . 
Same exposure times used for all images excited under the 488nm laser. Brightfield was 
each time adjusted to achieve high resolution of cells’ boundaries.  Figure showing 
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Figure 4.8: Comparison between AGR-2 and AGR-3 localization by microscopy. After 
fixation the protein was visualized using anti-AGR2 monoclonal antibody (panels A-C) 1.2 
anti-AGR3 (panels D-F) and 4.1 anti-AGR3 (panels G-I) antibodies. Alexa-conjugated 
secondary antibody was applied (Alexa-549, Molecular Probes).  Nuclei were visualized by 
DAPI. Images captured by Sony Cool Snap 3.2 camera (Anti-AGR3: panels B, E and H, 
DAPI: A, D and G, merge: C, F and I) by Zeiss Axionplan microscope . Same exposure 
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To sum up, of all four antibodies tested, only 1.2 and 2.2 antibodies can be used for 
further applications. Immunoblotting experiments favoured the 1.2 antibody against 
all the others when it comes to AGR-3 recognition in cell lysates (Figure 4.5 A lane 
1) but before immunoprecipitation, as well as in immunofluorescence. The 2.2 
antibody failed to detect endogenous AGR-3 protein from cell lysate (Figure 4.5 C 
lanes 1 and 5) and was only efficient in immunofluorescent experiments, where it 
recognized cell-membrane AGR-3 (Figures 4.6 panels D-F and 4.7 panels A-I). 
Interestingly, the recognition epitope for this antibody is not the leader sequence of 
the protein, as it would be expected for this staining pattern (Figure 4.3). The third 
antibody, 3.1, was totally inadequate for either immunoblotting or 
immunofluorescent experiments, and therefore its used was discontinued. The last 
antibody, 4.1, was behaving as a polyclonal one and recognised AGR-2 along with 
AGR-3 epitopes (Figure 4.4 green label), whereas in IF experiments it gave a 
combined pattern of monoclonal anti-AGR2 and 1.2 anti-AGR3 antibodies (Figures 
4.6 panels G-I and 4.8 panels G-I) patetrns. This antibody’s recognition epitopes 
shared some identical peptide sequences, which explains these multi-binding 
properties of the antibody but will not be further analysed in this thesis. 
 
 




4.2.2.1. Endogenous AGR-3 under normal conditions 
 
Endogenous AGR-3 expression was tested in the MCF- cell line, since this is the one 
used throughout the whole project. MCF-7 cells were found positive for AGR-3 and 
were used to study the localization of the protein. To elucidate the exact position of 
the protein within the cell, subcellular fractionation experiments along with 
fluorescent microscopy studies were performed.  Four different fractions were 
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isolated, representing proteins of the cytoplasm, cell membrane and organelles, 
nucleus and cytoskeleton, respectively. Interestingly, AGR-3 was detected in the F1 
cytoplasmic and F2 cell membrane and organelles fraction, in the MCF-7 cell line 
(Figure 4.9 A). No nuclear nor cytoskeleton localization was observed. MDA-MB 
231 breast cancer cells which are ER-negative were tested for AGR-3 expression and 
found negative. In immunofluorescence experiments the 1.2 antibody gave a 
repetitive string-like pattern along with some diffused cytoplasmic staining on the 
same MCF-7 cells (Figure 4.9 B). The 1.2 antibody is therefore consistent in 




Figure 4.9: Intracellular localization of  endogenous AGR-3 by chemical fraction and 
immunofluorescence. A) MCF-7 and MDA-MB 231 negative control cells were tested for 
endogenous AGR-3 and analysed by fractionation methodologies into F1 (cytosolic), F2 
(membrane/organelles), F3 (nuclear), and F4 (cytoskeletal) as indicated. The distribution of 
endogenous AGR-3 (~ 19 kDa) was determined by immunoblotting with the 1.2 anti-AGR3-
specific antibody. B) Immunofluorescence of the same cells with the same anti-AGR3-
specific antibody and Alexa 488 secondary antibody. Images visualised by Zeiss Axionplan 
and captured by Sony CoolSnap HQ camera. A:DAPI, B:anti-AGR3, C:Merge. Figures A 
and B are representative of at least 3 independent experiments (scalebar:10μm).  
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4.2.2.2 Endogenous AGR-3 after irradiation 
 
Since AGR-2 was found to be induced by UV and act as a p53 inhibitor [474] and 
also AGR-2 and AGR-3 were both found to be upregulated in breast cancer [199] 
and belong to the same family [199, 468] , the effects of UV in AGR-3 expression 
levels were tested (Figure 4.10 A). MCF-7 cells were irradiated and analysed by IF 
after six hours. In order to define the right dose that would allow visible results in 
AGR-3 localization patterns, three different doses were used, 10, 50 and 150 J/m2 
(Figure 4.10 B). No translocation of the protein was observed in neither of these 
doses although in the highest dose applied the fluorescent signal aggregated in some 
cells. AGR-3 was still detected in this string-like cytosolic reticulum and also 
distributed in a diffused pattern within the cytoplasm of the cells, but this reticulum 
was not as extended as in the non-UV control and looked rather disrupted and 
condensed, due to UV damage (Figure 4.10 B, panels B, E, H, and K). The presence 
of condensed apoptotic nuclei was enhanced as irradiation doses were increased, as 
expected. In order to ensure that the expression levels of the protein remained the 
same, immunoblotting analysis followed after chemical fractionation (Figure 4.10 
A). Interestingly, AGR-3 was detected in the cytoplasm and cell 
membrane/organelles fractions in untreated cells as well as cells treated with 50J/m2, 
an intermediate dose applied, causing not too much cell death but sufficient to induce 
cellular response. No nuclear, nor cytoskeleton localization shift was observed, after 
UV damage. The ratio between cytoplasmic and cell membrane/organelles AGR-3 
was unchanged, with cytoplasmic AGR-3 being expressed in higher levels compared 
to the membrane/organellar expression levels (Figure 4.10 A).  
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Figure 4.10: UV irradiation does not alter endogenous AGR-3 localization in MCF-7 
cells. A) MCF-7 were irradiated at 50J/ m2 and 6h post-UV analysed by using chemical 
fractionation methodologies into F1 (cytosolic), F2 (membrane/organelles), F3 (nuclear), and 
F4 (cytoskeletal) as indicated. The distribution of endogenous AGR-3 (~ 19 kDa) was 
determined by the 1.2 anti-AGR3-specific antibody. B) Immunofluorescence of the same 
cells irradiated with different doses of UV starting from 10J/m2 (panels D-F), 50J/m2 (panels 
G-I and 150J/m2 (panels J-L) and incubated with the same 1.2 anti-AGR3-specific antibody 
and Alexa-488 secondary antibody. Images visualised by Zeiss Axionplan and captured by 
Sony CoolSnap HQ camera. A, D, G, and J:DAPI, B, E, H and K:anti-AGR3, C, F, I and 
L:Merge. Figures A and B are representative of 3 independent experiments (scalebar:10μm).  
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4.2.3 Mitochondrial co-localization of AGR-3 in MCF-7 cells 
 
The first observations for AGR-3 localization regarding the 1.2 antibody resulted in a 
string-like pattern around the nucleus (Figure 4.6 panels A-C). This specific pattern 
resembled the mitochondria pattern within a cell, so further studies were performed 
to determine co-localization of AGR-3 and mitochondria. Mitotracker Red 
(Molecular Probes, Invitrogen) was used as a mitochondrial marker along with anti-
Golgin and anti-PDI antibodies staining the Golgi compartment and ER, 
respectively. As expected, AGR-3 was strongly co-localized with the mitochondria 
(Figure 4.11 A) and the co-localization rate, as determined by Leica software Leica 
Application Suite, LAS AF, varied between 85-100% (data not shown). AGR-3 
covers most of Mitotracker’s signal with only a few red-only (indicated by white 
arrows) or green-only areas that represent non-colocalization areas. Brightfield 
microscopy determined the boundaries of the nucleus and the cell. Minus 
primary/+secondary antibody controls were used in all the experiments to determine 
unspecific binding (data not shown). As far as the ER and Golgi are concerned, 
AGR-3 did not co-localize with any of those markers (data not shown). After 
confirming co-localization of AGR-3 with the mitochondrial by microscopy, 
chemical extraction of mitochondria versus cytoplasm was applied (Figure 4.11 B). 
As expected, endogenous AGR-3 was detected in high levels in the mitochondrial 
fraction as well as in the cytoplasmic fraction (Figure 4.11 B upper panel) consistent 
with the microscopy data. Efficient mitochondria isolation was tested by an anti-
cytochrome c antibody (Figure 4.11 B lower panel) which is mitochondrial under 
non-stress conditions. MCF-7 cells have an extended cytoplasm, representing 80% of 
total cell volume. Therefore, the cytoplasmic fraction should contain a lot of protein 
and equal µg of cytoplasm and mitochondria, where AGR-3 mainly resides, both 
contain high levels of the protein.  
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Figure 4.11: Endogenous AGR-3 co-localizes with the mitochondria. A) MCF-7 cells 
were incubated with Mitotracker Red and after fixation blotted against AGR-3 with the 1.2 
anti-AGR3-specific antibody. Alexa488 secondary was used to visualize the protein. 
Brightfields are shown in panels A , E and I; AGR-3 localization is highlighted in panels C, 
G and K, mitochondria are depicted in panels B, F and J and the extent of co-localization of 
AGR-3 and Mitotracker Red was determined by merging the respective images (D, H and L) 
using a Leica SP5 confocal microscope. Panel I-L is a higher magnification of panel E-H. 
Figure is representative of at least 5 independent experiments. B) Cytosolic and 
mitochondrial distribution of endogenous AGR-3 (lane 1-2, upper panel) in MCF-7 using the 
1.2 anti-AGR3-specific antibody. Anti-cytochrome c (16kDa) was used a mitochondrial 
fraction marker (lane 2, bottom panel). L: White arrows indicate non-colocalization areas. 
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4.2.4 Anterior Gradient 2 and Anterior Gradient 3 co-localization 
 
Co-staining for endogenous AGR-2 and AGR-3 simultaneously was beyond reach as 
both antibodies derived from immunized mice. As shown in Figure 4.12 I, the two 
proteins exhibit quite distinct localization patterns and the possibility of them being 
in the same compartment is not high. To further characterize the localization of 
AGR-3 as well as compare it to that of AGR-2, MCF-7 cells were transfected with 
either full length or mature AGR-2 RFP (Figure 4.12 II panels B and F respectively) 
and co-staining for endogenous AGR-3 was applied by the 2.2 or 1.2 antibody 
(Figure 4.12 II panels E-H and A-D) respectively. When it came to studying full 
length AGR-2wt RFP and endogenous AGR-3, the 2.2 antibody was used (Figure 
4.12 II panels A-D). As already mentioned, this antibody recognised cell membrane 
AGR-3 and it was considered as more adequate since full length AGR-2wt is the one 
that supposed to be secreted although AGR-2wt RFP did not show any signs of 
secretion so far. No co-localization between the two proteins was observed (Figure 
4.12 II panel D). Full length AGR-2wt RFP showed the same granular appearance 
within the cytoplasm, as several times before, and AGR-3 was detected in the cell 
membrane of the cell. When it came to mature AGR-2wt RFP and endogenous AGR-
3 the 1.2 antibody was used because it is the one that recognises mitochondrial and 
cytoplasmic AGR-3 and mature AGR-2wt RFP is the one distributed in a diffused 
way within the cytoplasm apart from the nucleus. Mature AGR-2wt RFP was nuclear 
and diffused cytoplasmic, whereas AGR-3 was detected in this string-like reticulum, 
that represents the mitochondria, and in the cytoplasm where it was not distributed in 
a diffused way, like AGR-2wt RFP does, but followed a granular pattern (Figure 
4.12 II panels E-H). Therefore, no colocalization of the proteins was observed 
(Figure 4.12 II panel H) in either case. 
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Figure 4.12: Endogenous AGR-3 do not co-localize with AGR-2. I) Endogenous AGR-2 
(panels A-C) and AGR-3 (panels D-F) in MCF-7 cells. Anti-AGR-2 monoclonal and anti-
AGR-3 1.2 antibodies were used. Alexa 594 secondary was used to visualize the protein. 
Images visualised by Zeiss Axionplan and captured by Sony CoolSnap HQ camera. DAPI: 
panels A and D, anti-AGR2: panel B, anti-AGR3:panel E and Merge: panels C and F  
(scalebar:10μm). II) MCF-7 cells were transfected with the indicated vector expressing full-
length AGR-2wt RFP (panels A-D) or mature AGR-2wt RFP. Endogenous AGR-3 was 
detected by the 1.2 or 2.2 anti-AGR3-specific antibody (panels E-H and A-D respectively). 
Brightfields are shown in panels A and E, AGR-3 localization is highlighted in panels C and 
G, full length AGR-2wt RFP is depicted in panels B, mature AGR-2wt RFP in panel F and 
the extent of co-localization of AGR-3 and AGR-2 RFP constructs was determined by 
merging the respective images (panels D and H ) using a Leica SP5 confocal microscope. 
Figures are representative of at least 3 independent experiments.  
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 4.2.5 AGR-3 silencing and implications of mitochondria 
 
In order to study the role of AGR-3, siRNA to the protein was applied and the 
expression levels of a series of proteins were tested. MCF-7 cells were transfected 
with siRNA unspecific control and siRNA specific to a unique AGR-3 sequence. 
Untransfected controls were also included in the experiment (Figures 4.13 and 4.14). 
siRNA was applied and the cells were harvested every day, at the same time, during 
a five-day time course. Since AGR-3 was found to be a mitochondria-localized 
protein in MCF-7 cells, a series of mitochondrial apoptotic or survival markers were 
tested. anti-Bax, anti-Bax6A7 and anti-Beclin1 anti-antibodies were used (as 
indicated on the right-hand margin of figures 4.13-4.14). AGR-3 expression levels 
are depicted in the first from top panel of each figure. Interestingly, when AGR-3 
was silenced no alterations in Bcl-2 and Bid expression levels were detected (data 
not shown). On the other hand, after 48h and 72h of AGR-3 silencing, total Bax 
levels were particularly increased but returned to normal levels after 96h of AGR-3 
depletion (Figure 4.13 second panel from bottom). In this case, ‘normal’ is defined as 
the expression levels observed at t0. What is more, after 48h of AGR-3 silencing, a 
decrease in Beclin-1 autophagy-marker protein was detected in cells that had the 
protein depleted but not in the untransfected and si-control transfected cells. Same 
reduction was detected at 72h and 96h post-depletion (Figure 4.13 third panel from 
bottom). Untransfected cells and cells transfected with control siRNA had 
significantly higher expression levels of Beclin-1 after 48h, indicating the induction 
of autophagy. At t0, no Beclin-1 protein was detected in neither of the samples, due 
to low levels of autophagy in a newly-split cell population (data not shown).  
Interestingly, Bax6A7 conformational change, characteristic of apoptosis, was 
observed when AGR-3 was depleted (Figure 4.14 A second panel from bottom). 
When mitochondria are undergoing apoptosis, then Bax changes conformation and 
the 6A7 epitope is exposed in the outer mitochondrial membrane, enabling the 
antibody to detect it. Twenty-four hours after AGR-3 silencing Bax conformational 
change is slightly detected and this effect is further induced after 48h and even more 
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after 72h. Interestingly, after 72h untransfected and siRNA control transfected cells 
also show elevated levels of Bax conformational change, but this is expected due to 
normal levels of apoptotic death occurring in cells growing in the same media and 
being overconfluent for long. Moreover, apoptotic cells are released in the media and 
toxic substances can further affect the remaining cells viability. In that case again 
AGR-3 siRNA shows the strongest band when compared to the other two 
untransfected and transfected with sicontrol cells which can be explained by the 
synergistic effect of AGR-3 depletion and the above stress conditions. It is worth 
mentioning that siRNA for AGR-3 is pretty effective and total depletion of the 




Figure 4.13: AGR-3 silencing is followed by Beclin-1 depletion. MCF-7 cells  untreated or 
treated with siRNA against AGR-3 or control siRNA for 48-72 and 96 hours. Lysates were 
immunoblotted to determine changes in AGR-3/ Beclin-1/ Bax levels. β-actin was used as a 
loading control. Figure is representative of 2 independent experiments. 
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Figure 4.14: AGR-3 silencing is followed by Bax conformational change. MCF-7 cells 
were left untreated or treated with siRNA against AGR-3 or control siRNA, siCon, for 0-24-
48-72 and 96 hours. Lysates were immunoblotted to determine changes in AGR-3 levels (A 
and B), conformationally changed Bax levels, Bax 6A7, (A and B). β-actin was used as a 
loading control for total protein levels. Figure showing is representative of 2 independent 
experiments. 
 
It is worth mentioning that differences in the timepoints where siRNA efficiently 
depleted the AGR-3 protein were observed and this can be due to cell ‘age’. siRNA 
applied in cells of early passages was more efficient in shorter timepoints (Figure 
4.14 first panel from top) whereas cells grown for longer needed more time to totaly 











4.3.1 Monoclonal antibodies vary in ability detecting AGR-3 
 
After characterising a series of mouse antibodies (Moravian Biotechnologies, Czech 
Republic) generated to identify the AGR-3 protein a lot of interesting data were 
obtained. The 1.2 antibody when used in immunoblotting identified cytoplasmic and 
cell membrane/organelles fraction AGR-3 (Figure 4.9) and when used in 
immunofluoresence experiment gave a string-like pattern which was totally co-
localized with the mitochondria in MCF-7 cells (Figure 4.11). On the other hand, the 
2.2 antibody which recognizes a different epitope to the 1.2 antibody, is totally 
inappropriate for immunoblotting, as no detection of AGR-3 was observed (Figure 
4.5) whereas in immunofluorescence experiments gives a cell membrane-specific 
staining pattern (Figures 4.6 and 4.7). The 3.1 antibody is totally inefficient in 
immunoblotting as well as immunofluorescence applications. Last but not least, the 
4.1 antibody is the one that recognises both AGR-2 and AGR-3 epitopes and gives a 
mixed pattern of mitochondria-like, due to AGR-3 epitopes, and cytoplasmic, due to 
AGR-2 epitopes, staining when applied in immunofluorescence, acting as a 
polyclonal instead of a monoclonal one (Figures 4.4 and 4.8). A possible reason 
explaining the finding that two monoclonal antibodies, 1.2 and 2.2, give such 
different patterns when applied in immunofluoresence experiments might be the 
presence of a hidden epitope when the protein is in its native form, such as in 
microscopy studies where no denaturating step is involved, whereas this epitope is 
exposed after heating at 95°C for western analysis and co-immunoprecipitation 
experiments. It is worth mentioning that the different staining of the two antibodies, 
1.2 and 2.2, could have been explained if the 2.2 antibody recognised an epitope in 
the leader sequence of AGR-3 which is supposed to be secreted and therefore 
detected in the cell membrane, but this is not the case here. Moreover, a possible 
reason might be the phosphorylation of the 2.2 recognition epitope when the protein 
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is in its native form and therefore the detection of a cell membrane-specific 
localization after microscopic observation.  
 
 
4.3.2 AGR-3 is a mitochondrial protein implicated in cell death 
 
 
4.3.2.1 AGR-3 depletion promotes Bax conformational change 
 
In HeLa and Cos cells AGR-3 was found to be retained in the endoplasmic reticulum 
when the putative KDEL-like motif is present whereas this equilibrium was shifted 
to the Golgi compartment after deleting these last four aminoacids [483]. The same 
study also revealed that AGR-3 was ER-localized in 60% of cells tested, Golgi and 
ER mixed in 30% of cells and Golgi-only in 10% of cells tested. After the discovery 
that AGR-3 co-localizes with the mitochondria in MCF-7 cells, we next wondered 
whether AGR-3 silencing affects the pro-apoptotic or anti-apoptotic mitochondrial 
proteins. AGR-3 inhibition had no effect on the expression levels of Bid, Bcl-2, but 
changed the conformation of Bax and led to the N-terminal 6A7 epitope exposure, as 
detected by the anti-Bax 6A7 conformation-specific antibody [271, 272] (Figure 
4.14). Bax is an apoptosis-promoting protein that normally resides in the cytoplasm 
of healthy cells but under specific apoptotic stimuli it translocates to the 
mitochondrial membrane [221, 565], where it oligomerizes and forms pores that 
enable cytochrome c and other pro-apoptotic factors release [176]. Coincident with 
activation and translocation to the outer mitochondrial membrane, Bax undergoes a 
conformation change that exposes the 6A7 epitope and induces oligomerization [271, 
272, 473]. When AGR-3 is totally depleted, then total Bax levels are increased and 
this epitope, indicative of apoptosis, is being exposed (Figure 4.14). Interestingly, no 
Bid induction is observed after AGR-3 silencing (data not shown). Bid is a pro-
apoptotic Bcl-2 family member that is processed after proteolytic cleavage and 
triggers Bax conformational change [140, 178]. When tBid (truncated Bid) activates 
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Bax, then Bax translocates to the outer mitochondrial membrane where it 
oligomerizes and the apoptotic cascade is initiated [639]. Since there is no alteration 
on Bid levels but only on Bax, it is suggested that AGR-3 acts downstream Bid and 
upstream Bax in the apoptotic cascade. Studies have suggested that tBid alone is not 
sufficient to induce Bax translocation and that Bax-lipid interactions are sometimes 
essential to promote activation [639], so maybe something similar applies to AGR-3 
and Bid with AGR-3 inhibiting Bid to activate Bax and so when AGR-3 is absent 
Bid is free to interact with Bax. Goping and co-workers have previously dissected 
how changes at the Bax N- and C- termini affect the ability of the protein to target to 
intracellular membranes [221]. They concluded that the C-terminal Bax -helix is a 
signal-anchor required for membrane targeting and insertion but elements at the N-
terminus are key-players to regulating this process. Deletion of the N-terminal 20 
amino acids of Bax (encompassing the 6A7 epitope) stimulated Bax targeting to 
mitochondrial membranes in vitro and increased its pro-apoptotic activity in vivo 
[221]. In the same study it was suggested that exposure of the 6A7 epitope occurs 
when the N-terminus is released from some inhibitory interaction with the rest of the 
protein that may mask the C-terminal targeting sequence or a site of interaction with 
another protein. Bax activation happens in a series of steps including Bax-lipid 
interaction, 6A7 epitope exposure that is not essential for Bax membrane insertion 
[639] and tBid as a potential triggering factor for Bax membrane insertion, indicating 
the multiple levels of regulation and control for this procedure. A possible candidate 
for Bax regulation might be AGR-3 which can act by a different pathway from the 
Bid one, promoting epitope exposure but not affecting Bid levels. Apoptosis and its 
characteristic pathways are very complex and allow multiple crosstalk and control 
mechanisms amongst them, so further experiments need to be performed in order to 
establish the exact AGR-3 function. Our data showing activation of apoptotic Bax 
when AGR-3 is silenced are consistent to its ability to enhance colony formation and 
induce cell survival in breast cancer panels [270], suggesting an anti-apoptotic role 
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4.3.2.2 AGR-3 silencing induces an autophagy-marker’s expression levels 
 
 Another interesting but puzzling finding was that AGR-3 silencing negatively 
affects Beclin-1 expression (Figure 4.13). Beclin-1, a mammalian ortholog of Apg6, 
was first identified as a Bcl-2 interacting protein [360] and was the first mammalian 
autophagy gene discovered [359]. MCF-7 cells are devoid of caspase-3 activity and a 
lot of studies have revealed that autophagy plays an important role when it comes to 
cell death in this particular cell line [634, 635]. Beclin-1 along with Atg 7 protein are 
key player in this cell death process [2, 13]. Akar and coworkers discovered that 
silencing of Bcl-2 induces autophagic cell death in MCF-7 cells as proven by GFP-
LC3 II induction and lead to Atg5 and Beclin-1 increase [13]. A possible explanation 
can be that AGR-3 acts in an opposite way of that of Bcl-2 and act in favour of 
autophagy, therefore when silenced caspase-dependent cell death is being induced as 
it can also happen with other molecules that favour one type of cell death instead of 
another [516]. No LC-3 cleavage was observed in our experiments (data not shown) 
but this can be due to difficulty detecting native LC3 in cells. For that reason the 
generation of an MCF-7 LC3-GFP stable cell line would be really useful. Another 
interesting explanation that can be taken into account is that some molecules, such as 
fenretinide, do not strictly stimulate an apoptotic response but are capable of 
inducing autophagy when the apoptotic pathway is deregulated [187]. Caspase 
deficiency is a form of deregulated apoptotic pathway, so there is the possibility that 
AGR-3 under these conditions only, can promote autophagy but more cell lines 
should be tested to further characterize this observation. Another possible 
explanation might be that AGR-3 is not alone sufficient to totally inhibit apoptosis in 
favour of autophagy in caspase-3 deficient cells, and that can explain why when 
silenced neither apoptosis is being highly induced nor autophagy is totally reduced. 
Moreover, studies have revealed that reduction or total loss of Beclin-1 expression 
abrogates the autophagic response of MCF-7 cells to DNA damage, allowing cells to 
die by apoptosis [2]. Although DNA damage was not the case here, maybe AGR-3 
loss leads to Beclin-1 reduction and this cascade triggers mitochondrial apoptosis 
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that is detected by Bax conformational change. Or perhaps and opposite mechanism 
involving AGR-3 inhibition of Bax translocation and increase of autophagosomes 
formation is valid here, as in the case of cathepsins and Bid inhibition by drugs [341, 
626], so when AGR-3 is present no Bax translocation occurs. Calpain, a calcium-
dependent cysteine protease, is another example of a molecule that disrupts the 
equilibrium between autophagy and apoptosis and favours one type of cell death of 
the other. Indeed, when calpain is inhibited it induces Bax activation, cytochrome c 
release, PARP cleavage and reduces Beclin-1 expression in oridonin-induced L929 
cells [112]. The above studies suggested that inhibition of autophagy increased the 
apoptotic response and vice versa, indicating a rather antagonistic relationship, which 
can also be the case in our studies and suggesting AGR-3 as a molecular switch 
between the two processes. Paradoxically, later studies revealed that Beclin-1 
contains a conserved BH3 domain and interacts with Bcl-2/Bcl-xL suggesting a role 
in initiating apoptosis [438, 533] or even helps loading mitochondria to 
autophagosomes [166, 333, 438]. All the above observations reveal a multi-tasking 
Beclin-1 molecule which is involved in autophagy as well as apoptosis depending on 
the stress conditions or cell type and therefore a similar role for AGR-3, which 
upregulates Beclin-1, can be proposed. Also one has to consider that in some cases 
autophagy act as a means of delaying apoptosis or prolonging survival in non-
invasive breast tumour cells [2], so absence of AGR-3/ Beclin-1 weakens autophagy 
and no apoptosis delay happens which therefore leads to Bax translocation and 
initiation of apoptosis. The boundaries between Type I and II cell death have never 
been completely clear and perhaps do not exist due to intrinsic factors among 
different cell types and the crosstalk among organelles within each type. Apoptosis 
can begin with autophagy, autophagy can end with apoptosis, and blockage of 
caspase activity can cause a cell to default to Type II cell death from Type I [367]. 
Experiments are underway to verify the exact mechanism of AGR-3 function in 
terms of cell death. 
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4.3.3 Conclusions of chapter 
 
The results in this chapter demonstrated the significance of monoclonal antibodies 
into detecting variable epitopes that can give totally different staining patterns. 
Indeed, the protein was detected in the mitochondria and cell membrane by two 
different antibodies. Mitochondrial AGR-3 was the one targeted with siRNA and 
depleted from cells in an attempt to detect differences in other mitochondrial 
proteins. Interestingly, AGR-3 silencing was followed by reduction in Beclin-1 
expression levels and increase in conformationaly-changed Bax expression levels, 
suggesting a role in autophagy and apoptosis equilibrium.  This is distinct from the 
localization of AGR-2 and highlights the distinct roles of AGR-2 and AGR-3 in 
reducing the activity of pro-apoptotic pathways. These data also suggest that the 
AGR-2 and AGR-3 proteins (+ associated pathway) might represent anti-cancer drug 
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5.1 Introduction  
 
5.1.1 Combinatorial application of nucleic acid-based agents  
 
Cancer development is a multi-step processes which at its core involves clonal 
evolution under natural selection resulting in the survival of cells with an enhanced 
capacity to evade normal growth control.  The core genetic outline of the cancer cell 
is being developed and involves universal perturbation in sets of signal transduction 
pathways regulated by well-studied proteins such as RAS, WNT, ARF, BRCA, Bcl-
2,  TGF-β, p16, and p53 as well as small signalling molecules such as TGF-B, TNF, 
and interferons [245].  This had led to drug-discovery programmes in each of these 
areas concerning molecular-targeted smart cancer drugs.  
The progress made in cancer biology, genetics and biotechnology has led to a major 
evolution in cancer drug design and development, from non-specific, cytotoxic 
agents to specific, molecular-targeted smart cancer drugs [283]. These agents are 
characterised by improved selectivity for cancer versus normal cells and are 
associated with better anti-tumor effectiveness and lower toxicity [551]. The new 
generation of anti-cancer drugs requires low concentrations and minimizes unwanted 
side effects. The strategy behind antisense therapy is the development of specific 
therapeutic agents that aim to correct the mutations and abnormal expression of 
oncogenes by decreasing gene expression, inducing degradation of target mRNA and 
causing premature termination of transcription [283]. A fascinating class of anti-
cancer drugs include antisense oligonucleotides (ASOs) or small interfering RNAs 
(siRNAs) which are able to specifically down-regulate the expression of the target 
genes. These small molecules are specific for a range of proteins including inhibitors 
of apoptosis, cell cycle and growth promoting protein kinases, de-acetylases that 
modify the transcription programme of a cell, and enzyme machines that regulate 
protein degradation like the proteasome.  The combination of nucleic acid-based 
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agents with conventional chemotherapeutic drugs have shown synergistic inhibitory 
effects in terms of cell proliferation, tumour growth,  induction of cell cycle arrest 
and apoptosis [632]. These two strategies (ASOs and siRNAs) will help to improve 
current therapeutic regimens. In addition, the combination of targeted drugs with 
common chemotherapeutic agents might be able to make resistant cells again 
sensitive towards a chemotherapeutic agent. Another rapidly emerging field of 
research concerning the development of highly specific anti-cancer drugs is focused 




5.1.2 Aptamers as novel anti-cancer drugs 
 
In 1990, Robertson and Joyce invented new techniques on the mutation, 
amplification and selection of Tetrahymena RNA enzymes in vitro that cleaved DNA 
or RNA with high efficiency in an attempt to discover RNAs with novel catalytic 
function [492]. At the same time, Tuerk and Gold isolated high affinity nucleic acid 
ligands by a procedure based on multiple cycles of ligand selection from a pool of 
variants and then amplification of the ones that bound to the T4 DNA polymerase 
[592]. Multiple round of selection exponentially enriched the pool and the strongest 
candidates that bound to the DNA polymerase were further characterised. Amongst 
them was the wt sequence of the bacteriophage mRNA and a similar sequence 
differed at four positions. The technique used could yield high-affinity ligands for 
any protein that binds nucleic acids as part of its function and then these ligands 
could be developed and modified for any other target [592]. Independently, a third 
group identified small RNA molecules that bound to specific targets at the same time 
and they were the ones that termed these molecules as aptamers [172]. They used 
small RNA molecules that interacted with targets that mimicked metabolic cofactors 
and after iterative rounds of selection, mutated the final candidates to map the exact 
region of interaction. In the early 90s was therefore, the initiation of the systematic 
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evolution of ligands by exponential enrichment (SELEX) or in vitro selection for 
production of oligonucleotide aptamers with high affinity toward target molecules 
(Figure 5.1). 
Aptamers, from the latin word “aptus”=bind and the Greek word “meros”=particles, 
posses highly selective molecular recognition properties and can target specific key 
molecules inside or outside a diseased cell [172]. They were first described in viruses 
and particularly in pathways that regulate HIV-1 replication [129]. Aptamers can be 
RNA or DNA  ligands [172, 186, 492, 592]. Aptamers can be fused to several 
molecules useful for upstream application such as microscopy, chromatography, 
electrophoresis, without affecting their affinity to the target [305]. The susceptibility 
of the aptamers to various modifications makes them a valuable tool for 
biotechnology, drug therapy, diagnostics, target validation, genetic screening and 
purification processes [478]. Their functional asset that distinguishes them from the 
widely used antibodies is the fact that aptamers distinct between closely related but 
non-identical members of a protein family, or between different functional or 
conformational states of the same protein [44]. They also present a highly stable 3-
dimensional structure that ensures efficient and tight binding to their targets along 
with resistance to nuclease degradation [283]. They are characterised by high 
stability despite of the environment, lack of immunogenicity [181] and a smaller size 
which makes them more efficient to penetrating tumors and then removed by 
circulating blood (Table 5.1).  
The first approved aptamer with therapeutic function was the anti-human VEGF 
aptamer (VEGF: vascular endothelial grow factor) first tested in rhesus monkeys 
[591]. The PEGylated form of this aptamer was called Pegaptanib and used as the 
medicinal active component of the newly developed drug for the treatment of wet 
age related macular degeneration. The pharmaceutical product Macugen1 
(pegaptanib sodium injection) from Pfizer Inc./OSI Pharmaceuticals was approved in 
December 2004 (USA) and January 2006 (Europe) [101, 371]. Other examples of 










Antibodies often suffer variations 
from batch to batch 
Smaller size and chemically synthesized without 
batch variation 
 
Production requires the use of 
animals 
 
In vitro production, rapidly, reproducibly and 
accurately with no animals or cell lines involved 
Labelling can cause reduction or 
loss in affinity 
Can be labelled without affecting their affinity 
 
Cross-reactivity in other species High specificity within species 
Manipulation only under 
physiological conditions 
Selection conditions can be manipulated, 
temperature, pH, buffer, etc. 
 
Limited to molecules that produce 
an immunoresponse 
Able to bind with drugs or toxic substances or 
targets with low immunogenicity 
 
No live cell applicability Highly efficient for live cell applications and 
study  of interactions [186] 
Sensitive to temperature and 
humidity changes 
Storage and transport can be done at room 
temperature 
 
Limited applicability only as 
detection probes 
Can be used as detection probes, inhibitors or 
regulators of protein function or even competitors 
[79] 
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Target Aptamer/assay Field of application Reference 
 




[44, 371]  
Thrombin DNA aptamer (thrombin 
inhibitor ARC-138) 
 
Therapy, anticoagulant [434] 
Factor IXa RNA aptamer (factor 
IXa inhibitor) and its 
antidote REG1 
Therapy, anticoagulant [161, 434]  


















The identification of active compounds is succeeded through specialized and highly 
sophisticated cycles of selection and amplification which require encoding strategies 
for the resolution of the molecules. Approaches thoroughly used are based in 
displaying peptides, proteins or antibody fragments on phage or cell surfaces, which 
convert the amino acids sequence into genetic information that can be amplified in 
vivo. Most aptamers are capable of regulating the biological function of the 
compound molecules, are excellent candidates for drugs or drug leads. Two general 
types of experimental procedures have been applied, one designed to find peptide-
based ligands in vitro (phage display), the other tailored to identify protein to protein 
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5.1.2.1 SELEX isolation of aptamers 
 
SELEX stands for Systematic Evolution of Ligands by EXponential enrichment. 
First described in 1990 [172, 592], this method refers to isolation of nucleic acid 
ligands by exponential enrichment of a potential target pool. 
The SELEX procedure conscists of iterative cycles of in vitro selection and 
enzymatic amplification of nucleic acids that drives the selection towards relatively 
few, but optimized structural motifs for binding [224]. By these iterative cycles of 
selection and purification the initial random olignucleotide pool is narrowed down to 
a minimum group of ligand oligonucleotides that show high specificity and affinity 
for the target. The binding complexes are the partitioned from unbound and weakly 
bound oligonucleotides. This is one of the crucial steps towards the selection of 
highly specific and efficient aptamers. Target bounds are amplified by PCR (in the 
case of DNA) or RT-PCR (in case of RNA). This ds DNA is then transformed to a 
new oligonucleotide enriched pool that is used for binding to the target in a new 
SELEX round. After the last round the selected oligonucleotides are cloned and 
sequenced and then tested for their affinity and specificity in binding assays. The 
region required for binding can be reduced by mutation and truncation experiments 
[560]. Several techniques were evolved from SELEX and can be used in the 
generation of aptamers such as photoSELEX, capillary electrophoresis SELEX, 
blended SELEX, genomic SELEX that vary in applicability but they all offer high 
specificity and quality aptamers . 
Various molecules can be used as targets for an aptamer selection. The smallest 
molecular target so far used for an aptamer selection is ethanolamine, a simple 
structured molecule (C2 chain) with two functional groups (–OH, –NH2) [381] 
widely used in cosmetic industry but also associated with Schizophrenia [264] and 
Alzheimer disease as well as characterised as a carcinogenic substance. Other targets 
can be Neomycin [606], T4 DNA polymerase [592], ATP [513], cAMP [317], 
African trypanosomes [259], amino acids [376], Zn+2 [117], NAD/FAD [79], 
Shephadex [556], coA [512], interferonγ [329] and a lot more. 
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5.1.3 Peptide aptamers 
 
Peptide aptamers were developed after nucleic acid aptamers and are combinatorial 
protein reagents that bind to target proteins with high specificity and strong affinity. 
Aptamers can interfere with the function of their associated intracellular targets and 
also probe for regulatory networks within cells [32, 68, 123, 127, 283]. The design of 
peptide aptamers is inspired directly from the structure of immunoglobulins or T cell 
receptors, where variable peptidic loops are displayed by constant framework regions 
[32] (Figure 5.2). Peptide aptamers are most commonly used as disrupters of protein 
interactions due to their ability to bind to a region of the target protein and disrupt the 
scaffold that would otherwise mediate protein-protein interaction [127]. They also 
[200] 
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aid to validating therapeutic targets at the intracellular level but also have therapeutic 
potential, both as lead structures for drug design and also as a basis for the 
development of protein drugs [263]. The most widely used expression system for 
combinatorial protein libraries has been the filamentous bacteriophage M13. Briefly, 
a phage library is added to a plastic dish coated with a protein target and unbound 
phages are washed away. Binding particles are eluted, amplified and added back to 
the dish. Significant enrichment of binding molecules is achieved by multiple rounds 




Figure 5.2: Recognition protein molecules. Three major classes of constrained recognition 
protein molecules are depicted: immunoglobulin G (IgG), T cell receptor (TCR) and peptide 
aptamer. Black lines represent constant framework or scaffold residues. Blue lines represent 
variable peptidic regions. Red dotted lines represent disulfide bonds. Major distinguishing 
features of peptide aptamers include the much smaller size and the absence of requirement of 
disulfide bonds to ensure structural constraint of the variable region, as opposed to IgG and 
TCR molecules (image adapted from [32]) 
 
 
Peptide aptamers belong to the most popular methods used to validate targets as they 
act upon protein expression levels in cellular or animal models. Aptamers along with 
other specific ligands such as chemical or biotherapeutic molecules, do not affect 
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protein expression levels but aim at inhibiting protein function unlike gene knockouts 
that abolish expression, antisense or RNA interference methods that reduce 
expression to various extents and also overexpression of target proteins either 
constitutively or in an inducible fashion [32]. For example, a range of peptide 




5.1.4 Aptamers to Anterior Gradient 2 
 
Two sets of peptide-aptamers were identified from a 12-mer peptide combinatorial 
library that can interact with the AGR-2 protein [424]. One of them was chosen and 
passed through four rounds of selection and alanine scan, substitution mutagenesis of 
every single aminoacid to alanine to identify the minimum number of aminoacids 
required for efficient binding to AGR-2, narrowed it down to six in number 
consisting a bioactive hexapeptide PTTIYY core consensus site [424].  Given the 
likelihood that AGR-2 contains a peptide-binding groove, Murray and colleagues 
further evaluated whether a mutant derivative of the hexapeptide (PTTIYY) 
consensus sequence with altered binding to AGR-2 could be generated.  Substitution 
scan mutagenesis at each position (1-6) of the hexapeptide core identified the class of 
amino acid residues that were tolerated as AGR2-binding peptides. Especially 
notable from the mutagenesis scan is that the double hydrophobic residues YY are 
required for AGR2-binding [424]. Accordingly, AGR-2 binding directly to a series 
of peptides containing the core PTTIYY sequence was attenuated when the C-
terminal Y was mutated to an alanine [424]. Such peptides containing the PTTIYY 
motif can be used to affinity purify the AGR-2 protein from crude lysates [52]. 
Based on this data, a bioactive AGR2-binding peptide containing the PTTIYY core 
was cloned into AcGFP expression vector for creating an AcGFP fusion scaffold to 
analyze effects of the peptide on the AGR-2 pathway in cells, analysed in this thesis. 
GFP scaffolds have been utilized in monitoring localization of the binding 
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[203] 
 
interaction, detecting functional activity, expression levels and quality of  the 
aptamer by analysing fluorescent signals of different intensity [1, 458]. 
 
 
5.1.5 Objectives of chapter 
 
As described above, novel technologies for identifying potential anti-cancer drugs 
have utilised the generation of small molecules interfering with the function of target 
genes. AGR-2 is now known to reside in the nucleus and behave as a p53 inhibitor, 
attenuating p53 phosphorylation at Ser15.  In this chapter siRNA molecules and novel 
peptide-aptamers against AGR-2 were evaluated to determine whether inhibition of 
AGR-2 has any effect on stimulation of the p53 pathway. If so, this would hold 
promise for targeting AGR-2 as a drug target for stimulating the p53 pathway in 
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5.2 Results  
 
 
5.2 .1 Cloning of Peptide Aptamers  
 
5.2.1.1 Conventional cloning 
 
Three peptides, 60bp in length, identified to bind AGR-2 by phage display library 
[424], were cloned in order to define their role in the AGR-2 pathway. The wt 
aptamer has high affinity to AGR-2 whereas the Y-A substitution aptamer less and 
the premature stop aptamer even less when compared to the other two (data 
confirmed by ELISA, Dr. Murray). These peptides can serve as potential inhibitors 
or activators of AGR-2 and therefore affect p53 or other genes of the tumour 
suppression pathway. 60bp oligos were cloned into a GFP or RFP vector and co-
localization along with co-immunoprecipitation experiments determined their 
binding affinity to AGR-2. The first vector tested was the EGFP-C3 vector (4.2kb, 
Clontech). 
 Forward and reverse oligo were annealed to form a double-strand oligo which was 
inserted into the appropriate EGFP-C3 vector, by conventional cloning techniques 
including digestion-ligation-bacterial expression. Due to the small size of the oligos 
compared to the EGFP-C3 vector (70-fold smaller) certain problems appeared during 
the cloning process. PCR product formation was optimized by adjusting the cycling 
parameters, including the cycle number and primer annealing temperature but no 
positive results were obtained. A different strategy was then chosen˙ Different 
restriction sites were integrated at the end of the oligos and different vectors were 
used for cloning. Each step of the cloning procedure (annealing, restriction digest, 
dephosphorylation, ligation) was tested for its effectiveness, by electrophoresis, and 
different molar ratios of vector: insert were tried each time, varying from 1:1 to 1:10. 
Again, no positive clones were found after sequencing analysis. A major problem 
faced throughout the whole process was the high amount of colonies, present in the 
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digested and dephosphorylated vector, either in the presence or absence of T4 DNA 
ligase, indicating insufficient digestion of the vector. The vector was gel purified 
(Qiagen) to eliminate traces of uncut plasmid, but the problem persisted.  
 
 
5.2.1.2 Sequential cloning 
 
Since neither of the above mentioned strategies was fruitful, a third method was 
adopted. The whole GFP gene was amplified with the oligo sequence on its C-
terminus as a tag. After the amplification, the whole gene was cloned into a AcGFP-
vector, which was previously digested to exclude the GFP gene (613-1329). This 
method was adopted because of the size of the insert (750bp) compared to the vector. 
The AcGFP-C1 vector was PCR amplified with a first set of primers that annealed to 
the N-terminus of the GFP gene and included the AgeI restriction site, unique and at 
the very start of the GFP gene, and the reverse primer annealed to the 18-first base 
pairs of the MCS region and included the first 21 base pairs of the aptamer wt 
(PTTIYY core). The 750bp DNA fragment amplified included the GFP gene along 
with the first 18 bases of the MCS and the first 21 bases of the aptamer sequence 
which were integrated as an extra sequence, as a tag. This fragment was PCR-
purified (Qiagen) and a second round of PCR followed with the same forward 
primer, AgeI site and GFP sequence, but a different reverse one. This time the 
reverse primer included the rest of the aptamer wt sequence, including 12bp of the 
already amplified aptamer sequence which served as a recognition site for annealing, 
and an EcoRI restriction site for the MCS. The AcGFP-C1 vector was cut with AgeI 
and EcoRI. AgeI cuts in the beginning of the GFP gene and EcoRI in the MCS. After 
amplification the GFP-aptamer wt fragment and the AcGFP-C1 vector were digested 
with the two restriction endonucleases, purified (Qiagen Gel Purification kit) and 
ligated to the GFP-aptamer as described in Materials and Methods. Positive clones 
were isolated from E.coli cells and sequence analysis verified the correct ones used 
for further experiments. 
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5.2.1.3 Site-directed mutagenesis of the GFP-Aptamer wt 
 
In order to test the effect of the GFP-Aptamer wt, containing the PTTIYY core, to 
the AGR-2 activity and the specificity of the interaction, negative controls were 
essential to the studies. For that reason, GFP-Aptamer mutants were created by site-
directed mutagenesis, following the manufacturer’s protocol (Stratagene). The first 
Y-A mutation was selected because ELISA experiments had shown that a single 
mutation from Lysine to Alanine at position 22 of the aptamer had significantly less 
binding affinity to AGR-2 (Dr Euan Murray). The premature stop aptamer mutant 
did not contain the whole core and had even less binding affinity to AGR-2. 
Therefore, the three negative controls included (i) GFP alone with no fusion peptide 
cloned; (ii) GFP vector containing the bioactive PTTIYY sequence but containing a 
stop codon before the PTTIYY peptide start which produces a GFP control protein 
(termed as GFP-aptamer premature stop), and (iii) GFP containing the bioactive 
AGR2-binding peptide but with the single attenuating point mutation, PTTIYA 
(termed as GFP-aptamer Y-A) 
 
 
5.2.2 Localization of the Aptamers in MCF-7 cells. 
 
In order to study the localization of the AcGFP-C1 Aptamer wt/Y-A/stop mutants, 
the aptamers were transfected in MCF-7 cells and subcellular fractionation 
experiments were performed. Monoclonal anti-GFP antibody was used to detect the 
aptamer. All the aptamers were detected in the cytoplasmic fraction (Figure 5.3 A) 
although expression levels were not similar between the aptamers. The GFP-Apt stop 
had the lowest expression levels (Figure 5.3). The AcGFP-C1 vector was also 
detected in the aforementioned fractions. Coomassie Blue stain verified the 
fractionation efficiency and equal loading of each fraction (Figure 5.3 B). 
Fluorescent microscopy showed the GFP-Aptamers (wt/stop/22Y-A) in the 
cytoplasm (Figure 5.1 I-III) and no co-localization with ER and Golgi markers was 
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observed (data not shown). Interestingly, a lot of nuclei transfected with the wt or the 
mutants, showed a distinguished pyknotic shape. GFP-artificial nuclear staining was 
observed in all the aptamer-transfected cells along with the GFP-control transfected 
ones (Figure 5.5), although no GFP was detected in the nucleus after chemical 





Figure 5.3: GFP-Aptamers are localized in the cytoplasm of MCF-7 cells. A) MCF-7 
cells transfected with each of the GFP-Aptamers, wt/premature stop mutant/ 22Y-A. 
Untransfected and GFP-vector controls were included. The cells were processed using 
fractionation methodologies into F1 (cytosolic), F2 (membrane/organelles), F3 (nuclear), and 
F4 (cytoskeletal) as indicated. The distribution of the GFP-tagged aptamers ( ~ 30 kDa) was 
determined by immunoblotting. B) Representative Coomassie blue stain as fractionation 
control *: histones as defined by MS.  Figure is representative of 3 independent experiments.  
[207] 
 




Figure 5.4: Intracellular localization GFP-Aptamers in MCF-7 cells by fluorescent 
microscopy. MCF-7 cells were transfected with the indicated vector expressing GFP-
Aptamer wt (panels IA-IF)/Y-A (panels IIA-IIF)/stop(panels IIIA-IIIF). DAPI staining 
shows the location of the nucleus (panels I,II,III A and I, II, III D), FITC depicts the 
localization of each aptamer (I, II, III B and I, II, III E) and merge images are shown in 
panels I, II, III C and I, II, IIIF. Images visualized by Zeiss Axionplan microscope and 
captured with the photometric CoolSnap HQ camera. Same exposure times applied for all 
images. Figure is representative of at least 3 independent experiments (scalebar:10μm). 
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Figure 5.5: Intracellular localization of GFP-vector control in MCF-7 cells by 
fluorescent microscopy MCF-7 cells were transfected with the indicated vector 
expressing GFP (panels A-F). DAPI staining shows the location of the nucleus (panels A and 
D), FITC depicts the localization of each aptamer (B and E) and merge images are shown in 
panels C and F. Images visualized by Zeiss Axionplan microscope and captured with the 
photometric CoolSnap HQ camera. Same exposure times applied for all images. Figure is 
representative of at least 3 independent experiments  
 
 
5.2.3 Aptamers induce the formation of pyknotic nuclei  
 
Quantative studies, counting the number of aptamer-transfected pyknotic nuclei 
(Figure 5.6) against the total number of transfected cells revealed that the GFP-
aptamerwt stimulated the formation of pyknotic nuclei the most. A total of 1000 
nuclei per chamber in randomly chosen fields were counted under a Zeiss 
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epifluorescent microscope (Figure 5.7). The GFP-Aptamer wt had very high levels of 
pyknotic nuclei, reaching a percentage of 75% of total cell population (Figure 5.7 B, 
blue label). The GFP-Aptamerstop and the GFP-Aptamer Y-A had less pyknotic nuclei 
percentage when compared to the GFP-Aptamer wt, (Figure 5.7 B, orange and purple 
labels respectively). The GFP-Aptamer stop was shown to be a little less drastic than 
the GFP-Aptamer Y-A and 55% of abnormal nuclei against 58%, respectively. 
Interestingly, the AcGFP-C1 vector only samples had also high levels of pyknotic 
nuclei, indicating the toxicity of the GFP (Figure 5.7 B, green label). Nevertheless, 
the pyknotic nuclei observed in the GFP control were lower than the GFP-Aptamerwt 
ones and of equal levels to the GFP-aptamer Y-A/stop which were used as an 
unspecific binding control, as expected.   
Moreover, live cell imaging further supported the initial observations made in fixed 
cells. MCF-7 GFP-Aptamer wt -transfected cells were monitored for V days at a 10-
minutes interval base (data not shown). The m-cherry vector was used as a nuclear 
marker (kindly provided by Dr David Lierres, Dundee). Several fields were screened. 
In most occasions, cells transfected with the GFP-Aptamer wt started to show signs 




Figure 5.6: Aptamers induce the formation of pyknotic nuclei in MCF-7. Representative 
figure of pyknotic nuclei induced by GFP-Aptamer compared to normal ones, white 
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arrowhead, is shown. DAPI staining shows the location of the nucleus (panels A and D), 
FITC depicts the localization of each aptamer (panels B and E) and merge images are shown 
in panels C and F. Images visualized by Zeiss Axionplan microscope and captured with the 
photometric CoolSnap HQ camera. Same exposure times applied for all images. Figure is 




Figure 5.7: Quantative studies on pyknotic nuclei induction after GFP-Aptamer 
expression. A) Cartoon of GFP-Aptamers wt/truncated and 22 Y-A mutants and their 
affinity to AGR-2. B) Quantative analysis of pyknotic nuclei in MCF-7 cells after each 
aptamer’s transfection. The percentage of abnormal versus normal nuclei is presented. Blue 
label :GFP-Aptamer wt Purple label: GFP-Aptamer Y-A Orange label: GFP-Aptamer stop 
and Green label: GFP control vector. A total of 1500 nuclei per aptamer were counted. 
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5.2.4 Aptamers induced p53 translocation before and after UV 
irradiation 
 
Upon initial characterization of the GFP-Aptamer wt (GFP-PTTIYY) fusion protein, 
it was noticed that upon transfection of vectors encoding GFP-PTTIYY, wt, and GFP 
control, there was significant stabilization of p53 protein (Figure 5.8 upper panel). 
This correlated with a striking stabilization of AGR-2 protein presumably due to 
perturbation of the AGR-2 protein degradation pathway (Figure 5.8 second from top 
panel). Correlating with this, the GFP-Aptamer wt is also expressed at higher steady-
state levels which presumably correlates with the enhanced stability of the AGR-2 




Figure 5.8: GFP-Aptamer wt titration stabilised p53 and AGR-2. Increasing 
concentration of GFP-Aptamer wt was added to MCF-7 cells and p53/AGR-2 expression 
levels were tested by immunoblotting. Stabilization of p53 and AGR-2 was observed in the 
GFP-Aptamer wt–transfected cells. β-actin was used as a loading control. Figure showing 
representative of 2 experiments. 
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In order to define the less lethal but most effective dose of UV that will be applied to 
MCF-7 cells for Aptamer transfection, a series of different doses and lysis buffers 
was tested. Doses starting from 1J/m2 and reaching 100J/m2 energy were tested 
(Figure 5.9 A:high dose titration and B:low dose titration), but all indicated 10J/m2 as 
the ideal dose for irradiated MCF-7 cells, since in that scale p53 phosphorylation at 
Ser15 was induced and therefore measurements on p53 activation could be made 
(Figure 5.9 A and B, third from bottom panel). Total AGR-2 expression levels were 
increased between 1-10J/m2 independent of lyses buffers used (Figure 5.9 A but not 
B due to overexposed signal). Total levels of p53 were also increased between the 
same 1-10J/m2 doses, following the same pattern as phosphorylated p53 which is the 
active one. Therefore, 10J/m2 was the adequate dose to test for any effects of the 
aptamers on AGR-2 and p53 expression levels. 
Presence of the GFP-Aptamer wt did not induce nor reduce AGR-2 expression levels 
in the cytosol and membrane/organelles but significantly reduced AGR-2 in the 
nuclear fraction (Figure 5.10 A). As far as the control GFP-AptamerY-A is concerned, 
no alteraction in AGR-2 localization was observed in any of the three fractions.  
Interestingly, GFP-Aptamer wt altered the localization of the p53 protein as well 
(Figure 5.10 A). Before irradiation and in the presence of the GFP-Aptamer wt, p53 
was mislocalized from the cytosolic fraction where it is normally detected in MCF-7 
cells, and distributed in the membrane/organelles and nuclear fraction as well. 
Irradiation further induced this effect and especially when it came to the 
membrane/organelles and nuclear fraction. Interestingly, the localization of the 
aptamer was not affected by UV. The effect of UV in p53 distribution patterns was 
minimised in the case of the GFP-AptamerY-A. Indeed, before UV no change in p53 
cytosolic localization was detected, whereas after irradiation p53 was mislocalised to 
the membrane/organelles and nuclear fraction. Same observations were made in the 
case of untransfected samples as expected, since the GFP-Aptamer Y-A was used as 
a control due to deficient binding to AGR-2. Quantification of p53 in the first three 
fraction verified the above observation, that the GFP-Aptamerwt (YY in Figure 5.10 
B) induced p53 nuclear translocation in non-irradiated cells after UV damage to a 
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much higher degree compared to the GFP-Aptamer Y-A and GFP-control 
treansfected cells. p53 nuclear levels before UV in the GFP-Aptamer wt transfected 
cells were undetectable by the programme although immunoblotting showed clear 
redistribution of the protein to the nucleus. Coommasie staining was used as a 
loading and fractionation control. GFP-Aptamer Y-A also acted synergistically to 




Figure 5.9: UV titration and p53 levels. A) MCF-7 cells were UV-irradiated with high 
doses of UV and expression levels of AGR-2 (row A4 and B3), p53 (row A1, row A2 
represents shorter exposure and B2) and phosphorylated p53 at Serine15 (row A3 and B1) 
were determined by immunoblotting. A) High dose UV titration. B) Low dose UV titration. 
β-actin was used as a loading control. 
[214] 
 
Chapter 5                                                                                                     Results 
 
 
Figure 5.10. Effects of GFP-Aptamer wt/YA expression on p53 subcellular localization 
after UV damage. A) Changes in p53 localization induced by the GFP-Aptamer wt protein. 
MCF-7 cells were transfected with GFP-Aptamer wt/ GFP-Aptamer Y-A and also left 
untreated as a control, for 24h. The cells were harvested 6 hours post-irradiation and 
fractionated to determine changes in the subcellular distribution of p53 protein. Changes in 
AGR-2 localization induced by the EGFP-PTTIYY (Aptamer wt) protein. B: Quantitation of 
p53 protein levels in F1, F2, and F3 before and after UV verified p53 elevated levels C) 
Loading controls for total protein in fractions F1, F2, and F3 were developed by coomassie 
blue staining of protein after denaturing gel electrophoresis, *: Histones protein as identified 
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5.2.5 Silencing of AGR-2 also induced p53 translocation before and after 
UV irradiation 
 
Since AGR-2 was found to act as a p53 inhibitor [474], we analyzed whether AGR-2 
protein depletion using siRNA had any effect on p53 protein subcellular localization. 
AGR-2 protein can be depleted to differing degrees using four distinct siRNA 
hybrids (Figure 5.11) at different timepoints. siRNA #5 and #6 were the ones that 
resulted in attenuation in AGR-2 protein levels ( Figure 5.11) after 24-48h when 
compared to the untransfected and sicontrol-transfected cells. p53 total protein 
expression levels remained unchanged even though AGR-2 was totally depleted from 
the cells (Figure 5.11). Therefore, siRNA #5 and #6 were the ones used during the 
UV radiation experiments that followed (Figure 5.12 A, B and C). 
Since AGR-2 can inhibit p53 only after UV irradiation in H1299 cells [474], MCF-7 
cells were subjected to siRNA, irradiated with 10J/m2 and different subcellular 
fractions were analysed for p53 and AGR-2 protein expression levels.  In control 
siRNA-transfected cells, UV induced relocalization of p53 from the cytosol to 
membrane/organelles and nuclear fraction as expected (Figure 5.12 A top panel and 
B black label). Slight induction in AGR-2’s protein levels in all the fractions was 
observed, coherent to the UV titration data that showed elevated levels of total AGR-
2 after irradiation (Figure 5.9). Surprisingly, AGR-2 depletion was most notably 
detected in the F3 nuclear fraction (Figure 5.12 A bottom panel) and was 
accompanied by redistribution of p53 protein into the membrane/organelles and 
nuclear F2 and F3 fractions, irrespective to irradiation and the type of siRNA specific 
to AGR-2 (siRNA#6 or #5 Figure 5.12 A). UV slightly induced these redistribution 
patterns of p53 but had no effect on AGR-2 protein levels in the cytosolic and 
membrane/organelles fraction of the AGR-2 siRNA-transfected samples. 
Representative loading controls after control or AGR-2 siRNA using coomassie blue 
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Figure 5.11: AGR-2 depletion after four different siRNA pools. MCF-7 cells were 
treated with a range of four distinct siRNA oligonucleotides (#5-8) targeting AGR-2 and 
the protein’s expression levels were determined by immunoblotting in different 
timepoints at a four-day timecourse. siRNA #5 and #6 were the most efficient ones in 
terms of AGR-2 depletion after 48h. 
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 Figure 5.12: AGR-2 depletion alters the localization of p53. A) MCF-7 cells were 
treated with siRNA#5, or #6 or control siRNA and after fractionation into the F1, F2, F3 and 
F4 fractions, lysates were immunoblotted to determine changes in p53 levels and AGR-2 
levels B) Quantitation of p53 protein levels in the cytosol/membrane-organelles/nuclear 
fraction after siRNA control or AGR2-specific #5 before UV. C) Loading controls for total 
protein in fractions F1, F2, F3 and F4 in control and #5 siRNA-AGR2 treatments were 
developed by Coomassie blue staining of protein after denaturing gel electrophoresis. 
RU:relativeunits.




5.3.1 Aptamers to AGR-2 induce the formation of pyknotic nuclei but 
cells do not show signs of apoptosis or autophagy 
 
A high level of pyknotic nuclei in cells expressing the GFP-PTTIYY fusion (GFP-
Aptamerwt) peptide was detected.  Quantitation revealed that approximately 75% of 
transfected cells had altered nuclear morphology with another 25% exhibiting normal 
nuclear morphology (Figure 5.7). Using GFP control, GFP-STOP-PTTIYY (GFP-
Aptamer stop), or GFP-PTTIYA (GFP-Aptamer Y-A) as a series of negative 
controls, a similar ~50% background of normal/abnormal nuclei were observed 
(Figure 5.7). Since MCF-7 cells are caspase-3 deficient and also follow autophagy as 
their main pathway of cell death under specific condition such as Tamoxifen or other  
anti-estrogen treatment, paclitaxel, starvation and UV [2, 80, 128, 225, 289, 452, 
453, 516], we tested both types of cell death, apoptosis and autophagy. When it came 
to apoptosis since no caspase-3 cleaved products could be used as an apoptotic 
marker and since literature suggests that although caspase-3 deficient MCF-7 cells 
can undergo apoptosis through caspase-8 activation that leads to PARP cleavage [7, 
144, 288, 373], we investigated the PARP pathway. No PARP cleaved products were 
detected after aptamers transfection (data not shown). Moreover, Annexin-V staining 
was negative (data not shown). Annexin-V is a Ca+2 -dependent, phospholipid 
binding protein with a high affinity for phospholipid phosphatidylserine that 
translocates from the inner to the outer leaflet of the plasma membrane during early 
apoptosis.  
The next step was to investigate whether autophagy was the main pathway induced 
by aptamers transfection. MCF-7 cells utilize autophagy as their predominant type of 
cell death under certain conditions previously mentioned [80, 225, 452, 453] 
although contradictory views also exist in the field. LC-3 is a strong marker of 
autophagic cell death, as it is being cleaved in LC-3 I and LC-3 II when autophagy 
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takes place [346, 453]. Aptamer transfection in MCF-7 cells and western blot 
analysis with an anti-LC3 II antibody did not reveal any signs of autophagy (data not 
shown). Microscopic analysis of transfected with the aptamers cells had no signs of 
large autophagic vacuoles or other hallmarks of autophagy in the majority of the cells 
(data not shown). It is commonly accepted that determination between types of cell 
death is difficult to achieve, as there are no clear signs that enable strict classification 
in one type and also cell death types often overlap or switch between each other. The 
formation of pyknotic nuclei was a clear characteristic of the cells that were 
transfected with the aptamer but no other features of apoptosis or autophagy were 
detected. Further studies need to be performed in order to elucidate the pathway 
leading to pyknotic nuclei formation. Moreover, different cell lines that are caspase-
3- and AGR-2-positive should be tested to further support the aforementioned data. 
 
 
5.3.2 Aptamers to AGR-2 stabilize AGR-2 and promote nuclear 
accumulation of p53 
 
The transfection of EGFP-PTTIYY fusion peptide followed by subcellular fraction, 
demonstrated that p53 protein is indeed stabilized relative to the EGFP-PTTIYA 
control and EGFP-control (Figure 5.8).  This also correlates with enhanced AGR-2 
protein stabilization. The fact that no in vivo binding was observed between AGR-2 
and the aptamers after co-immunoprecipitation and FRET co-localization 
experiments (data not shown), might indicate the spontaneous and dynamic nature of 
the interaction. Moreover, there is always the possibility that this delicate in vivo 
binding of the protein and the aptamer is easily disrupted after chemical 
manipulation following immunoprecipitation and fixation methods.  
Given that AGR-2 acts as a p53 inhibitor after UV damage we examined whether the 
EGFP-PTTIYY, wt, peptide fusion exhibited greater stimulation of p53 nuclear entry 
in irradiated MCF-7 cells (Figure5.10). UV damage induces p53 response and 
disrupts the balance of gene expression leading to growth arrest, DNA repair or 
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apoptosis, thus preventing the proliferation of genetically damaged cells [602, 604]. 
p53 stability and DNA binding activity are modulated by post-translational 
modifications such as acetylation and phosphorylation. Phosphorylation at several 
different serines or threonines residues in p53 has been shown to occur after UV or 
other DNA damage [507]. Five serines in the C-terminal portion and seven serines 
and one threonine within the N-terminal 46 amino acids are known to be inducibly 
phosphorylated [290].  UV damage and ionizing radiation specifically induces 
phosphorylation at the N-terminus of p53 at residues Ser15, Ser20 and Ser37 [539]. 
Rapid nuclear localization of p38 kinase as well as p53 stabilization is also observed 
after UV damage [77]. The data presented here showed enhanced p53 
phosphorylation at Ser15 after UV dose titration with the highest phosphorylation 
happening at 10J/m2, which was the dose chosen for all the experiments that 
followed. 
 UV stimulates p53 abundance in MCF-7 cells that have wild type p53 [241]. 
Transfection of GFP-Aptamerwt fusion in the irradiated cells resulted in accumulation 
of p53 in the membrane and nuclear fractions relative to GFP controls and depletion 
of AGR-2 from the nuclear fraction. Enhanced exposure of the immunoblot 
demonstrated that this peptide stimulated a shift in p53 protein localization into 
membrane, nuclear, and cytosolic F1-F3 fractions, relative to the GFP-Aptamer Y-A 
and GFP control (Figure 5.10). The stimulation in p53 protein presence in the 
cytoskeletal fraction is presumably due to the dynein-mediated microtubule transport 
pathway that promotes nuclear entry of p53 protein after stress [214]. Abnormal p53 
cellular localization has been considered to be one of the mechanisms that could 
inactivate p53 function. In breast cancers p53 is mainly localized in the cytoplasm 
[412] suggesting that the inactivation of wild-type p53 in cancer cells could partly 
result from a defect in the regulation of p53 subcellular localization [70, 358, 410, 
412]. 
Moreover, the GFP-Aptamer wt and AGR-2 siRNA both deplete AGR-2 from the 
nuclear fraction while on the other hand accumulate p53 in the nucleus. Therefore, 
the GFP-Aptamer wt acts as an AGR-2 inhibitor, having effects in p53 nuclear 
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translocation as well. After AGR-2 inhibition, p53 is free to enter the nucleus and act 
as a transcription factor. The Y-A substitution GFP-Aptamer has no affinity to AGR-
2 and therefore no signs of p53 nuclear translocation were observed, further 
supporting the specificity of the interaction-inhibition between the GFP-Aptamer wt 
and the AGR-2 protein.  
 
 
5.3.3 p53 nuclear import is promoted by AGR-2 depletion 
 
Previous data showed that AGR-2 inhibition of p53 and related clonogenic survival 
is mediated by the “mature” isoform which has an intact C-terminus and UV 
irradiation triggers the maximal inhibition of p53 by this form of AGR-2 [474]. Our 
data supported that this mature isoform of AGR-2 protein has a relatively specific 
nuclear and cytoplasmic expression. We analyzed whether this active isoform of 
AGR-2 co-localized with p53 protein and/or altered the p53 subcellular localization. 
In many tumour cell lines, p53 protein accumulates in the nucleus after irradiation to 
initiate transcription. To study the effects of AGR-2 in p53 after DNA damage we 
depleted AGR-2 from MCF-7 cells and irradiate them before isolating different 
subcellular fractions. Surprisingly, AGR-2 silencing was only happened in the F3 
nuclear fraction while at the same time resulted in p53 relocalization and 
accumulation to the same nuclear fraction (Figure 5.12). UV further stimulated this 
effect and more p53 was translocated to the nucleus compared to non-irradiated and 
control siRNA-transfected cells (Figure 5.12). A possible mechanism of p53 
inhibition by AGR-2 is summarised below. When AGR-2 is active and present in the 
nucleus, then p53 can no longer enter the nucleus and stimulate transcription.  
Abnormal p53 cellular localization and especially nuclear export has been considered 
to be one of the mechanisms that could inactivate p53 function [358]. It has been 
shown that the p53 protein has both an NLS (nuclear localization signal) and NES 
(nuclear export signal) sequence [431, 617] that is recognised by certain receptors, 
named ‘importins’ and ‘exportins’, and so is subject to both nuclear import and 
[222] 
 
Chapter 5                                                                                                       Discussion 
export via a fast, energy-dependent pathway [400]. Since a defect in p53 nuclear 
translocation would impair its biological function, the cellular trafficking of p53 
must be tightly regulated to ensure normal and optimal function [409, 502]. It is 
therefore proposed that AGR-2 functions as Bcl-2 and c-myc do, which alter the 
subcellular trafficking of p53 during the cell cycle and accumulate it in the cytoplasm 
of p53 co-transfected cells during a critical period in G1. By this mechanism they are 
able to overcome p53-induced apoptosis and cell cycle arrest [502]. It is suggested 
that AGR-2 does not allow p53 to enter the nucleus and when the first is depleted 
p53 is free to act. The exact mechanism of this nuclear export, e.g. interaction with 
other proteins, awaits further elucidation. 
The significance of AGR-2 in drug therapy as a prognostic factor and also as a drug 
target is supported by studies with aromatase inhibitors [374] and tamoxifen [270]. 
Anastrozole and letrozole are highly specific and efficient inhibitors of the aromatase 
enzyme, leading to profound estrogen deprivation in postmenopausal women. 
Mackay and coworkers identified genes that respond to estrogen withdrawal in 
primary breast tumours in vivo, and may be used to understand and predict the 
response of patients to AI treatment [374]. AGR-2 was amongst the ones 
downregulated after AIs treatments. Recent data form a clinical collaborative study 
(including T.Hupp group) indicated that AGR-2 and AGR-3 expression can serve as 
a negative prognostic factor in ERα positive breast cancers treated with tamoxifen 
[270]. Moreover, the same study showed that AGR-2 overexpression was correlated 
with that of cyclin D1 which is a known negative predictive factor for tamoxifen 
response [557]. The previously identified suppression of AGR-2 expression by 
letrozole suggests a potential diagnostic-linked strategy for the treatment of AGR-2 
positive tumours in tamoxifen resistant patients using aromatase inhibitors [374]. On 
the other hand AGR-2 has been associated with a poor response to hormonal therapy 
and therefore survival [282] although a contradictory study suggested that AGR-2 is 
a marker of differentiation linked with significantly longer overall survival times 
[207]. More research should be focused on the connection between AGR-2 and 
breast cancer treatment. Our data on p53 inhibition combined with AGR-2 
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upregulation by tamoxifen [270] could explain why AGR-2 positive patients show 
resistance to tamoxifen and have lower survival [282] due to AGR-2 induced p53 
inactivation. These data along with downregulation of the protein by aromatase 
inhibitors [374], suggest a selectively resistance function of AGR-2 to different drugs 
and can be used to treating Tamoxifen-resistant patients that have high AGR-2 levels 
and positively affect response to endocrine therapy. Peptide aptamers that inhibit 
AGR-2 function and activate p53 can be used as excellent drug leads towards 
targeted breast cancer therapy, through reconstitution of a functional p53 protein able 
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5.3.4 Conclusions of chapter  
Aptamers against AGR-2 were capable of inducing nuclear import of p53 consistent 
with effects of AGR2-specific siRNA that depleted the protein from the nucleus and 
promoted p53 nuclear import. The aforementioned data combined with studies 
supporting the mature form of AGR-2 as the one being active as a p53 inhibitor and 
as shown here the one that is localized to the nucleus, set the basis for defining the 
mechanism of p53 inhibition.  Since this mechanism is defined, novel anti-cancer 
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6.1 Conclusions and future work 
 
The work presented here investigated the role of AGR-2 as a protein unregulated in 
breast cancer. AGR-2 is now known to be over-produced in a range of human 
cancers including breast, oesophagus, lung, prostate, and pancreas [207, 374, 403, 
611].  In order to elucidate the exact mechanism of AGR-2 function we had to define 
the localization of the protein. Fluorescent tags were used to monitor the protein’s 
localization within the cell. Since AGR-2 is present in two isoforms, (i) the full 
length with an N-terminal signal sequence and (ii) the mature which derives from the 
first after proteolytic cleavage of the leader sequence [3] we fused both isoforms to 
fluorescent proteins and investigate any differences in the distribution patterns. 
Interestingly the presence of the leader sequence determines endoplasmic reticulum-
retention which was further enhanced by mutating the putative C-terminal ER-
retention KTEL sequence to KDEL, which is characteristic of ER resident proteins, 
leading to a dramatic change in co-localization rate from 33% to 80%. Deletion or 
substitutional changes of the C-terminal KTEL tetrapeptide did not significantly alter 
ER co-staining compared to the wild type protein, totally consistent with data in 
HeLa cells supporting that the putative ER-retention KTEL motif is not required to 
ensure endoplasmic reticulum withholding [483]. No secretion of the protein was 
observed in MCF-7 cells. 
On the other hand, deletion of the N-terminal leader sequence totally altered the 
protein’s distribution pattern and led to predominant nuclear retention with only a 
few signs of endoplasmic reticulum co-localization. Neither KDEL nor KAEL 
substitutions were capable of enormous changes in the nuclear distribution of this 
isoform, although the rate of ER co-staining changed. Interestingly, deletion of this 
tetrapeptide resulted in total loss of the protein from the nucleus and resulted in a 
peculiar diffuse cytosolic pattern, suggesting that the presence of a minimum KXEL 
peptide at the C-terminus of the protein is essential to maintain its nuclear position. It 
would be of interest to test mutations in the remaining amino acids of the KTEL 
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tetrapeptide apart from this Threonine and further define the minimum amino acid 
composition required for nuclear localization.  
Very recent data published, identified a novel member of the PDI superfamily, 
named Erp16, as an ER-resident protein [292]. The protein has a cleavable signal 
peptide and a putative ER-retention EDEL tetrapeptide, and it resides in the luminal 
compartment of the endoplasmic reticulum of HeLa cells. In the same study, the 
EDEL-deletion mutant was present in the supernatant apart from the cell lysate, 
supporting the secretory potential of the protein when the EDEL ER-retention 
sequence is absent. It was also found that when the wt protein was overexpressed and 
Brefeldin A/or Tunicamicyn/ or dithiothreitol treatment followed, neither PARP nor 
pro-caspase-3 cleavage were observed, which was not the case with the EDEL-
truncated mutant which was not able to completely inhibit apoptosis. These results 
thus indicated that endogenous ERp16 suppresses apoptosis induced by ER stress.  
ERp16 share some common features with AGR-2 in terms of structure, localization 
and function. Both proteins have cleavable N-terminal signal sequences, both reside 
in the ER although in the case of AGR-2 this retention is partial, both inhibit cell 
death by different mechanisms each (Erp16 attenuates the induction of apoptosis by 
brefeldin A, tunicamycin, or dithiothreitol, whereas AGR-2 inhibits p53 nuclear 
translocation) and in both deletion of the extreme C-terminal putative ER-retention 
tetrapeptide attenuates their function. Our hypothesis suggest that AGR-2 have 
evolved from the strict role of PDIs and released from the endoplasmic reticulum to 
the cytosol and nucleus where it was able to develop new functions such as p53 
inhibition. AGR-3 falls into the same category and re-localized to the mitochondria 
where it developed its new function regarding cell death.   
It is worth mentioning that recently a newly identified protein named CAP10-like 
was cloned and characterised [574]. This protein had a hydrophobic leader sequence 
at its N-terminus and an endoplasmic reticulum retention KTEL motif at the C-
terminus just like AGR-2. The protein was characterised as and ER-resident protein 
as it strongly co-localized with endoplasmic reticulum markers. Moreover, it was 
present in two transcripts, one of 1.9kb and one of 3.5 kb, with the second isoform 
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being more plentiful in tissues such as liver, spleen, heart and kidney whereas the 
short isoform was less abundant in all the tissues tested [574]. This protein affects 
U937 cells growth rate by promoting cell proliferation just like AGR-2 [474] does in 
H1299. The above data suggest that the presence of a leader sequence do not 
guarantee secretion of the protein and that when this signal sequence is combined 
with putative ER-retention tetrapeptides, ER-residency can be achieved although in 
different extents, since AGR-2 is not totally co-localized to the ER and CAP10-like 
is an ER-resident protein. 
Combining the observation that the mature form is the nuclear one with the already 
published data that this form is the active one that inhibits p53 and that deletion of 
the last ten amino acids, including KTEL sequence, is sufficient to disrupt this 
interaction [474] and also exclude the protein from the nucleus as supported here by 
RFP deletion mutant, it is suggested that the nucleus is the area that p53 inhibition 
takes place through the mechanism of nuclear exclusion. Our hypothesis was further 
strengthened after depleting the protein from the nuclear fraction, by small 
interference RNA technologies, and observing nuclear accumulation of p53. UV 
irradiation that activates p53 to enter the nucleus and start transcription of certain 
genes acted synergistically with AGR-2 depletion and further induced this import. 
Two models emerge from these findings. The first one involves in situ inhibition of 
active p53 from AGR-2 when both are present in the nucleus whereas the second 
refers to inhibition of the p53 protein from entering the nucleus and becoming 
transcriptionally active. The use of Leptomycin to block nuclear entry would be a 
potential experimental strategy to further characterise these models. 
The use of concepts in the peptide therapeutics field has also led us to develop 
bioactive peptide aptamers that bind to AGR-2 and which can stimulate nuclear 
accumulation of p53. In our research we have used these AGR2-binding consensus 
site peptides to begin to determine whether p53 pathway responses can be altered and 
we show that the ability of AGR-2 to mediate nuclear exclusion of p53 can be 
attenuated using the bioactive peptide with the PTTIYY core consensus sequence. 
AGR-2 attenuation using siRNA gave rise to qualitatively similar results. These data 
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provide proof of principle that the AGR-2 pathway might prove to be a target whose 
inhibition would stimulate the p53 response to DNA damage and provide a peptide 
lead for drug design aimed at blocking the pro-oncogenic function of AGR-2. 
Ongoing research in microarrays has revealed that the PTTIYY aptamer, wt, is 
capable of inducing expression of p53-upregulated genes (Dr Murray, unpublished 
data), further supporting the aptamer’s stabilization and activation effect on the 
tumour suppressor gene as well as the inhibitory effect on AGR-2.  
As a final approach to evaluate whether the AGR2-hexapeptide could perturb 
subcellular localization of p53 protein, the bioactive PTTIYY and attenuated 
PTTIYA peptides were introduced into cells by fusion with an optimized 
heptapeptide cell membrane permeabilizing peptide derived from the antennapedia 
protein  named penetratin [198, 579].  The incubation of PTTIYY- and PTTIYA–
penetratin peptides at a concentration of 50µM stimulated relocalization of p53 
protein to the F3 nuclear fractions, with the wild-type peptide inducing more p53 
relocalization than the attenuated point mutant peptide (Dr. Murray, unpublished 
data) as it was the case with the GFP-aptamers analysed in this thesis.  The PTTIYA 
mutant peptide retained some bioactivity in promoting the nuclear import of p53 
which is similar to the intermediate activity of the GFP-fusion PTTIYA peptide. A 
titration of lower amounts of PTTIYY and PTTIYA peptide indicated that PTTIYY 
peptide was more active at lower concentrations (Dr. Murray, unpublished data). 
This data are consistent with the relative bioactivities of the GFP-fusion PTTIYY/A 
peptide constructs of results presented here, showing induction of p53 nuclear import 
in the GFP-Aptamerwt (PTTIYY) compared to the GFP-Aptamer Y-A one. The same 
AcGFP scaffold was validated previously to identify fusion peptides that inhibit 
p300, inhibit MDM2, and mimic IRF-1 protein effects on p53-dependent activity 
[148, 149].  
It was also shown that another member of the AGR family, AGR-3 is primarily 
mitochondrial. No AGR-2 co-localization was observed, neither with the mature nor 
the full length form of the protein, although both AGR-2 and AGR-3 are candidate 
members of the same thierodoxin family [468]. This can be explained by the 
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observation that many protein members of this family do not necessarily share the 
same compartment and are localized in separate areas of the cell, such as ER, Golgi 
nucleus and mitochondria [14, 15, 125, 232, 354, 451]. AGR-3 is not the only PDI 
family member that resides in the mitochondria, as other characterised members 
including ERp57 [451] and P5 [314] are also mitochondrial. In 1995 Rigobello and 
co-workers observed that rat liver mitochondria show a marked disulphide reductase 
activity in the presence of low-molecular-mass disulphides and later refined these 
observations and proposed that PDI along with thierodoxin reductase enzymes are 
localized in different mitochondrial compartments  and are probably involved in the 
redox regulation of mitochondrial functions and might co-operate in the maintenance 
of thiol homoeostasis [488]. The presence of a PDI protein in the mitochondria could 
contribute to some extent to the assembly and functioning of enzyme systems 
involving pore-forming proteins, receptors responsible for protein import, as well as 
pathways involved in the mitochondrial-dependent control of cell death such as pro-
apoptotic members of the Bcl-2 family [486]. Evidence presented here proposed 
AGR-3 to belong to this last category of PDI proteins that have a role in 
mitochondrial-dependent cell death. Indeed, depletion of AGR-3 leads to Bax 
conformational change and Beclin-1 decrease. Both proteins have a role in apoptosis 
and autophagy, respectively. Since there is no alteration in Bid levels, which is the 
one that activates Bax, but only in Bax levels, it is suggested that AGR-3 acts 
downstream Bid and upstream Bax in the apoptotic cascade [639]. Reduced Beclin-1 
expression levels were observed in the absence of AGR-3, suggesting a positive role 
of the protein in favour of autophagy and negative against apoptosis, as it was also 
observed with other molecules that support one death pathway against the other [187, 
516]. However, AGR-3 alone was not sufficient to totally shift the equilibrium from 
apoptosis to autophagy, since these pathways are highly sophisticated, inter-
connected to each other and require a whole cascade of molecules to function 
correctly [367]. More experiments are underway to further characterize the type of 
cell death induced by AGR-3 and also define the role of membrane-localized AGR-3.  
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Data obtained from Y2H interactions of AGR-3 and potential binding partners in 
breast cancer libraries (Hybrigenics, France) are being investigated to further 
elucidate the role of the novel gene. A lot of interesting genes have emerged 
including proliferation and cell growth enhancers (BAIAP3, HUWE1, IXL1, LRBA), 
cytoskeleton-associated proteins (CKAP2, HIP1R, MAST1, SPTBN1/4, TLN1 ), 
tumour suppressors (DLG1), migration stimulators (GIT1), drug resistance-
associated genes (GSTM4), apoptosis involved genes (KIBRA), proteosome 
activators (PSME1) and a lot more. Further research is underway into characterizing 
the above interactions in different cancers and shedding light towards the mechanism 
of AGR-3 function through protein complexes. 
 
Protein Function 
BAT3 multiple levels of interaction with 
apoptogenic mitochondrial 
intermembrane protein AIF (apopt
inducing factor) 
 
DLG1 Tumor suppressor,functions as a 
scaffolding protein that facilitates 
transmission of diverse downstrea
signals. In Drosophila hDLG inter
with the mitochondrial ribosomal 
protein S-34 (MRP-S34).present in
mammary ductal carcinoma 
 
MYBBP1A Enhanced mitochondrial biogenes
during neuronal differentiation 
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 It is worth mentioning, that although cell lines are a powerful tool for analysing the 
molecular AGR-2 or AGR-3 networks, they do not always mirror the complex 
biology of cells within a multicellular organism. To characterize the in vivo function 
and regulation of the genes, novel animal models need to be generated. Both genes 
are highly conserved from fish to humans [532], therefore these organisms can be 
utilised for studying the genes’ function in vertebrates. Zebrafish is an ideal model 
and also it has recently been shown that the molecular networks involved in tumour 
progression are conserved between humans and zebrafish [340]. Moreover, zebrafish 
is easy to study due to rapid external development which makes it perfect for 
developmental studies coupled with the ability to modify gene expression through 
silencing and analyse the derived symptoms directly [344]. What is more, generation 
of zebrafish lines defective in certain genes, such as p53, makes it easier to evaluate 
the role of the gene of interest [345].  Pilot experiments underway have shown that 
AGR-2 expression affects goblet cells of the gut and oesophagus (data kindly 
provided by Dr. Patton). AGR-2 morpholinos that are deficient in AGR-2 exhibit 
reduced formation of epithelial invaginations in the intestinal bulb, accompanied 
with absence of goblet cells and under-expanded anterior intestine compared to the 
control ones (data kindly provided by Dr. Patton). More research towards these 
models should be conducted to have the whole picture of AGR-2 and AGR-3 
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6.2 Preliminary data 
 
Apart from its function as a p53 inhibitor, subsequent studies have shown a 
significant role for AGR-2 in a range of biological pathways including cell migration 
[364], cellular transformation, metastasis [611], and limb regeneration in vertebrates 
[331]. Clinical studies have also implicated the protein in inflammatory bowel 
disease [652], hormone-dependent breast cancers [374, 662], and in predicting poor 
prognosis in prostate cancers [650]. The molecular mechanisms underlying these 
wide-ranging biological pathways trigged by AGR-2 are not defined and as the 
AGR-2 gene is confined to vertebrates, the AGR-2 gene pathway cannot be analyzed 
and solved directly in genetic systems like yeast. To characterize potential interaction 
with other protein and therefore start defining the role of the protein in many 
pathways, we conducted Y2H analysis to identify potential binding partners [40, 158, 
284, 653]. Surprisingly a lot of positive hits came out in breast and placenta prey 
libraries (Hybrigenics, France) (Chosen candidates to be tested in breast cancer cells 
are summarized in table 6.2). 
 
Table 6.2: AGR- binding partners. Potential AGR-2 binding protein identified by Y2H 
through a breast cancer library. Right column shows which were found to bind AGR-2 in 
MCF-7 cells. (NT:not tested, x:no binding, √: positive binding). 
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In order to confirm the interaction between AGR-2 and the positive hits from the 
Y2H, co-immunoprecipitations assays were performed. Plasmid DNA containing the 
gene of interest with an HA or FLAG sequence (LGN, C-KAP, RuvBL-2 plasmids 
kindly provided by Dr. E. Pohler,University of Dundee,  Rip140 plasmids: by Dr. E. 
Kiskinis, Imperial College, London) was transfected into MCF-7, from the European 
and the American collection as well.  
The first protein tested was the RuvBL2 protein (also known as Tip49, Reptin32); a 
DNA helicase essential for homologous recombination and DNA double-strand 
break repair [536, 619]. Functional analysis showed that this gene product has both 
ATPase and DNA helicase activities [281, 294, 302, 538] as it promotes DNA, RNA 
and DNA-RNA duplex unwinding. In particular, Ruvbl-2 is a protein implicated in 
chromatin acetylation and remodelling as a component of the NuA4 histone 
acetyltransferase complex [529] and also in nucleolar organization and trafficking in 
human cells. Ruvbl-2 was found to interact with centrosomes which harbour with 
several important cell cycle genes such as p33, BRCA1, Chk1, Chk2 etc [538] and 
also interacts with c-myc and β-catenin [42, 115, 398, 624] controlling their 
oncogenic activity. Moreover, the protein is a member of a twelve polypeptide 
chromatin remodelling complex (INO80), that has a role in DNA damage [304, 440, 
529] and also a novel component of the ATF2 trenscription factor which is 
implicated in the transcriptional control of several stress-response genes [115]. The 
protein is overexpressed in human hepatocellular carcinoma (HCC) where it is 
correlated to poor prognosis and weak differentiated tumours [498], in ovarian 
cancer [501], prostate cancer [313] and cervical cancer where it translocates 
depending on mitotic phases [538]. In the same study, it was found that Ruvbl-2 
silencing increased apoptosis and reduced cell growth in HCC cells, by elevated 
expression of pro-apoptotic genes, DNA fragmentation and caspase 3 activity[498]. 
Our data revealed that Ruvbl-2 is overexpressed in the cytoplasm, cell membrane and 
nucleus of MCF-7 (Figure 6.1 B and C) as also supported by literature for other 
cancerous cell lines [218, 498, 538, 624] and co-immunoprecipitated with AGR-2 in 
both cell lines tested, MCF-7 from the American and European collection (Figure 6.1 
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A). It was also shown that in the same MCF-7 cells, Ruvbl-2 and AGR-2 form a 
complex which is stabilized by p53 (unpublished data kindly provided by Magdalena 
Maslon, T.Hupp group). It would be of interest to further analyse this interaction 
which may shed light into new mechanisms of AGR-2 function in mitosis, cell 
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Figure 6.1: Ruvbl-2 binds AGR-2 in MCF-7 cells. The first potential binding partner 
tested was a DNA-helicase RuvBL-2. A) AGR-2 binds to RuvBL-2 after IP lysates from 
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RuvBL-2 HA-tagged and empty pcDNA3.1 control vector –transfected cells (American and 
European collection). B) Chemical fractionation identified RuvBL-2 in F1 cytoplasm/F2 
membrane-organelles and F3 nucleus fraction. C) IF of RuvBL-2 detected the protein in the 
nucleus and cytoplasm of cells. Untransfected control showed high autofluorescence when 
tested against the anti-HA antibody (panels A-C: B&W aquisition). RuvBL-2 HA tagged: 
panels D-E: B&W, panels F-H: RGB aquisition. Observed under a Zeiss Axionplan 




The second binding partner identified and tested was LGN. LGN is a heterotrimeric 
G-protein family member (whose name derived from its amino acid motif, 
containing 10 Leu-Gly-Asn motifs [63, 407] and mediates transduction of 
extracellular signals received by cell surface receptors into integrated cellular 
responses as well as contributing to the functional activity of Gα proteins by 
regulating metabolism of molecules in response to hormonal signals [63]. LGN 
belongs to a group of other proteins also known as GPSM2 or Pins. In Drosophila, 
PINS are required for spindle polarity, orientation, asymmetric division of 
neuroblasts, diverse polarity [266, 517] and for regulating planar polarity of sensory 
organs precursor cells [47, 457, 517, 644]. Localization of the protein is dynamic and 
changes during mitosis and interphase [63]. In mitosis the protein is concentrated at 
the midbody, which serves as a focal point for adhesion of proteins and leads to the 
abscission of the dividing cell [216]. It binds to a protein called NuMA [154, 155] 
which is a protein of the nuclear mitotic apparatus, and Lgl-2 [638] and together they 
organise the mitotic spindle [155, 210, 222, 247]. AGR-2 was found to co-
immunoprecipitate LGN (Figure 6.2 A) which was distributed in the nucleus and the 
cytoplasm in a diffused manner with cytosolic speckles, during interphase (Figure 
6.2 B). These localization patterns resembled the distribution of the protein in other 
cell types such as COS7 [63, 153, 216, 638]. In Xenopus egg extracts, LGN is a 
major negative regulator of aster formation and addition of exogenous LGN can 
block this process [154]. Overexpression of LGN in Xenopus causes disorientated 
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MTs formation, disruption of spindle organization and unequal chromosome 
segregation [154, 155]. AGR-2 on the other hand, plays a vital role in the anterior-
dorsal orientation of the Xenopus embryo and is also connected to mitotic events [3]. 
Possibly, LGN and AGR-2 are evolutionary-conserved members of a protein 
complex from Xenopus to human but further research should be conducted into that 
area. It is worth mentioning that MCF-7 cells had high levels of autofluorescence 
(Figure 6.2 B panels F-H) in the absence of the anti-HA antibody or even when 
transfected with pcDNA 3.1 control vector (Figure 6.2 panels I-K). LGN-HA 
transfected cells showed much stronger and specific signal (Figure 6.2 B panels A-






Chapter 6                                                                                              Preliminary data 
 
 
Figure 6.2: LGN binds AGR-2 in MCF-7 cells.  A) AGR-2 binds to LGN after IP lysates 
from LGN HA-tagged and empty pcDNA3.1 control vector –transfected cells. B)  LGN was 
detected in the nucleus and cytoplasm of MCF-7 cells (panels A-E). pcDNA 3.1 control 
transfected cells showed high autofluorescence when tested against the anti-HA antibody 
(panels I-K: B&W aquisition) and untransfected cells without primary antibody also 
autofluoresced (F-H B&W aquisition). LGN HA tagged: panels A-B: B&W, panels C-E: 
RGB aquisition. Observed under a Zeiss Axionplan microscope equipped with a Sony 
CoolSnap camera.  *: LGN-HA. Scalebar represents 10µm.  
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The last binding partner tested was Rip 140, also known as Nuclear receptor 
interacting protein 1 (NRIP1) [95], is a transcription factors that activate or suppress 
gene transcription, after interacting with ligand-activated receptors [332, 347, 572] 
by binding their hormone response elemens (HREs) [496]. The protein modulates 
transcriptional activity of the estrogen receptor [94, 95] represses receptor activity, 
including AR [87], GR [563, 572] and RAR [347, 613], by competing with 
coactivators for binding to receptors [563, 588]. As defined by Y2H and co-
immunoprecipitation experiments Rip140 binds AGR-2 (Figure 6.3 A) and 
immunofluorecent experiments detected the Rip140-FLAG protein (concstruct 
kindly provided by Dr. Kiskinis, Imperial College) in the nucleus in discrete foci as 
also supported by literature [572] (Figure 6.3 B panels A-F). pci-control vector  
showed totally unspecific fluorescent signal detected everywhere within the cell in a 
diffused manner (Figure 6.3 B panels G-I) while MCF-7 cells witoun primary 
antibody also showed enhanced fluorescence which was also unspecific (Figure 6.3 
B panesl J-L). Tazawa and colleagues also supported that Rip140 redistributes to 
larger nuclear domains upon binding to a nuclear receptor [572]. It would be of 
interest to define the exact mechanism of AGR-2 and Rip140 interaction which 
might implicate the estrogen receptor as well. The reason underlying this hypothesis 
is that AGR-2 is selectively co-expressed with the estrogen receptor and bears ERα -
response elements on its promoter whereas  Rip140 on the other hand modulates the 
receptor’s transcriptional activity [94, 299]. Since the only form of AGR-2 that 
localizes to the nucleus is the mature one, it is rational to consider that this form is 
the one that interacts with Rip140 which is also in the nucleus. 
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Figure 6.3: Rip140 binds AGR-2 in MCF-7 cells.  A) AGR-2 binds to LGN after IP lysates 
from Rip140-FLAG-tagged and empty pcI control vector –transfected cells. B)  Rip140-
FLAG was detected in discrete foci in the nucleus of MCF-7 cells. (panels A-F). pci control 
transfected cells emitted green fluorescence when tested against the anti-FLAG antibody 
(panels G-I) and untransfected cells without primary antibody also autofluoresced (panels  J-
L). (ALexa 488 secondary B, E, H and K). Images observed under a Zeiss Axionplan 
microscope equipped with a Sony CoolSnap camera. Scalebar represents 10μm. 
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Final Conclusion 
 
Data presented in this thesis confirmed AGR-2 gene product as a potential drug 
target for reactivating the p53 pathway in cancer cells.  Inhibition of AGR-2 can 
follow the steps of another nuclear p53 inhibitor, iASPP and therefore provide an 
important new strategy for treating tumours expressing wild-type p53 [51]. In this 
report, we defined the subcellular localization of AGR-2 and how this relates to its 
ability to inhibit the p53 tumour suppressor protein setting the basis for further 
manipulation of the mechanism of this inhibition and therefore cancer. Our data 
indicate that AGR-2 attenuates p53 transcriptional response through its localization 
and two models emerged supporting this inhibition by either inducing nuclear 
exclusion of p53 protein (Figure 6.5A/I) or by in situ inhibiting the tumour 
suppressor protein in irradiated or non cells (Figure 6.5A/II). These data provide a 
proof-of-principle that the AGR-2 pathway forms a novel type of pro-oncogenic drug 
target in cancers and highlights the utility of combining clinical proteomics with 
peptide combinatorial chemistry to discover and validate novel anti-cancer drug 
targets. The mechanism that regulates AGR-2 and mediates its effects in cancer 
growth in these various biological systems is yet not entirely defined. However, 
given the possibility that AGR-2 might prove to be a novel and wide-spread anti-
cancer drug target whose inhibition activates the p53 tumour suppressor, we further 
characterised and manipulated this mechanism by using peptide leads as therapeutic 
agents.  Our analysis has shown that (i) AGR-2 can mediate a change in nuclear-
cytoplasmic localization of p53 protein which is consistent with the link between p53 
nuclear localization and its function as a transcription factor and (ii) that aptamers 
can disrupt this exclusion by eliminating nuclear AGR-2 and therefore inducing p53 
activation. On the other hand, the other AGR- family protein member, AGR-3 
inhibits apoptosis through Bax inactivation, conferring resistance of cells to cell 
death and enhancing survival. Two member of the same family have evolved to 
function by two totally distinct mechanisms of promoting cancer cell grown and 
resistance to death. 
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Figure 6.5. Schematic model of AGR-2 and AGR-3 function. A) Nuclear mature AGR-2 
inhibits p53 translocation into the nucleus and when depleted, p53 enters the nucleus to 
transcripionally-activate target genes. Full length is localized in the ER but secretory 
designation is still pending (?) (I) and (II) represent the two different models on p53 
inhibition. B) Mitochondrial AGR-3 activates autophagy protein Beclin-1and inhibits pro-
apoptotic Bax, acting as a molecular switch towards autophagy (Designed by Servier 
Medical Art Tools software). 
                                                                                                                   Bibliography 
 
1. Abedi, M., Caponigro, G. and Kamb, A. 1998  "Green fluorescent protein as 
a scaffold for intracellular presentation of peptides". Nucleic Acids Res, 26 
(2). 623-630. 
2. Abedin, M.J., Wang, D., McDonnell, M.A., Lehmann, U. and Kelekar, A. 
2006  "Autophagy delays apoptotic death in breast cancer cells following 
DNA damage". Cell Death Differ, 14 (3). 500-510. 
3. Aberger, F., Weidinger, G., Grunz, H. and Richter, K. 1998  "Anterior 
specification of embryonic ectoderm: the role of the Xenopus cement gland-
specific gene XAG-2". Mech Dev, 72 (1-2). 115. 
4. Adam, P.J., Boyd, R., Tyson, K.L., Fletcher, G.C., Stamps, A., Hudson, L., 
Poyser, H.R., Redpath, N., Griffiths, M., Steers, G., Harris, A.L., Patel, S., 
Berry, J., Loader, J.A., Townsend, R.R., Daviet, L., Legrain, P., Parekh, R. 
and Terrett, J.A. 2003  "Comprehensive proteomic analysis of breast cancer 
cell membranes reveals unique proteins with potential roles in clinical 
cancer". J Biol Chem, 278 (8). 6482-6489. 
5. Adam, P.J., Boyd, R., Tyson, K.L., Fletcher, G.C., Stamps, A., Hudson, L., 
Poyser, H.R., Redpath, N., Griffiths, M., Steers, G., Harris, A.L., Patel, S., 
Berry, J., Loader, J.A., Townsend, R.R., Daviet, L., Legrain, P., Parekh, R. 
and Terrett, J.A. 2003  "Comprehensive Proteomic Analysis of Breast Cancer 
Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical 
Cancer". J Biol Chem, 278 (8). 6482-6489. 
6. Adams, J.M. and Cory, S. 1998  "The Bcl-2 Protein Family: Arbiters of Cell 
Survival". Science, 281 (5381). 1322-1326. 
7. Affar, E.B., Germain, M., Winstall, E., Vodenicharov, M., Shah, R.G., 
Salvesen, G.S. and Poirier, G.G. 2001  "Caspase-3-mediated Processing of 
Poly(ADP-ribose) Glycohydrolase during Apoptosis". J Biol Chem, 276 (4). 
2935-2942. 
8. Agarwal, M., Agarwal, A., Taylor, W. and Stark, G. 1995 "p53 controls both 
the G2/M and the G1 cell cycle checkpoints and mediates reversible growth 
arrest in human fibroblasts". Proc Natl Acad Sci U S A, 92 (18). 8493-8497. 
9. Aggarwal, B., Sethi, G., Baladandayuthapani, V., Krishnan, S. and Shishodia, 
S. 2007  "Targeting cell signaling pathways for drug discovery: an old lock 
needs a new key". J Cell Biochem, 102 (3). 580-592. 
10. Ahn, J. and Prives, C. 2001  "The C-terminus of p53: the more you learn the 
less you know". Nat Struct Mol Biol, 8 (9). 730-732. 
11. Aist, J. and Bayles, C. 1991  "Organelle motility within mitotic asters of the 
fungus Nectria haematococca". Eur J Cell Biol, 56 (2). 358-363. 
12. Aita, V.M., Liang, X.H., Murty, V.V.V.S., Pincus, D.L., Yu, W., Cayanis, E., 
Kalachikov, S., Gilliam, T.C. and Levine, B. 1999  "Cloning and Genomic 
Organization of Beclin 1, a Candidate Tumor Suppressor Gene on 
Chromosome 17q21". Genomics, 59 (1). 59-65. 
13. Akar, U., Chaves Reyez, A., Barria, M., Tari, A., Sanguino, A., Kondo, Y., 
Kondo, S., Arun, B., Lopez Berestein, G. and Ozpolat, B. 2008  "Silencing of 
[246] 
 
                                                                                                                   Bibliography 
Bcl-2 expression by small Interfering RNA induces autophagic cell death in 
MCF-7 breast cancer cells". Autophagy, 4 (5). 669-679. 
14. Alanen, H.I., Williamson, R.A., Howard, M.J., Hatahet, F.S., Salo, K.E.H., 
Kauppila, A., Kellokumpu, S. and Ruddock, L.W. 2006  "ERp27, a New 
Non-catalytic Endoplasmic Reticulum-located Human Protein Disulfide 
Isomerase Family Member, Interacts with ERp57". J Biol Chem, 281 (44). 
33727-33738. 
15. Alanen, H.I., Williamson, R.A., Howard, M.J., Lappi, A.-K., Jantti, H.P., 
Rautio, S.M., Kellokumpu, S. and Ruddock, L.W. 2003  "Functional 
Characterization of ERp18, a New Endoplasmic Reticulum-located 
Thioredoxin Superfamily Member". J Biol Chem, 278 (31). 28912-28920. 
16. Allen, T.M., Williamson, P. and Schlegel, R.A. 1988  "Phosphatidylserine as 
a Determinant of Reticuloendothelial Recognition of Liposome Models of the 
Erythrocyte Surface". PNAS, 85 (21). 8067-8071. 
17. Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thornberry, 
N.A., Wong, W.W. and Yuan, J. 1996  "Human ICE/CED-3 Protease 
Nomenclature". Cell, 87 (2). 171-171. 
18. Altmeyer, A., Maki, R., Feldweg, A., Heike, M., Protopopov, V., Masur, S. 
and Srivastava, P. 1996 "Tumor-specific cell surface expression of the-KDEL 
containing, endoplasmic reticular heat shock protein gp96". Int J Cancer, 69 
(4). 340-349. 
19. Ambrosini, G., Sambol, E., Carvajal, D., Vassilev, L., Singer, S. and 
Schwartz, G. 2007  "Mouse double minute antagonist Nutlin-3a enhances 
chemotherapy-induced apoptosis in cancer cells with mutant p53 by 
activating E2F1". Oncogene, 26 (24). 3473-3481. 
20. An, W.G., Kanekal, M., Simon, M.C., Maltepe, E., Blagosklonny, M.V. and 
Neckers, L.M. 1998  "Stabilization of wild-type p53 by hypoxia-inducible 
factor 1[alpha]". Nature, 392 (6674). 405-408. 
21. Anderson, W.F., Chatterjee, N., Ershler, W.B. and Brawley, O.W. 2002  
"Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, 
Epidemiology, and End Results Database". Breast Cancer Research and 
Treatment, 76 (1). 27-36. 
22. Anelli, T., Alessio, M., Mezghrani, A., Simmen, T., Talamo, F., Bachi, A. 
and Sitia, R. 2002  "ERp44, a novel endoplasmic reticulum folding assistant 
of the thioredoxin family". Embo J, 21 (4). 835-844. 
23. Angeloni, S.V., Martin, M.B., Garcia-Morales, P., Castro-Galache, M.D., 
Ferragut, J.A. and Saceda, M. 2004  "Regulation of estrogen receptor-alpha 
expression by the tumor suppressor gene p53 in MCF-7 cells". J Endocrinol, 
180 (3). 497-504. 
24. Arafah, B., Finegan, H., Roe, J., Manni, A. and Pearson, O. 1982  "Hormone 
dependency in N-nitrosomethylurea-induced rat mammary tumors." 
Endocrinology, 111 (2). 584-588. 
25. Archer, S., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I., Blamey, R., 
Nicholson, R. and Robertson, J. 1995  "Expression of ras p21, p53 and c-
[247] 
 
                                                                                                                   Bibliography 
erbB-2 in advanced breast cancer and response to first line hormonal therapy". 
Br J Cancer, 72 (5). 1259-1266. 
26. Arthur, C., Gupton, J., Kellogg, G., Yeudall, W., Cabot, M., Newsham, I. and 
Gewirtz, D. 2007  "Autophagic cell death, polyploidy and senescence 
induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel 
microtubule poison". Biochem Pharmacol, 74 (7). 981-991. 
27. Ashkenazi, A. and Dixit, V.M. 1998  "Death Receptors: Signaling and 
Modulation". Science, 281 (5381). 1305-1308. 
28. Aw, T. and Jones, D. 1985  "ATP concentration gradients in cytosol of liver 
cells during hypoxia". Am J Physiol Renal Physiol, 249 (5 Pt 1). 
29. Aw, T. and Jones, D. 1989  "Nutrient supply and mitochondrial function". 
Annu Rev Nutr, 23 (9). 229-251. 
30. Azim, H. and Azim Jr, H.A. 2008  "Targeting Her-2/neu in Breast Cancer: As 
Easy as This!" Oncology, 74 (3-4). 150-157. 
31. Baehrecke, E.H. 2003  "Autophagic programmed cell death in Drosophila". 
Cell Death Differ, 10 (9). 940-945. 
32. Baines, I.C. and Colas, P. 2006  "Peptide aptamers as guides for small-
molecule drug discovery". Drug Discov Today, 11 (7-8). 334-341. 
33. Baird, G.S., Zacharias, D.A. and Tsien, R.Y. 2000  "Biochemistry, 
mutagenesis, and oligomerization of DsRed, a red fluorescent protein from 
coral". PNAS, 97 (22). 11984-11989. 
34. Baker, S., Markowitz, S., Fearon, E., Willson, J. and Vogelstein, B. 1990  
"Suppression of human colorectal carcinoma cell growth by wild-type p53". 
Science, 249 (4971). 912-915. 
35. Ball, K., Lain, S., Fâhraeus, R., Smythe, C. and Lane, D. 1997  "Cell-cycle 
arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-
terminal domain of p21WAF1". Curr Biol, 7 (1). 71-80. 
36. Banin, S., Moyal, L., Shieh, S.Y., Taya, Y., Anderson, C.W., Chessa, L., 
Smorodinsky, N.I., Prives, C., Reiss, Y., Shiloh, Y. and Ziv, Y. 1998  
"Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage". 
Science, 281 (5383). 1674-1677. 
37. Barak, Y. and Oren, M. 1992  " Enhanced binding of a 95 kDa protein to p53 
in cells undergoing p53-mediated growth arrest." EMBO J, 11 (6). 2115-2121. 
38. Bardou, V.-J., Arpino, G., Elledge, R.M., Osborne, C.K. and Clark, G.M. 
2003  "Progesterone Receptor Status Significantly Improves Outcome 
Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine 
Therapy in Two Large Breast Cancer Databases". J Clin Oncol, 21 (10). 
1973-1979. 
39. Barkla, D. and Gibson, P. 1999 "The fate of epithelial cells in the human 
large intestine." Pathology, 31 (3). 230-238. 
40. Bartel, P.L., Roecklein, J.A., SenGupta, D. and Fields, S. 1996  "A protein 
linkage map of Escherichia coli bacteriophage T7". Nat Genet, 12 (1). 72-77. 
41. Basanez, G., Nechushtan, A., Drozhinin, O., Chanturiya, A., Choe, E., Tutt, 
S., Wood, K.A., Hsu, Y.T., Zimmerberg, J. and Youle, R.J. 1999  "Bax, but 
[248] 
 
                                                                                                                   Bibliography 
not Bcl-xL, decreases the lifetime of planar phospholipid bilayer membranes 
at subnanomolar concentrations". PNAS, 96 (10). 5492-5497. 
42. Bauer, A., Chauvet, S., Huber, O., Usseglio, F., Rothbacher, U., Aragnol, D., 
Kemler, R. and Pradel, J. 2000  "Pontin52 and reptin52 function as 
antagonistic regulators of beta-catenin signalling activity". Embo J, 19 (22). 
6121-6130. 
43. Baumann, D., Cook, M., Ma, L., Mushegian, A., Sanders, E., Schwartz, J. 
and Yu, C. 2008  " A family of GFP-like proteins with different spectral 
properties in lancelet Branchiostoma floridae". Biol Direct, 3 (28). 
44. Becker, K.C. and Becker, R.C. 2006  "Nucleic acid aptamers as adjuncts to 
vaccine development". Curr Opin Mol Ther, 8 (2). 122-129. 
45. Beham, A., Marin, M., Fernandez, A., Herrmann, J., Brisbay, S., Tari, A., 
Lopez-Berestein, G., Lozano, G., Sarkiss, M. and McDonnell, T. 1997  "Bcl-
2 inhibits p53 nuclear import following DNA damage". Oncogene, 15 (23). 
2767-2772. 
46. Bell, H.S. and Ryan, K.M. 2008  "iASPP Inhibition: Increased Options in 
Targeting the p53 Family for Cancer Therapy". Cancer Res, 68 (13). 4959-
4962. 
47. Bellaiche, Y., Radovic, A., Woods, D.F., Hough, C.D., Parmentier, M.L., 
O'Kane, C.J., Bryant, P.J. and Schweisguth, F. 2001  "The Partner of 
Inscuteable/Discs-Large Complex Is Required to Establish Planar Polarity 
during Asymmetric Cell Division in Drosophila". Cell, 106 (3). 355-366. 
48. Bendtsen, J., Nielsen, H., Von Heijne, G. and Brunak, S. 2004 "Improved 
prediction of signal peptides: SignalP 3.0". J Mol Biol, 340 (4). 783-795. 
49. Bennett, M.R., Gibson, D.F., Schwartz, S.M. and Tait, J.F. 1995  "Binding 
and Phagocytosis of Apoptotic Vascular Smooth Muscle Cells Is Mediated in 
Part by Exposure of Phosphatidylserine". Circ Res, 77 (6). 1136-1142. 
50. Benshalom, G. and Reese, T. 1985  "Ultrastructural observations on the 
cytoarchitecture of axons processed by rapid-freezing and freeze-
substitution". J Neurocytol, 14 (6). 943-960. 
51. Bergamaschi, D., Samuels, Y., O'Neil, N.J., Trigiante, G., Crook, T., Hsieh, 
J.-K., O'Connor, D.J., Zhong, S., Campargue, I., Tomlinson, M.L., Kuwabara, 
P.E. and Lu, X. 2003  "iASPP oncoprotein is a key inhibitor of p53 conserved 
from worm to human". Nat Genet, 33 (2). 162-167. 
52. Bergh, J. 1999  "Clinical studies of p53 in treatment and benefit of breast 
cancer patients". Endocr Relat Cancer, 6 (1). 51-59. 
53. Bergmann, A. 2007  "Autophagy and Cell Death: No Longer at Odds". Cell, 
131 (6). 1032-1034. 
54. Berns, E.M., Klijn, J.G., van Putten, W.L., de Witte, H.H., Look, M.P., 
Meijer-van Gelder, M.E., Willman, K., Portengen, H., Benraad, T.J. and 
Foekens, J.A. 1998  "p53 protein accumulation predicts poor response to 
tamoxifen therapy of patients with recurrent breast cancer". J Clin Oncol, 16 
(1). 121-127. 
55. Berns, E.M.J.J., Foekens, J.A., Vossen, R., Look, M.P., Devilee, P., Henzen-
Logmans, S.C., van Staveren, I.L., van Putten, W.L.J., Inganas, M., Gelder, 
[249] 
 
                                                                                                                   Bibliography 
M.E.M.-v., Cornelisse, C., Claassen, C.J.C., Portengen, H., Bakker, B. and 
Klijn, J.G.M. 2000  "Complete Sequencing of TP53 Predicts Poor Response 
to Systemic Therapy of Advanced Breast Cancer". Cancer Res, 60 (8). 2155-
2162. 
56. Bertucci, F. and Birnbaum, D. 2008  "Reasons for breast cancer 
heterogeneity". J. Biol., 7 (2). 6. 
57. Béthune, J., Wieland, F. and Moelleken, J. 2006  "COPI-mediated transport". 
J Membr Biol, 211 (2). 65-79. 
58. Betts, M.J., Russell, R.B., Barnes, M.R. and Gray, C. (eds.). Amino acid 
properties and consequences of substitutions. In Bioinformatics for 
Geneticists. Wiley, 2003. 
59. Bevis, B.J. and Glick, B.S. 2002  "Rapidly maturing variants of the 
Discosoma red fluorescent protein (DsRed)". Nat Biotech, 20 (1). 83-87. 
60. Blanc, C., Deveraux, Q.L., Krajewski, S., Janicke, R.U., Porter, A.G., Reed, 
J.C., Jaggi, R. and Marti, A. 2000  "Caspase-3 Is Essential for Procaspase-9 
Processing and Cisplatin-induced Apoptosis of MCF-7 Breast Cancer Cells". 
Cancer Res, 60 (16). 4386-4390. 
61. Blocker, A., Griffiths, G., Olivo, J., Hyman, A. and Severin, F. 1998  " A role 
for microtubule dynamics in phagosome movement". J Cell Sci, 111 (Pt 3). 
303-312. 
62. Blommaart, E., Luiken, J. and Meijer, A. 1997  "Autophagic proteolysis: 
control and specificity". J Mol Histol, 29 (5). 365-385. 
63. Blumer, J.B., Chandler, L.J. and Lanier, S.M. 2002  "Expression Analysis 
and Subcellular Distribution of the Two G-protein Regulators AGS3 and 
LGN Indicate Distinct Functionality.Localization of LGN to the midbody 
during cytokinesis ". J Biol Chem, 277 (18). 15897-15903. 
64. Boatright, K.M., Renatus, M., Scott, F.L., Sperandio, S., Shin, H., Pedersen, 
I.M., Ricci, J.-E., Edris, W.A., Sutherlin, D.P., Green, D.R. and Salvesen, G.S. 
2003  "A Unified Model for Apical Caspase Activation". Mol Cell, 11 (2). 
529-541. 
65. Bonafé, M., Salvioli, S., Barbi, C., Trapassi, C., Tocco, F., Storci, G., Invidia, 
L., Vannini, I., Rossi, M., Marzi, E., Mishto, M., Capri, M., Olivieri, F., 
Antonicelli, R., Memo, M., Uberti, D., Nacmias, B., Sorbi, S., Monti, D. and 
Franceschi, C. 2004  "The different apoptotic potential of the p53 codon 72 
alleles increases with age and modulates in vivo ischaemia-induced cell 
death". Cell Death Differ, 11 (9). 962-973. 
66. Bonifacino, J. and Weissman, A. 1998  "Ubiquitin and the control of protein 
fate in the secretory and endocytic pathways". Annu Rev Cell Dev Biol, 14. 
19-57. 
67. Borg, A., Baldetorp, B., Fernö, M., Killander, D., Olsson, H., Rydén, S. and 
Sigurdsson, H. 1994  " ERBB2 amplification is associated with tamoxifen 
resistance in steroid-receptor positive breast cancer". Cancer Lett, 81 (2). 
137-144. 
68. Borghouts, C., Kunz, C. and Groner, B. 2005  "Peptide aptamers: recent 
developments for cancer therapy". Expert Opinion 5(6). 783-797. 
[250] 
 
                                                                                                                   Bibliography 
69. Borgna, J.L. and Rochefort, H. 1981  "Hydroxylated metabolites of 
tamoxifen are formed in vivo and bound to estrogen receptor in target tissues". 
J Biol Chem., 256 (2). 859-868. 
70. Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A.K. and 
Coggi, G. 1995  "p53 gene mutations, p53 protein accumulation and 
compartmentalization in colorectal adenocarcinoma". Am J Pathol, 147 (3). 
790-798. 
71. Boyd, D. and Beckwith, J. 1990  "The role of charged amino acids in the 
localization of secreted and membrane proteins". Cell, 62 (6). 1031-1033. 
72. Brandon, M., Baldi, P. and Wallace, D. 2006  "Mitochondrial mutations in 
cancer". Oncogene, 25 (34). 4647-4662. 
73. Breedlove, G. and Busenhart, C. 2005  "Screening and detection of ovarian 
cancer". J of Midwifery & Women's Health, 50 (1). 51-54. 
74. Brenner, C. and Grimm, S. 2006  "The permeability transition pore complex 
in cancer cell death". Oncogene, 25 (34). 4744-4756. 
75. Brunner, N., Boysen, B., Jirus, S., Skaar, T.C., Holst-Hansen, C., Lippman, J., 
Frandsen, T., Spang-Thomsen, M., Fuqua, S.A.W. and Clarke, R. 1997  
"MCF7/LCC9: An Antiestrogen-resistant MCF-7 Variant in Which Acquired 
Resistance to the Steroidal Antiestrogen ICI 182,780 Confers an Early Cross-
Resistance to the Nonsteroidal Antiestrogen Tamoxifen". Cancer Res, 57 (16). 
3486-3493. 
76. Bueso Ramos, C.E., Yang, Y., deLeon, E., McCown, P., Stass, S.A. and 
Albitar, M. 1993  "The human MDM-2 oncogene is overexpressed in 
leukemias". Blood, 82 (9). 2617-2623. 
77. Bulavin, D.V., Saito, S., Hollander, M.C., Sakaguchi, K., Anderson, C.W., 
Appella, E. and Fornace, A.J., Jr. 1999  "Phosphorylation of human p53 by 
p38 kinase coordinates N-terminal phosphorylation and apoptosis in response 
to UV radiation". Embo J, 18 (23). 6845-6854. 
78. Bunone, G., Briand, P., Miksicek, R. and Picard, D. 1996  "Activation of the 
unliganded estrogen receptor by EGF involves the MAP kinase pathway and 
direct phosphorylation". EMBO J, 15 (9). 2174-2183. 
79. Burgstaller, P., Girod, A. and Blind, M. 2002  "Aptamers as tools for target 
prioritization and lead identification". Drug Discov Today, 7 (24). 1221-1228. 
80. Bursch, W., Ellinger, A., Kienzl, H., Torok, L., Pandey, S., Sikorska, M., 
Walker, R. and Hermann, R.S. 1996  "Active cell death induced by the anti-
estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells 
(MCF-7) in culture: the role of autophagy". Carcinogenesis, 17 (8). 1595-
1607. 
81. Butt, A., Caldon, C., McNeil, C., Swarbrick, A., Musgrove, E. and Sutherland, 
R. 2008  " Cell cycle machinery: links with genesis and treatment of breast 
cancer". Adv Exp Med Biol, 20 (630). 189-205. 
82. Buzdar, A., Plourde, P. and Hortobagyi, G. 1996 "Aromatase inhibitors in 
metastatic breast cancer." Semin Oncol., 4 (9). 28-32. 
[251] 
 
                                                                                                                   Bibliography 
83. Cabrera, M., Muñiz, M., Hidalgo, J., Vega, L., Martín, M. and Velasco, A. 
2003  " The retrieval function of the KDEL receptor requires PKA 
phosphorylation of its C-terminus". Mol Biol Cell, 14 (10). 4114-4125. 
84. Cahilly Snyder L., Yang-Feng, T., Francke, U. and George, D. 1987  
"Molecular analysis and chromosomal mapping of amplified genes isolated 
from a transformed mouse 3T3 cell line." Somat Cell Mol Genet, 13 (3). 235-
244. 
85. Campbell, R.E., Tour, O., Palmer, A.E., Steinbach, P.A., Baird, G.S., 
Zacharias, D.A. and Tsien, R.Y. 2002  "A monomeric red fluorescent 
protein". PNAS, 99 (12). 7877-7882. 
86. Cande, C., Cecconi, F., Dessen, P. and Kroemer, G. 2002  "Apoptosis-
inducing factor (AIF): key to the conserved caspase-independent pathways of 
cell death?" J Cell Sci, 115 (24). 4727-4734. 
87. Carascossa, S., Gobinet, J., Georget, V., Lucas, A., Badia, E., Castet, A., 
White, R., Nicolas, J.C., Cavailles, V. and Jalaguier, S. 2006  "Receptor-
Interacting Protein 140 Is a Repressor of the Androgen Receptor Activity". 
Mol Endocrinol, 20 (7). 1506-1518. 
88. Carew, J. and Huang, P. 2002  " Mitochondrial defects in cancer". Mol 
Cancer Res (9). 1-9. 
89. Carew, J., Zhou, Y., M., A., JD., C., Keating, M. and Huang, P. 2003  
"Mitochondrial DNA mutations in primary leukemia cells after 
chemotherapy: clinical significance and therapeutic implications". Leukemia, 
17 (8). 1437-1447. 
90. Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., 
Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, 
C.J., Ratcliffe, P., Moons, L., Jain, R.K., Collen, D. and Keshet, E. 1998  
"Role of HIF-1[alpha] in hypoxia-mediated apoptosis, cell proliferation and 
tumour angiogenesis". Nature, 394 (6692). 485-490. 
91. Caron de Fromentel, C. and Soussi, T. 1992 "TP53 tumor suppressor gene: a 
model for investigating human mutagenesis". Genes Chromosomes Cancer, 4 
(1). 1-15. 
92. Carrick, S., Ghersi, D., Wilcken, N. and Simes, J. 2004  " Platinum 
containing regimens for metastatic breast cancer". Cochrane Database Syst 
Rev (3). 
93. Casciola-Rosen, L., Nicholson, D.W., Chong, T., Rowan, K.R., Thornberry, 
N.A., Miller, D.K. and Rosen, A. 1996  "Apopain/CPP32 cleaves proteins 
that are essential for cellular repair: a fundamental principle of apoptotic 
death". J Exp Med, 183 (5). 1957-1964. 
94. Castet, A., Herledan, A., Bonnet, S., Jalaguier, S., Vanacker, J. and Cavaillès, 
V. 2006  "Receptor-interacting protein 140 differentially regulates estrogen 
receptor-related receptor transactivation depending on target genes". Mol 
Endocrinol, 20 (5). 1035-1047. 
95. Cavailles, V., Dauvois, S., L'Horset, F., Lopez, G., Hoare, S., Kushner, P.J. 
and Parker, M.G. 1995  "Nuclear factor RIP140 modulates transcriptional 
activation by the estrogen receptor". Embo J, 14 (15). 3741-3751. 
[252] 
 
                                                                                                                   Bibliography 
96. Cecconi, F., Alvarez-Bolado, G., Meyer, B.I., Roth, K.A. and Gruss, P. 1998  
"Apaf1 (CED-4 Homolog) Regulates Programmed Cell Death in Mammalian 
Development". Cell, 94 (6). 727-737. 
97. Chada, S. and Hollenbeck, P. 2004  "Nerve growth factor signaling regulates 
motility and docking of axonal mitochondria". Curr Biol, 14 (14). 1272-1276. 
98. Chalkley, R., Baker, P., Huang, L., Hansen, K., Allen, N., Rexach, M. and 
Burlingame, A. 2005  "Comprehensive analysis of a multidimensional liquid 
chromatography mass spectrometry dataset acquired on a quadrupole 
selecting, quadrupole collision cell, time-of-flight mass spectrometer: II. New 
developments in Protein Prospector allow for reliable and comprehensive 
automatic analysis of large datasets". Mol Cell Proteomics, 4 (8). 1194-1204. 
99. Chandel, N., Vander Heiden, M., Thompson, C. and Schumacker, P. 2000 
"Redox regulation of p53 during hypoxia." Oncogene, 19 (34). 3840-3848. 
100. Chandra, D., Liu, J.W. and Tang, D.G. 2002  "Early Mitochondrial 
Activation and Cytochrome c Up-regulation during Apoptosis". J Biol Chem, 
277 (52). 50842-50854. 
101. Chapman, J.A. and Beckey, C. 2006  "Pegaptanib: A Novel Approach to 
Ocular Neovascularization". Ann Pharmacother, 40 (7). 1322-1326. 
102. Chautan, M., Chazal, G., Cecconi, F., Gruss, P. and Golstein, P. 1999  
"Interdigital cell death can occur through a necrotic and caspase-independent 
pathway". Curr Biol, 9 (17). 967-970. 
103. Chehab, N.H., Malikzay, A., Stavridi, E.S. and Halazonetis, T.D. 1999  
"Phosphorylation of Ser-20 mediates stabilization of human p53 in response 
to DNA damage". PNAS, 96 (24). 13777-13782. 
104. Chen, H., Detmer, S.A., Ewald, A.J., Griffin, E.E., Fraser, S.E. and Chan, 
D.C. 2003  "Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial 
fusion and are essential for embryonic development". J Cell Sci, 160 (2). 189-
200. 
105. Chen, J. and Kadlubar, F. 2004 "Mitochondrial mutagenesis and oxidative 
stress in human prostate cancer". J Environ Sci Health C Environ Carcinog 
Ecotoxicol Rev, 22 (1). 1-12. 
106. Chen, J., Marechal, V. and Levine, A.J. 1993  "Mapping of the p53 and mdm-
2 interaction domains". Mol Cell Biol, 13 (7). 4107-4114. 
107. Chen, J., Wu, X., Lin, J. and Levine, A.J. 1996  "mdm-2 inhibits the G1 arrest 
and apoptosis functions of the p53 tumor suppressor protein". Mol Cell Biol, 
16 (5). 2445-2452. 
108. Chen, Z., Lu, W., Garcia Prieto, C. and Huang, P. 2007  "The Warburg effect 
and its cancer therapeutic implications". J Bioenerg Biomembr, 39 (3). 267-
274. 
109. Cheng, E., Kirsch, D., Clem, R., Ravi, R., Kastan, M., Bedi, A., Ueno, K. and 
Hardwick, J. 1997  "Conversion of Bcl-2 to a Bax-like death effector by 
caspases". Science, 278 (5345). 1966-1968. 
110. Cheng, J., Moyer, B.D., Milewski, M., Loffing, J., Ikeda, M., Mickle, J.E., 
Cutting, G.R., Li, M., Stanton, B.A. and Guggino, W.B. 2002  "A Golgi-
[253] 
 
                                                                                                                   Bibliography 
associated PDZ Domain Protein Modulates Cystic Fibrosis Transmembrane 
Regulator Plasma Membrane Expression". J Biol Chem, 277 (5). 3520-3529. 
111. Cheng, W., Berman, S., Ivanovska, I., Jonas, E., Lee, S., Chen, Y., 
Kaczmarek, L., Pineda, F. and Hardwick, J. 2006  "  Mitochondrial factors 
with dual roles in death and survival". Oncogene, 25 (34). 4697-4705. 
112. Cheng, Y., Qiu, F., Huang, J., Tashiro, S., Onodera, S. and Ikejima, T. 2008  
"Apoptosis-suppressing and autophagy-promoting effects of calpain on 
oridonin-induced L929 cell death". Arch Biochem Biophys, 475 (2). 148-155. 
113. Cheson, B. and Leonard, J. 2008  "Monoclonal antibody therapy for B-cell 
non-Hodgkin's lymphoma". N Engl J Med, 359 (6). 613-626. 
114. Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.-M., Scott, H., Hession, C., 
Garcia, I. and Browning, J.L. 1997  "TWEAK, a New Secreted Ligand in the 
Tumor Necrosis Factor Family That Weakly Induces Apoptosis". J Biol 
Chem., 272 (51). 32401-32410. 
115. Cho, S.-G., Bhoumik, A., Broday, L., Ivanov, V., Rosenstein, B. and Ronai, 
Z.e. 2001  "TIP49b, a Regulator of Activating Transcription Factor 2 
Response to Stress and DNA Damage". Mol Cell Biol, 21 (24). 8398-8413. 
116. Choi, J.H., Wong, A.S.T., Huang, H.F. and Leung, P.C. 2007  
"Gonadotropins and Ovarian Cancer". Endocr Rev, 28 (4). 440-461. 
117. Ciesiolka, J., Gorski, J. and Yarus, M. 1995  "Selection of an RNA domain 
that binds Zn2+". RNA, 1 (5). 538-550. 
118. Cleator, S., Heller, W. and Coombes, R.C. 2007  "Triple-negative breast 
cancer: therapeutic options". Lancet Oncol., 8. 235 - 244. 
119. Clérico, E., Maki, J. and Gierasch, L. 2008  "Use of synthetic signal 
sequences to explore the protein export machinery". Biopolymers, 90 (3). 
307-319. 
120. Clive, D.R. and Greene, J.J. 1996  "Cooperation of protein disulfide 
isomerase and redox environment in the regulation of NF-kappaB and AP1 
binding to DNA". Cell Biochem Funct, 14 (1). 49-55. 
121. Clore, G., Omichinski, J., Sakaguchi, K., Zambrano, N., Sakamoto, H., 
Appella, E. and Gronenborn, A. 1994  "High-resolution structure of the 
oligomerization domain of p53 by multidimensional NMR". Science, 265 
(5170). 386-391. 
122. Coezy, E., Borgna, J.-L. and Rochefort, H. 1982  "Tamoxifen and 
Metabolites in MCF7 Cells: Correlation between Binding to Estrogen 
Receptor and Inhibition of Cell Growth". Cancer Res, 42 (1). 317-323. 
123. Colas, P. 2000  "Combinatorial protein reagents to manipulate protein 
function". Curr Opin Chem Biol, 4 (1). 54-59. 
124. Coppari, S., Altieri, F., Ferraro, A., Chichiarelli, S., Eufemi, M. and Turano, 
C. 2002  "Nuclear localization and DNA interaction of protein disulfide 
isomerase ERp57 in mammalian cells". J Cell Biochem, 85 (2). 325-333. 
125. Coppari, S., Altieri, F., Ferraro, A., Chichiarelli, S., Eufemi, M. and Turano, 
C. 2002  "Nuclear localization and DNA interaction of protein disulfide 
isomerase ERp57 in mammalian cells". J Cell Biochem, 85 (2). 325-333. 
[254] 
 
                                                                                                                   Bibliography 
126. Cortez, D. 2005  "Unwind and slow down: checkpoint activation by helicase 
and polymerase uncoupling". Genes Dev, 19 (9). 1007-1012. 
127. Crawford, M., Woodman, R. and Ferrigno, P.K. 2003  "Peptide aptamers: 
Tools for biology and drug discovery". Brief Funct Genomic Proteomic, 2 (1). 
72-79. 
128. Cui, Q., Tashiro, S., Onodera, S., Minam, i.M. and Ikejima, T. 2007  
"Autophagy preceded apoptosis in oridonin-treated human breast cancer 
MCF-7 cells". Biol Pharm Bull, 30 (5). 859-864. 
129. Cullen, B.R. and Greene, W.C. 1989  "Regulatory pathways governing HIV-1 
replication". Cell, 58 (3). 423-426. 
130. D'Assoro, A., Busby, R., Acu, I., Quatraro, C., Reinholz, M., Farrugia, D., 
Schroeder, M., Allen, C., Stivala, F., Galanis , E. and Salisbury, J. 2008  
"Impaired p53 function leads to centrosome amplification, acquired ERalpha 
phenotypic heterogeneity and distant metastases in breast cancer MCF-7 
xenografts". Oncogene, 27 (28). 3901-3911. 
131. Dai, J., Liu, B., Caudill, M., Zheng, H., Qiao, Y., Podack, E. and Li, Z. 2003  
"Cell surface expression of heat shock protein gp96 enhances cross-
presentation of cellular antigens and the generation of tumor-specific T cell 
memory". Cancer Immun, 3 (1). 1-2. 
132. Damber, J. and Aus, G. 2008  "Prostate cancer". The Lancet, 371 (9625). 
1710-1721. 
133. Dauvois, S., White, R. and Parker, M.G. 1993  "The antiestrogen ICI 182780 
disrupts estrogen receptor nucleocytoplasmic shuttling". J Cell Sci, 106 (4). 
1377-1388. 
134. David, H., Ellermann, J. and Uerlings, I. 1992  "Primary phase of hepatocytic 
autophagocytosis under ischaemic conditions." Exp Toxicol Pathol, 44 (2). 
74-80. 
135. Davidoff, A.M., Kerns, B.-J.M., Dirk Iglehart, J. and Marks, J.R. 1991  
"Maintenance of p53 Alterations throughout Breast Cancer Progression". 
Cancer Res, 51 (10). 2605-2610. 
136. Dawson, R., Muller, L., Dehner, A., Klein, C., Kessler, H. and Buchner, J. 
2003  "The N-terminal Domain of p53 is Natively Unfolded". J Mol Biol, 332 
(5). 1131-1141. 
137. De Duve, C. and Wattiaux, R. 1966  "Functions of Lysosomes". Annu Rev 
Physiol, 28 (1). 435-492. 
138. Denecke, J., De Rycke, R. and Botterman, J. 1992  "Plant and mammalian 
sorting signals for protein retention in the endoplasmic reticulum contain a 
conserved epitope". EMBO J, 11 (6). 2345-2355. 
139. Denzer, A., Nabholz, C. and Spiess, M. 1995  "Transmembrane orientation of 
signal-anchor proteins is affected by the folding state but not the size of the 
N-terminal domain". EMBO J., 14 (24). 6311-6317. 
140. Desagher, S., Osen-Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, 
S., Maundrell, K., Antonsson, B. and Martinou, J.-C. 1999  "Bid-induced 
Conformational Change of Bax Is Responsible for Mitochondrial 
Cytochrome c Release during Apoptosis". J Cell Biol, 144 (5). 891-901. 
[255] 
 
                                                                                                                   Bibliography 
141. Desta, Z., Ward, B.A., Soukhova, N.V. and Flockhart, D.A. 2004  
"Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by 
the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A 
and CYP2D6". J Pharmacol Exp Ther, 310 (3). 1062-1075. 
142. Ding, H., McGill, G., Rowan, S., Schmaltz, C., Shimamura, A. and Fisher, D. 
1998  "Oncogene-dependent regulation of caspase activation by p53 protein 
in a cell-free system". J Biol Chem, 273 (43). 28378-28383. 
143. Doelling, J.H., Walker, J.M., Friedman, E.M., Thompson, A.R. and Vierstra, 
R.D. 2002  "The APG8/12-activating Enzyme APG7 Is Required for Proper 
Nutrient Recycling and Senescence in Arabidopsis thaliana". J Biol Chem, 
277 (36). 33105-33114. 
144. Doman, R.K., Perez, M. and Donato, N.J. 1999  "JNK and p53 Stress 
Signaling Cascades Are Altered in MCF-7 Cells Resistant to Tumor Necrosis 
Factor-Mediated Apoptosis". J Interferon Cytokine Res, 19 (3). 261-269. 
145. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, 
C.A., Butel, J.S. and Allan, B. 1992  "Mice deficient for p53 are 
developmentally normal but susceptible to spontaneous tumours". Nature, 
356 (6366). 215-221. 
146. Donepudi, M., Sweeney, A.M., Briand, C. and Grütter, M.G. 2003  "Insights 
into the Regulatory Mechanism for Caspase-8 Activation". Mol Cell, 11 (2). 
543-549. 
147. Dornan, D., Eckert, M., Wallace, M., Shimizu, H., Ramsay, E., Hupp, T. and 
Ball, K. 2004  "Interferon regulatory factor 1 binding to p300 stimulates 
DNA-dependent acetylation of p53". Mol Cell Biol, 24 (22). 10083-10098. 
148. Dornan, D., Eckert, M., Wallace, M., Shimizu, H., Ramsay, E., Hupp, T. and 
KL., B. 2004  "Interferon regulatory factor 1 binding to p300 stimulates 
DNA-dependent acetylation of p53". Mol Cell Biol, 24 (22). 10083-10098. 
149. Dornan, D. and Hupp, T. 2001  " Inhibition of p53-dependent transcription by 
BOX-I phospho-peptide mimetics that bind to p300". EMBO Rep, 2 (2). 139-
144. 
150. Dos Santos, N.M.S., Taverne Thiele, J.J., Barnes, A.C., Van Muiswinkel, 
W.B., Ellis, A.E. and Rombout, J.H.W.M. 2001  "The gill is a major organ 
for antibody secreting cell production following direct immersion of sea bass 
(Dicentrarchus labrax, L.) in a Photobacterium damselae ssp. piscicida 
bacterin: an ontogenetic study". Fish Shellfish Immunol, 11 (1). 65-74. 
151. Doyle, D.M. and Miller, K.D. 2008  "Development of new targeted therapies 
for breast cancer". Breast Cancer, 15 (1). 49-56. 
152. Drummond, I.A., Lee, A.S., Resendez, E., Jr. and Steinhardt, R.A. 1987  
"Depletion of intracellular calcium stores by calcium ionophore A23187 
induces the genes for glucose-regulated proteins in hamster fibroblasts". J 
Biol Chem, 262 (26). 12801-12805. 
153. Du, Q. and Macara, I.G. 2004  "Mammalian Pins Is a Conformational Switch 
that Links NuMA to Heterotrimeric G Proteins". Cell, 119 (4). 503-516. 
[256] 
 
                                                                                                                   Bibliography 
154. Du, Q., Stukenberg, P.T. and Macara, I.G. 2001  "A mammalian Partner of 
inscuteable binds NuMA and regulates mitotic spindle organization". Nat 
Cell Biol, 3 (12). 1069-1075. 
155. Du, Q., Taylor, L., Compton, D.A. and Macara, I.G. 2002  "LGN Blocks the 
Ability of NuMA to Bind and Stabilize Microtubules: A Mechanism for 
Mitotic Spindle Assembly Regulation". Curr Biol, 12 (22). 1928-1933. 
156. Dudani, A., Austin, R., Venner, T. and Gupta, R. 1990  " Effects of 
antimitotic and antimitochondrial agents on the cellular distribution of 
microtubules and mitochondria". Cytobios, 63 (253). 95-108. 
157. Dumont, P., Leu, J., Della Pietra, A., George, D. and Murphy, M. 2003  "The 
codon 72 polymorphic variants of p53 have markedly different apoptotic 
potential". Nat Genet, 33 (3). 357-365. 
158. Dunn, J.J. and Studier, F.W. 1983  "Complete nucleotide sequence of 
bacteriophage T7 DNA and the locations of T7 genetic elements". J Mol Biol, 
166 (4). 477-535. 
159. Dunn, W.A., Jr. 1990  "Studies on the mechanisms of autophagy: formation 
of the autophagic vacuole". J Biol Chem, 110 (6). 1923-1933. 
160. Duong, V., Boulle, N., Daujat, S., Chauvet, J., Bonnet, S., Neel, H. and 
Cavaillès, V. 2007  " Differential regulation of estrogen receptor alpha 
turnover and transactivation by Mdm2 and stress-inducing agents". Cancer 
Res, 67 (11). 5513-5521. 
161. Dyke, C.K., Steinhubl, S.R., Kleiman, N.S., Cannon, R.O., Aberle, L.G., Lin, 
M., Myles, S.K., Melloni, C., Harrington, R.A., Alexander, J.H., Becker, R.C. 
and Rusconi, C.P. 2006  "First-in-Human Experience of an Antidote-
Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a 
Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled 
Regulation of Factor IXa Activity". Circulation, 114 (23). 2490-2497. 
162. Dyson, M., Shadbolt, S., Vincent, K., Perera, R. and McCafferty, J. 2004  
"Production of soluble mammalian proteins in Escherichia coli: identification 
of protein features that correlate with successful expression." BMC 
Biotechnol., 4 (32). 
163. Early Breast Cancer Trialists' Collaborative Group. 2005  "Effects of 
chemotherapy and hormonal therapy for early breast cancer on recurrence 
and 15-year survival: an overview of the randomised trials". Lancet, 365 
(9472). 1687 - 1717. 
164. Eccles, D., Russell, S., Haites, N., Atkinson, R., Bell, D., Gruber, L., Hickey, 
I., Kelly, K., Kitchener, H. and Leonard, R. 1992 " Early loss of 
heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics 
Group." Oncogene, 7 (10). 2069-2072. 
165. Eckert, B. 1986  "Alteration of the distribution of intermediate filaments in 
PtK1 cells by acrylamide. II: Effect on the organization of cytoplasmic 
organelles". Cell Motil Cytoskeleton, 6 (1). 15-24. 
166. Edinger, A.L. and Thompson, C.B. 2003  "Defective autophagy leads to 
cancer". Cancer Cell, 4 (6). 422-424. 
[257] 
 
                                                                                                                   Bibliography 
167. El-Aneed, A. 2004  "Current strategies in cancer gene therapy". European 
Journal of Pharmacology, 498 (1-3). 1-8. 
168. El-Deiry, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J., Lin, 
D., Mercer, W., Kinzler, K. and Vogelstein, B. 1993  "WAF1, a potential 
mediator of p53 tumor suppression". Cell, 75 (4). 817-825. 
169. Elledge, R. and Allred, D.C. 1998  "Prognostic and predictive value of p53 
and p21 in breast cancer". Breast Cancer Res Treat, 52 (1). 79-98. 
170. Elledge, R.M., Green, S., Howes, L., Clark, G.M., Berardo, M., Allred, D.C., 
Pugh, R., Ciocca, D., Ravdin, P., O'Sullivan, J., Rivkin, S., Martino, S. and 
Osborne, C.K. 1997  "bcl-2, p53, and response to tamoxifen in estrogen 
receptor-positive metastatic breast cancer: a Southwest Oncology Group 
study". J Clin Oncol, 15 (5). 1916-1922. 
171. Ellgaard, L., Molinari, M. and Helenius, A. 1999  "Setting the Standards: 
Quality Control in the Secretory Pathway". Science, 286 (5446). 1882-1888. 
172. Ellington, A.D. and Szostak, J.W. 1990  "In vitro selection of RNA molecules 
that bind specific ligands". Nature, 346 (6287). 818-822. 
173. Elston, C. and Ellis, I. 2002  "Pathological prognostic factors in breast cancer. 
I. The value of histological grade in breast cancer: experience from a large 
study with long-term follow-up." Histopathology, 41 (3A). 154-161. 
174. Elston CW, E.I. 2002  "Pathological prognostic factors in breast cancer. I. 
The value of histological grade in breast cancer: experience from a large 
study with long-term follow-up." Histopathology, 41 (3A). 154-161. 
175. Emptage, N. 2001  "Fluorescent imaging in living systems". Curr Opin 
Pharmacol, 1 (5). 521-525. 
176. Epand, R.F., Martinou, J.-C., Montessuit, S., Epand, R.M. and Yip, C.M. 
2002  "Direct evidence for membrane pore formation by the apoptotic protein 
Bax". Biochem Biophys Res Commun, 298 (5). 744-749. 
177. Erster, S., Mihara, M., Kim, R., Petrenko, O. and Moll, U. 2004  "  In vivo 
mitochondrial p53 translocation triggers a rapid first wave of cell death in 
response to DNA damage that can precede p53 target gene activation". Mol 
Cell Biol, 24 (15). 6728-6741. 
178. Eskes, R., Desagher, S., Antonsson, B. and Martinou, J.-C. 2000  "Bid 
Induces the Oligomerization and Insertion of Bax into the Outer 
Mitochondrial Membrane". Mol Cell Biol, 20 (3). 929-935. 
179. Esposito, D. and Chatterjee, D.K. 2006  "Enhancement of soluble protein 
expression through the use of fusion tags". Curr Opin Biotechnol, 17 (4). 
353-358. 
180. Everett, R.D., Lomonte, P., Sternsdorf, T., Van Driel, R. and Orr, A. 1999  
"Cell cycle regulation of PML modification and ND10 composition". J Cell 
Sci, 112 (24). 4581-4588. 
181. Eytech Study Group 2002  "Preclinical and phase 1A clinical evaluation of an 
anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-
related macular degeneration". Retina, 22 (2). 143-152. 
182. Fabian, C. 2001  "Breast cancer chemoprevention: beyond tamoxifen". Breast 
Cancer Res, 3 (2). 99-103. 
[258] 
 
                                                                                                                   Bibliography 
183. Fadok, V.A., Savill, J.S., Haslett, C., Bratton, D.L., Doherty, D.E., Campbell, 
P.A. and Henson, P.M. 1992  "Different populations of macrophages use 
either the vitronectin receptor or the phosphatidylserine receptor to recognize 
and remove apoptotic cells". J Immunol, 149 (12). 4029-4035. 
184. Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratton, D.L. and 
Henson, P.M. 1992  "Exposure of phosphatidylserine on the surface of 
apoptotic lymphocytes triggers specific recognition and removal by 
macrophages". J Immunol, 148 (7). 2207-2216. 
185. Falck, J., Coates, J. and Jackson, S.P. 2005  "Conserved modes of recruitment 
of ATM, ATR and DNA-PKcs to sites of DNA damage". Nature, 434 (7033). 
605-611. 
186. Famulok, M., Blind, M. and Mayer, G. 2001  "Intramers as promising new 
tools in functional proteomics". Chem Biol, 8 (10). 931-939. 
187. Fazi, B., Bursch, W., Fimia, G., Nardacci, R., Piacentini, M., Di Sano, F. and 
Piredda, L. 2008  " Fenretinide induces autophagic cell death in caspase-
defective breast cancer cells". Autophagy, 4 (4). 435-441. 
188. Fearon, E.R. 1997  "Human Cancer Syndromes: Clues to the Origin and 
Nature of Cancer". Science, 278 (5340). 1043-1050. 
189. Fehrenbacher, K., Yang, H., Gay, A., Huckaba, T. and Pon, L. 2004  "Live 
cell imaging of mitochondrial movement along actin cables in budding yeast". 
Curr Biol, 14 (22). 1996-2004. 
190. Ferguson, H.A., Marietta, P.M. and Van Den Berg, C.L. 2003  "UV-induced 
Apoptosis Is Mediated Independent of Caspase-9 in MCF-7 Cells:". J Biol 
Chem, 278 (46). 45793-45800. 
191. Ferguson, M., Luciani, M., Finlan, L., Rankin, E., Ibbotson, S., Fersht, A. and 
Hupp, T. 2004  "The development of a CDK2-docking site peptide that 
inhibits p53 and sensitizes cells to death". Cell Cycle, 3 (1). 80-89. 
192. Fernandes-Alnemri, T., Armstrong, R.C., Krebs, J., Srinivasula, S.M., Wang, 
L., Bullrich, F., Fritz, L.C., Trapani, J.A., Tomaselli, K.J., Litwack, G. and 
Alnemri, E.S. 1996  "In vitro activation of CPP32 and Mch3 by Mch4, a 
novel human apoptotic cysteine protease containing two FADD-
like domains". PNAS, 93 (15). 7464-7469. 
193. Ferrari, D. and Söling, H. 1999 "The protein disulphide-isomerase family: 
unravelling a string of folds." Biochem J, 1 (339 ). 1-10. 
194. Ferrari, D.M. and Soling, H.D. 1999  "The protein disulphide-isomerase 
family: unravelling a string of folds". Biochem J, 339 ( Pt 1). 1-10. 
195. Fidler, I.J., Raz, A., Fogler, W.E., Kirsh, R., Bugelski, P. and Poste, G. 1980  
"Design of Liposomes to Improve Delivery of Macrophage-augmenting 
Agents to Alveolar Macrophages". Cancer Res, 40 (12). 4460-4466. 
196. Finlay, C.A. 1993  "The mdm-2 oncogene can overcome wild-type p53 
suppression of transformed cell growth". Mol Cell Biol, 13 (1). 301-306. 
197. Finley, R.L., Zhang, H., Zhong, J. and Stanyon, C.A. 2002  "Regulated 
expression of proteins in yeast using the MAL61-62 promoter and a mating 
scheme to increase dynamic range". Gene, 285 (1-2). 49-57. 
[259] 
 
                                                                                                                   Bibliography 
198. Fischer, P., Zhelev, N., Wang, S., Melville, J., Fåhraeus, R. and Lane, D. 
2000  "Structure-activity relationship of truncated and substituted analogues 
of the intracellular delivery vector Penetratin". J Pept Res, 55 (2). 163-172. 
199. Fletcher, G.C., Patel, S., Tyson, K., Adam, P.J., Schenker, M., Loader, J.A., 
Daviet, L., Legrain, P., Parekh, R., Harris, A.L. and Terrett, J.A. 2003  "hAG-
2 and hAG-3, human homologues of genes involved in differentiation, are 
associated with oestrogen receptor-positive breast tumours and interact with 
metastasis gene C4.4a and dystroglycan". Br J Cancer, 88 (4). 579-585. 
200. Fliss, M., Usadel, H., Caballero, O., Wu, L., Buta, M., Eleff, S., Jen, J. and 
Sidransky, D. 2000  " Facile detection of mitochondrial DNA mutations in 
tumors and bodily fluids". Science, 287 (5460). 2017-2019. 
201. Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., 
Pandolfi, P., Will, H., Schneider, C. and Del Sal, G. 2000  "Regulation of p53 
activity in nuclear bodies by a specific PML isoform". EMBO J, 19 (22). 
6185-6195. 
202. Forman, D., Lynch, K. and Smith, R. 1987  " Organelle dynamics in lobster 
axons: anterograde, retrograde and stationary mitochondria". Brain Res, 412 
(1). 96-106. 
203. Foulkes, W.D., Stefansson, I.M., Chappuis, P.O., Begin, L.R., Goffin, J.R., 
Wong, N., Trudel, M. and Akslen, L.A. 2003  "Germline BRCA1 Mutations 
and a Basal Epithelial Phenotype in Breast Cancer". J Natl Cancer Inst., 95 
(19). 1482-1485. 
204. Frank, S., Gaume, B., Bergmann-Leitner, E.S., Leitner, W.W., Robert, E.G., 
Catez, F., Smith, C.L. and Youle, R.J. 2001  "The Role of Dynamin-Related 
Protein 1, a Mediator of Mitochondrial Fission, in Apoptosis". Dev Cell, 1 (4). 
515-525. 
205. Freedman, D., Epstein, C., Roth, J. and Levine, A. 1997 "A genetic approach 
to mapping the p53 binding site in the MDM2 protein." Mol Med, 3 (4). 248-
259. 
206. Freedman, R.B., Hirst, T.R. and Tuite, M.F. 1994  "Protein disulphide 
isomerase: building bridges in protein folding." Trends Biochem Sci, 19 (8). 
331-336. 
207. Fritzsche, F.R., Dahl, E., Pahl, S., Burkhardt, M., Luo, J., Mayordomo, E., 
Gansukh, T., Dankof, A., Knuechel, R., Denkert, C., Winzer, K.-J., Dietel, M. 
and Kristiansen, G. 2006  "Prognostic Relevance of AGR2 Expression in 
Breast Cancer". Clin Cancer Res, 12 (6). 1728-1734. 
208. Furukawa, K., Fu, W., Li, Y., Witke, W., Kwiatkowski, D. and Mattson, M. 
1997  "The actin-severing protein gelsolin modulates calcium channel and 
NMDA receptor activities and vulnerability to excitotoxicity in hippocampal  
neurons". J Neurosci, 17 (21). 8178-8186. 
209. Futreal, P., Söderkvist, P., Marks, J., Iglehart , J., Cochran, C., Barrett, J. and 
Wiseman, R. 1992  "Detection of frequent allelic loss on proximal 
chromosome 17q in sporadic breast carcinoma using microsatellite length 
polymorphisms." Cancer Res, 52 (9). 2624-2627. 
[260] 
 
                                                                                                                   Bibliography 
210. Gaglio, T., Saredi, A. and Compton, D.A. 1995  "NuMA is required for the 
organization of microtubules into aster-like mitotic arrays". J Cell Biol, 131 
(3). 693-708. 
211. Gao, X., Zacharek, A., Salkowski, A., Grignon, D.J., Sakr, W., Porter, A.T. 
and Honn, K.V. 1995  "Loss of Heterozygosity of the BRCA1 and Other Loci 
on Chromosome 17q in Human Prostate Cancer". Cancer Res, 55 (5). 1002-
1005. 
212. Gatenby, R. and Gillies, R. 2004  "Why do cancers have high aerobic 
glycolysis?" Nat Rev Cancer, 4 (11). 891-899. 
213. Gerner, C., Holzmann, K., M., M., Gotzmann, J., Grimm, R. and Sauermann, 
G. 1999  "Reassembling proteins and chaperones in human nuclear matrix 
protein fractions". J Cell Biochem, 74 (2). 145-151. 
214. Giannakakou, P., Sackett, D., Ward, Y., Webster, K., Blagosklonny, M. and 
Fojo, T. 2000  "p53 is associated with cellular microtubules and is transported 
to the nucleus by dynein". Nat Cell Biol, 2 (10). 709-717. 
215. Giuseppe, C. 2007  "Estrogen and prostate cancer: An eclipsed truth in an 
androgen-dominated scenario". J Cell Biochem, 102 (4). 899-911. 
216. Glotzer, M. 2001  "Animal cell cytokinesis". Annu Rev Cell Dev Biol, 17 (1). 
351-386. 
217. Goder, V. and Spiess, M. 2003  "Molecular mechanism of signal sequence 
orientation in the endoplasmic reticulum". EMBO J, 22 (14). 3645-3653. 
218. Gohshi, T., Shimada, M., Kawahire, S., Imai, N., Ichimura, T., Omata, S. and 
Horigome, T. 1999  "Molecular cloning of mouse p47, a second group 
mammalian RuvB DNA helicase-like protein: homology with those from 
human and Saccharomyces cerevisiae". J Biochem, 125 (5). 939-946. 
219. Goldstein, I., Hoffstein, S., Gallin and Weissmann, G. 1973 "Mechanisms of 
lysosomal enzyme release from human leukocytes: microtubule assembly and 
membrane fusion induced by a component of complement". Proc Natl Acad 
Sci U S A, 70 (10). 2916-2920. 
220. Goldstein, J., Waterhouse, N., Juin, P., Evan, G. and Green, D. 2000  "The 
coordinate release of cytochrome c during apoptosis is rapid, complete and 
kinetically invariant". Nat Cell Biol, 3 (3). 156-162. 
221. Goping, I.S., Gross, A., Lavoie, J.N., Nguyen, M., Jemmerson, R., Roth, K., 
Korsmeyer, S.J. and Shore, G.C. 1998  "Regulated Targeting of BAX to 
Mitochondria". J Biol Chem, 143 (1). 207-215. 
222. Gordon, M.B., Howard, L. and Compton, D.A. 2001  "Chromosome 
Movement in Mitosis Requires Microtubule Anchorage at Spindle Poles". J 
Cell Biol, 152 (3). 425-434. 
223. Gordon, P.B., Kovacs, A.L. and Seglen, P.O. 1987  "Temperature 
dependence of protein degradation, autophagic sequestration and 
mitochondrial sugar uptake in rat hepatocytes". Biochim Biophys Acta, 929 
(2). 128-133. 
224. Göringer, H., Homann, M. and Lorger, M. 2003  " In vitro selection of high-




                                                                                                                   Bibliography 
225. Górka, M., Daniewski, W., Gajkowska, B., Lusakowska, E., Godlewski, M. 
and Motyl, T. 2005  "Autophagy is the dominant type of programmed cell 
death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new 
sesquiterpene analogs of paclitaxel." Anticancer Drugs, 16 (7). 777-788. 
226. Goss, P. 2008  "Addressing the future: combination with targeted therapies, 
adjuvant setting and beyond". Anticancer Drugs, 19 (2). S3-5. 
227. Graeber, T.G., Peterson, J.F., Tsai, M., Monica, K., Fornace, A.J., Jr. and 
Giaccia, A.J. 1994  "Hypoxia induces accumulation of p53 protein, but 
activation of a G1-phase checkpoint by low-oxygen conditions is independent 
of p53 status". Mol Cell Biol, 14 (9). 6264-6277. 
228. Green, D.R. and Kroemer, G. 2004  "The Pathophysiology of Mitochondrial 
Cell Death". Science, 305 (5684). 626-629. 
229. Griffin, F.M., Jr., Griffin, J.A., Leider, J.E. and Silverstein, S.C. 1975  
"Studies on the mechanism of phagocytosis. I. Requirements for 
circumferential attachment of particle-bound ligands to specific receptors on 
the macrophage plasma membrane". J Exp Med, 142 (5). 1263-1282. 
230. Griffin, F.M., Jr., Griffin, J.A. and Silverstein, S.C. 1976  "Studies on the 
mechanism of phagocytosis. II. The interaction of macrophages with anti-
immunoglobulin IgG-coated bone marrow-derived lymphocytes". J Exp Med, 
144 (3). 788-809. 
231. Griffiths, G., Ericsson, M., Krijnse Locker, J., Nilsson, T., Goud, B., Söling, 
H., Tang, B., Wong, S. and Hong, W. 1994  "Localization of the Lys, Asp, 
Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate 
compartment in mammalian cells". J Cell Biol, 127 (6 Pt 1). 1557-1574. 
232. Grillo, C., D'Ambrosio, C., Consalvi, V., Chiaraluce, R., Scaloni, A., 
Maceroni, M., Eufemi, M. and Altieri, F. 2007  "DNA-binding Activity of the 
ERp57 C-terminal Domain Is Related to a Redox-dependent Conformational 
Change". J Biol Chem, 282 (14). 10299-10310. 
233. Grimm , S. and Brdiczka, D. 2007  " The permeability transition pore in cell 
death". Apoptosis, 12 (5). 841-855. 
234. Gross, A., McDonnell, J.M. and Korsmeyer, S.J. 1999  "BCL-2 family 
members and the mitochondria in apoptosis". Genes Dev, 13 (15). 1899-1911. 
235. Grossman, S., Perez, M., Kung, A., Joseph, M., Mansur, C., Xiao, Z., Kumar, 
S., Howley, P. and Livingston, D. 1998  "p300/MDM2 complexes participate 
in MDM2-mediated p53 degradation". Mol Cell, 2 (4). 405-415. 
236. Gruss, H.J. and Dower, S.K. 1995  "Tumor necrosis factor ligand 
superfamily: involvement in the pathology of malignant lymphomas". Blood, 
85 (12). 3378-3404. 
237. Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M.A., Hayashi, N., 
Higashino, K., Okamura, H., Nakanishi, K., Kurimoto, M., Tanimoto, T., 
Flavell, R.A., Sato, V., Harding, M.W., Livingston, D.J. and Su, M.S.S. 1997  
"Activation of Interferon-gamma Inducing Factor Mediated by Interleukin-
1beta Converting Enzyme". Science, 275 (5297). 206-209. 
238. Gudjonsson, T., Rønnov Jessen, L., Villadsen, R., Rank, F., Bissell, M. and 
Petersen, O. 2002  "Normal and tumor-derived myoepithelial cells differ in 
[262] 
 
                                                                                                                   Bibliography 
their ability to interact with luminal breast epithelial cells for polarity and 
basement membrane deposition". J Cell Sci, 115 (Pt 1). 39-50. 
239. Gupta, K., Kshirsagar, S., Li, W., Gui, L., Ramakrishnan, S., Gupta, P., Law, 
P.Y. and Hebbel, R.P. 1999  "VEGF Prevents Apoptosis of Human 
Microvascular Endothelial Cells via Opposing Effects on MAPK/ERK and 
SAPK/JNK Signaling". Exp Cell Res, 247 (2). 495-504. 
240. Haes, A.J., Giordano, B.C. and Collins, G.E. 2006  "Aptamer-Based 
Detection and Quantitative Analysis of Ricin Using Affinity Probe Capillary 
Electrophoresis". Anal Chem, 78 (11). 3758-3764. 
241. Hain, J., Weller, E., Jung, T. and Burkart, W. 1996  "Effects of ionizing- and 
UV B-radiation on proteins controlling cell cycle progression in human cells: 
comparison of the MCF-7 adenocarcinoma and the SCL-2 squamous cell 
carcinoma cell line." Int J Radiat Biol, 70 (3). 261-271. 
242. Hakem, R., Hakem, A., Duncan, G.S., Henderson, J.T., Woo, M., Soengas, 
M.S., Elia, A., de la Pompa, J.L., Kagi, D., Khoo, W., Potter, J., Yoshida, R., 
Kaufman, S.A., Lowe, S.W., Penninger, J.M. and Mak, T.W. 1998  
"Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo". 
Cell, 94 (3). 339-352. 
243. Hanaoka, H., Noda, T., Shirano, Y., Kato, T., Hayashi, H., Shibata, D., 
Tabata, S. and Ohsumi, Y. 2002  "Leaf Senescence and Starvation-Induced 
Chlorosis Are Accelerated by the Disruption of an Arabidopsis Autophagy 
Gene". Plant Physiol, 129 (3). 1181-1193. 
244. Hanein, D., Matlack, K., Jungnickel, B., Plath, K., Kalies, K., Miller, K., 
Rapoport, T. and Akey, C. 1996  "Oligomeric rings of the Sec61p complex 
induced by ligands required for protein translocation". Cell, 87 (4). 721-732. 
245. Hannahan, D. and Weinberg, R.A. 2000  "The Hallmarks of Cancer". Cell, 
100 (1). 57-70. 
246. Hardt, B., Kalz Fuller, B., Aparicio, R., Volker, C. and Bause, E. 2003  
"(Arg)3 within the N-terminal domain of glucosidase I contains ER targeting 
information but is not required absolutely for ER localization". Glycobiology, 
13 (3). 159-168. 
247. Haren, L. and Merdes, A. 2002  "Direct binding of NuMA to tubulin is 
mediated by a novel sequence motif in the tail domain that bundles and 
stabilizes microtubules". J Cell Sci, 115 (9). 1815-1824. 
248. Harris, A., Nicholson, S., Sainsbury, J., Farndon, J. and Wright, C. 1989  
"Epidermal growth factor receptors in breast cancer: association with early 
relapse and death, poor response to hormones and interactions with neu". J 
Steroid Biochem, 34 (1-6). 123-131. 
249. Harris, S.L. and Levine, A.J. 2005  "The p53 pathway: positive and negative 
feedback loops". Oncogene, 24 (17). 2899-2908. 
250. Hartmann, E., Rapoport, T. and Lodish, H. 1989 "Predicting the orientation 




                                                                                                                   Bibliography 
251. Hermann, G., King, E. and Shaw, J. 1997  "The yeast gene, MDM20, is 
necessary for mitochondrial inheritance and organization of the actin 
cytoskeleton". J Cell Biol, 137 (1). 141-153. 
252. Hermann, G.J. and Shaw, J.M. 1998  "Mitochondrial dynamics in yeast". 
Annu Rev Cell Dev Biol, 14 (1). 265-303. 
253. Higashimoto, Y., Saito, S.i., Tong, X.-H., Hong, A., Sakaguchi, K., Appella, 
E. and Anderson, C.W. 2000  "Human p53 Is Phosphorylated on Serines 6 
and 9 in Response to DNA Damage-inducing Agents". J Biol Chem, 275 (30). 
23199-23203. 
254. Hinds, P., Finlay, C., Quartin, R., Baker, S., Fearon, E., Vogelstein, B. and 
Levine, A. 1990 "Mutant p53 DNA clones from human colon carcinomas 
cooperate with ras in transforming primary rat cells: a comparison of the "hot 
spot" mutant phenotypes". Cell Growth Differ, 1 (12). 571-580. 
255. Hirao, A., Kong, Y.Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., 
Liu, D., Elledge, S.J. and Mak, T.W. 2000  "DNA Damage-Induced 
Activation of p53 by the Checkpoint Kinase Chk2". Science, 287 (5459). 
1824-1827. 
256. Hirokawa, N. 1982  "Cross-linker system between neurofilaments, 
microtubules, and membranous organelles in frog axons revealed by the 
quick-freeze, deep-etching method". J Cell Biol, 94 (1). 129-142. 
257. Hollenbeck, P. and Saxton, W. 2005  "The axonal transport of mitochondria". 
J Cell Sci, 118 (Pt 23). 5411-5419. 
258. Hollstein, M., Rice, K., Greenblatt, M., Soussi, T., Fuchs, R., Sørlie, T., 
Hovig, E., Smith-Sørensen, B., Montesano, R. and Harris, C. 1994  "Database 
of p53 gene somatic mutations in human tumors and cell lines". Nucleic 
Acids Res, 22 (17). 3551-3555. 
259. Homann, M. and Goringer, H.U. 1999  "Combinatorial selection of high 
affinity RNA ligands to live African trypanosomes". Nucl Acids Res, 27 (9). 
2006-2014. 
260. Homburg, C.H., de Haas, M., von dem Borne, A.E., Verhoeven, A.J., 
Reutelingsperger, C.P. and Roos, D. 1995  "Human neutrophils lose their 
surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis 
in vitro". Blood, 85 (2). 532-540. 
261. Honda, R., Tanaka, H. and Yasuda, H. 1997  "Oncoprotein MDM2 is a 
ubiquitin ligase E3 for tumor suppressor p53". FEBS Letters, 420 (1). 25-27. 
262. Hope, I.A. and Struhl, K. 1986  "Functional dissection of a eukaryotic 
transcriptional activator protein, GCN4 of Yeast". Cell, 46 (6). 885-894. 
263. Hoppe Seyler, F., Crnkovic Mertens, Tomai, E. and Butz, K. 2004  "Peptide 
aptamers: specific inhibitors of protein function". Curr Mol Med, 4 (5). 529-
538. 
264. Horrobin, D.F. 1998  "The membrane phospholipid hypothesis as a 
biochemical basis for the neurodevelopmental concept of schizophrenia". 
Schizophr Res, 30 (3). 193-208. 
[264] 
 
                                                                                                                   Bibliography 
265. Horton, P. and Nakai, K. 1997  "Better prediction of protein cellular 
localization sites with the k nearest neighbors classifier". Proc Int Conf Intell 
Syst Mol Biol, 5. 147-152. 
266. Horvitz, H.R. and Herskowitz, I. 1992  "Mechanisms of asymmetric cell 
division: Two Bs or not two Bs, that is the question". Cell, 68 (2). 237-255. 
267. Hotchkiss, K.A., Matthias, L.J. and Hogg, P.J. 1998  "Exposure of the cryptic 
Arg-Gly-Asp sequence in thrombospondin-1 by protein disulfide isomerase". 
Biochim Biophys Acta, 1388 (2). 478-488. 
268. Houston, S., Plunkett, T., Barnes, D., Smith, P., Rubens, R. and Miles, D. 
1999  "Overexpression of c-erbB2 is an independent marker of resistance to 
endocrine therapy in advanced breast cancer". Br J Cancer, 79 (7-8). 1220-
1226. 
269. Howard, A.D., Kostura, M.J., Thornberry, N., Ding, G.J., Limjuco, G., 
Weidner, J., Salley, J.P., Hogquist, K.A., Chaplin, D.D. and Mumford, R.A. 
1991  "IL-1-converting enzyme requires aspartic acid residues for processing 
of the IL-1 beta precursor at two distinct sites and does not cleave 31- kDa 
IL-1 alpha". J Immunol, 147 (9). 2964-2969. 
270. Hrstka, R., Nenutil, R., Fourtouna, A., Howie, J., Naughton, C., Macleod, K., 
Larionov, A., Dixon, M., Langdon, S., Murray, E., Knoflickova, D., 
Petrakova, K., Holcakova, J., Hayward, R., Hupp, T.R. and Vojtesek, B. 2008  
"Elevated Expression of AGR2 and AGR3 in Response to Tamoxifen 
Treatment in Breast Cancers". In press. 
271. Hsu, Y.-T. and Youle, R.J. 1998  "Bax in Murine Thymus Is a Soluble 
Monomeric Protein That Displays Differential Detergent-induced 
Conformations". J Biol Chem, 273 (17). 10777-10783. 
272. Hsu, Y.-T. and Youle, R.J. 1997  "Nonionic Detergents Induce Dimerization 
among Members of the Bcl-2 Family". J Biol Chem, 272 (21). 13829-13834. 
273. Huber, M., Bahr, I., Kratzschmar, J.R., Becker, A., Muller, E.C., Donner, P., 
Pohlenz, H.D., Schneider, M.R. and Sommer, A. 2004  "Comparison of 
proteomic and genomic analyses of the human breast cancer cell line T47D 
and the antiestrogen-resistant derivative T47D-r". Mol Cell Proteomics, 3 (1). 
43-55. 
274. Hulo, N., Bairoch, A., Bulliard, V., Cerutti, L., De Castro, E., Langendijk-
Genevaux, P.S., Pagni, M. and Sigrist, C.J.A. 2006  "The PROSITE 
database". Nucleic Acids Res, 34 (suppl.1). 227-230. 
275. Hupp, T., Meek, D., Midgley, C. and Lane, D. 1992  "Regulation of the 
specific DNA binding function of p53". Cell, 71 (5). 875-886. 
276. Hupp, T.R. and Lane, D.P. 1994  "Allosteric activation of latent p53 
tetramers". Current Biology, 4 (10). 865-875. 
277. Hurd, C., Khattree, N., Dinda, S., Alban, P. and Moudgil, V. 1997  
"Regulation of tumor suppressor proteins, p53 and retinoblastoma, by 
estrogen and antiestrogens in breast cancer cells". Oncogene, 15 (8). 991-995. 
278. Hwang, H. and Clurman, B. 2005  "Cyclin E in normal and neoplastic cell 
cycles". Oncogene, 24 (17). 2776-2786. 
[265] 
 
                                                                                                                   Bibliography 
279. Ichikawa, A., Ando, J. and Suda, K. 2008  "G1 arrest and expression of 
cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast 
cancer cells". Hum Cell, 21 (2). 28-37. 
280. Ignatiadis, M. and Sotiriou, C. 2008  "Understanding the Molecular Basis of 
Histologic Grade". Pathobiology, 75 (2). 104-111. 
281. Ikura, T., Ogryzko, V.V., Grigoriev, M., Groisman, R., Wang, J., Horikoshi, 
M., Scully, R., Qin, J. and Nakatani, Y. 2000  "Involvement of the TIP60 
Histone Acetylase Complex in DNA Repair and Apoptosis". Cell, 102 (4). 
463-473. 
282. Innes, H.E., Liu, D., Barraclough, R., Davies, M.P., O'Neill, P.A., Platt-
Higgins, A., de Silva Rudland, S., Sibson, D.R. and Rudland, P.S. 2006  
"Significance of the metastasis-inducing protein AGR2 for outcome in 
hormonally treated breast cancer patients". Br J Cancer, 94 (7). 1057 - 1065. 
283. Ireson, C. and Kelland, L. 2006  "Discovery and development of anticancer 
aptamers". Mol Cancer Ther, 5 (12). 2957-2962. 
284. Ito, T., Chiba, T., Ozawa, R., Yoshida, M., Hattori, M. and Sakaki, Y. 2001  
"A comprehensive two-hybrid analysis to explore the yeast protein 
interactome". Proc Natl Acad Sci U S A, 98 (8). 4569-4574. 
285. Itoh, N. and Nagata, S. 1993  "A novel protein domain required for apoptosis. 
Mutational analysis of human Fas antigen". J Biol Chem., 268 (15). 10932-
10937. 
286. Jackson, S.E., Craggs, T.D. and Huang, J.-r. 2006  "Understanding the 
folding of GFP using biophysical techniques". Expert Rev Proteomics, 3 (5). 
545-559. 
287. Jackson, T.A., Richer, J.K., Bain, D.L., Takimoto, G., S. , Tung, L. and 
Horwitz, K.B. 1997  "The Partial Agonist Activity of Antagonist-Occupied 
Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding 
Coactivator L7/SPA and the Corepressors N-CoR or SMRT". Mol Endocrinol, 
11 (6). 693-705. 
288. Janicke, R.U., Ng, P., Sprengart, M.L. and Porter, A.G. 1998  "Caspase-3 Is 
Required for alpha -Fodrin Cleavage but Dispensable for Cleavage of Other 
Death Substrates in Apoptosis". J Biol Chem, 273 (25). 15540-15545. 
289. Janicke, R.U., Sprengart, M.L., Wati, M.R. and Porter, A.G. 1998  "Caspase-
3 Is Required for DNA Fragmentation and Morphological Changes 
Associated with Apoptosis". J Biol Chem, 273 (16). 9357-9360. 
290. Jay, G., Khoury, G., DeLeo, A.B., Dippold, W.G. and Old, L.J. 1981  "p53 
transformation-related protein: detection of an associated phosphotransferase 
activity". Proc Natl Acad Sci U S A, 78 (5). 2932-2936. 
291. Jeong, S. and Seol, D. 2008  "The role of mitochondria in apoptosis". BMB 
Rep, 41 (1). 11-22. 
292. Jeong, W., Lee, D.Y., Park, S. and Rhee, S.G. 2008  "ERp16, an Endoplasmic 
Reticulum-resident Thiol-disulfide Oxidoreductase:Biochemical properties 
abd role in apoptosis induced by Endoplasmic reticulum stress ". J Biol Chem, 
283 (37). 25557-25566. 
[266] 
 
                                                                                                                   Bibliography 
293. Jiang, G. and Sancar, A. 2006  "Recruitment of DNA Damage Checkpoint 
Proteins to Damage in Transcribed and Nontranscribed Sequences". Mol Cell 
Biol, 26 (1). 39-49. 
294. Jin, J., Cai, Y., Yao, T., Gottschalk, A.J., Florens, L., Swanson, S.K., 
Gutierrez, J.L., Coleman, M.K., Workman, J.L., Mushegian, A., Washburn, 
M.P., Conaway, R.C. and Conaway, J.W. 2005  "A Mammalian Chromatin 
Remodeling Complex with Similarities to the Yeast INO80 Complex". J Biol 
Chem, 280 (50). 41207-41212. 
295. Johnson, N., Speirs, V., Curtin, N. and Hall, A. 2008  "A comparative study 
of genome-wide SNP, CGH microarray and protein expression analysis to 
explore genotypic and phenotypic mechanisms of acquired antiestrogen 
resistance in breast cancer". Breast Cancer Res Treat, 111 (1). 55-63. 
296. Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. 1995  "Rescue of 
embryonic lethality in Mdm2-deficient mice by absence of p53". Nature, 378 
(6553). 206-208. 
297. Jordan, V. 1982  "Metabolites of tamoxifen in animals and man: 
identification, pharmacology and significance". Breast Cancer Res Treat, 2 
(2). 123-138. 
298. Jordan, V., Collins, M., Rowsby, L. and Prestwich, G. 1977 "A 
monohydroxylated metabolite of tamoxifen with potent antioestrogenic 
activity." J Endocrinol., 75 (2). 305-316. 
299. Joyeux, A., Cavailles, V., Balaguer, P. and Nicolas, J.C. 1997  "RIP 140 
Enhances Nuclear Receptor-Dependent Transcription in Vivo in Yeast". Mol 
Endocrinol, 11 (2). 193-202. 
300. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., 
Kominami, E., Ohsumi, Y. and Yoshimori, T. 2000  "LC3, a mammalian 
homologue of yeast Apg8p, is localized in autophagosome membranes after 
processing". Embo J, 19 (21). 5720-5728. 
301. Kahana, J. and Silver, P. 2001  "Use of the A. victoria green fluorescent 
protein to study protein dynamics in vivo". Curr Protoc Neurosci, 5 (5). 15. 
302. Kanemaki, M., Makino, Y., Yoshida, T., Kishimoto, T., Koga, A., Yamamoto, 
K., Yamamoto, M., Moncollin, V., Egly, J.-M., Muramatsu, M. and Tamura, 
T.-a. 1997  "Molecular Cloning of a Rat 49-kDa TBP-Interacting Protein 
(TIP49) That Is Highly Homologous to the Bacterial RuvB". Biochem 
Biophys Res Commun, 235 (1). 64-68. 
303. Kastan, M., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. 1991  
"Participation of p53 protein in the cellular response to DNA damage". 
Cancer Res, 51 (23 Pt 1). 6304-6311. 
304. Kawashima, S., Ogiwara, H., Tada, S., Harata, M., Wintersberger, U., 
Enomoto, T. and Seki, M. 2007  "The INO80 complex is required for 
damage-induced recombination". Biochem Biophys Res Commun, 355 (3). 
835-841. 
305. Kawazoe, N., Ito, Y. and Imanishi, Y. 1997  "Bioassay Using a Labeled 




                                                                                                                   Bibliography 
306. Kelekar, A. and Thompson, C.B. 1998  "Bcl-2-family proteins: the role of the 
BH3 domain in apoptosis". Trends Cell Biol, 8 (8). 324-330. 
307. Kellen, E., Vansant, G., Christiaens, M., Neven, P. and Van Limbergen, E. 
2008  "Lifestyle changes and breast cancer prognosis: a review". Breast 
Cancer Res Treat, Epub ahead of print. 
308. Kern, S., Kinzler, K., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. and 
Vogelstein, B. 1991  " Identification of p53 as a sequence-specific DNA-
binding protein". Science, 252 (5013). 1708-1711. 
309. Kerr JF, W.A., Currie AR 1972  "Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics." Br J Cancer, 26 (4). 239-
257. 
310. Kim, H., Rafiuddin-Shah, M., Tu, H.-C., Jeffers, J.R., Zambetti, G.P., Hsieh, 
J.J.D. and Cheng, E.H.Y. 2006  "Hierarchical regulation of mitochondrion-
dependent apoptosis by BCL-2 subfamilies". Nat Cell Biol, 8 (12). 1348-1358. 
311. Kim, H.Y. and Gladyshev, V.N. 2004  "Methionine Sulfoxide Reduction in 
Mammals: Characterization of Methionine-R-Sulfoxide Reductases". Mol 
Biol Cell, 15 (3). 1055-1064. 
312. Kim, J., Huang, W.-P., Stromhaug, P.E. and Klionsky, D.J. 2002  
"Convergence of Multiple Autophagy and Cytoplasm to Vacuole Targeting 
Components to a Perivacuolar Membrane Compartment Prior to de Novo 
Vesicle Formation". J Biol Chem, 277 (1). 763-773. 
313. Kim, J.H., Choi, H.J., Kim, B., Kim, M.H., Lee, J.M., Kim, I.S., Lee, M.H., 
Choi, S.J., Kim, K.I., Kim, S.I., Chung, C.H. and Baek, S.H. 2006  "Roles of 
sumoylation of a reptin chromatin-remodelling complex in cancer metastasis". 
Nat Cell Biol, 8 (6). 631-639. 
314. Kimura, T., Horibe, T., Sakamoto, C., Shitara, Y., Fujiwara, F., Komiya, T., 
Yamamoto, A., Hayano, T., Takahashi, N. and Kikuchi, M. 2008  "Evidence 
for Mitochondrial Localization of P5, a Member of the Protein Disulphide 
Isomerase Family". J Biochem, 144 (2). 187-196. 
315. Klein, C. and Vassilev, L. 2004 "Targeting the p53-MDM2 interaction to 
treat cancer". Br J Cancer, 91 (8). 1415-1419. 
316. Klionsky, D.J., Cregg, J.M., Dunn, W.A., Emr, S.D., Sakai, Y., Sandoval, 
I.V., Sibirny, A., Subramani, S., Thumm, M., Veenhuis, M. and Ohsumi, Y. 
2003  "A Unified Nomenclature for Yeast Autophagy-Related Genes". Dev 
Cell, 5 (4). 539-545. 
317. Koizumi, M. and Breaker, R.R. 2000  "Molecular Recognition of cAMP by 
an RNA Aptamer". Biochemistry, 39 (30). 8983-8992. 
318. Komiya, T., Tanigawa, Y. and Hirohashi, S. 1999  "Cloning of the gene gob-
4, which is expressed in intestinal goblet cells in mice". Biochim Biophys 
Acta, 1444 (3). 434-438. 
319. Konishi, N., Shimada, K., Ishida, E. and Nakamura, M. 2005  "Molecular 
pathology of prostate cancer". Pathol Int, 55 (9). 531-539. 
320. Kosta, A., Roisin-Bouffay, C., Luciani, M.-F., Otto, G.P., Kessin, R.H. and 
Golstein, P. 2004  "Autophagy Gene Disruption Reveals a Non-vacuolar Cell 
Death Pathway in Dictyostelium". J Biol Chem, 279 (46). 48404-48409. 
[268] 
 
                                                                                                                   Bibliography 
321. Kothakota, S., Azuma, T., Reinhard, C., Klippel, A., Tang, J., Chu, K., 
McGarry, T.J., Kirschner, M.W., Koths, K., Kwiatkowski, D.J. and Williams, 
L.T. 1997  "Caspase-3-Generated Fragment of Gelsolin: Effector of 
Morphological Change in Apoptosis". Science, 278 (5336). 294-298. 
322. Koya, R., Fujita, H., Shimizu, S., Ohtsu, M., Takimoto, M., Tsujimoto, Y. 
and Kuzumaki, N. 2000  "Gelsolin inhibits apoptosis by blocking 
mitochondrial membrane potential loss and cytochrome c release". J Biol 
Chem, 275 (20). 15343-15349. 
323. Kozutsumi, Y., Segal, M., Normington, K., Gething, M.-J. and Sambrook, J. 
1988  "The presence of malfolded proteins in the endoplasmic reticulum 
signals the induction of glucose-regulated proteins". Nature, 332 (6163). 462-
464. 
324. Kraiss, S., Quaiser, A., Oren, M. and Montenarh, M. 1988  "Oligomerization 
of oncoprotein p53". J Virol, 62 (12). 4737-4744. 
325. Kroemer G, Z.N., Susin SA. 1997  "Mitochondrial control of apoptosis." 
Immunol Today, 18 (1). 44-51. 
326. Krysko, D.V., Denecker, G., Festjens, N., Gabriels, S., Parthoens, E., 
D'Herde, K. and Vandenabeele, P. 2006  "Macrophages use different 
internalization mechanisms to clear apoptotic and necrotic cells". Cell Death 
Differ, 13 (12). 2011-2022. 
327. Krysko, D.V., Vanden Berghe, T., D'Herde, K. and Vandenabeele, P. 2008  
"Apoptosis and necrosis: Detection, discrimination and phagocytosis". 
Methods, 44 (3). 205-221. 
328. Kubbutat, M.H.G., Jones, S.N. and Vousden, K.H. 1997  "Regulation of p53 
stability by Mdm2". Nature, 387 (6630). 299-303. 
329. Kubik, M.F., Bell, C., Fitzwater, T., Watson, S.R. and Tasset, D.M. 1997  
"Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro- /amino-
modified RNA ligands to human IFN-gamma that inhibit receptor binding". J 
Immunol, 159 (1). 259-267. 
330. Kuida, K., Zheng, T.S., Na, S., Kuan, C.-Y., Yang, D., Karasuyama, H., 
Rakic, P. and Flavell, R.A. 1996  "Decreased apoptosis in the brain and 
premature lethality in CPP32-deficient mice". Nature, 384 (6607). 368-372. 
331. Kumar, A., Godwin, J.W., Gates, P.B., Garza-Garcia, A.A. and Brockes, J.P. 
2007  "Molecular Basis for the Nerve Dependence of Limb Regeneration in 
an Adult Vertebrate". Science (5). 772-777. 
332. Kumar, M.B., Tarpey, R.W. and Perdew, G.H. 1999  "Differential 
Recruitment of Coactivator RIP140 by Ah and Estrogen Receptors.Absense 
of a role for LXXLL motifs". J Biol Chem, 274 (32). 22155-22164. 
333. Kundu, M. and Thompson, C.B. 2005  "Macroautophagy versus 
mitochondrial autophagy: a question of fate?" Cell Death Differ, 12 (S2). 
1484-1489. 
334. Kuperwasser, C., Pinkas, J., Hurlbut, G.D., Naber, S.P. and Jerry, D.J. 2000  
"Cytoplasmic Sequestration and Functional Repression of p53 in the 




                                                                                                                   Bibliography 
335. Kurokawa, H., Lenferink, A., Simpson, J., Pisacane, P., Sliwkowski, M., 
Forbes, J. and Arteaga, C. 2000  "Inhibition of HER2/neu (erbB-2) and 
mitogen-activated protein kinases enhances tamoxifen action against HER2-
overexpressing, tamoxifen-resistant breast cancer cells". Cancer Res, 60 (20). 
5887-5894. 
336. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. 
and Pavletich, N.P. 1996  "Structure of the MDM2 Oncoprotein Bound to the 
p53 Tumor Suppressor Transactivation Domain". Science, 274 (5289). 948-
953. 
337. Kuwana, T., Bouchier-Hayes, L., Chipuk, J.E., Bonzon, C., Sullivan, B.A., 
Green, D.R. and Newmeyer, D.D. 2005  "BH3 Domains of BH3-Only 
Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane 
Permeabilization Both Directly and Indirectly". Mol Cell, 17 (4). 525-535. 
338. Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A.J., Elowitz, 
M.B. and Alon, U. 2004  "Dynamics of the p53-Mdm2 feedback loop in 
individual cells". Nat Genet, 36 (2). 147-150. 
339. Laín, S., Midgley, C., Sparks, A., Lane, E.B. and Lane, D.P. 1999  "An 
Inhibitor of Nuclear Export Activates the p53 Response and Induces the 
Localization of HDM2 and p53 to U1A-Positive Nuclear Bodies Associated 
with the PODs". Exp Cell Res, 248 (2). 457-472. 
340. Lam, S. and Gong, Z. 2006  "Modeling liver cancer using zebrafish: a 
comparative oncogenomics approach". Cell Cycle, 5 (6). 573-577. 
341. Lamparska Przybysz, M., Gajkowska, B. and Motyl, T. 2005  "Cathepsins 
and BID are involved in the molecular switch between apoptosis and 
autophagy in breast cancer MCF-7 cells exposed to camptothecin". J Physiol 
Pharmacol, 56 (3). 159-179. 
342. Lamprakos, P. (ed.), Helios Greek Encyclopaedia. Athens Press, 1998. 
343. Land, H., Parada, L. and Weinberg, R. 1983  "Tumorigenic conversion of 
primary embryo fibroblasts requires at least two cooperating oncogenes". 
Nature, 304 (5927). 596-602. 
344. Langheinrich, U. 2003  "Zebrafish: a new model on the pharmaceutical 
catwalk". Bioessays, 25 (9). 904-912. 
345. Langheinrich, U., Hennen, E., Stott, G. and Vacun, G. 2002  "Zebrafish as a 
model organism for the identification and characterization of drugs and genes 
affecting p53 signaling". Curr Biol, 10 (23). 2023-2028. 
346. Lavieu, G., Scarlatti, F., Sala, G., Carpentier, S., Levade, T., Ghidoni, R., 
Botti, J. and Codogno, P. 2006  "Regulation of Autophagy by Sphingosine 
Kinase 1 and Its Role in Cell Survival during Nutrient Starvation". J Biol 
Chem, 281 (13). 8518-8527. 
347. Lee, C.-H., Chinpaisal, C. and Wei, L.-N. 1998  "Cloning and 
Characterization of Mouse RIP140, a Corepressor for Nuclear Orphan 
Receptor TR2". Mol Cell Biol, 18 (11). 6745-6755. 
348. Lee, C.Y. and Baehrecke, E.H. 2001  "Steroid regulation of autophagic 




                                                                                                                   Bibliography 
349. Leist, M., Single, B., Castoldi, A.F., Kuhnle, S. and Nicotera, P. 1997  
"Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the 
Decision Between Apoptosis and Necrosis". J Exp Med, 185 (8). 1481-1486. 
350. Lemasters, J.J., Nieminen, A.-L., Qian, T., Trost, L.C., Elmore, S.P., 
Nishimura, Y., Crowe, R.A., Cascio, W.E., Bradham, C.A., Brenner, D.A. 
and Herman, B. 1998  "The mitochondrial permeability transition in cell 
death: a common mechanism in necrosis, apoptosis and autophagy". Biochim 
Biophys Acta, 1366 (1-2). 177-196. 
351. Lewandowski, S.A., Thiery, J., Jalil, A., Leclercq, G., Szczylik, C. and 
Chouaib, S. 2005  "Opposite effects of estrogen receptors alpha and beta on 
MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity". 
Oncogene, 24 (30). 4789. 
352. Lewis, J., Vijayanathan, V., Thomas, T., Pestell, R., Albanese, C., Gallo, M. 
and Thomas, T. 2005  " Activation of cyclin D1 by estradiol and spermine in 
MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and 
phosphorylation of  ATF-2". Oncol Res, 15 (3). 113-128. 
353. Lewis, M. and Pelham, H. 1992  "Ligand-induced redistribution of a human 
KDEL receptor from the Golgi complex to the endoplasmic reticulum". Cell, 
68 (2). 353-364. 
354. Lewis, M.J., Mazzarella, R.A. and Green, M. 1986  "Structure and assembly 
of the endoplasmic reticulum: biosynthesis and intracellular sorting of ERp61, 
ERp59, and ERp49, three protein components of murine endoplasmic 
reticulum". Arch Biochem Biophys, 245 (2). 389-403. 
355. Lewis, M.J., Sweet, D.J. and Pelham, H.R.B. 1990  "The ERD2 gene 
determines the specificity of the luminal ER protein retention system". Cell, 
61 (7). 1359-1363. 
356. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, 
E.S. and Wang, X. 1997  "Cytochrome c and dATP-Dependent Formation of 
Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade". Cell, 
91 (4). 479-489. 
357. Li, W.W., Alexandre, S., Cao, X. and Lee, A.S. 1993  "Transactivation of the 
grp78 promoter by Ca2+ depletion. A comparative analysis with A23187 and 
the endoplasmic reticulum Ca(2+)-ATPase inhibitor thapsigargin". J Biol 
Chem, 268 (16). 12003-12009. 
358. Liang, S.H. and Clarke, M.F. 1999  "A Bipartite Nuclear Localization Signal 
Is Required for p53 Nuclear Import Regulated by a Carboxyl-terminal 
Domain". J Biol Chem, 274 (46). 32699-32703. 
359. Liang, X.H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, 
H. and Levine, B. 1999  "Induction of autophagy and inhibition of 
tumorigenesis by beclin 1". Nature, 402 (6762). 672-676. 
360. Liang, X.H., Kleeman, L.K., Jiang, H.H., Gordon, G., Goldman, J.E., Berry, 
G., Herman, B. and Levine, B. 1998  "Protection against Fatal Sindbis Virus 




                                                                                                                   Bibliography 
361. Lin, J., Chen, J., Elenbaas, B. and Levine, A.J. 1994  "Several hydrophobic 
amino acids in the p53 amino-terminal domain are required for transcriptional 
activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein". 
Genes Dev, 8 (10). 1235-1246. 
362. Lin, Y.C., Lin, J.H., Chou, C.W., Chang, Y.F., Yeh, S.H. and Chen, C.C. 
2008  "Statins Increase p21 through Inhibition of Histone Deacetylase 
Activity and Release of Promoter-Associated HDAC1/2". Cancer Res, 68 (7). 
2375-2383. 
363. Lindén, M., Li, Z., Paulin, D., Gotow, T. and Leterrier, J. 2001  " Effects of 
desmin gene knockout on mice heart mitochondria". J Bioenerg Biomembr, 
33 (4). 333-341. 
364. Liu, D., Rudland, P., Sibson, D., Platt Higgins, A. and Barraclough, R. 2005  
"Human homologue of cement gland protein, a novel metastasis inducer 
associated with breast carcinomas". Cancer Res, 65 (9). 3796-3805. 
365. Liu, E.S., Ou, J.H. and Lee, A.S. 1992  "Brefeldin A as a regulator of grp78 
gene expression in mammalian cells". J Biol Chem, 267 (10). 7128-7133. 
366. Liu, X., Kim, C.N., Yang, J., Jemmerson, R. and Wang, X. 1996  "Induction 
of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and 
Cytochrome c". Cell, 86 (1). 147-157. 
367. Lockshin, R. and Zakeri, Z. 2004  "Apoptosis, autophagy, and more". Int J 
Biochem Cell Biol, 36 (12). 
368. Lombardi, M., Castoria, G., Migliaccio, A., Barone, M.V., Di Stasio, R., 
Ciociola, A., Bottero, D., Yamaguchi, H., Appella, E. and Auricchio, F. 2008  
"Hormone-dependent nuclear export of estradiol receptor and DNA synthesis 
in breast cancer cells". J Cell Biol, 182 (2). 327-340. 
369. Lønning, P. 2007 "Breast cancer prognostication and prediction: are we 
making progress?" Ann Oncol, 18 (8). 3-7. 
370. Lyons, S.K. and Clarke, A.R. 1997  "Apoptosis and carcinogenesis". Br Med 
Bull, 53 (3). 554-569. 
371. Maberley, D. 2005  "Pegaptanib for neovascular age-related macular 
degeneration". Issues Emerg Health Technol (76). 1-4. 
372. MacFarlane, M., Ahmad, M., Srinivasula, S.M., Fernandes-Alnemri, T., 
Cohen, G.M. and Alnemri, E.S. 1997  "Identification and Molecular Cloning 
of Two Novel Receptors for the Cytotoxic Ligand TRAIL". J Biol Chem., 
272 (41). 25417-25420. 
373. MacFarlane, M., Merrison, W., Dinsdale, D. and Cohen, G.M. 2000  "Active 
Caspases and Cleaved Cytokeratins Are Sequestered into Cytoplasmic 
Inclusions in TRAIL-induced Apoptosis". J Cell Biol, 148 (6). 1239-1254. 
374. Mackay, A., Urruticoechea, A., Dixon, J.M., Dexter, T., Fenwick, K., 
Ashworth, A., Drury, S., Larionov, A., Young, O., White, S., Miller, W., 
Evans, D. and Dowsett, M. 2007  "Molecular response to aromatase inhibitor 
treatment in primary breast cancer". Breast Cancer Res, 9 (3). R37. 
375. Mairal, T., Cengiz Özalp, V., Lozano Sánchez, P., Mir, M., Katakis, I. and 
O’Sullivan, C. 2008  "Aptamers: molecular tools for analytical applications". 
Anal Bioanal Chem, 390 (4). 989-1007. 
[272] 
 
                                                                                                                   Bibliography 
376. Majerfeld, I. and Yarus, M. 1994  "An RNA pocket for an aliphatic 
hydrophobe". Nat Struct Biol, 1 (5). 287-292. 
377. Majno, G. and Joris, I. 1995  "Apoptosis, oncosis, and necrosis. An overview 
of cell death." Am J Pathol, 146 (1). 3-15. 
378. Malayeri, R., Pirker, R. and Huber, H. 2001  "New drugs in the palliative 
chemotherapy of advanced non-small-cell lung cancer". Onkologie, 24 (5). 
416-421. 
379. Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F., Jr., Nelson, C.E., Kim, 
D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., Tainsky, M.A. and et al. 1990  
"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, 
and other neoplasms". Science, 250 (4985). 1233-1238. 
380. Maltzman, W. and Czyzy, L. 1984  "UV irradiation stimulates levels of p53 
cellular tumor antigen in nontransformed mouse cells." Mol Cell Biol, 4 (9). 
1689–1694. 
381. Mann, D., Reinemann, C., Stoltenburg, R. and Strehlitz, B. 2005  "In vitro 
selection of DNA aptamers binding ethanolamine". Biochem Biophys Res 
Commun, 338 (4). 1928-1934. 
382. Marchant, J., Stutzmann, G., Leissring, M., LaFerla, F. and Parker, I. 2001  
"Multiphoton-evoked color change of DsRed as an optical highlighter for 
cellular and subcellular labeling". Nat Biotechnol, 19 (7). 645-649. 
383. Marchenko, N., Zaika, A. and Moll, U. 2000  "Death signal-induced 
localization of p53 protein to mitochondria. A potential role in apoptotic 
signaling". J Biol Chem, 275 (21). 16202-16212. 
384. Marchetti, P., Castedo, M., Susin, S., Zamzami, N., Hirsch, T., Macho, A., 
Haeffner, A., Hirsch, F., Geuskens, M. and Kroemer, G. 1996  
"Mitochondrial permeability transition is a central coordinating event of 
apoptosis". J Exp Med, 184 (3). 1155-1160. 
385. Mariathasan, S., Newton, K., Monack, D.M., Vucic, D., French, D.M., Lee, 
W.P., Roose-Girma, M., Erickson, S. and Dixit, V.M. 2004  "Differential 
activation of the inflammasome by caspase-1 adaptors ASC and Ipaf". Nature, 
430 (6996). 213-218. 
386. Martin, S.A.M., Blaney, S.C., Houlihan, D.F. and Secombes, C.J. 2006  
"Transcriptome response following administration of a live bacterial vaccine 
in Atlantic salmon (Salmo salar)". Mol Immunol, 43 (11). 1900-1911. 
387. Martinez, J., Georgoff, I., Martinez, J. and Levine, A.J. 1991  "Cellular 
localization and cell cycle regulation by a temperature-sensitive p53 protein". 
Genes Dev, 5 (2). 151-159. 
388. Marzo I. , Brenner, C., Zamzami, N., Jürgensmeier, J.M., Susin, S.A., Vieira, 
H.L.A., Prévost, M.-C., Xie, Z., Matsuyama, S., Reed, J.C. and Kroemer, G. 
1998  "Bax and Adenine Nucleotide Translocator Cooperate in the 
Mitochondrial Control of Apoptosis". Science, 281 (5385). 2027-2031. 
389. Massarweh, S. and Schiff, R. 2006  "Resistance to endocrine therapy in breast 
cancer: exploiting estrogen receptor/growth factor signaling crosstalk". 
Endocr Relat Cancer, 13 (1). S15-24. 
[273] 
 
                                                                                                                   Bibliography 
390. Matsuura-Tokita, K., Takeuchi, M., Ichihara, A., Mikuriya, K. and Nakano, 
A. 2006  "Live imaging of yeast Golgi cisternal maturation". Nature, 441 
(7096). 1007. 
391. Matz, M.V., Fradkov, A.F., Labas, Y.A., Savitsky, A.P., Zaraisky, A.G., 
Markelov, M.L. and Lukyanov, S.A. 1999  "Fluorescent proteins from 
nonbioluminescent Anthozoa species". Nat Biotech, 17 (10). 969-973. 
392. May, P. and May, E. 1999  "Twenty years of p53 research: structural and 
functional aspects of the p53 protein". Oncogene, 18 (53). 7621-7636. 
393. Mayo, L.D., Dixon, J.E., Durden, D.L., Tonks, N.K. and Donner, D.B. 2002  
"PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to 
Chemotherapy". J Biol Chem, 277 (7). 5484-5489. 
394. McConnell, S., Stewart, L., Talin, A. and Yaffe, M. 1990  "Temperature-
sensitive yeast mutants defective in mitochondrial inheritance". J Cell Biol, 
111 (3). 967-976. 
395. McMillan, D.R., Gething, M.-J. and Sambrook, J. 1994  "The cellular 
response to unfolded proteins: intercompartmental signaling". Curr Opin 
Biotechnol, 5 (5). 540-545. 
396. Medina, D., Kittrell, F., Shepard, A., Contreras, A., Rosen, J. and Lydon, J. 
2003  "Hormone dependence in premalignant mammary progression". 
Cancer Res, 63 (5). 1067-1072. 
397. Meijer, A.H., Verbeek, F.J., Salas-Vidal, E., Corredor-Adámez, M., Bussman, 
J., van der Sar, A.M., Otto, G.W., Geisler, R. and Spaink, H.P. 2005  
"Transcriptome profiling of adult zebrafish at the late stage of chronic 
tuberculosis due to Mycobacterium marinum infection". Mol Immunol, 42 
(10). 1185-1203. 
398. Menssen, A. and Hermeking, H. 2002  "From the Cover: Characterization of 
the c-MYC-regulated transcriptome by SAGE: Identification and analysis of 
c-MYC target genes". Proc Natl Acad Sci U S A, 99 (9). 6274-6279. 
399. Mevorach, D., Mascarenhas, J.O., Gershov, D. and Elkon, K.B. 1998  
"Complement-dependent Clearance of Apoptotic Cells by Human 
Macrophages". J Exp Med, 188 (12). 2313-2320. 
400. Middeler, G., Zerf, K., Jenovai, S., Thulig, A., Tschödrich Rotter, M., 
Kubitscheck, U. and Peters, R. 1997  "The tumor suppressor p53 is subject to 
both nuclear import and export, and both are fast, energy-dependent and 
lectin-inhibited". Oncogene, 14 (12). 1407-1417. 
401. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P. 
and Moll, U. 2003  " p53 has a direct apoptogenic role at the mitochondria". 
Mol Cell, 11 (3). 577-590. 
402. Milner, D., Mavroidis, M., Weisleder, N. and Capetanaki, Y. 2000  "Desmin 
cytoskeleton linked to muscle mitochondrial distribution and respiratory 
function". J Cell Biol, 150 (6). 1283-1298. 
403. Missiaglia, E., Blaveri, E., Terris, B., Wang, Y., Costello, E., Neoptolemos, J., 
Crnogorac, J.T. and Lemoine, N. 2004  "Analysis of gene expression in 
cancer cell lines identifies candidate markers for pancreatic tumorigenesis 
and metastasis". Int J Cancer, 112 (1). 100-112. 
[274] 
 
                                                                                                                   Bibliography 
404. Miura, M., Zhu, H., Rotello, R., Hartwieg, E.A. and Yuan, J. 1993  
"Induction of apoptosis in fibroblasts by IL-1[beta]-converting enzyme, a 
mammalian homolog of the C. elegans cell death gene ced-3". Cell, 75 (4). 
653-660. 
405. Miyawaki, A., Nagai, T. and Mizuno, H. 2005  "Engineering fluorescent 
proteins". Adv Biochem Eng Biotechnol, 8 (95). 1-15. 
406. Mizuno, H., Sawano, A., Eli, P., Hama, H. and Miyawaki, A. 2001  "Red 
Fluorescent Protein from Discosoma as a Fusion Tag and a Partner for 
Fluorescence Resonance Energy Transfer". Biochemistry, 40 (8). 2502-2510. 
407. Mochizuki, N., Cho, G., Wen, B. and Insel, P.A. 1996  "Identification and 
cDNA cloning of a novel human mosaic protein, LGN, based on interaction 
with G alpha i2". Gene, 181 (1-2). 39-43. 
408. Molinari, A., Bontempo, P., Schiavone, E., Verdicchio, M., Napolitano, M., 
Nola, E., Moncharmont, B., Medici, N., Nigro, V., Armetta, I., Abbondanza, 
C. and Puca, G. 2000  "Estradiol induces functional inactivation of p53 by 
intracellular redistribution". Cancer Res, 60 (10). 2594-2597. 
409. Moll, U., Marchenko, N. and Zhang, X. 2006  "p53 and Nur77/TR3 - 
transcription factors that directly target mitochondria for cell death induction". 
Oncogene, 25 (34). 4725-4743. 
410. Moll, U.M., LaQuaglia, M., Bénard, J. and Riou, G. 1995  "Wild-type p53 
protein undergoes cytoplasmic sequestration in undifferentiated 
neuroblastomas but not in differentiated tumors". PNAS, 92 (10). 4407-4411. 
411. Moll, U.M., Ostermeyer, A.G., Haladay, R., Winkfield, B., Frazier, M. and 
Zambetti, G. 1996  "Cytoplasmic sequestration of wild-type p53 protein 
impairs the G1 checkpoint after DNA damage". Mol Cell Biol, 16 (3). 1126-
1137. 
412. Moll, U.M., Riou, G. and Levine, A.J. 1992  "Two distinct mechanisms alter 
p53 in breast cancer: mutation and nuclear exclusion". PNAS, 89 (15). 7262-
7266. 
413. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. 1992  
"The mdm-2 oncogene product forms a complex with the p53 protein and 
inhibits p53-mediated transactivation". Cell, 69 (7). 1237-1245. 
414. Montes de Oca Luna, R., Wagner, D. and Lozano, G. 1995  "Rescue of early 
embryonic lethality in mdm2-deficient mice by deletion of p53". Nature, 378 
(6553). 203-206. 
415. Morais da Silva, S., Gates, P.B. and Brockes, J.P. 2002  "The Newt Ortholog 
of CD59 Is Implicated in Proximodistal Identity during Amphibian Limb 
Regeneration". Dev Cell, 3 (4). 547-555. 
416. Morris, R. and Hollenbeck, P. 1995  "Axonal transport of mitochondria along 
microtubules and F-actin in living vertebrate neurons". J Cell Biol, 131 (5). 
1315-1326. 
417. Morris, S. and Carey, L. 2006 "Trastuzumab and beyond: New possibilities 




                                                                                                                   Bibliography 
418. Morrison, R.N., Cooper, G.A., Koop, B.F., Rise, M.L., Bridle, A.R., Adams, 
M.B. and Nowak, B.F. 2006  "Transcriptome profiling the gills of amoebic 
gill disease (AGD)-affected Atlantic salmon (Salmo salar L.): a role for 
tumor suppressor p53 in AGD pathogenesis?" Physiol Genomics, 26 (1). 15-
34. 
419. Mose Larsen, P., Bravo, R., Fey, S., Small, J. and Celis, J. 1982 "Putative 
association of mitochondria with a subpopulation of intermediate-sized 
filaments in cultured human skin fibroblasts". Cell, 31 (3 Pt 2). 681-692. 
420. Moudgil, V.K., Dinda, S., Khattree, N., Jhanwar, S., Alban, P. and Hurd, C. 
2001  "Hormonal regulation of tumor suppressor proteins in breast cancer 
cells". J Steroid Biochem Mol Biol, 76 (1-5). 105. 
421. Moulder, S. and Hortobagyi, G.N. 2007  "Advances in the Treatment of 
Breast Cancer". Clin Pharmacol Ther, 83 (1). 26-36. 
422. Mower, D.A., Jr., Peckham, D.W., Illera, V.A., Fishbaugh, J.K., Stunz, L.L. 
and Ashman, R.F. 1994  "Decreased membrane phospholipid packing and 
decreased cell size precede DNA cleavage in mature mouse B cell apoptosis". 
J Immunol, 152 (10). 4832-4842. 
423. Munro, S. and Pelham, H.R.B. 1987  "A C-terminal signal prevents secretion 
of luminal ER proteins". Cell, 48 (5). 899-907. 
424. Murray, E., McKenna, E.O., Burch, L.R., Dillon, J., Langridge Smith, P., 
Kolch, W., Pitt, A. and Hupp, T.R. 2007  "Microarray-Formatted Clinical 
Biomarker Assay Development Using Peptide Aptamers to Anterior 
Gradient-2". Biochemistry, 46 (48). 13742-13751. 
425. Muzio, M., Salvesen, G.S. and Dixit, V. 1997  "FLICE Induced Apoptosis in 
a Cell-free System. Cleavage of caspase zymogens". J Biol Chem, 272 (5). 
2952-2956. 
426. Na, S., Chuang, T.-H., Cunningham, A., Turi, T.G., Hanke, J.H., Bokoch, 
G.M. and Danley, D.E. 1996  "D4-GDI, a Substrate of CPP32, Is Proteolyzed 
during Fas-induced Apoptosis". J Biol Chem, 271 (19). 11209-11213. 
427. Narita, M., Shimizu, S., Ito, T., Chittenden, T., Lutz, R., Matsuda, H. and 
Tsujimoto, Y. 1998  "Bax interacts with the permeability transition pore to 
induce permeability transition and cytochrome c release in isolated 
mitochondria". Proc Natl Acad Sci U S A., 95 (25). 14681-14686. 
428. Nemajerova, A., Erster, S. and Moll, U. 2005  "The post-translational 
phosphorylation and acetylation modification profile is not the determining 
factor in targeting endogenous stress-induced p53 to mitochondria". Cell 
Death Differ, 12 (2). 197-200. 
429. Newton, H. 2007  "Small-molecule and antibody approaches to molecular 
chemotherapy of primary brain tumors". Curr Opin Investig Drugs, 8 (12). 
1009-1021. 
430. Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., 
Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., Akslen, L.A., 
Ragaz, J., Gown, A.M., Gilks, C.B., van de Rijn, M. and Perou, C.M. 2004  
"Immunohistochemical and Clinical Characterization of the Basal-Like 
Subtype of Invasive Breast Carcinoma". Clin Cancer Res, 10 (16). 5367-5374. 
[276] 
 
                                                                                                                   Bibliography 
431. Nigg, E.A. 1997  "Nucleocytoplasmic transport: signals, mechanisms and 
regulation". Nature, 386 (6627). 779-787. 
432. Nigro, J., Baker, S., Preisinger, A., Jessup, J., Hostetter, R., Cleary, K., 
Bigner, S., Davidson, N., Baylin, S. and Devilee, P. 1989  "Mutations in the 
p53 gene occur in diverse human tumour types". Nature, 342 (6250). 705-708. 
433. Nilsson, T. and Warren, G. 1994  "Retention and retrieval in the endoplasmic 
reticulum and the Golgi apparatus". Curr Opin Cell Biol, 6 (4). 517-521. 
434. Nimjee, S.M., Rusconi, C.P., Harrington, R.A. and Sullenger, B.A. 2005  
"The potential of aptamers as anticoagulants". Trends Cardiovasc Med, 15 
(1). 41-45. 
435. Nopanitaya, W. and Misch, D.W. 1974  "Developmental cytology of the 
midgut in the flesh-fly, Sarcophaga bullata (Parker)". Tissue Cell, 6 (3). 487-
502. 
436. Novoselov, V.V., Alexandrova, E.M., Ermakova, G.V. and Zaraisky, A.G. 
2003  "Expression zones of three novel genes abut the developing anterior 
neural plate of Xenopus embryo". Gene Expr Patterns, 3 (2). 225-230. 
437. Nutt, L.K., Pataer, A., Pahler, J., Fang, B., Roth, J., McConkey, D.J. and 
Swisher, S.G. 2002  "Bax and Bak Promote Apoptosis by Modulating 
Endoplasmic Reticular and Mitochondrial Ca2+ Stores". J Biol Chem, 277 
(11). 9219-9225. 
438. Oberstein, A., Jeffrey, P.D. and Shi, Y. 2007  "Crystal Structure of the Bcl-
XL-Beclin 1 Peptide Complex: Beclin 1 is a novel BH3-only protein". J Biol 
Chem, 282 (17). 13123-13132. 
439. Ocker, M. and Schneider Stock, R. 2007  "Histone deacetylase inhibitors: 
Signalling towards p21cip1/waf1". Int J Biochem Cell Biol, 39 (7-8). 1367-
1374. 
440. Ogiwara, H., Ui, A., Kawashima, S., Kugou, K., Onoda, F., Iwahashi, H., 
Harata, M., Ohta, K., Enomoto, T. and Seki, M. 2007  "Actin-related protein 
Arp4 functions in kinetochore assembly". Nucl Acids Res, 35 (9). 3109-3117. 
441. Okamoto, T., Minamikawa, T., Edward, G., V., V. and Herman, E. 1999  
"Posttranslational removal of the carboxyl-terminal KDEL of the cysteine 
protease SH-EP occurs prior to maturation of the enzyme". J Biol Chem, 274 
(16). 11390-11398. 
442. Okamoto, T., Shimada, T., Hara-Nishimura, I., Nishimura, M. and 
Minamikawa, T. 2003  "C-Terminal KDEL Sequence of A KDEL-Tailed 
Cysteine Proteinase (Sulfhydryl-Endopeptidase) Is Involved in Formation of 
KDEL Vesicle and in Efficient Vacuolar Transport of Sulfhydryl-
Endopeptidase". Plant Physiol, 132 (4). 1892-1900. 
443. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. and Vogelstein, B. 
1992  "Amplification of a gene encoding a p53-associated protein in human 
sarcomas". Nature, 358 (6381). 80-83. 
444. Oltval, Z.N., Milliman, C.L. and Korsmeyer, S.J. 1993  "Bcl-2 
heterodimerizes in vivo with a conserved homolog, Bax, that accelerates 
programed cell death". Cell, 74 (4). 609-619. 
[277] 
 
                                                                                                                   Bibliography 
445. Opalka, B., Dickopp, A. and Kirch, H.C. 2002  "Apoptotic Genes in Cancer 
Therapy". Cells Tissues Organs, 172 (2). 126-132. 
446. Opat, A., Houghton, F. and Gleeson, P. 2000  "Medial Golgi but not late 
Golgi glycosyltransferases exist as high molecular weight complexes. Role of 
luminal domain in complex formation and localization". J Biol Chem, 275 
(16). 11836-11845. 
447. Oren, M. and Levine, A.J. 1983  "Molecular cloning of a cDNA specific for 
the murine p53 cellular tumor antigen". Proc Natl Acad Sci U S A, 80 (1). 56-
59. 
448. Ormö, M., Cubitt, A., Kallio, K., Gross, L., Tsien, R. and Remington, S. 1996  
"Crystal structure of the Aequorea victoria green fluorescent protein". Science, 
273 (5280). 1392-1395. 
449. Ostermeyer, A., Runko, E., Winkfield, B., Ahn, B. and Moll, U. 1996  
"Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is 
relocated to the nucleus by a C-terminal peptide". PNAS, 93 (26). 15190-
15194. 
450. Otto, G.P., Wu, M.Y., Kazgan, N., Anderson, O.R. and Kessin, R.H. 2003  
"Macroautophagy Is Required for Multicellular Development of the Social 
Amoeba Dictyostelium discoideum". J Biol Chem, 278 (20). 17636-17645. 
451. Ozaki, T., Yamashita, T. and Ishiguro, S.-i. 2008  "ERp57-associated 
mitochondrial [mu]-calpain truncates apoptosis-inducing factor". Biochim 
Biophys Acta, 1783 (10). 1955-1963. 
452. Paglin, S., Hollister, T., Delohery, T., Hackett, N., McMahill, M., Sphicas, E., 
Domingo, D. and Yahalom, J. 2001  "A Novel Response of Cancer Cells to 
Radiation Involves Autophagy and Formation of Acidic Vesicles". Cancer 
Res, 61 (2). 439-444. 
453. Paglin, S., Lee, N.-Y., Nakar, C., Fitzgerald, M., Plotkin, J., Deuel, B., 
Hackett, N., McMahill, M., Sphicas, E., Lampen, N. and Yahalom, J. 2005  
"Rapamycin-Sensitive Pathway Regulates Mitochondrial Membrane Potential, 
Autophagy, and Survival in Irradiated MCF-7 Cells". Cancer Res, 65 (23). 
11061-11070. 
454. Pan, G., Ni, J., Wei, Y.-F., Yu, G.-l., Gentz, R. and Dixit, V.M. 1997  "An 
Antagonist Decoy Receptor and a Death Domain-Containing Receptor for 
TRAIL". Science, 277 (5327). 815-818. 
455. Pan, G., O'Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R., Ni, J. and 
Dixit, V.M. 1997  "The Receptor for the Cytotoxic Ligand TRAIL". Science, 
276 (5309). 111-113. 
456. Parks, G. and Lamb, R. 1991  "Topology of eukaryotic type II membrane 
proteins: importance of N-terminal positively charged residues flanking the 
hydrophobic domain". Cell, 64 (4). 777-787. 
457. Parmentier, M.-L., Woods, D., Greig, S., Phan, P.G., Radovic, A., Bryant, P. 
and O'Kane, C.J. 2000  "Rapsynoid/Partner of Inscuteable Controls 




                                                                                                                   Bibliography 
458. Paschke, M., Tiede, C. and Höhne, W. 2007  "Engineering a circularly 
permuted GFP scaffold for peptide presentation". J Mol Recognit, 20 (5). 
367-378. 
459. Pastorino, J.G., Chen, S.-T., Tafani, M., Snyder, J.W. and Farber, J.L. 1998  
"The Overexpression of Bax Produces Cell Death upon Induction of the 
Mitochondrial Permeability Transition". J Biol Chem, 273 (13). 7770-7775. 
460. Pecorino, A.L. (ed.), Molecular Biology of Cancer. Oxford Press, 2002. 
461. Pecorino, A.L. (ed.), Molecular Biology of Cancer. Oxford Press, 2005. 
462. Pedersen, P. 2007 "The cancer cell's "power plants" as promising therapeutic 
targets: an overview". J Bioenerg Biomembr, 39 (1). 1-12. 
463. Pelicano, H., Xu, R., M., D., Feng, L., Sasaki, R., Carew, J., Hu, Y., Ramdas, 
L., Hu, L., Keating, M., Zhang, W., Plunkett, W. and Huang, P. 2006  
"Mitochondrial respiration defects in cancer cells cause activation of Akt 
survival pathway through a redox-mediated mechanism". J Cell Biol, 175 (6). 
913-923. 
464. Pellegata, N.S., Cajot, J.F. and Stanbridge, E.J. 1995  "The basic carboxy-
terminal domain of human p53 is dispensable for both transcriptional 
regulation and inhibition of tumor cell growth". Oncogene, 11 (2). 337-349. 
465. Pereira, A., Dalby, B., Stewart, R., Doxsey, S. and Goldstein, L. 1997  " 
Mitochondrial association of a plus end-directed microtubule motor 
expressed during mitosis in Drosophila". J Cell Biol, 136 (5). 1081-1090. 
466. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, 
C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., 
Pergamenschikov, A., Williams, C., Zhu, S.X., Lonning, P.E., Borresen-Dale, 
A.-L., Brown, P.O. and Botstein, D. 2000  "Molecular portraits of human 
breast tumours". Nature, 406 (6797). 747-752. 
467. Persson, S., Rosenquist, M., Knoblach, B., Khosravi-Far, R., Sommarin, M. 
and Michalak, M. 2005  "Diversity of the protein disulfide isomerase family: 
identification of breast tumor induced Hag2 and Hag3 as novel members of 
the protein family". Mol Phylogenet Evol, 36 (3). 734-740. 
468. Persson, S., Rosenquist, M., Knoblach, B., Khosravi-Far, R., Sommarin, M. 
and Michalak, M. 2005  "Diversity of the protein disulfide isomerase family: 
Identification of breast tumor induced Hag2 and Hag3 as novel members of 
the protein family". Mol Phylogenet Evol, 36 (3). 734-740. 
469. Pesanti, E. and Axline, S. 1975  "Phagolysosome formation in normal and 
colchicine-treated macrophages". J Exp Med, 142 (4). 903-913. 
470. Petek, E., Windpassinger, C., Egger, H., Kroisel, P.M. and Wagner, K. 2000  
"Localization 1 of the human anterior gradient-2 gene (AGR2) to 
chromosome band 7p21.3 by radiation hybrid mapping and fluorescencein 
situ hybridisation". Cytogenet Genome Res, 89 (3-4). 141-142. 
471. Peters, R. and Sikorski, R. 1999  "Protein Expression:Folding to Green". 
Science, 285 (5431). 1229-. 
472. Peto, R., Boreham, J., Clarke, M., Davies, C. and Beral, V. 2000  "UK and 
USA breast cancer deaths down 25% in year 2000 at ages 20-69 years". The 
Lancet, 355 (9217). 1822-1822. 
[279] 
 
                                                                                                                   Bibliography 
473. Peyerl, F.W., Dai, S., Murphy, G.A., Crawford, F., White, J., Marrack, P. and 
Kappler, J.W. 2006  "Elucidation of some Bax conformational changes 
through crystallization of an antibody-peptide complex". Cell Death Differ, 
14 (3). 447-452. 
474. Pohler, E., Craig, A.L., Cotton, J., Lawrie, L., Dillon, J.F., Ross, P., 
Kernohan, N. and Hupp, T.R. 2004  "The Barrett's Antigen Anterior 
Gradient-2 Silences the p53 Transcriptional Response to DNA Damage". Mol 
Cell Proteomics, 3 (6). 534-547. 
475. Prasher, D., Eckenrode, V., Ward, W., Prendergast, F. and Cormier, M. 1992  
"Primary structure of the Aequorea victoria green-fluorescent protein". Gene, 
111 (2). 229-233. 
476. Presley, J.F. 2005  "Imaging the secretory pathway: The past and future 
impact of live cell optical techniques". Biochim Biophys Acta, 1744 (3). 259. 
477. Prives, C. 1998  "Signaling to p53: Breaking the MDM2-p53 Circuit". Cell, 
95 (1). 5-8. 
478. Proske, D., Blank, M., Buhmann, R. and Resch, A. 2005  "Aptamers--basic 
research, drug development, and clinical applications". Appl Microbiol 
Biotechnol, 69 (4). 367-374. 
479. Puziss, J.W., Fikes, J.D. and Bassford, P.J. 1989  "Analysis of mutational 
alterations in the hydrophilic segment of the maltose-binding protein signal 
peptide". J Bacteriol, 171 (5). 2303-2311. 
480. Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., 
Eskelinen, E., Mizushima, N., Ohsumi, Y., Cattoretti, G. and Levine, B. 2003  
"Promotion of tumorigenesis by heterozygous disruption of the beclin 1 
autophagy gene." J Clin Invest, 112 (12). 1809-1820. 
481. Rakha, E., Maysa, E., El-Sayed, A.R., Green, A.H.S., Lee, J.F., Robertson, 
I.O. and Ellis, O. 2007  "Prognostic markers in triple-negative breast cancer". 
Cancer  109 (1). 25-32. 
482. Rakha, E., Putti, T.C., Abd El-Rehim, D.M., Paish, C., Green, A.R., Powe, 
D.G., Lee, A.H., Robertson, J.F. and Ellis, I.O. 2006  "Morphological and 
immunophenotypic analysis of breast carcinomas with basal and 
myoepithelial differentiation". J Pathol., 208 (4). 495-506. 
483. Raykhel, I., Alanen, H., Salo, K., Jurvansuu, J., Nguyen, V.D., Latva-Ranta, 
M. and Ruddock, L. 2007  "A molecular specificity code for the three 
mammalian KDEL receptors". J Cell Biol, 179 (6). 1193-1204. 
484. Reid, B.J. 2001  "p53 and neoplastic progression in barrett's esophagus". Am 
J Gastroenterol, 96 (5). 1321-1323. 
485. Reid, B.J., Blount, P.L. and Rabinovitch, P.S. 2003  "Biomarkers in Barrett's 
esophagus". Gastrointest Endosc Clin N Am, 13 (2). 369-397. 
486. Rigobello, M.P., Donella-Deana, A., Cesaro, L. and Bindoli, A. 2001  
"Distribution of protein disulphide isomerase in rat liver mitochondria". 
Biochem J, 356 (2). 567-570. 
487. Rigobello, M.P., Donella-Deana, A., Cesaro, L. and Bindoli, A. 2000  
"Isolation, purification, and characterization of a rat liver mitochondrial 
protein disulfide isomerase". Free Radic Biol Med, 28 (2). 266-272. 
[280] 
 
                                                                                                                   Bibliography 
488. Rigobello, M.P., Turcato, F. and Bindoli, A. 1995  "Inhibition of Rat Liver 
Mitochondrial Permeability Transition by Respiratory Substrates". Arch 
Biochem Biophys, 319 (1). 225-230. 
489. Risbud, M., Fertala, J., Vresilovic, E., Albert, T. and Shapiro, I. 2005 
"Nucleus pulposus cells upregulate PI3K/Akt and MEK/ERK signaling 
pathways under hypoxic conditions and resist apoptosis induced by serum 
withdrawal". Spine, 30 (8). 882-889. 
490. Rizzuto, R., Pinton, P., Carrington, W., Fay, F.S., Fogarty, K.E., Lifshitz, 
L.M., Tuft, R.A. and Pozzan, T. 1998  "Close Contacts with the Endoplasmic 
Reticulum as Determinants of Mitochondrial Ca2+ Responses". Science, 280 
(5370). 1763-1766. 
491. Roach, H.I. and Clarke, N.M.P. 2000  "Physiological cell death of 
chondrocytes in vivo is not confined to apoptosis". J Bone Joint Surg Br, 82-
B (4). 601-613. 
492. Robertson, D.L. and Joyce, G.F. 1990  "Selection in vitro of an RNA enzyme 
that specifically cleaves single-stranded DNA". Nature, 344 (6265). 467-468. 
493. Robertson, D.W., Katzenellenbogen, J.A., Long, D.J., Rorke, E.A. and 
Katzenellenbogen, B.S. 1982  "Tamoxifen antiestrogens. A comparison of the 
activity, pharmacokinetics, and metabolic activation of the cis and trans 
isomers of tamoxifen". J Steroid Biochem, 16 (1). 1-13. 
494. Rojo, M., Legros, F., Chateau, D. and Lombes, A. 2002  "Membrane 
topology and mitochondrial targeting of mitofusins, ubiquitous mammalian 
homologs of the transmembrane GTPase Fzo". J Cell Sci, 115 (8). 1663-1674. 
495. Rokhlin, O.W., Glover, R.B., Guseva, N.V., Taghiyev, A.F., Kohlgraf, K.G. 
and Cohen, M.B. 2006  "Mechanisms of Cell Death Induced by Histone 
Deacetylase Inhibitors in Androgen Receptor-Positive Prostate Cancer Cells". 
Mol Cancer Res, 4 (2). 113-123. 
496. Rosenfeld, M.G. and Glass, C.K. 2001  "Coregulator Codes of 
Transcriptional Regulation by Nuclear Receptors". J Biol Chem, 276 (40). 
36865-36868. 
497. Roth, J., M., D., Freedman, D., T., S. and Levine, A. 1998  " Nucleo-
cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 
protein via a pathway used by the human immunodeficiency virus rev 
protein". EMBO J, 17 (2). 554-564. 
498. Rousseau, B., Ménard, L., Haurie, V., Taras, D., JF., B., Moreau Gaudry, F., 
Metzler, P., Hugues, M., Boyault, S., Lemière, S., Canron, X., Costet, P., 
Cole, M., Balabaud, C., Bioulac Sage, P., Zucman Rossi, J. and Rosenbaum, 
J. 2007  "Overexpression and role of the ATPase and putative DNA helicase 
RuvB-like 2 in human hepatocellular carcinoma". Hepatology, 46 (4). 1108-
1118. 
499. Runnebaum, I., Nagarajan, M., Bowman, M., Soto, D. and Sukumar, S. 1991  
"Mutations in p53 as potential molecular markers for human breast cancer". 
Proc Natl Acad Sci U S A, 88 (23). 10657-10661. 
500. Russell, S., Hickey, G., Lowry, W., White, P. and Atkinson, R. 1990  " Allele 
loss from chromosome 17 in ovarian cancer." Oncogene, 5 (10). 1581-1583. 
[281] 
 
                                                                                                                   Bibliography 
501. Russo, C.A., Weber, T.K., Volpe, C.M., Stoler, D.L., Petrelli, N.J., 
Rodriguez-Bigas, M., Burhans, W.C. and Anderson, G.R. 1995  "An Anoxia 
Inducible Endonuclease and Enhanced DNA Breakage as Contributors to 
Genomic Instability in Cancer". Cancer Res, 55 (5). 1122-1128. 
502. Ryan, J.J., Prochownik, E., Gottlieb, C.A., Apel, I.J., Merino, R., Nu, G. and 
Clarke, M.F. 1994  "c-myc and bcl-2 modulate p53 function by altering p53 
subcellular trafficking during the cell cycle". PNAS, 91 (13). 5878-5882. 
503. Ryerse, J.S. 1979  "Developmental changes in Malpighian tubule cell 
structure". Tissue Cell, 11 (3). 533-551. 
504. Sabbatini, P. and McCormick, F. 1999  "Phosphoinositide 3-OH Kinase 
(PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally 
Dependent Apoptosis". J Biol Chem, 274 (34). 24263-24269. 
505. Saito, H., Inazawa, J., Saito, S., Kasumi, F., Koi, S., Sagae, S., Kudo, R., 
Saito, J., Noda, K. and Nakamura, Y. 1993 "Detailed deletion mapping of 
chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 
often and commonly deleted in tumors." Cancer Res, 53 (14). 3382-3385. 
506. Saito, S.i., Goodarzi, A.A., Higashimoto, Y., Noda, Y., Lees-Miller, S.P., 
Appella, E. and Anderson, C.W. 2002  "ATM Mediates Phosphorylation at 
Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation". J 
Biol Chem, 277 (15). 12491-12494. 
507. Sakaguchi, K., Herrera, J.E., Saito, S.i., Miki, T., Bustin, M., Vassilev, A., 
Anderson, C.W. and Appella, E. 1998  "DNA damage activates p53 through a 
phosphorylation-acetylation cascade". Genes Dev, 12 (18). 2831-2841. 
508. Salih, A., Larkum, A., Cox, G., Kuhl, M. and Hoegh-Guldberg, O. 2000  
"Fluorescent pigments in corals are photoprotective". Nature, 408 (6814). 
850-853. 
509. Salvesen, G.S. and Dixit, V.M. 1999  "Caspase activation: The induced-
proximity model". PNAS, 96 (20). 10964-10967. 
510. Samuels Lev, Y., O'Connor, D.J., Bergamaschi, D., Trigiante, G., Hsieh, J.-
K., Zhong, S., Campargue, I., Naumovski, L., Crook, T. and Lu, X. 2001  
"ASPP Proteins Specifically Stimulate the Apoptotic Function of p53". Mol 
Cell, 8 (4). 781-794. 
511. Sansome, C., Zaika, A., Marchenko, N.D. and Moll, U.M. 2001  "Hypoxia 
death stimulus induces translocation of p53 protein to mitochondria: 
Detection by immunofluorescence on whole cells". FEBS Letters, 488 (3). 
110-115. 
512. Saran, D., Frank, J. and Burke, D.H. 2003  "The tyranny of adenosine 
recognition among RNA aptamers to coenzyme A". BMC Evol Biol, 3. 26. 
513. Sassanfar, M. and Szostak, J.W. 1993  "An RNA motif that binds ATP". 
Nature, 364 (6437). 550-553. 
514. Satoh, M., Hamamoto, T., Seo, N., Kagawa, Y. and Endo, H. 2003  
"Differential sublocalization of the dynamin-related protein OPA1 isoforms 
in mitochondria". Biochem Biophys Res Commun, 300 (2). 482-493. 
515. Saville, G.P., Patmanidi, A.L., Possee, R.D. and King, L.A. 2004  "Deletion 
of the Autographa californica nucleopolyhedrovirus chitinase KDEL motif 
[282] 
 
                                                                                                                   Bibliography 
and in vitro and in vivo analysis of the modified virus". J Gen Virol, 85 (4). 
821-831. 
516. Scarlatti, F., Maffei, R., Beau, I., Codogno, P. and Ghidoni, R. 2008  "Role of 
non-canonical Beclin 1-independent autophagy in cell death induced by 
resveratrol in human breast cancer cells". Cell Death Differ, 15 (8). 1318-
1329. 
517. Schaefer, M., Petronczki, M., Dorner, D., Forte, M. and Knoblich, J.A. 2001  
"Heterotrimeric G Proteins Direct Two Modes of Asymmetric Cell Division 
in the Drosophila Nervous System". Cell, 107 (2). 183-194. 
518. Schlumpberger, M., Schaeffeler, E., Straub, M., Bredschneider, M., Wolf, 
D.H. and Thumm, M. 1997  "AUT1, a gene essential for autophagocytosis in 
the yeast Saccharomyces cerevisiae". J Bacteriol, 179 (4). 1068-1076. 
519. Scorrano, L., Oakes, S.A., Opferman, J.T., Cheng, E.H., Sorcinelli, M.D., 
Pozzan, T. and Korsmeyer, S.J. 2003  "BAX and BAK Regulation of 
Endoplasmic Reticulum Ca2+: A Control Point for Apoptosis". Science, 300 
(5616). 135-139. 
520. Screaton, G.R., Mongkolsapaya, J., Xu, X.-N., Cowper, A.E., McMichael, 
A.J. and Bell, J.I. 1997  "TRICK2, a new alternatively spliced receptor that 
transduces the cytotoxic signal from TRAIL". Current Biology, 7 (9). 693-
696. 
521. Semenza, J.C., Hardwick, K.G., Dean, N. and Pelham, H.R.B. 1990  "ERD2, 
a yeast gene required for the receptor-mediated retrieval of luminal ER 
proteins from the secretory pathway". Cell, 61 (7). 1349-1357. 
522. Sevier, C.S. and Kaiser, C.A. 2002  "Formation and transfer of disulphide 
bonds in living cells". Nat Rev Mol Cell Biol, 3 (11). 836-847. 
523. Shamu, C.E., Cox, J.S. and Walter, P. 1994  "The unfolded-protein-response 
pathway in yeast". Trends Cell Biol, 4 (2). 56-60. 
524. Shaulsky, G., Ben Zeev, A. and Rotter, V. 1990  " Subcellular distribution of 
the p53 protein during the cell cycle of Balb/c 3T3 cells". Oncogene, 5 (11). 
1707-1711. 
525. Shaulsky, G., Goldfinger, N., Peled, A. and Rotter, V. 1991  " Involvement of 
wild-type p53 protein in the cell cycle requires nuclear localization". Cell 
Growth Differ, 2 (12). 661-667. 
526. Shaulsky, G., Goldfinger, N., Tosky, M., Levine, A. and Rotter, V. 1991  
"Nuclear localization is essential for the activity of p53 protein". Oncogene, 6 
(11). 2055-2065. 
527. Shaw, A., Rottier, P. and Rose, J. 1988  "Evidence for the loop model of 
signal-sequence insertion into the endoplasmic reticulum". Proc Natl Acad 
Sci U S A, 85 (20). 7592-7596. 
528. Sheahan, M., Rose, R. and McCurdy, D. 2004  "Organelle inheritance in 
plant cell division: the actin cytoskeleton is required for unbiased inheritance 
of chloroplasts, mitochondria and endoplasmic reticulum in dividing 
protoplasts". Plant J, 37 (3). 379-390. 
[283] 
 
                                                                                                                   Bibliography 
529. Shen, X., Mizuguchi, G., Hamiche, A. and Wu, C. 2000  "A chromatin 
remodelling complex involved in transcription and DNA processing". Nature, 
406 (6795). 541-544. 
530. Shieh, S.Y., Taya, Y. and Prives, C. 1999  "DNA damage-inducible 
phosphorylation of p53 at N-terminal sites including a novel site, Ser20, 
requires tetramerization." EMBO J, 18 (7). 1815-1823. 
531. Shigeaki, K., Hideki, E., Yoshikazu, M., Takuya, K., Shimami, U., Haruna, 
S., Shoichi, M., Yukiko, G., Eisuke, N., Hiroyuki, K., Daniel, M. and Pierre, 
C. 1995  "Activation of the Estrogen Receptor Through Phosphorylation by 
Mitogen-Activated Protein Kinase". Science, 270 (5241). 1491 - 1494. 
532. Shih, L.-J., Lu, Y.-F., Chen, Y.-H., Lin, C.-C., Chen, J.-A. and Hwang, S.-
P.L. 2007  "Characterization of the agr2 gene, a homologue of X. laevis 
anterior gradient 2, from the zebrafish, Danio rerio". Gene Expr Patterns, 7 
(4). 452-460. 
533. Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, T., Arakawa-Kobayashi, 
S., Thompson, C.B. and Tsujimoto, Y. 2004  "Role of Bcl-2 family proteins 
in a non-apoptotic programmed cell death dependent on autophagy genes". 
Nat Cell Biol, 6 (12). 1221-1228. 
534. Shimizu, S., Narita, M., Tsujimoto, Y. and Tsujimoto, Y. 1999  "Bcl-2 family 
proteins regulate the release of apoptogenic cytochrome c by the 
mitochondrial channel VDAC". Nature, 399 (6735). 483-487. 
535. Shimomura, O. 2005  "The discovery of aequorin and green fluorescent 
protein". J Microsc, 217 (Pt 1). 
536. Shinagawa, H. and Iwasaki, H. 1996  "Processing the holliday junction in 
homologous recombination". Trends Biochem Sci, 21 (3). 107-111. 
537. Shrestha, S. and Deo, S. 2006  "Anthozoa red fluorescent protein in 
biosensing". Anal Bioanal Chem, 386 (3). 515-524. 
538. Sigala, B., Edwards, M., Puri, T. and Tsaneva, I.R. 2005  "Relocalization of 
human chromatin remodeling cofactor TIP48 in mitosis". Exp Cell Res, 310 
(2). 357. 
539. Siliciano, J.D., Canman, C.E., Taya, Y., Sakaguchi, K., Appella, E. and 
Kastan, M.B. 1997  "DNA damage induces phosphorylation of the amino 
terminus of p53". Genes Dev, 11 (24). 3471-3481. 
540. Sirvent, J., Fortuño-Mar, A., Olona, M. and Orti, A. 2001  " Prognostic value 
of p53 protein expression and clinicopathological factors in infiltrating ductal 
carcinoma of the breast. A study of 192 patients." Histol Histopathol, 16 (1). 
99-106. 
541. Skliris, G., Leygue, E., Watson, P. and Murphy, L. 2008  " Estrogen receptor 
alpha negative breast cancer patients: estrogen receptor beta as a therapeutic 
target". J Steroid Biochem Mol Biol, 109 (1-2). 1-10. 
542. Skulachev, V.P. 1996  "Why are mitochondria involved in apoptosis? 
Permeability transition pores and apoptosis as selective mechanisms to 




                                                                                                                   Bibliography 
543. Slee, E.A., Harte, M.T., Kluck, R.M., Wolf, B.B., Casiano, C.A., Newmeyer, 
D.D., Wang, H.-G., Reed, J.C., Nicholson, D.W., Alnemri, E.S., Green, D.R. 
and Martin, S.J. 1999  "Ordering the Cytochrome c-initiated Caspase 
Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a 
Caspase-9-dependent Manner". J Biol Chem, 144 (2). 281-292. 
544. Smirnov, D.R., Zweitzig, B.W., Foulk, M., Miller, C., Doyle, G.V., Pienta, 
K.J., Meropol, N.J., Weiner, L.M., Cohen, S.J., Moreno, J.G., Connelly, M.C., 
Terstappen, L.W.M.M. and O Hara, S.M. 2005 "Global gene expression 
profiling of circulating tumor cells". Cancer Res, 65 (12). 4993-4997. 
545. Smirnova, E., Griparic, L., Shurland, D.-L. and Van der Bliek, A.M. 2001  
"Dynamin-related Protein Drp1 Is Required for Mitochondrial Division in 
Mammalian Cells". Mol Biol Cell, 12 (8). 2245-2256. 
546. Smith, C.A., Farrah, T. and Goodwin, R.G. 1994  "The TNF receptor 
superfamily of cellular and viral proteins: Activation, costimulation, and 
death". Cell, 76 (6). 959-962. 
547. Soanes, K.H., Figuereido, K., Richards, R.C., Mattatall, N.R. and Ewart, K.V. 
2004  "Sequence and expression of C-type lectin receptors in Atlantic salmon 
( Salmo salar)". Immunogenetics, 56 (8). 572-584. 
548. Soengas, M.S., Alarcón, R.M., Yoshida, H., Giaccia, A.J., Hakem, R., Mak, 
T.W. and Lowe, S.W. 1999  "Apaf-1 and Caspase-9 in p53-Dependent 
Apoptosis and Tumor Inhibition". Science, 284 (5411). 156-159. 
549. Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., 
Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, H., 
Matese, J.C., Brown, P.O., Botstein, D., Lonning, P.E. and Borresen-Dale, 
A.-L. 2001  "Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications". PNAS, 98 (19). 10869-10874. 
550. Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, 
S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., Perou, C.M., Lonning, 
P.E., Brown, P.O., Borresen-Dale, A.-L. and Botstein, D. 2003  "Repeated 
observation of breast tumor subtypes in independent gene expression data 
sets". PNAS, 100 (14). 8418-8423. 
551. Spänkuch, B. and Strebhardt, K. 2008  "Combinatorial application of nucleic 
acid-based agents targeting protein kinases for cancer treatment". Curr 
Pharm Des, 14 (11). 1098-1112. 
552. Spiess, M. 1995  "Heads or tails:what determines the orientation of proteins 
in the membrane". FEBS Letters, 369 (1). 76-79. 
553. Srinivasula, S.M., Ahmad, M., Fernandes-Alnemri, T. and Alnemri, E.S. 
1998  "Autoactivation of Procaspase-9 by Apaf-1-Mediated Oligomerization". 
Mol Cell, 1 (7). 949-957. 
554. Srinivasula, S.M., Fernandes-Alnemri, T., Zangrilli, J., Robertson, N., 
Armstrong, R.C., Wang, L., Trapani, J.A., Tomaselli, K.J., Litwack, G. and 
Alnemri, E.S. 1996  "The Ced-3/Interleukin 1beta Converting Enzyme-like 
Homolog Mch6 and the Lamin-cleaving Enzyme Mch2alpha Are Substrates 
for the Apoptotic Mediator CPP32". J Biol Chem, 271 (43). 27099-27106. 
[285] 
 
                                                                                                                   Bibliography 
555. Srinivasula, S.M., Manzoor., A., Fernandes-Alnemri, T., Litwack, G. and 
Alnemri, E.S. 1996  "Molecular ordering of the Fas-apoptotic pathway: The 
Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates 
multiple Ced-3/ICE-like cysteine proteases". PNAS, 93 (25). 14486-14491. 
556. Srisawat, C., Goldstein, I.J. and Engelke, D.R. 2001  "Sephadex-binding 
RNA ligands: rapid affinity purification of RNA from complex RNA 
mixtures". Nucl Acids Res, 29 (2). e4. 
557. Stendahl, M., Kronblad, A., Rydén, L., Emdin, S., Bengtsson, N. and 
Landberg, G. 2004  "Cyclin D1 overexpression is a negative predictive factor 
for tamoxifen response in postmenopausal breast cancer patients". Br J 
Cancer, 90 (10). 1942-1948. 
558. Sternsdorf, T., Guldner, H., Szostecki, C., Grötzinger, T. and Will, H. 1995  
"Two nuclear dot-associated proteins, PML and Sp100, are often co-
autoimmunogenic in patients with primary biliary cirrhosis". Scand J 
Immunol, 42 (2). 257-268. 
559. Stewart, N., Hicks, G., Paraskevas, F. and Mowat, M. 1995  "Evidence for a 
second cell cycle block at G2/M by p53". Oncogene, 10 (1). 109-115. 
560. Stoltenburg, R., Reinemann, C. and Strehlitz, B. 2007  "SELEX. A 
(r)evolutionary method to generate high-affinity nucleic acid ligands". 
Biomol Eng, 24 (4). 381-403. 
561. Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., 
Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., 
Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, 
H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., 
Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, 
M.F., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Usdin, T.B., 
Toshiyuki, S., Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, 
G.J., Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J., McKernan, 
K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., 
Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalon, D.K., Muzny, D.M., 
Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Ketteman, M., 
Madan, A., Rodrigues, S., Sanchez, A., Whiting, M., Young, A.C., 
Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, 
E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, 
R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smailus, D.E., 
Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A. 2002  "Generation 
and initial analysis of more than 15,000 full-length human and mouse cDNA 
sequences". Proc Natl Acad Sci U S A, 99 (26). 16899-16903. 
562. Strawbridge, A.B. and Blum, J.S. 2007  "Autophagy in MHC class II antigen 
processing". Curr Opinn in Immunol, 19 (1). 87-92. 
563. Subramaniam, N., Treuter, E. and Okret, S. 1999  "Receptor Interacting 
Protein RIP140 Inhibits Both Positive and Negative Gene Regulation by 
Glucocorticoids". J Biol Chem, 274 (25). 18121-18127. 
564. Summerhayes, I., Wong, D. and Chen, L. 1983  " Effect of microtubules and 
intermediate filaments on mitochondrial distribution". J Cell Sci, 61. 87-105. 
[286] 
 
                                                                                                                   Bibliography 
565. Sundararajan, R. and White, E. 2001  "E1B 19K Blocks Bax Oligomerization 
and Tumor Necrosis Factor Alpha-Mediated Apoptosis". J Virol, 75 (16). 
7506-7516. 
566. Suzuki, K., Takayoshi, K., Yoshiaki, K., Noboru, M., Takeshi, N. and 
Yoshinori, O. 2001  "The pre-autophagosomal structure organized by 
concerted functions of APG genes is essential for autophagosome formation." 
Embo J 20. 5971-5981. 
567. Takahashi, A., Alnemri, E.S., Lazebnik, Y.A., Fernandes-Alnemri, T., 
Litwack, G., Moir, R.D., Goldman, R.D., Poirier, G.G., Kaufmann, S.H. and 
Earnshaw, W.C. 1996  "Cleavage of lamin A by Mch2alpha but not CPP32: 
Multiple interleukin 1beta -converting enzyme-related proteases with distinct 
substrate recognition properties are active in apoptosis". PNAS, 93 (16). 
8395-8400. 
568. Takimoto, G., Graham, J., Jackson, T., Tung, L., Powell, R., Horwitz, L. and 
Horwitz, K. 1999  "Tamoxifen resistant breast cancer: coregulators determine 
the direction of transcription by antagonist-occupied steroid receptors". J 
Steroid Biochem Mol Biol, 69 (1-6). 45-50. 
569. Tang, J., Yu, T., Guo, L., Xie, J., Shao, N. and He, Z. 2007  "In vitro 
selection of DNA aptamer against abrin toxin and aptamer-based abrin direct 
detection". Biosens Bioelectron, 22 (11). 2456-2463. 
570. Tao, W. and Levine, A.J. 1999  "Nucleocytoplasmic shuttling of oncoprotein 
Hdm2 is required for Hdm2-mediated degradation of p53". PNAS, 96 (6). 
3077-3080. 
571. Tartaglia, L.A., Ayres, T.M., Wong, G.H.W. and Goeddel, D.V. 1993  "A 
novel domain within the 55 kd TNF receptor signals cell death". Cell, 74 (5). 
845-853. 
572. Tazawa, H., Osman, W., Shoji, Y., Treuter, E., Gustafsson, J.-A. and 
Zilliacus, J. 2003  "Regulation of Subnuclear Localization Is Associated with 
a Mechanism for Nuclear Receptor Corepression by RIP140". Mol Cell Biol, 
23 (12). 4187-4198. 
573. Teasdale, R. and Jackson, M. 1996  " Signal-mediated sorting of membrane 
proteins between the endoplasmic reticulum and the golgi apparatus". Annu 
Rev Cell Dev Biol, 12. 27-54. 
574. Teng, Y., Liu, Q., Ma, J., Liu, F., Han, Z., Wang, Y. and Wang, W. 2006  
"Cloning, expression and characterization of a novel human CAP10-like gene 
hCLP46 from CD34+ stem/progenitor cells". Gene, 371 (1). 7-15. 
575. Terasaki, M., Chen, L. and Fujiwara, K. 1986  "Microtubules and the 
endoplasmic reticulum are highly interdependent structures". J Cell Biol, 103 
(4). 1557-1568. 
576. Thomas, C.J., Brown, H.L., Hawes, C.R., Lee, B.Y., Min, M.-K., King, L.A. 
and Possee, R.D. 1998  "Localization of a Baculovirus-Induced Chitinase in 
the Insect Cell Endoplasmic Reticulum". J Virol, 72 (12). 10207-10212. 
577. Thompson, D. and Weigel, R. 1998  "hAG-2, the human homologue of the 
Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen 
[287] 
 
                                                                                                                   Bibliography 
receptor in breast cancer cell lines". Biochem Biophys Res Commun, 251 (1). 
111-116. 
578. Thomson, C.S., Brewster, D.H., Dewar, J.A. and Twelves, C.J. 2004  
"Improvements in survival for women with breast cancer in Scotland between 
1987 and 1993: impact of earlier diagnosis and changes in treatment". 
European Journal of Cancer, 40 (5). 743-753. 
579. Thorén, P., Persson, D., Karlsson, M. and Nordén, B. 2000  "The 
antennapedia peptide penetratin translocates across lipid bilayers - the first 
direct observation". FEBS Letters, 482 (3). 265-268. 
580. Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper, D.M., Timkey, T., 
Garcia-Calvo, M., Houtzager, V.M., Nordstrom, P.A., Roy, S., Vaillancourt, 
J.P., Chapman, K.T. and Nicholson, D.W. 1997  "A Combinatorial Approach 
Defines Specificities of Members of the Caspase Family and Granzyme B. 
Functional Relationships established for key mediators of apoptosis." J Biol 
Chem, 272 (29). 17907-17911. 
581. Tidow, H., Melero, R., Mylonas, E., Freund, S.M.V., Grossmann, J.G., 
Carazo, J.M., Svergun, D.I., Valle, M. and Fersht, A.R. 2007  "From the 
Cover: Quaternary structures of tumor suppressor p53 and a specific p53 
DNA complex". Proc Natl Acad Sci U S A, 104 (30). 12324-12329. 
582. Tilly, K.I., Banerjee, S., Banerjee, P.P. and Tilly, J.L. 1995  "Expression of 
the p53 and Wilms' tumor suppressor genes in the rat ovary: gonadotropin 
repression in vivo and immunohistochemical localization of nuclear p53 
protein to apoptotic granulosa cells of atretic follicles". Endocrinology, 136 
(4). 1394-1402. 
583. Tiwari, B.S., Belenghi, B. and Levine, A. 2002  "Oxidative Stress Increased 
Respiration and Generation of Reactive Oxygen Species, Resulting in ATP 
Depletion, Opening of Mitochondrial Permeability Transition, and 
Programmed Cell Death". Plant Physiol, 128 (4). 1271-1281. 
584. Torii, I., Morikawa, S., Nagasaki, M., Nokano, A. and Morikawa, K. 2001  
"Differential endocytotic characteristics of a novel human B/DC cell line 
HBM-Noda: effective macropinocytic and phagocytic function rather than 
scavenging function". Immunology, 103 (1). 70-80. 
585. Torregrosa, D., Bolufer, P., Lluch, A., Antonio López, J., Barragán, E., Ruiz, 
A., Guillem, V., Munárriz, B. and García Conde, J. 1997  "Prognostic 
significance of c-erbB-2/neu amplification and epidermal growth factor 
receptor (EGFR) in primary breast cancer and theor relation to estradiol 
receptor (ER) status". Clinica Chimica Acta, 262 (1-2). 99-119. 
586. Townsley, F., Wilson, D. and Pelham, H. 1993  " Mutational analysis of the 
human KDEL receptor: distinct structural requirements for Golgi retention, 
ligand binding and retrograde transport". EMBO J, 12 (7). 2821-2829. 
587. Travers, K.J., Patil, C.K., Wodicka, L., Lockhart, D.J., Weissman, J.S. and 
Walter, P. 2000  "Functional and Genomic Analyses Reveal an Essential 
Coordination between the Unfolded Protein Response and ER-Associated 
Degradation". Cell, 101 (3). 249-258. 
[288] 
 
                                                                                                                   Bibliography 
588. Treuter, E., Albrektsen, T., Johansson, L., Leers, J. and Gustafsson, J.A. 1998  
"A Regulatory Role for RIP140 in Nuclear Receptor Activation". Mol 
Endocrinol, 12 (6). 864-881. 
589. Tsujimoto, Y. and Shimizu, S. 2000  "Bcl-2 family: Life-or-death switch". 
FEBS Letters, 466 (1). 6-10. 
590. Tsukada, M. and Ohsumi, Y. 1993  "Isolation and characterization of 
autophagy-defective mutants of Saccharomyces cerevisiae". FEBS Letters, 
333 (1-2). 169-174. 
591. Tucker, C.E., Chen, L.S., Judkins, M.B., Farmer, J.A., Gill, S.C. and Drolet, 
D.W. 1999  "Detection and plasma pharmacokinetics of an anti-vascular 
endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus 
monkeys". J Chromatogr B Biomed Sci Appl, 732 (1). 203-212. 
592. Tuerk, C. and Gold, L. 1990  "Systematic evolution of ligands by exponential 
enrichment: RNA ligands to bacteriophage T4 DNA polymerase". Science, 
249 (4968). 505-510. 
593. Turano, C., Coppari, S., Altieri, F. and Ferraro, A. 2002  "Proteins of the PDI 
family: unpredicted non-ER locations and functions". J Cell Physiol, 193 (2). 
154-163. 
594. Van de Rijn, M., Perou, C.M., Tibshirani, R., Haas, P., Kallioniemi, O., 
Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Kochli, O.R., Mross, F., 
Dieterich, H., Seitz, R., Ross, D., Botstein, D. and Brown, P. 2002  
"Expression of Cytokeratins 17 and 5 Identifies a Group of Breast 
Carcinomas with Poor Clinical Outcome". Am J Pathol. , 161 (6). 1991-1996. 
595. Van Gestel, K., Köhler, R. and Verbelen, J. 2002 "Plant mitochondria move 
on F-actin, but their positioning in the cortical cytoplasm depends on both F-
actin and microtubules". J Exp Bot, 53 (369). 659-667. 
596. Vander Heiden, M.G., Chandel, N.S., Williamson, E.K., Schumacker, P.T. 
and Thompson, C.B. 1997  "Bcl-xL Regulates the Membrane Potential and 
Volume Homeostasis of Mitochondria". Cell, 91 (5). 627-637. 
597. Vennema, H., Heijnen, L., Rottier, P.J., Horzinek, M.C. and Spaan, W.J. 
1992  "A novel glycoprotein of feline infectious peritonitis coronavirus 
contains a KDEL-like endoplasmic reticulum retention signal". J Virol, 66 (8). 
4951-4956. 
598. Ventura, A.C. and Merajver, S.D. 2008  "Genetic Determinants of Aggressive 
Breast Cancer". Annual Review of Medicine, 59 (1). 199-212. 
599. Vercammen, D., Beyaert, R., Denecker, G., Goossens, V., Van Loo, G., 
Declercq, W., Grooten, J., Fiers, W. and Vandenabeele, P. 1998  "Inhibition 
of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by 
Tumor Necrosis Factor". J Exp Med, 187 (9). 1477-1485. 
600. Verkhusha, V.V. and Lukyanov, K.A. 2004  "The molecular properties and 
applications of Anthozoa fluorescent proteins and chromoproteins". Nat 
Biotech, 22 (3). 289-296. 
601. Vitale, A. and Denecke, J. 1999  "The endoplasmic reticulum-gateway of the 
secretory pathway". Plant Cell, 11 (4). 615-628. 
[289] 
 
                                                                                                                   Bibliography 
602. Vogelstein, B., Lane, D. and Levine, A.J. 2000  "Surfing the p53 network". 
Nature, 408 (6810). 307-310. 
603. Von Heijne, G. 1985  "Signal sequences : The limits of variation". J Mol Biol, 
184 (1). 99-105. 
604. Wahl, G.M. and Carr, A.M. 2001  "The evolution of diverse biological 
responses to DNA damage: insights from yeast and p53". Nat Cell Biol, 3 
(12). E277-E286. 
605. Waldo, G.S., Standish, B.M., Berendzen, J. and Terwilliger, T.C. 1999  
"Rapid protein-folding assay using green fluorescent protein". Nat Biotech, 
17 (7). 691-695. 
606. Wallis, M.G., von Ahsen, U., Schroeder, R. and Famulok, M. 1995  "A novel 
RNA motif for neomycin recognition". Chem Biol, 2 (8). 543-552. 
607. Walter, P. and Johnson, A. 1994  "Signal sequence recognition and protein 
targeting to the endoplasmic reticulum membrane". Annu Rev Cell Biol, 10. 
87-119. 
608. Wang, C.W. and Klionsky, D.J. 2003  "The molecular mechanism of 
autophagy". Mol Med, 9 (3-4). 65-76. 
609. Wang, S., Konorev, E.A., Kotamraju, S., Joseph, J., Kalivendi, S. and 
Kalyanaraman, B. 2004  "Doxorubicin Induces Apoptosis in Normal and 
Tumor Cells via Distinctly Different Mechanisms". J. Biol. Chem., 279 (24). 
25535-25543. 
610. Wang, X., Pai, J.-t., Wiedenfeld, E.A., Medina, J.C., Slaughter, C.A., 
Goldstein, J.L. and Brown, M.S. 1995  "Purification of an Interleukin-
1[IMAGE] Converting Enzyme-related Cysteine Protease That Cleaves 
Sterol Regulatory Element-binding Proteins between the Leucine Zipper and 
Transmembrane Domains". J Biol Chem, 270 (30). 18044-18050. 
611. Wang, Z., Hao, Y. and Lowe, A.W. 2008  "The Adenocarcinoma-Associated 
Antigen, AGR2, Promotes Tumor Growth, Cell Migration, and Cellular 
Transformation". Cancer Res, 68 (2). 492-497. 
612. Wayne, W.K., Devon, A., Thompson, A., Renee, V.H. and Ronald, J.W. 1998  
"Differential screening and suppression subtractive hybridization identified 
genes differentially expressed in an estrogen receptor-positive breast 
carcinoma cell line". Nucleic Acids Res, 26 (4). 1116-1123. 
613. Wei, L.-N., Farooqui, M. and Hu, X. 2001  "Ligand-dependent Formation of 
Retinoid Receptors, Receptor-interacting Protein 140 (RIP140), and Histone 
Deacetylase Complex Is Mediated by a Novel Receptor-interacting Motif of 
RIP140". J Biol Chem, 276 (19). 16107-16112. 
614. Wei, X., Yu, Z.K., Ramalingam, A., Grossman, S.R., Yu, J.H., Bloch, D.B. 
and Maki, C.G. 2003  "Physical and Functional Interactions between PML 
and MDM2". J Biol Chem, 278 (31). 29288-29297. 
615. Weinberg, R. 1991  "Tumor suppressor genes". Science, 254 (5035). 1138-
1146. 
616. Weir, B. and Yaffe, M. 2004  "Mmd1p, a novel, conserved protein essential 
for normal mitochondrial morphology and distribution in the fission yeast 
Schizosaccharomyces pombe". Mol Biol Cell, 15 (4). 1656-1665. 
[290] 
 
                                                                                                                   Bibliography 
617. Weis, K. 1998  "Importins and exportins: how to get in and out of the 
nucleus". Trends Biochem Sci, 23 (5). 185-189. 
618. Weisleder, N., Taffet, G. and Capetanaki, Y. 2004  " Bcl-2 overexpression 
corrects mitochondrial defects and ameliorates inherited desmin null 
cardiomyopathy". Proc Natl Acad Sci U S A, 101 (3). 769-774. 
619. West, S.C. 1997  "Processing of recombination intermediates by the RuvABC 
proteins". Annu Rev Genet, 31 (1). 213-244. 
620. Whenham, N., D'Hondt, V. and Piccart, M. 2008  "HER2-positive breast 
cancer: from trastuzumab to innovatory anti-HER2 strategies". Clin Breast 
Cancer, 8 (1). 38-49. 
621. Wiebe, V., Osborne, C., Fuqua, S. and DeGregorio, M. 1993  "Tamoxifen 
resistance in breast cancer". Crit Rev Oncol Hematol, 14 (3). 173-188. 
622. Wilson, D., Lewis, M. and Pelham, H. 1993  "pH-dependent binding of 
KDEL to its receptor in vitro". J Biol Chem, 268 (10). 7465-7468. 
623. Wiman, K. 2006  "Strategies for therapeutic targeting of the p53 pathway in 
cancer". Cell Death Differ, 13 (6). 921-926. 
624. Wood, M.A., McMahon, S.B. and Cole, M.D. 2000  "An ATPase/Helicase 
Complex Is an Essential Cofactor for Oncogenic Transformation by c-Myc". 
Mol Cell, 5 (2). 321-330. 
625. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. 1993  "The p53-mdm-2 
autoregulatory feedback loop". Genes Dev, 7 (7a). 1126-1132. 
626. Wu, Y., Tan, H., Huang, Q., Kim, Y., Pan, N., Ong, W., Liu, Z., Ong, C. and 
Shen, H. 2008  " Autophagy plays a protective role during zVAD-induced 
necrotic cell death". Autophagy, 4 (4). 457-466. 
627. Wyllie, A.H. 1997  "Apoptosis: an overview". Br Med Bull., 53 (3). 451-465. 
628. Xu, Y., Piston, D.W. and Johnson, C.H. 1999  "A bioluminescence resonance 
energy transfer (BRET) system: Application to interacting circadian clock 
proteins". Proc Natl Acad Sci U S A, 96 (1). 151-156. 
629. Yaffe, M., Harata, D., Verde, F., Eddison, M., T., T. and Nurse, P. 1996  
"Microtubules mediate mitochondrial distribution in fission yeast". Proc Natl 
Acad Sci U S A, 93 (21). 11664-11668. 
630. Yaffe, M., Stuurman, N. and Vale, R. 2003  "Mitochondrial positioning in 
fission yeast is driven by association with dynamic microtubules and mitotic 
spindle poles". Proc Natl Acad Sci U S A, 100 (20). 11424-11428. 
631. Yamamoto, K., Fujii, R., Toyofuku, Y., Saito, T., Koseki, H., Hsu, V. and 
Aoe, T. 2001  "The KDEL receptor mediates a retrieval mechanism that 
contributes to quality control at the endoplasmic reticulum". EMBO J, 20 (12). 
3082-3091. 
632. Yang, D.C., Head, J.F. and Elliott, R.L. 2002  "Gene targets of antisense 
therapies in breast cancer". Expert Opin Ther Targets, 6 (3). 375-385. 
633. Yang, J.-P., Hori, M., Sanda, T. and Okamoto, T. 1999  "Identification of a 
Novel Inhibitor of Nuclear Factor-kappa B, RelA-associated Inhibitor". J Biol 
Chem, 274 (22). 15662-15670. 
[291] 
 
                                                                                                                   Bibliography 
634. Yang, S., Zhou, Q. and Yang, X. 2007  "Caspase-3 status is a determinant of 
the differential responses to genistein between MDA-MB-231 and MCF-7 
breast cancer cells". Biochim Biophys Acta, 1773 (6). 903-911. 
635. Yang, X.H., Sladek, T.L., Liu, X., Butler, B.R., Froelich, C.J. and Thor, A.D. 
2001  "Reconstitution of Caspase 3 Sensitizes MCF-7 Breast Cancer Cells to 
Doxorubicin- and Etoposide-induced Apoptosis". Cancer Res, 61 (1). 348-
354. 
636. Yanushevich, Y.G., Staroverov, D.B., Savitsky, A.P., Fradkov, A.F., 
Gurskaya, N.G., Bulina, M.E., Lukyanov, K.A. and Lukyanov, S.A. 2002  "A 
strategy for the generation of non-aggregating mutants of Anthozoa 
fluorescent proteins". FEBS Letters, 511 (1-3). 11-14. 
637. Yarbrough, D., Wachter, R.M., Kallio, K., Matz, M.V. and Remington, S.J. 
2001  "Refined crystal structure of DsRed, a red fluorescent protein from 
coral, at 2.0-Ã resolution". PNAS, 98 (2). 462-467. 
638. Yasumi, M., Sakisaka, T., Hoshino, T., Kimura, T., Sakamoto, Y., Yamanaka, 
T., Ohno, S. and Takai, Y. 2005  "Direct Binding of Lgl2 to LGN during 
Mitosis and Its Requirement for Normal Cell Division". J Biol Chem, 280 (8). 
6761-6765. 
639. Yethon, J.A., Epand, R.F., Leber, B., Epand, R.M. and Andrews, D.W. 2003  
"Interaction with a Membrane Surface Triggers a Reversible Conformational 
Change in Bax Normally Associated with Induction of Apoptosis". J Biol 
Chem, 278 (49). 48935-48941. 
640. Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, 
M. 1991  "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is 
inhibited by interleukin-6". Nature, 352 (6333). 345-347. 
641. Yoon, Y., Krueger, E.W., Oswald, B.J. and McNiven, M.A. 2003  "The 
Mitochondrial Protein hFis1 Regulates Mitochondrial Fission in Mammalian 
Cells through an Interaction with the Dynamin-Like Protein DLP1". Mol Cell 
Biol, 23 (15). 5409-5420. 
642. Yoshida, H., Kong, Y.-Y., Yoshida, R., Elia, A.J., Hakem, A., Hakem, R., 
Penninger, J.M. and Mak, T.W. 1998  "Apaf1 Is Required for Mitochondrial 
Pathways of Apoptosis and Brain Development". Cell, 94 (6). 739-750. 
643. Youle, R. and Strasser, A. 2008  "The BCL-2 protein family: opposing 
activities that mediate cell death". Nat Rev Mol Cell Biol, 9 (1). 47-59. 
644. Yu, F., Morin, X., Cai, Y., Yang, X. and Chia, W. 2000  "Analysis of partner 
of inscuteable, a Novel Player of Drosophila Asymmetric Divisions, Reveals 
Two Distinct Steps in Inscuteable Apical Localization". Cell, 100 (4). 399-
409. 
645. Yuan, J., Shaham, S., Ledoux, S., Ellis, H.M. and Horvitz, H.R. 1993  "The C. 
elegans cell death gene ced-3 encodes a protein similar to mammalian 
interleukin-1[beta]-converting enzyme". Cell, 75 (4). 641-652. 
646. Yue, Z., Jin, S., Yang, C., Levine, A.J. and Heintz, N. 2003  "Beclin 1, an 
autophagy gene essential for early embryonic development, is a 
haploinsufficient tumor suppressor". PNAS, 100 (25). 15077-15082. 
[292] 
 
                                                                                                                   Bibliography 
647. Zambetti, G. and Levine, A. 1993  "A comparison of the biological activities 
of wild-type and mutant p53". FASEB J., 7 (10). 855-865. 
648. Zamzami, N., Marzo, I., Susin, S., Brenner, C., Larochette, N., Marchetti, P., 
Reed, J., Kofler, R. and Kroemer, G. 1998  "The thiol crosslinking agent 
diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing 
mitochondrial permeability transition". Oncogene, 16 (8). 1055-1063. 
649. Zaraisky, A.G., Lukyanov, S.A., Vasiliev, O.L., Smirnov, Y.V., Belyavsky, 
A.V. and Kazanskaya, O.V. 1992  "A novel homeobox gene expressed in the 
anterior neural plate of the Xenopus embryo". Dev Biol, 152 (2). 373-382. 
650. Zhang, J., Gong, A., Cheville, J., Smith, D. and Young, C. 2005  " AGR2, an 
androgen-inducible secretory protein overexpressed in prostate cancer". 
Genes Chromosomes Cancer, 43 (3). 249-259. 
651. Zhao, Y., Yang, H., Zhang, X. and Chen, G. 2005  "Mutation in D-loop 
region of mitochondrial DNA in gastric cancer and its significance". World J 
Gastroenterol, 11 (21). 3304-3306. 
652. Zheng, W., Rosenstiel, P., Huse, K., Sina, C., Valentonyte, R., Mah, N., 
Zeitlmann, L., Grosse, J., Ruf, N., Nurnberg, P., Costello, C.M., Onnie, C., 
Mathew, C., Platzer, M., Schreiber, S. and Hampe, J. 2006  "Evaluation of 
AGR2 and AGR3 as candidate genes for inflammatory bowel disease". Genes 
Immun, 7 (1). 11-18. 
653. Zhong, J., Zhang, H., Stanyon, C.A., Tromp, G. and Finley, R.L., Jr. 2003  
"A Strategy for Constructing Large Protein Interaction Maps Using the Yeast 
Two-Hybrid System:Regulated Expression Arrays and Two-Phase Mating". 
Genome Res., 13 (12). 2691-2699. 
654. Zhou, M., Gu, L., Findley, H.W., Jiang, R. and Woods, W.G. 2003  "PTEN 
Reverses MDM2-mediated Chemotherapy Resistance by Interacting with p53 
in Acute Lymphoblastic Leukemia Cells". Cancer Res, 63 (19). 6357-6362. 
655. Zhou, Q. and Salvesen, G.S. 1997  "Activation of pro-caspase-7 by serine 
proteases includes a non-canonical specificity". Biochem J, 324 (2). 361-364. 
656. Zhu, W., Qin, W., P., B., A., W., Puckett, C. and Sauter, E. 2005  
"Mitochondrial DNA mutations in breast cancer tissue and in matched nipple 
aspirate fluid". Carcinogenesis, 26 (1). 145-152. 
657. Ziyaie, D., Hupp, T. and Thompson, A. 2000  " P53 and breast cancer". 
Breast, 9 (5). 239-246. 
658. Zong, W.-X., Li, C., Hatzivassiliou, G., Lindsten, T., Yu, Q.-C., Yuan, J. and 
Thompson, C.B. 2003  "Bax and Bak can localize to the endoplasmic 
reticulum to initiate apoptosis". J Biol Chem, 162 (1). 59-69. 
659. Zou, H., Henzel, W.J., Liu, X., Lutschg, A. and Wang, X. 1997  "Apaf-1, a 
Human Protein Homologous to C. elegans CED-4, Participates in 
Cytochrome c-Dependent Activation of Caspase-3". Cell, 90 (3). 405-413. 
660. Zou, J., Ye, Y., Welshhans, K., Lurtz, M., Ellis, A.L., Louis, C., Rehder, V. 
and Yang, J.J. 2005  "Expression and optical properties of green fluorescent 















661. Zou, L. and Elledge, S.J. 2003  "Sensing DNA Damage Through ATRIP 
Recognition of RPA-ssDNA Complexes". Science, 300 (5625). 1542-1548. 
662. Zweitzig, D., Smirnov, D., Connelly, M., Terstappen, L., O’Hara, S. and 
Moran, E. 2007  "Physiological stress induces the metastasis marker AGR2 in 





List of websites 
 
1.  Introduction 
www.who.int/topics/cancer/en/       
 




3. Localization of AGR-2 
www.georgetown.edu
www.BDbiosciences.com
www.tsienslab.usbc
www.expasy.org
www.russell.embl-heidelberg.de 
 
